The role of thrombin and antithrombin-therapy in interventional cardiology by Herrman, J.P.R.
The role of 
thrombin and antithrombin .... therapy 
in interventional cardiology 
De rol van 
thrombine en antithrombine-therapie 
in interventie cardiologie 
J. P R. Herrman 
Promotie commissie 
Promotor 
Prof dr. P.W. Serruys 
Overige leden 
Prof. dr. J.R.T.C. Roelandt 
Prof. dr. F.W.A. Verheugt 
Prof. dr. B. Lowenberg 
Cover 
Angiographic observation of a post-
stenotic intracoronary thrombus. 
Thrombin (blue) and argatroban (red) 
separately. The pronoullced residues 
in the thrombin molecule represellt the 
active binding site. 
Argatroban-thrombin complex. 
The small argatrobGlI 1Il0lecule exactly 
fits the active site and blocks the action 
of thrombin. (By Takao Matsuzaki, 
NIitsubishi Chemical Corporation, 
Tokyo, Japall). 
Typesetting 
A. Herrmall, Utrecht 
ISBN 90-9009981-6 
Fillancial support by the Netherlands 
Hearl Foundatioll for the publication of 
this thesis is gratefully acknowledged. 
The role of 
thrombin and antithrombin-therapy 
in interventional cardiology 
De rol van 
thrombine en antithrombine-therapie 
in interventie cardiologie 
Proefschrift 
ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus Prof. dr. P.W.c. Akkermans en volgens besluit 
van het College voor Promoties. 
De open bare verdediging zal plaatsvinden 
op woensdag 19 februari 1997 om 15.45 uur 
door 
Johannes Paulus Remigius Herrman 
geboren te Beuningen 
For 
my mother Bep Herrman t 
For her III/dying love and faith ill /lie. 
For 
Pleun and Hilde 
The child is father to the lIIail. 
(Willialll ll'lordsworth, 1807) 

Contents 
11 Introduction 
Current State 
15 Chapter 1 
81 
J.P.R. Herrman, W.R.M. Hermans,J, Vos, P.W. Serruys. 
Pharmacological approaches to the prevention of restenosis following 
angioplasty. The search for The Holy Grail? (Part I) Drugs 
1993;46(1):18-52 (Part II) Drugs 1993;46(2):249-262. 
Chapter 2 
A.G. Violaris, R. Melkert, J.P.R. Herrman, P.W. Serruys. Role of 
angiographically identifiable thrombus on long term luminal renarro-
wing after coronary angioplasty: A quantitative angiographic analysis. 
Circulation 1996;93:889-897. 
Methodology and trial design 
99 Chapter 3 
115 
125 
135 
151 
V.A.W.M. Umans, W.R.M. Hermans,J.P.R. Herrman,J. Pameyer, 
P.W. Serruys. Experiences of a quantitative coronary angiographic core 
laboratory in restenosis prevention trials. Quantitative coronary angio-
graphy in clinical practice. P.W. Serruys, D.P. Foley and P.J. de Feyter 
(eds.) Kluwer Academic Publishers, Dordrecht, 1993;121-135. 
Chapter 4 
J.P.R. Herrman, D. Keane, Y. Ozaki, A. den Boer, P.W. Serruys. 
Assessment of radiographic quality of coronary guiding catheters. 
Catheterization and Cardiovascular Diagnosis 1994;33:55-60. 
Chapter 5 
Y. Ozaki, D. Keane, J.P.R. Herrman, D. Foley, J. Haase, A. den Boer, 
C. di Mario, P.W. Serruys. Coronary arteriography for quantitative 
analysis: Experimental and clinical comparison of cinefilm and video 
recordings. American Heart Journal 1995; 129:471-5. 
Chapter 6 
Jean-Paul R. Herrman, Aida Azar, Victor A.W.M. Umans, 
Eric Boersma, Gerrit-Anne v. Es and Patrick W. Serruys. Inter- and 
intra-observer variability in the qualitative categorization of coronary 
angiograms. InternationalJournal of Cardiac Imaging 1996; 12:21-30. 
Chapter 7 
J.P.R. Herrman, H. Suryapranata, P. den Heijer, M.J.B. Kutryk, 
L. Gabriel and P.W. Serruys. Argatroban during percutaneous trans-
luminal coronary angioplasty; results of a dose verification study. 
Journal of Thrombosis and Thrombolysis 1996;3:367-375. 
169 Chapter 8 
J.P.R. Herrman, V.A.W.M. Umans, P.F. Peerboom, D. Keane, 
J.J.M.M. Rijnierse, D. Bach, P. Kobi, R. Kerry, Ph. Close,].W. Deckers 
and P.W. Serruys, on behalf of the HELVETICA study group. 
Evaluation of recombinant hirudin (CGP 39 393!TM REV ASC) in 
the prevention of restenosis after percutaneous transluminal coronary 
angioplasty: Rationale and design of the HELVETICA trial, 
a multi-center randomized double blind heparin controlled study. 
European Heart Journal 1995(supplement L);16:56-62. 
Results 
183 Chapter 9 
201 
P.W. Serruys,J.P.R. Herrman, R. Simon, W. Rutsch, C. Bode, 
G.]. Laarman, R. van Dijk, A.A. van den Bos, V.A.W.M. Umans, 
K.A.A. Fox, P. Close and].W. Deckers for the HELVETICA inves-
ti-gators. A comparison of hirudin with heparin in the prevention of 
restenosis after coronary angioplasty. 
New England Journal of Medicine 1995;333(12):757-63. 
Chapter 10 
].P.R. Herrman, E. Boersma, A. Marzocchi, G. Guagliumi, A. Zeiher, 
J. Delean Dominguez, H. Emanuelsson, C. Macaya, V. Legrand, 
G. Binaghi, T. Colman, C. Hanet, S. Klugmann, E. Schroeder, 
N. Danchin, G. Heyndrickx, D. Gulba, M.C. Morice, F. Zijlstra, 
A. Betriu, H. Bonnier, L. Campolo, G. Specchia, B. Lancelin, B. Letac 
and P.W. Serruys on behalf of the HELVETICA investigators. Clinical 
outcome in patients undergoing coronary angioplasty for unstable 
angina pectoris. Predictors of adverse in-hospital and 3D-weeks clinical 
outcome following percutaneous transluminal coronary angioplasty 
in 1141 patients receiving either desirudin or heparin therapy: 
A multivariable analysis. Submitted to the European Heart Journal. 
Conclusion 
223 Chapter 11 
245 ! 249 
252 
254 
255 
J.P.R. Herrman and P.W. Serruys. The current role of antithrombins in 
interventional cardiology. Current review of Interventional Cardiology 
edn 3. D Holmes jr, and PW Serruys (eds). 
Current medicine; 1996, chapter 18. 
Overview of the thesis / Samenvatting van de dissertatie 
Acknowledgements 
Curriculum vitae 
Publications 


Introduction 
Thrombin and thrombus. The plasma coagulation system is activated in 
response to vascular injury and, within several minutes, thrombin is generated by 
a series of linked proteolytic reactions that take place on cell surfaces. These reac-
tions are balanced by naturally occurring inhibitory and procoagulant molecules. 
Thrombin has three major actions which are it's powerfull stimulus for platelet 
aggregation and activation; fibrinogen conversion to insoluble fibrin strands in 
the final common pathway for strengthening of the platelet plug; and it can acti-
vate factor XIII which leads to crosslinking and stabilisation of the fibrin clot. In 
addition, thrombin regulates many postthrombotic cellular events like chemoat-
traction of inflammatory cells and growth regulation of endothelial and vascular 
cells. Thus, thrombin is involved in both acute coronary occlusion and late reste-
nosis following coronary angioplasty. Although the haemostatic system has evol-
ved to minimise blood loss from injured vessels, there is little actual difference 
between the physiological process of normal haemostasis and the pathological 
events leading to coronary thrombosis and related events. Because of this simila-
rity, thrombosis has been described as haemostasis occurring in the wrong place 
at the wrong time. The triggering event is the interaction of normal blood compo-
nents with the abnormal vessel wall surface as in a diseased and atherosclerotic 
vessel or after successful coronary angioplasty. 
Antithrombotic therapy Antithrombotic therapy has changed little during the 
past few decades. Despite their limitations aspirin, heparin and warfarin have 
been the mainstays in the treatment of the majority of cardiovascular and cere-
brovascular thrombotic diseases. 
The effects of acetyl salicylic acid (an acetylated substrate from the salix alba) 
were first described in the 'Corpus Hypocraticum'. In this document the drug 
was indicated to relief fever, pain during labour and it was indicated for use in 
reumatoid inflammatory processes. Felix Hoffman developed the chemical 
method to refine the active substance and ultimately he patented aspirin in 1899. 
The antithrombotic properties of acetyl salicylic acid were discovered by K. 
Breddin. This expanded the indications for its use. The drug has been marketed 
for almost one century already! It has the ability to inhibit platelet activation by 
irreversibly blocking the conversion of arachidonic acid to PGG2 as a precursor 
for thromboxane A2 and B2. However, in the endothelial cell it also results in 
blockade of prostaglandin PGI2 generation. Thromboxane A2 is a powerful pla-
telet aggregator and vasoconstrictor, but since the biologic action of TxA2 and 
PGI2 are opposing, acetyl salicylic acid is an antagonist of itself. Although acetyl 
salicylic acid can be easily administered, it cannot be titrated to any marker of 
therapeutic efficacy. 
The antithrombotic capacities of heparins (discovered by McLean and colle-
agues in 1916) are achieved by the reversible binding with the natural circulating 
anticoagulant antithrombin III. The binding is responsible for a lOOO-fold acce-
leration of antithrombin III - heparin binding to factor IIa. The effectivity of 
heparins is inhibited by fibrin II monomers, thrombospondin and platelet factor 
4 which is present in the platelet rich thrombus. The inaccessability of the large 
II 
heparin-antithrombin III complex to clot bound thrombin or factor Xa in the 
prothrombinase complex is an additional major limitation. Heparin is a mixture 
of heterogenous sized depolymerized heparin molecules and is therefore, subject 
to lot to lot variety. The mechanism of action is moderated by antithrombin III, 
and heparin is therefore ineffective in patients having insufficient antithrombin 
III-levels. 
Dicumarols' anticoagulant effect was discovered by accident, by Link in 1930. Its 
action does not assail the extrinsic pathway, but on the other hand does hinder 
several commonly used drugs. Furthermore, there is a delay between administra-
tion and therapeutic effect. 
Another drawback to conventional antithrombotic therapy is the available tests 
we use to assess their therapeutic efficacy. Tests are performed in a static sample 
of whole blood which may not be relevant to an actual site of arterial injury past 
which blood is constantly flowing and to which activated platelets are adhering. 
The limitations of conventional antithrombotic therapy in clinical cardiology 
comprise thrombolysis, percutaneous transluminal coronary angioplasty and 
surgery which may be marked by resistant thrombotic complications. After 
thrombolysis, early reperfusion of the infarct-related artery is not achieved in 15 
to 20% of treatedpatients [1, 2] and a similar proportion of patients achieve only 
incomplete perfusion [1-3]. After successful reperfusion, reocclusion of the 
infarct related artery or its clinical correlate, reinfarction, or both, occur in 5 to 
10% of the patients at hospital discharge [2,4], and in up to 30% of the patients at 
3 months [5]. In unstable angina, progression to myocardial infarction still 
occurs in 5 to 7% of the patients [6,7]. In coronary angioplasty, abrupt closure or 
myocardial infarction complicates the procedure in 5 to 10% of the patients. An 
additional 5 to 10% of the patients require urgent repeat revascularization [8-12]. 
In all of these syndromes, these thrombotic events are associated with increased 
mortality and thus are important targets for more effective antithrombotic therapy. 
Antithrombin therapy Newer antithrombins that overcome the limitations of 
conventional antithrombotic drugs and reduce the complication rate in clinical 
care are being studied for use in acute coronary syndromes and interventions. 
These agents have the potential to be more effective, more specific and safer inhi-
bitors of the various steps of the coagulation cascade. In this thesis we review the 
role of thrombin, thrombusformation and antithrombins - argatroban and desi-
rudin in particular - in interventional cardiology. 
Argatroban, an arginine derivative, is a potent, synthetic, small molecule (527 
dalton) direct competitive thrombin inhibitor which is specific for the catalytic 
site of thrombin. The molecule is designed in 1971 to match this binding site pre-
cisely. It is in clinical use in Japan (licensed as NOV ASTAN®) and is in worldwi-
de, advanced clinical development as an antithrombotic agent for the treatment 
of heparin induced thrombocytopenia and heparin induced thrombocytopenia 
thrombosis syndrome, as well as for adjunctive treatment to thrombolytic therapy 
in acute myocardial infarction, in unstable angina pectoris and use as an antico-
agulant in coronary interventional procedures (chapter 7 of this thesis). 
12 
Hirudin is a protein originally isolated from the medicinal leech (Hirudo 
Medicinalis). The anticoagulant property of leech saliva was discovered in 1884 
by John B. Haycraft. It was needed by the leech to prevent the victim's blood from 
clotting. Initially, the compound was extracted from homogenized leech heads, 
and in 1913 it was processed for anticoagulant purposes during haemodialysis 
[13) and used first in humans in the 1920s [14). A serious drawback was the limi-
ted availability of leeches, since breeding trials failed and the medicinal leech was 
placed on the list of endangered species. Interest in hirudin and its related comp-
ounds (hirulog and hirugen) has increased over the past decade as recombinant 
DNA technology has now become available to manufacture these drugs in phar-
macological quantities. 
In chapters 9 and 10 of this thesis we describe the results of our studies with 
desulphato-hirudin or desirudin (marketed as REV ASC™). 
In this thesis I hope to have clarified the current position and role of thrombin 
and antithrombin-therapy in interventional cardiology. 
Jean-Paul R Herrman, Rotterdam 
November 30, 1996 
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Chapter 1 - Pharlllacological approaches to restenosis prevention 
Summary Luminal renarrowing after balloon angioplasty still hampers the 
long term vessel patency in a substantial percentage of patients. 
Morphologically, the restenotic lesion comprises hyperplasia of intimal tissue, 
which is mainly characterised by proliferation of smooth muscle cells of the 
synthetic type with abundant extracellular matrix production, chiefly composed 
ofproteoglycans. Unravelling the underlying pathophysiologicai process 
enables more specific intervention in basic interactions and cell responses. 
Critical events in the development of rest en otic tissue are platelet aggregation 
and thrombus formation, while the release of several mediators promotes pro-
liferation and migration of various cell types. All ofthese steps give access for a 
diversity of pharmacological interventions. With this in mind, antithrombotic, 
antiplatelet, antiproliferative, anti-inflammatory, calcium channel blocking and 
lipid-lowering drugs have been investigated in the prevention of rest enos is. 
Other newer approaches likely to receive more attention in the future include 
antibodies to growth factors, gene transfer therapy and antisense oligonucleoti-
des. Whether there is a feasible monotherapy, whether we have to focus on a 
drug combination or whether we are only searching for 'the holy grail' remain to 
be answered. (Drugs 1993;46(1): 18-52 (Part I) and (2):249-262 (Part II).) 
Percutaneous trans luminal coronary angioplasty (PTCA) is an accepted treat-
ment for providing relief of angina pectoris in patients with single- and multives-
sel disease. Increased experience and advances in technology have resulted in a 
higher primary success rate (90% to 95%) and a lower complication rate (4% to 
5%). Despite the therapeutic success of coronary angioplasty, the exact mecha-
nisms of dilatation remain speculative and involve multiple processes, including 
endothelial denudation with rapid accumulation of platelet and fibrin; cracking, 
splitting or disruption of the intima and atherosclerotic plaque; dehiscence of the 
intima and plaque from the underlying media; and stretching or tearing of the 
media, with persistent aneurysmal dilatation of the media and adventitia 
(McBride et al. 1988; Waller 1989). 
The major limitation of PTCA is the high incidence of restenosis which 
limits the long term benefit of the procedure. Restenosis is the angiographic 
renarrowing at the site of PTCA, frequently accompanied by recurrence of 
symptoms of angina. The incidence of restenosis varies between 17% and 40%, 
the wide variation being a consequence of whether there has been complete 
angiographic follow up, as well as the way in which restenosis is defined (Holmes 
et al. 1984; Kaltenbach et al. 1985; Nobuyoshi et al. 1988; Serruys et al. 1988). 
Over the past ten years we have been unable to influence significantly the rate of 
this late complication. Although many of the risk factors for restenosis have been 
identified (Table I), most of these are difficult to influence and we are unable to 
I6 
TableI 
Variables associated with higher restenosis rates in patients with follow-up angiography. 
Hemodynamic or 
Author Year Patients Clinical Procedure-related Lesion-related 
Holmes ct al. 1984 557 Male sex l'rc-PTCA TSG ;, 40 mmHg I're-I'TCA DS > 70% 
Can. dass Ill-IV Post-PTCA TSG;, 20 mmHg I'TCAonCAllG 
No previous MI Angina onset < 2 months 
Diabetes Mellitus 
Kaltenbach ct al. 1985 333 Medication? Repeat I'TCA 
I'TCA in graft 
Scholl et al. 1981 45 Variant angina Eccentric or calcified lesion 
Dangoissc ct a!. 1982 31 Variant angina 
> 9 inflations 
David et al. 1984 191 Variant angina I're-I'TCA DS > 90% 
l'ost-I'TCA DS > 50% 
Concentric stenosis 
Diffuse disease 
Absence of dissection 
Dorms cr a!. 1984 46 Prox graft 
Marantz ct a!. 1984 73 l'ost-PTCA TSG > 18 mmHg Irregular lesion prc-PTCA 
> 7 atmospheres Large change DS 
Margolis ct a!. 1984 216 Diabetes Mellitus (insulin) 
Schmitz eta!' 1984 86 Larger balloon size less rcstcnm;is 
Levine ct al. 1985 100 Inflation pressure l'ost-PTCA DS > 30% 
<8ATM Relative change less than 55%1 
Mata et al. 1985 60 Balloon artery ratio:S;; 0.9 l.AD or LCX >RCA 
Calcified stenosis 
Post-I'TCA DS > 40% 
Probst ct aJ. 1985 94 Collaterals pre-I'TCA 
Occlusion pressure> 45 mmHg 
Scrruys et al. 1985 28* PTCA for total occlusion 
Bertrand et al. 1986 229 'Dynamic' coronary 
stenosis (Spontaneous 
or provoked spasm) 
Clark ct al. 1986 124* More inflations 
Higher Inflation Pressure 
Hollman etal. 1986 536 Diabetes Mellitus Multivcsscll'TCA 
I'rc-I'TCA DS;' 90% 
Post-PTCA DS > 40% 
Absence of intimal tear 
I .cimgrubcr et a!. 1986 998 Old age Post-I'TCA TSG 15 mmHg LAD> RCA> LCX 
Unstable angina l'ost-I'TCA DS > 30% 
Angina onset <2 mths Absence of dissection 
Powelson et a!. 1986 50 Presence of intimal disruption 1 
Roubin et al. 1986 411 ** Multi-lesion PTCA in one vessel 
Vebis etal. 1986 100 Length ofpre-PTCA stenosis >2mm 
Hirshfe1d Jr. et al. 1987 209 LAD> LCX or RCA 
j"Hnimalluminal diameter < 0,64 mm 
Normal diameter < 3,0 mm 
Short duration heparin 
therapy 
Guiteras et al. 1987 100 Hypertension Residual stenosis 
Eccentricity of lesion 
TableI 
continued 
Author Year Patients 
Myler et al. 1987 164** 
Rapold et al. 1987 178 
Simonton ct at. 1987 123 
Urban etal. 1987 91 
Vandormacl ct a1. 1987 129** 
De Feyter ct al. 1988 158*** 
Galan et al. 1988 160 
Lambert ct aJ. 1988 119** 
Weinstein ct al. 1988 54 
Bertrand ct a1. 1989 437 
Ellis ctal. 1989 308 
Ucbis eta!. 1989 272 
Rcnkin ct al. 1990 111 
Rupprecht et al. 1990 473 
1 = Early restenosis r::; 2 days]j 
CABG= Coronary artery bypass graft; 
DS= diameter stenosisj 
'J'SG= Transstenotic gradientj 
C. W.P= Coronary wedge pressure; 
Clinieal 
Diabetes Mellitus 
Hypercholesterolemia 
New onset angina 
Current smoking 
Variant angina 
Diabetes Mellitus 
C.W.P230mmHg 
Hemodynamic 01' 
Procedurewrelated 
Inflation pressure> 10 atm 
Lesion-related 
Prc-PTCA DS > 95%) 
l'ost-PTCA> 45% 
Multivcsscl Disease 
Slow distal flow 
Difficulty crossing lesion 
History prior MI 
Male Gender Proximal LAD disease 
Diabetes Mellitus Increased length stenosis (> :::::: 1 Dmm) 
Presence of collatcrals 
Multivcsscl disease 
LAD disease 
Transient ST-dcprcssion 
Continuing Smoker 
Diabetes Mellitus 
Recurrence of angina 
Unstable Angina 
> = 3 inflations 
Prolonged single inflation 
* = patients with total occlusionj 
High grade stenosis Prc-PTCA 
Large residual stenosis 
Dilatation of both bifurcation lesions 
Presence of ergonovine induced spasm 
before and after [,TCA 
Stenosis at bend point of coronary artery 
Post-PTCA luminal diameter 
Large residual stenosis post-
[,TCA 
High grade stenosis prc-PTCA 
** = patients with multi-Iesionsj 
*** = patients with unstable angina. 
Drugs 1993;46(1):18-52 (Part I) and (2):249-262 (Part II) 
predict reliably which patients or vessel segments will develop restenosis. Until 
now, there has not been a pharmacological solution to restenosis. The use of one 
of the new interventional devices, such as the atherectomy catheter (Simpson et 
al. 1991), the excimer laser (Margolis et al. 1991), stent (Serruys et al. 1991 a) or 
the rotablator (Buchbinder et al. 1991), has also not succeeded in preventing re-
stenosis. The reason that a clinically significant restenosis occurs in only a mino-
rity of the dilated vessels remains an enigma. It seems that the solution to the pro-
blem of restenosis depends on an understanding of the controlled healing 
process, which occurs in 60-80% of the vessels dilated. 
1. Possible Mechanism of Rest enos is After PTCA 
Beside the pathology of the dilated vessels of patients who died shortly after 
PTCA, or at a later stage (Essed et al. 1983, Austin et al. 1985, Nobuyoshi et al. 
1991), it has become possible to remove and examine primary and restenotic 
lesions with the use of the trans luminal atherectomy device (Johnson et al. 1990, 
Safian et al. 1990, Garett et al. 1990). Primary stenotic lesions consist in the 
majority of cases of atherosclerotic plaque composed of dense fibrous tissue and 
variable amounts of fatty atheromatous debris. However, in a small group only 
intimal hyperplasia was observed, histological identical to restenotic lesions. 
Restenotic lesions showed in most cases intimal hyperplasia (characterised by 
proliferation of smooth muscle cells of the synthetic type with abundant extracel-
lular matrix chiefly composed of proteoglycans), and in a minority only athero-
sclerotic plaque was observed. Smooth muscle cell proliferation seems to playa 
pivotal role in the restenosis process. 
Recently two models have been proposed to explain the very complex pro-
cess of restenosis. Forrester et al. (1991) hypothesised that restenosis is a mani-
festation of the general wound healing process expressed specifically in vascular 
tissue following injury. The process that results in restenosis is indeed initiated at 
the time the disruptive action of the inflated balloon on the endothelium and/or 
intima and/or media takes place during PTCA. As intact endothelium prevents 
platelet aggregation, a superficial endothelial injury leads to local platelet and leu-
cocyte adhesion, but most of the platelets do not undergo a release action. 
However, in case of a deep endothelial injury (as with a successful angioplasty) 
the haemostatic system is activated. Blood is exposed to collagen and other sub-
stances of the sub intima which are potent stimuli for platelet aggregation media-
ted by the release of adenosine diphosphate (ADP), serotonin, thromboxane A2 
(TXA2), and the adhesive molecules fibrinogen, fibronectin, thrombospondin 
and von Willebrand Factor (figure 1a). These substances activate neighboring 
platelets via different metabolic pathways, and promote intramural thrombus 
formation which could cause restenosis (Stein et al. 1989, Coller 1990). Thus the 
inflammatory phase begins with coagulation of blood and fibronectin, while pla-
telets aggregate at the wound surface, releasing promoters for local vasoconstric-
tion, coagulation and mitosis (figure 1 b). 
Removal of heparin from the surface of endothelial and smooth muscle cells 
by endoglycosidase creates receptivity for the action of growth factors. These are 
produced in an abundant variety, interacting in a complex way. Several growth 
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Figure 1 A and IB 
A. Schematic presentation of platelet 
activation, caused by the exposure of 
subendothelial collagen and lamillin to 
circulating blood. Platelet adhesion is 
mediated by ADP, serotollin, thl'ombo-
xalle and the adhesive molecules which 
bind to glycoprotein recept01's on platelets. 
B. This adhesion leads to activation and 
aggregation with release of coagulants, 
lIlitogens and vasoconstlictors. 
BC = endthelial cell; 
Ca++ = Calcium iollS; 
lA (B or C)lllA (B)IIIIAJ(B) = 
glycoproteine receptor lA (B 01' C)I 
IIA (B)IIIIAI(B); 
Th = throlllbospondin; 
F = fibronectin; 
V = vitrollectin; 
v lfIF = von lfIillebrand Factor; 
PDGF-BB = platelet derived growth 
factor type BB; 
BGF = epidennal growth factor; 
bFGF = basic fibroblastic growth factol;' 
fJ-TGF = fJ-transforlllillg growth factor. 
Figure 2 
Schematic presentation of the stimulation 
of smooth muscle cells (SMC) by several 
growth factors, causing them to prohjerate 
and migmte from the medial layer into 
the intima of the vessel wall. This res-
ponse can be associated with abundallt 
connective tissue fonnation. 
BC = endthelial cell; 
lGF = sOlllatomedin 
(illsulill like growth factor); 
PDGF-BB = platelet derived growth 
factor type BB; 
BGF = epidermal growth factor; 
bFGF = basic fibroblastic growth factor; 
fJ-TGF = fJ-tmllsforming growth factor; 
TNF = tulllor necrosis factor. 
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factors including platelet-derived growth factor (PDGF), epidermal growth fac-
tor (EGF) and transforming growth factor beta (TGF-f3) are released concomi-
tantly from thrombocytes, smooth muscle cells, endothelium and macrophages. 
Also somatome din (insulin like growth factor; IGF-I) and angiotensin have been 
identified as mitogenic contributors. They stimulate smooth muscle cells and 
fibroblasts to proliferate and migrate from the medial layer into the intima of the 
vessel wall. In some patients this response is exaggerated and is associated with 
overproduction connective tissue. This results in hyperplasia of the intima with a 
reduction in luminal diameter, and causes restenosis (Clowes & Schwartz 1985, 
Ross 1986, Liu et al. 1989), (figure 2). Thus the granulation phase is marked by 
endothelial cell migration and proliferation from the wound margin to cover the 
wound surface. Smooth muscle cells begin to migrate and proliferate from 
adjacent tissue to the injured area, determined by the action of growth factors and 
their opposites. 
Contractile characteristics of smooth muscle cells disappear in favour of 
synthetic elements such as increased amounts of synthetic organelles, loss of 
capacity to contract and increased capacity to divide. Within about 7 days, the 
phase of extracellular matrix deposition and remodelling takes over, and large 
levels of chondroitin-sulfate and dermatan sulfate are produced. Both stimulate 
cell migration and proliferation, and therefore are central in the healing process. 
Within several months, replacement of the proteoglycanes by collagen and elastin 
completes the wound healing process. 
Schwartz et al. (1991a) proposed an alternative model, based on observa-
tions in a porcine coronary injury model. In response to arterial injury, platelets, 
fibrin and red blood cells accumulate at the injured site, the so-called thrombotic 
phase. In the subsequent recruitment stage, this thrombus endothelialises and 
mononuclear cells infiltrate on the lumen side of the vessel. In the proliferative 
phase, cells (which stain positive for a-actin) form a thin cap just beneath the 
endothelial surface. These smooth muscle cells or myofibroblasts resorb the 
remaining thrombotic material towards the media. Since the smooth muscle cells 
first appear at the luminal side of the endothelialised thrombus, their origin is 
apparently not the media. Schwartz et al. (1991a) conclude from these observa-
tions that the magnitude of the luminal narrowing process may derive more from 
the volume of local mural thrombus at the site of arterial injury than from uncon-
trolled cellular proliferation. 
Each of these steps could be sites of pharmacological intervention that may 
prevent the restenosis process (Forrester et al. 1991). The drugs which could 
reduce or prevent restenosis are listed in table II. In this review we will concentra-
te on the drugs that have been tested to prevent restenosis in animal models and 
in post-angioplasty patients. These are summarised in table III. 
2. AnhnalModels 
Lack of a practical animal restenosis model has limited the ability to investigate 
potential therapies. It is difficult to create arterial stenoses in animals that resem-
ble exactly human coronary artery disease for the following reasons: a) the 
dimensions of the arteries in the animal model should be similar to these in 
21 
Chapter 1 - Pharmacological approaches to restellosis preventioll 
human beings; b) the development of lesions should occur in an accelerated fas-
hion; c) lesions must produce high-grade, including total, angiographically 
detectable luminal diameter narrowing; and d) the histological composition of 
lesions should be similar to the complex lesions that are typical of human athero-
sclerosis (Gal et al. 1990). 
At least 4 different species (pigs, rats, dogs and rabbits) have been used to 
test new drugs in their ability to prevent restenosis (Le Veen et al. 1982). There is 
no consensus as to the way that the stenosis should be created (i.e. inflated bal-
loon, infused air, electrical stimulation, or oversized stent implantation) or 
whether an atherogenic diet should be added, as there is no animal with identical 
atherosclerotic disease to humans. The vessel studie (iliac, femoral, carotid or 
coronary arteries, aorta) is also different. Furthermore, the way in which resteno-
sis is assessed differs between the different models. Some use the degree of plate-
let deposition at the site of arterial injury, while others use the percentage of inti-
mal mitosis observed in the damaged arteries (Steele et al. 1985; Wilentz et al. 
1987). Angiography is frequently used to assess restenosis, although some use 
visual evaluation and others use a computerised-assisted technique to assess re-
stenosis. In summary, no consensus has been reached as to the definition of reste-
nosis that should be used when a new drug is tested in animals. 
Recently a model of human restenosis was developed in pigs fed a standard 
non -atherogenic diet (Schwartz et al. 1991 b). Metallic foreign bodies were 
implanted percutaneously in porcine coronary arteries, with oversized PTCA 
balloons inflated to high pressure. Results of histological examination of lesions 
showed a marked proliferation of medial smooth muscle cells. The histopatholo-
gical features of the proliferative response were identical to those observed in 
human cases of restenosis following angioplasty. This animal model may there-
fore be useful in understanding the development of the restenotic lesions and in 
testing restenosis-preventing drugs since this model more closely resembles the 
response in human restenosis. 
3. Drugs Investigated for Restenosis Prevention 
3.1 Antithrombotic Agents Exposure of collagen of the media, as well as mate-
rial of the atheromatous plaque, activates the intrinsic and extrinsic coagulation 
system. Thrombin present first in minute amounts promotes its own generation 
by activating factors V, VIII and XIII by a positive feedback loop, and initiates an 
autocatalytic reaction leading to rapid production of large quantities of the pro-
thrombin complex via the amplification mechanism. Thrombin stimulates plate-
lets to release and promotes fibrinogen conversion. Antithrombotic and especial-
ly anti-thrombin drugs are therefore attractive agents in restenosis prevention. 
3.1.1 Coumadin Coumadin has major effects on the coagulation proteins' factor 
II, VII, IX, and X, protein C and S. This vitamin-K-inhibitor affects the carboxy-
lation system necessary for conversion of glutamic acid residues into gamma-car-
boxyglutamic acid, and results in a decreased capacity to bind phospholipid for 
its activation (Wessler & GiteI1986). Correction of vitamin K inhibition can be 
readily achieved by administration ofphytomenadione (vitamin K-1) or transfu-
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Table II 
Summary of potential targets and drugs in preventing restenosis. 
Thrombosis 
Coumadin, heparin, low molecular weight heparin, hirudin, 
PPACK, r-ATS, TAP synthetic peptide inhibitor of thrombin 
Aspririn, dipyridamole, thromboxane A2 synthetase inhibitor 
(nafragel), thromboxane A2 receptor blocker, synthetase 
inhibitor combined with endoperoxide receptor blocker, 
prostacyclin and analogues 
Ticlopidine, serotonin antagonist, GPIIB/IIIA receptor blocker, 
Arg-Gly-Asp pep tides, Lys-Gly-Asp pep tides, monoclonal 
antibodies against von Wille brand Factor, omega-3 fatty acids 
Cell proliferation 
Angiotensin converting enzyme inhibitor, colchine, platelet 
derived growth factor antagonist, HGM Co-enzyme A reductase 
inhibitor, angiopeptin, serotonin antagonist, low molecular 
weight heparin, cytostatic agents and other antiproliferative 
drugs 
Inhibitor ofinflammation 
Corticosteroids, non steroidal anti inflammatory drugs 
Coronary vasospasm 
Calcium antagonists 
Lipid regulators 
Omega-3 fatty acids, HGM co-enzyme A reductase inhibitor 
Abbreviations: GP IIb/IlIa = glycoprotein IIb/IlIa; PPACK = d-
phenyl-analyl-l-prolyl-l-arginyl-chloromethyl ketone; r-ATS = 
antistasin;TAP=tick anticoagulant peptide. 
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sion of blood, plasma, or plasma concentrates rich in vitamin K-dependent clot-
ting factors. 
There is evidence that coumadin is effective in preventing thrombosis in 
venous bypass grafts, and an anti-vitamin K regimen was tested in a trial in which 
248 patients were randomly assigned to receive either aspirin 325 mg daily 
(n= 126) or coumadin (122) at a dosage which resulted in a prothrombin time 
that was 2 to 2.5 times the normal value (Thornton et al. 1984). Restenosis was 
angiographically documented in 27% of the aspirin group, versus 36% of the 
patients treated with coumadin. A loss of> 50% of the gain achieved at the time of 
PTCA or an increase in the stenosis of >30% (NHLBI IV), or the development of 
ischaemia during exercise testing if no angiogram was available, were used as re-
stenosis criteria. The results favoured the aspirin strategy (figure 3), but the dif-
ference was only significant for a subgroup of patients with a long history of chest 
pain (> 6 months). In patients with poor compliance, restenosis rates were 32% 
in the group treated with coumadin versus 20% in the group given aspirin. 
A more recent randomiszed trial involving 110 patients investigated the 
effect of a combination of coumadin with verapamil compared with verapamil 
alone (Urban et al. 1988). The incidence of restenosis (NHLBI IV) was 25% by 
lesion and 29% by patient in the group given coumadin, and 33 and 37%, respec-
tively, in the control group. Although the incidence of angiographic restenosis 
tended to be lower with coumadin, none of the differences were significant (figu-
re 3). Dill et al. (1992) failed to show any beneficial effect on the patency of chro-
nically occluded coronary arteries, recanalised by PTCA, by using coumadin or 
aspirin. Ninety eight patients were randomised after a successful recanalisation 
to either aspirin 250 mg or coumadin (Quick's time ~ 25%), in addition to intra-
venous heparin. In the aspirin treated group, 12 of 19 patients presented with re-
stenosis at 3 months' follow up angiography, while 14 ofthe 24 coumadin treated 
patients had an angiographic recurrence of luminal narrowing. Reocclusion 
occurred in 37, respectively 42% (7/19 patients, 10/24 patients). 
A randomised trial should be performed to evaluate the efficacy of couma-
din in the prevention of restenosis that would ensure adequate medication com-
pliance with reliable and safe monitoring of prothrombin time. 
3.1.2 Heparin Heparin was discovered in the beginning ofthis century (McLean 
1916). It is a heterogeneous mixture of glycosaminoglycans with a molecular 
weight ranging from 2000 to 40,000 D, composed of repeating glucosamine and 
glucuronic acid sugar residues (Casu 1985). It inhibits smooth muscle cell 
growth in vitro, as well as angiogenesis and proliferation of Schwann cells and 
epithelial cells. In animal studies, heparin has been shown to inhibit proliferation 
and migration of vascular smooth muscle cells (Clowes & Clowes 1986; Clowes 
& Karnovsky 1977). Growth inhibition with heparin is proportional to heparin 
fragment size, with a maximal potency observed in the decamers or larger seg-
ments. The earliest mechanism for this effect proposed that heparin scavenges 
cationic growth factors, such as fibroblastic growth factor (FGF) and PDGF. 
Furthermore, binding and internalisation of heparin by smooth muscle cells 
makes them less responsive to growth stimuli after vessel injury. Sulphation and 
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acetylation of the sugar moieties in this agent increases antiproliferative activity. 
The anti-thrombotic capacity of heparin is achieved through reversible bin-
ding with the natural circulating anticoagulant antithrombin III. This binding is 
responsible for a lOOO-fold acceleration of antithrombin III-heparin binding to 
factor IIa. This complex also involves activated coagulation proteins (factors X, 
IX, XI and XII) (Bettmann 1987; Ockelford 1986). A recent publication (Araki 
et al. 1992) reports the finding that heparin reduces the thrombogenecity of a 
damaged vessel wall in vivo. In mesenteric arteries of rats, they observed that the 
adherence of heparin was limited exclusively to the injured parts of the vessel, 
and inhibited clot formation by local antithrombin activity. They concluded that 
the antithrombotic action of heparin might be due to inactivation of the thrombo-
genic site. 
Because of the central position of factor Xa in the coagulation cascade, the 
conversions downstream, including thrombin generation, are also inhibited by 
heparin. 
Since early discontinuation of heparin after angioplasty is associated with 
acute occlusion of the dilated arterial segment, anticoagulation seems to be 
important in the early stages after PTCA. However, the optimal duration of 
heparin therapy is still unknown (Gabliani et al. 1988). A prospective trial invol-
ving 209 patients showed a possible beneficial effect of postangioplasty heparin 
therapy. Prolongation of heparin administration from 2 to > 30 hours reduced 
the incidence of stenosis from 60 to 40% (Hirshfeld et al. 1987). However, in a 
randomised study with 416 patients (469 stenoses) a decrease in restenosis follo-
wing extended heparin treatment could not be confirmed (Ellis et al. 1989a). 
Restenosis was defined as a narrowing of> 50% of the vessel at the time of follow-
up angiography, which was performed in only 58.4% of the heparin recipients 
and 64.5% of those given placebo. No differences in restenosis rate were found in 
patients randomly assigned to placebo or 18 to 24 hours' heparin administration 
post-PTCA (all patients received aspirin for 6 months). More bleeding compli-
cations were observed in the group of patients who were treated with heparin 
(8.2% vs 3.8%). Acute total closure was observed more frequently in the group 
given placebo (2.4%) than in the group treated with heparin (1.8%) but the corre-
sponding restenosis rate was 36.7% versus 41.2%. 
Recently, Lehmann et al. (1991) randomised 23 patients to daily subcuta-
neous administration of heparin 10 000 units for an unspecified duration, or to 
usual (probably nonpharmacological care. 14 of 17 of the heparin treated 
patients (82%) experienced restenosis, compared with 2 of 6 (33%) in the place-
bo group. Restenosis was defined by quantitative angiographic analysis. Thus, 
long term heparin use after successful angioplasty paradoxically increases the 
likelihood of angiographic restenosis and adverse clinical outcome. 
Perin et al. (1990) retrospectively compared baseline and post-heparin acti-
vated clotting times (ACT) between 76 patients with angiographic restenosis and 
18 patients without restenosis. Patients with restenosis had significantly lower 
post-heparin ACT values than those without restenosis. There therefore appears 
to be a relationship between the procedural response to a bolus dose of heparin 
and the subsequent development ofrestenosis. 
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Another study (Walford et al. 1991) randomised 211 patients after success-
ful PTCA to heparin 1000 U/hour for 12-24 hours or placebo. Paradoxically, 
early complications were significantly more common in the active treatment 
group, but no effect was documented on the restenosis rate and clinical endpoints 
at 19-months' follow up. 
Thus, so far, conflicting data have been reported, and it appears reasonable 
to conclude, that heparin does not affect the restenosis rate dramatically. 
Interestingly, cyclodextrin tetradecasulfate has been used during artery 
dilatation in rabbits (Herrmann et al. 1991). This synthetic heparin analogue 
resulted in a restenosis rate of 25% (2 out of 8) compared with 75% placebo (6 
out of 8). The minimal luminal diameter was significantly increased in the treated 
group at I-month follow up. 
GM 1-077 is a novel non-anticoagulant high molecular weight heparin deri-
vative. This periodate oxidised heparin was investigated in rabbits undergoing 
balloon angioplasty in the femoral artery (Dube et al. 1992; Timms et al. 1992). 
The decrease in lumen diameter from immediately after angioplasty to 28 days 
after continuous intravenous infusion of GM1-077 was investigated at two dose 
regimens, 0.1 or 0.33 mg/kg/hr, and compared to a control group (Timms et al. 
1992). The decrease in lumen diameter in 14 animals given the higher dosage was 
significantly lower than in the 17 controls, with those given the lower dose 
somewhere in between. 
Dube et al. (1992) studied the effect of GM1-077 22 mg/kg/day subcutane-
ously on morphometric parameters, and detected a 1.8-fold greater inhibition of 
intimal thickening than with the control drug, subcutaneous heparin 7.6 
mg/kg/day. 
3.1.3 Low Molecular Weight Heparins Because low molecular weight heparins 
(LMWH) affect platelet aggregation and platelet-dependent thrombin genera-
tion to a lesser extent than conventional heparin, they have fewer adverse effects. 
They have weaker antifactor IIa activity, but greater antifactor Xa effects. Both 
are known to inhibit the proliferation of vascular smooth muscle cells (propor-
tional to heparin fragment size and concentration), and thrombosis after endo-
thelial injury in rats (Clowes et al. 1977; Majesky et al. 1987). The mechanism of 
this inhibition is not clear (Gordon et al. 1987). 
LMWH have been used after transluminal angioplasty (T A) of rabbit iliac 
arteries (Pow et al. 1989). One group (n=9) received LMWH 10 mg/kg/day sub-
cutaneously immediately prior to T A until follow-up angiography 1 month later, 
and another second group (n=12) received placebo. After 4 weeks, all animals in 
the placebo group and 3 of 9 in the group given LMWH had a loss of> 50% of the 
gain in diameter after T A. Histologic findings showed reduced intimal hyperpla-
sia and no formation of thrombus in the group tested with LMWH. 
Another study in atherosclerotic rabbits by Currier et al. (1991) examined 
the effect of enoxaparin low dose (1 mg/kg/day) for 4 weeks or high dose (10 
mglkg/day) for 2 or 4 weeks. At follow-up angiography the mean luminal diame-
ter was 0.82 ± 0.17mm for low dose enoxaparin, 1.04 ± 0.20mm for 2-week high 
dose (p=0.03 vs control) and 1.19 ± 0.09mm for 4-week high dose enoxaparin 
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(p=O.OOl vs control). Restenosis, defined as a loss of 50% of the initial gain, was 
found in all control vessels, in 2 of 9 vessels given the 2-week high dose regimen, 
and in 3 of 9 vessels in the 4- week high dose group, demonstrating that LMWH 
can inhibit restenosis in animal models, and may be useful in humans. 
Oda et al. (1992) investigated the long term effect (8 weeks) of enoxaparin 
administration on intimal hypertrophy in normolipidaemic and in hypercholes-
terolaemic rabbits after balloon injury in the abdominal aorta. The labelling index 
and the ratio of intimal to media thickness were used to detect drug effects. At the 
end of the study period, the inhibitory effect of the drug seen earlier, after intra-
aortal intervention in the hyperlipidaemic rabbits, was lost, while after 56 days, a 
significant inhibitory effect on intimal hypertrophy could be detected in the nor-
molipidaemic animals (intima/media ratio 1.45 in controls vs 0.65 after treat-
ment; p<O.Ol). 
Oberhoff et al. (1990) showed a significant reduction in the extent of intimal 
mitosis in the 7 days after balloon angioplasty in rabbits given LMWH, resulting 
in only a moderate increase of intimal thickness after 28 days compared with a 
control group. In two additional studies a significant effect of LMWH and 
unfractioned heparin on mitogenic activity of smooth muscle cells compared to 
placebo in carotid arteries of rabbits was confirmed (Oberhoff et al. 1991). They 
concluded that migration and proliferation of smooth muscle cells can be redu-
ced by early treatment with LMWH after balloon angioplasty and further clinical 
investigation is advocated. 
Similar data were reported by Unterberg et al. (1992), who implanted stents 
in the coronaries of hypercholesterolaemic pigs. Angiographic follow up after 
4 weeks' administration of LMWH 200 U/kg showed 2 significant stenoses 
in the placebo group (33%), whereas all the vessels in the LMWH group 
were patent. Diameter reduction was 41 versus 22% (p<O.Ol). 
Heras et al. (1992) investigated the inhibition of thrombus formation in pig 
arteries with deep injuries, using four dosages (100, 200,400 and 500 U/kg) of 
the LMWH CY 216 in comparison with unfractionated heparin (100 U/kg) and 
placebo. Examination of the treated injured vessels after 1 hour showed platelet 
deposition of 22, 29, 9, 9, 11 and 42 * 106/cm2, respectively, with these drugs. 
For fibrinogen deposition, the corresponding values were 19, 19,21, 14, 12, and 
35 molecules *10 12/cm2. Thus, the predominantly anti-factor X activity does 
not clearly inhibit the deposition of thrombotic material after deep arterial injury. 
In addition to routine post-PTCA medication, De Vries and associates 
(1991) treated 49 patients with tedelparin (dalteparin sodium) 5000U, starting 
on the day of PTCA and subsequently daily for 30 days. Restenosis, defined as 
>50% reduction in lumen diameter, was documented in 18 of the 46 patients 
(39%) who had follow up angiography at 4 to 6 months, and thus LMWH did not 
affect the restenosis rate. 
A pilot investigation reported the restenosis rates in 22 patients after 3 
months' treatment either aspirin 100 to 300 mg/day (n= 11) or tedelparin 80 U/kg 
(Schmidt et al. 1990). Repeat coronary angiography at the end of this treatment 
period showed 6 stenoses in the aspirin recipients, and only 3 in the LMWH 
group. The small number of cases actually does not allow statistical analysis and 
conclusions, but larger scale studies are in preparation. 
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Recently a group in Boston completed the ERA (Enoxaparin Restenosis 
after Angioplasty) study comparing Enoxaparin 40 mg q.d. subcutaneously with 
placebo, for 28 days, starting within 2 hours after angioplasty, in the prevention 
of restenosis (Faxon et al. 1992). A total of 459 patients were enrolled and 86% 
completed the study protocol, including angiographic follow-up. Treatment 
comparison resulted in an insignificant difference between the two groups (52% 
with active treatment vs 51 % with placebo). Futher, analysis of demographic data 
and the use of other definitions for angiographic restenosis did not reveal any dif-
ference between the two groups. 
3.1.4 Hirudin A new anticoagulant drug, originally extracted from the leech 
Hirudo medicinalis and now produced by genetically manipulated micro-orga-
nisms, is hirudin. This 7 kD single-chain polypeptide composed of 65 amino 
acids, prevents fibrinogen clotting and thrombin-catalysed activation of factors 
V, VIII and XIII, protein C and thrombin-induced platelet activation by directly 
binding to thrombin at multiple sites, and also where thrombin is clot-bound 
(Weitz et al. 1990). Hirudin has been shown to be more effective in preventing 
thrombosis than heparin in a porcine model, by quantifying platelet and fibrin-
ogen deposition (Dewanjee et al. 1984). This latter effect is probably because 
hirudin is a more potent and more specific thrombin antagonist (Heras et al. 
1989, 1990), that does not require antithrombin III or heparin cofactor II for its 
activity, and is not neutralised by platelet factor IV or other heparin-neutralising 
factors (Fareed et al 1991). 
Sarembock et al. (1991) evaluated the effect of hirudin on restenosis follo-
wing balloon angioplasty in 29 rabbits. Given a 2-hour infusion, the hirudin-allo-
cated animals showed significantly less restenosis 28 days after dilatation, asses-
sed by angiography (luminal diameter reduction) and by quantitative 
histopathology (luminal cross-sectional area narrowing by plaque at necropsy). 
Buchwald et al. (1993) were able to influence platelet and fibrinogen depo-
sition after stentimplantation in minipigs; this was significant in a subgroup 
where medial tear was present at histologic examination. Hirudin (1 mg/kg bolus 
then 1 mg/kg/h intravenously) in combination of aspirin 250 mg, was compared 
with a combination of heparin (100 Ulkg bolus then 50 Ulkg/h), aspirin 250 mg, 
and dextran 500 ml. Examination 12 hours after stenting showed a siginificantly 
lower average platelet count in the hirudin group than in the heparin group (64.3 
vs 19.7* 106platelets/stent; p<0.05). 
The effects of three dosages of recombinant hirudin versus a single dose of 
heparin and placebo on deep carotid injury caused by balloon dilatation in 50 
pigs was studied by Heras et al. (1990). Platelet deposition in 5 groups given 
placebo, heparin 50 U/kg, or hirudin 0.3, 0.7, or 1.0 mg/kg was 54 ±21, 33 ±9, 22 
± 6,8 ± 1 and 7 ±1, respectively. The significance of these observations was con-
firmed by electron microscopy. In the high dose hirudin-treated groups, platelet 
deposition was reduced to only one single layer. 
A pilot study in 79 hirudin-treated patients and 39 controls given 
heparin revealed similar safety and tolerability for both drugs (van den Bos et al. 
1992). Trials designed to test the efficacy of hirudin on early and late complica-
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tions of PTCA have just started recruiting patients in Europe and the United 
States. 
Hirudin binding to thrombin is achieved by two specific binding sites. 
Hirugen mimics the peptide domain of hirudin, and binds to the fibrinogen bin-
ding and cleavage site of thrombin. PPACK (d-phenyl-analyl-I-prolyl-I-arginyl-
chloromethyl ketone) binds the active site of thrombin. 
With the use of a new infusion balloon catheter, the effect of local delivery of 
PPACK on platelet deposition was tested at the site of balloon angioplasty in an 
ex vivo whole artery perfusion model (Leung et al. 1990). Platelet deposition was 
significantly reduced with the use of this new antithrombin agent compared with 
the control model. 
Hirulog is the name for a novel class of thrombin inhibitors that inhibits both 
the thrombin catalytic site and the fibrinogen binding exosite of thrombin 
(Maraganore et al. 1990). Hirulog has been administrated safely to healthy 
human volunteers (Dawson et al. 1991), and in patients undergoing PTCA 
(Bonan et a1.1992a; Topol et a1.1991). The Cleveland group recently reported 
the results of hirulog administration in atherosclerotic rabbits after angioplasty. 
The drug was implanted around dilated femoral segments in the adventitial layer, 
but did not influence neointimal proliferation (Guzman et al. 1993). 
Another leech-derived drug is antistasin (r-ATS), a long-acting factor Xa-
inhibitor, initially isolated from the salivary glands of the Mexican leech (Nutt et 
al. 1988), has been studied together with tick anticoagulant peptide (TAP), a 
short-acting specific inhibitor of factor Xa. These experimental drugs were tes-
ted in rabbits during balloon angioplasty, followed by 2-hours infusion (Ragosta 
et al. 1992). The reduction in luminal diameter, measured at 28 day follow-up 
angiography, was significantly less in the antistasin (-0.17 ± 0.11 mm) and TAP 
(- 0.26 ±0.22 mm) groups compared with the control group given heparin (-0.66 
±0.58 mm, p ~ 0.02). 
3.1.5 Synthetic Peptide Inhibitor of Thrombin In 1988, two abstracts repor-
ted the efficacy of synthetic peptide inhibitor of thrombin. Schneider et al. 
(1988) showed that treatment with synthetic peptide inhibitor of thrombin 
morphologically abolished acute thrombus formation and significantly reduced 
deposition of 111 In-labelled platelets on carotid endarterectomy sites in 
baboons. 
Another study showed that argatroban (argipidine) prevented occlusion in 
rabbits, while all control animals showed occlusion that was not prevented by 
heparin alone or in combination with alteplase (tissue plasminogen activator) 
after exposure to collagen in a femoral arterial thrombosis model Gang et al. 
1988). The same group recently described the effect of the synthetic and compe-
titive thrombin inhibitor argatroban on trombus formation in the rabbit femoral 
artery model. When compared with heparin treatment, a I-hour infusion of 
argatroban reduced residual thrombus severity significantly Gang et al. 1992). In 
this respect it could have properties that diminish the long term restenosis. 
The interest in the antithrombotic approach can be illustrated by the num-
ber and size oftrials that are planned for the near future. 
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3.2 Antiplatelet Agents 
Platelets play an important role in the development of restenosis after PTCA 
(Faxon et al. 1984), since postinjury myointimal hyperplasia in at least some ani-
mal models does not occur in the presence of profound thrombocytopenia. To 
prevent platelet deposition (which occurs within minutes of the procedure) and 
the associated release of smooth muscle cell mitogenic factors, anti-platelet the-
rapy appears to be a logical approach. 
3.2.1 Aspirin Dose finding studies Aspirin is a popular drug in restenosis preven-
tion trials. In animal models it reduces platelet-thrombus deposition in a dosage 
of 1 mg/kg/day when given in addition to heparin (Perin et al. 1990). Aspirin has 
the ability to inhibit platelet TXA2 synthetase and subsequent platelet activation, 
by irreversibly blocking the enzyme cyclo-oxygenase which is responsible for the 
conversion of arachidonic acid to intermediate prostaglandin G 2 (PGG2). This 
latter compound normally leads to the formation of TXA2 and thromboxane B2. 
Thromboxane A2 is a powerful platelet aggregator and vasoconstrictor. Low 
doses of aspirin result in decreased production of this substance in platelets. 
However, high dose aspirin results in cyclo-oxygenase inhibition in endothelial 
cells as well, which is usually responsible for the conversion of arachidonic acid to 
prostaglandin 12 (Oates et al. 1988). Since the biologic actions of TXA2 and 
PGI2 are opposing, aspirin at high doses may be less effective in preventing reste-
nosis. In addition, it only partially inhibits platelet aggregation induced by ADP, 
collagen or thrombin. Consequently, the effect of PDGF and other mitogens 
released from platelets may still affect proliferation of smooth muscle cells (Stein 
et al. 1989). Several studies have been carried out to evaluate the advantages of 
different doses of aspirin (Figure 3). 
Intravenous given ASA in a high dosage (1000 mg), in addition to a bolus of 
10.000 U of heparin suppressed thrombin generation beyond the reduction indu-
ced by 10.000U of heparin solely (plasma fragment F1.2 monitoring in 24 
patients), and could therefore reduce the mitogenic respons in PTCA patients 
(Andreotti et al. 1992). 
Dyckmans and colleagues (1988), randomly assigned 203 patients to either 
aspirin 1500 mg/day or 320 mg/day. In a preliminary report, 40% of these 
patients had been restudied 6 months after PTCA. Results of follow-up angio-
graphy showed restenosis (>50% diameter stenosis) in 13 of 44 patients in the 
group taking the lower dose (31 %) compared with 9 of 42 patients in the group 
with the higher dose (21 %). 
In another randomised trial, the effectiveness of aspirin 80 or 1500 mg/day, 
starting on the day before PTCA, in the prevention of restenosis and acute com-
plications after PTCA was compared in 495 patients (Mufson et al. 1988). 
Results of follow-up angiography were available in only 166 patients. In the 
group treated with the lower dosage of aspirin, 47% had restenosis (>50% diame-
ter stenosis in 1 or more sites) compared with 51 % in the group receiving the hig-
her dosage. There were no differences in success or acute complication rates 
between the groups. Thus, restenosis was not influenced favourably by the use of 
a higher dose of aspirin. 
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A smaller trial compared the effects of aspirin 100 with 1000 mg/day, star-
ting 1 day before PTCA for 6 months (Schanzenbacher et al. 1988). In addition, 
all patients received calcium antagonists and long-acting nitrates. Restenosis (cli-
nically significant stenosis) requiring repeat-PTCA or coronary artery bypass 
graft (CABG) occurred in 7 of the 40 patients in the group taking aspirin 100 mg 
daily (18%) and in 8 of the 39 patients treated with 1000 mg aspirin (21 %). The 
investigators concluded that restenosis is not favourably influenced by the use of 
high versus low dose aspirin. 
Kadel et al. (1990) also were unable to detect significant differences regar-
ding the rate of restenosis in their patients, randomised to 350 or 1400 mg of 
aspirin daily,although the results tended to favour the lower dosage (21 versus 
31 % restenosis). 
Data from studies of similar design can be combined to obtain a more 
powerful analysis of the effects of treatment. Meta-analysis of the pooled reste-
nosis data of the investigations of Dyckmans et al. (1988), Mufson et al. (1988), 
Schanzenbacher et al. (1988) and Kadel et al. (1990), using the Cochran-
Mantel-Haenszel method, gives an overall relative risk for restenosis of 1.2 when 
a daily aspirin dosage of> 1000 mg is used, compared with a dosage of < 350 mg. 
The 95% confidence interval (CI) is insignificant. 
Comparisons with Placebo In several studies, the effect induced by aspirin, with or 
without dipyridamole 225 mg, was compared with placebo (Figure 3). 
Finci et al. (1988) designed a single-blind trial to compare aspirin 100 mg 
daily with placebo. However, it was prematurely discontinued after 40 patients 
were enrolled because of reports showing the benefit of aspirin (combined with 
dipyridamole) in preventing acute thrombosis in dilated vessels and the need for 
urgent bypass surgery (Barnathan et al. 1987). In this particlar study, results of 
follow-up angiography at 6 months (95% of the patients) surprisingly showed an 
incidence of restenosis (>50% diameter stenosis) that was two times higher in 
aspirin recipients compared with the group given placebo (33% versus 14%). 
Although this difference seems impressive, it was not statistically significant 
because of the small numbers. 
Taylor and associates (1991) compared aspirin 100mg and placebo in 216 
patients for 2 weeks, starting before PTCA. Follow-up angiography 6 months 
later showed restenosis in 45 of the 104 placebo-allocated and in 38 of the 108 
aspirin treated patients (35% vs 43%, nonsignificant). Thus, no convincing 
results could be shown for the beneficial effect of aspirin. 
In a well designed trial at the Montreal Heart Institute and Toronto General 
Hospital (Schwartz et al. 1988), 376 patients were randomly assigned to a daily 
combination of aspirin 990 mg and dipyridamole 225 mg, or to placebo, begin-
ning the day before PTCA until follow-up angiography 4 to 7 months later. More 
acute complications were observed in the placebo group, including 13 peripro-
cedural myocardial infarctions versus 3 in the actively treated group (p < 0.05). 
However, no differences were observed in the restenosis rate (increase in diame-
ter stenosis from <50% after-PTCA to >50% at follow-up): 39% (127 patients) 
in the placebo recipients versus 38% (122 patients) in the active treatment group. 
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All patients received heparin until 12 hours after the procedure (500 U/hour) and 
diltiazem until follow-up angiography. 
Chesebro et al. (1989) randomly assigned 207 patients (297 stenoses) to 
either aspirin 975 mg/day and dipyridamole 225 mg/day or to placebo from the 
day before PTCA until 6 months later. There was no difference in restenosis rate, 
defined in a linear model based on the minimum lumen diameter obtained by 
quantitative angiography. There were fewer acute complications (occlusion, 
myocardial infarction, repeat PTCA, CABG wihin 48 hour) in the aspirin and 
dipyridamole recipients (11 versus 20%) confirming the results of the Canadian 
trial. 
White et al. reported in 1987 a restenosis study in which they compared a 
two drug regimen versus placebo. Active therapy consisted of either 750 mg 
ticlopidine, or 650 mg aspirin plus 225 mg dipyridamol, starting 4 to 5 days prior 
to PTCA. Repeat angiography in 75% of the study population showed a small but 
insignificant beneficial effect of aspirin/dipyridamol at visual assessment, alt-
hough quantitative analysis in a small subset of patients (32%) demonstrated an 
opposite risk ratio. 
Meta-analysis according to the Cochran-Mantel-Haenszel method of the 
pooled restenosis data from the four studies of Taylor et al. (1991), Finci et al. 
(1988), Schwartz et al 1988 and White et al. (1987) gives an overall relative risk 
of restenosis with aspirin treatment versus placebo of 0.932 (95% CI includes 1). 
It has to be mentioned that the dosage of aspirin used was quite divergent, making 
meta analysis less justifiable. These trials clearly showed that, although aspirin 
does not influence the incidence of restenosis, it definitely has a positive influen-
ce on acute complications during or immediately after angioplasty. 
Recent work in atherosclerotic rabbits, however, showed different results. 
Aspirin 60 mg/day and coumadin (1.5 normal prothrombin time) were given as 
combination therapy starting 7 days before iliac trans luminal angioplasty until 
final angiography 4 weeks later. Luminal diameter decreased from 1.7mm post 
angioplasty to 0.6 mm at follow-up in the control group, while in the treated rab-
bits the stenosis diameter only changed from 1.4 mm post intervention to 1.3 mm 
after 4 weeks. Restenosis (loss of >50% of initial post-transluminal angioplasty 
gain) was observed in 2 of 10 rabbits given aspirin plus coumadin versus all 12 
control rabbits. This suggests strongly that early combination therapy reduced 
restenosis in this animal model, and that platelet activation is a key element in the 
restenosis process (Franklin et al. 1990). 
Five days' pretreatment with aspirin 75 to 300 mg/day or an intravenous 
bolus of 1000mg during PTCA, in addition to a bolus of heparin 10,OOOU sup-
pressed thrombin generation beyond the reduction induced by heparin alone in 
24 patients (Andreotti et al. 1992). The results favoured those receiving aspirin 
1000 mg. 
3.2.2 Dipyridamole In a rabbit model, aspirin and dipyridamole decreased pla-
telet-thrombus deposition and restenosis after transluminal angioplasty (Faxon 
et al. 1984a). The mechanism(s) by which dipyridamole has been suggested to 
inhibit platelet function include: 1) inhibition of the phosphodiesterase enzyme 
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in platelets, resulting in an increase in intraplatelet cyclic AMP and the conse-
quent potentiation of the platelet-inhibiting actions of prostacyclin; 2) direct sti-
mulation of the release of this eicosanoid by vascular endothelium; and 3) inhibi-
tion of cellular uptake and metabolism of adenosine, thereby increasing its levels 
at the platelet-vascular interface. Finally, in addition to such direct effects, dipy-
ridamole may augment the platelet-inhibiting action of aspirin through pharma-
cokinetic interaction (Fitzgerald 1987). However, in clinical trials (Schwartz et 
al. 1988, Chesebro et al. 1989, White et al. 1987) no effect has been shown on 
restenosis rate after angioplasty (Figure 3). 
3.2.3 Thromboxane A2 Since aspirin blocks cyclo oxygenase in both platelets 
and endothelial cells, it inhibits the formation of TXA2, as well as prostacyclin. 
TXA2 is a potent aggregating agent and vasoconstrictor, and it was deemed use-
ful to antagonize these actions during and after PTCA, while at the same time 
leaving prostacyclin production of the vascular endothelium unaffected. 
Therefore, a specific approach has been attempted, such as the use of TXA2 
synthetase inhibition or TXA2 receptor blockade (Figure 3). 
Thromboxane A2-synthetase inhibitor In rabbits, it was shown that a selective 
TX synthetase inhibitor was more effective than heparin or aspirin in inhibiting 
platelet deposition after balloon angioplasty (Sanborn et al. 1986). Another 
TXA2 synthetase inhibitor nafragel (DP 1904), was tested in a small number of 
patients to prevent restenosis after PTCA (Yabe et al. 1989). It was given a mini-
mum of 5 days before PTCA and was continued until follow-up angiography> 3 
months later. Restenosis was defined as > 50% loss of initial gain in luminal dia-
meter. The results showed that 4 of 18 patients (22%) given with nafragel had 
restenosis versus 8 of 15 patients (53%) in the placebo group. 
Thl'omboxane A r l'eceptot' blocker Vapiprost (GR32191), a new TXA2 receptor 
blocker, has been shown to inhibit completely prostaglandin endoperoxide and 
TXA2 induced platelet aggregation, serotonin secretion and beta-thromboglo-
bulin secretion without any effect on the actions of prostacyclin (Hornby et al. 
1989). Because of the inhibitory action of vapiprost on platelet aggregation, 
mural thrombus formation and platelet protein storage granule secretion, a trial 
was conducted to assess its effect on the prevention of restenosis after coronary 
angioplasty (Serruys et al. 1991b). This trial (CARPORT; Coronary Artery 
Restenosis Prevention On Repeated Thromboxane-Antagonism) randomly 
assigned 697 patients in 6 clinics throughout Europe to a TXAz-receptor bloc-
ker, 80 mg intravenous before PTCA and 40 mg orally for 6 months, or 250 mg 
intravenous aspirin before PTCA and placebo for 6 months. No difference was 
observed between the mean difference in diameter of treated lesions between 
post-PTCA and follow-up angiogram: -0.31 ± 0.53 in the control group and 
-0.30 ± 0.54 in those receiving the TXA2 receptor antagonist. Using a loss of 
0.72 mm or more as restenosis criterion (Reiber et al. 1985) restenosis rates were 
19% in the control group and 21 % in the vapiprost group. There were also no dif-
ference in clinical events (death, CABG, repeat-PTCA, non-fatal myocardial 
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infarction) between the 2 groups. Thus, no benefit was shown of long term 
TXA2 receptor blockade with vapiprost used as single pharmacological agent 
against restenosis. 
In the US, vapiprost was tested in a similar multi-center restenosis trial 
(Feldman et al. 1992). 1192 patients were randomised to aspirin 325 mg/day 
before PTCA and placebo afterwards, or to vapiprost 80 mg/day followed by 40, 
or 80 mg daily for 6 months. Angiographic restenosis, defined as a change in 
minimal luminal diameter of more than twice the standard deviation, resulting in 
a cut-off point of 0.62 mm, was not affected by the drug (restenosis rate 39% with 
vapiprost versus 35% with aspirin plus placebo). The clinical event rate in both 
groups however was reduced by 21 %, primarily because of a reduction in MI and 
repeat PTCA (p = 0.02). 
Finci et al. (1989) tested the sulphonamide derivate sulotroban (BM13177) 
which blocks TXA2-receptors, versus placebo in 107 patients. Fiftyseven 
patients completed the study protocol, including 6 months' angiography. The 
difference in restenosis rate was insignificant, namely 57% in the treated and 56% 
in the control group. 
Sulotroban was also investigated by Bove et al. (1992).755 patients were 
randomized to sulotroban 3200 mg/day, aspirin 325 mg/day, or placebo for 6 
months. Stenosis diameter changes after PTCA were not influenced by selective 
TXA2 antagonism (minimal luminal diameter at 6 months in placebo group 
1.43mm, in the sulotroban group 1.43mm, and in the aspirin groupl.54mm). 
3.2.4 Ridogrel Ridogrel (R68060) is a combined TXB 2 synthetase inhibitor and 
thromboxane-prostaglandin endoperoxide receptor blocker that eliminates 
almost all TXB 2 with a concomitant increase in 6-keto-PGFla in serum. 
It was tested recently in 32 patients in combination with heparin in a PTCA 
setting and appeared to be safe. Further studies seem to be warranted to assess 
the effectiveness in preventing early and late restenosis (Timmermans et al. 
1991) . 
3.2.5 Sulfinpyrazone In contrast to aspmn, sulfinpyrazone is a competitive 
(reversible) inhibitor of platelet cyclo-oxygenase, but the exact mechanism of its 
antithrombotic activity is not clearly understood. Faxon et al. (1984a) showed 
a reduction in restenosis in rabbits. There is no clinical evidence to date to sup-
port a role for sulfinpyrazone in the prevention of restenosis after coronary 
angioplasty. 
3.2.6 Dextran Dextran interferes with platelet activity by changing membrane 
function or by interacting with von Wille brand factor-factor VIII complex. 
Although it has been shown to be efficacious during PTCA there is no role es-
tablished for dextran in restenosis prevention (Harker & Fuster 1986, Swan-
sonetaI.1984). 
3.2.7 Prostacyc1in or Prostacyc1in Analogues Vessel wall injury and platelet 
adhesion to endothelium might interfere with local production of prostacyclin, 
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and promote further platelet aggregation and thrombus formation. Prostacyclin 
is a potent naturally occurring vasodilator that protects platelets from being acti-
vated (Moncada & Vane 1976). Regular aspirin therapy eliminates, in the greater 
part, both TXA2 and TXB2 production, but also affectsendothelial production 
of prostacyclin. This reduces the usefulness of aspirin treatment, although it has 
advantageous effects. Therefore, administration of prostacyclin as additional 
therapy might play an important role in restenosis prevention (Figure 3) and has 
been tested in a prospective trial. Two hundred and seventy patients were ran-
domly assigned to placebo (n=136) or prostacyclin 5 to 7 mg/min intravenously) 
(n=134) just before PTCA and up to 48 hours after PTCA (Kundtson et al. 
1990). All patients received aspirin 325mg and dipyridamole 225mg beginning 
before angioplasty until follow-up angiography 6 months later. Short-term admi-
nistration of prostacyclin did not significantly reduce the risk of restenosis com-
pared with placebo (27 versus 32% rate). Restenosis was defined as >50% narro-
wing at follow-up angiography or > 50% loss of immediate gain after angioplasty. 
Acute vessel closure and ventricular tachyarrhythmias were more common in the 
control group than in patients who received prostacyclin. 
Another study randomised 132 patients to either prostacyclin (4ng/kg/min) 
or placebo infusion for 36 hours after PTCA. Patients were followed for 6 
months and were then restudied. No benefit was seen in prevention of restenosis 
(defined as a loss of 50% of the gain achieved at PTCA) (Gershlick et al. 1990). 
Ciprostene is a chemically stable analogue of prostacyclin. To study the 
effect of ciprostene during PTCA, 311 patients were randomly assigned to 
ciprostene shortly before PTCA (40ng/kg/min) until 48 hours after PTCA (120 
ng/kg/min), or to placebo (Raizner et al. 1988). Acute closure occurred in 3 
patients in the placebo group and none in the ciprostene-treated group. The cli-
nical endpoints of this trial included death, myocardial infarction, repeat-PTCA 
and CABG. In 23 of the 139 patients treated with ciprostene (17%), one or other 
of these clinical endpoints was observed, compared with 47 of the 137 placebo 
recipients (34%; p=0.0008). Angiograms of 86% of the patients who completed 
the protocol were retrospectively analysed (Raizner et al. 1993). Change in mini-
mal lumen diameter was 0.32mm in the ciprostene group and 0.57mm in the con-
trol group (p=0.025), confirming the earlier experience. 
The same protocol was recently followed by Darius et al. (1991), who ran-
domised 32 patients to ciprostene or placebo. Twenty minutes of intra coronary 
infusion were followed by a 24 hour intravenous infusion, combined with a 24 
hour heparin infusion, aspirin 100 mg and nifedipine 60 mg daily. In 24 patients, 
a 6 month follow-up angiogram was obtained. Coronary artery stenosis was redu-
ced by PTCA from 83 to 31 % in the ciprostene group, and from 81 ± 3 to 34 ± 3% 
in the placebo group. At 6 months follow-up angiography, the percent stenosis in 
the ciprostene-treated group was still significantly lower when compared with 
pre-PTCA status (55 versus 83% ; p=0.012),in contrast to those given placebo 
63 versus 81 %). Platelet aggregation studies revealed significant inhibition of 
PAF-induced aggregation after intra-coronary and after 4 hours of i.v. infusion. 
More clinical testing is necessary for the correct interpretation of these results. 
Meta-analysis of the trials performed by Raizner et al. (1988), Knudtson et 
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al. (1990) and Gershlicket al. (1990) [Darius did not define a cut-off point for 
restenosis], gives an overall relative risk of 0.82, with the upper limit of the 95% 
CI of 1.008. 
3.2.8 Prostaglandin El Prostaglandin El (PGE l ) differs from prostacyclin 
(PGI2) in the number of double bonds in the acyl side chain, and by the type of 
substituent group that is attached to the ring. 
Since the deposition of platelets after angioplasty in porcine carotid arteries 
was reduced significantly more after infusion with PGE I even more than with 
prostacyclin or dipyridamole, a study was attempted to determine the effect of 
intra-coronary administration followed by intravenous PGE 1 on early restenosi's 
(See et al. 1987). Eighty patients were randomly assigned to placebo or infusion 
of 20 to 40 ng/kg/min, 12 hours before PTCA. Clinical follow-up showed abrupt 
occlusion in 3 of 40 patients in the placebo group compared with none in the 
PGE I-treated group. An additional repeat PTCA was necessary in 4 of 40 place-
bo recipients but in none of thase given PGE l' No angiographic study has asses-
sed the effect of PGE 1 on late restenosis. 
3.2.9 Tic10pidine Ticlopidine is chemically unrelated to other antithrombotic 
agents. Its mechanism of action is not exactly known, but there is evidence that 
this potent platelet inhibitor alters platelet membrane activity, probably by block-
ing the interaction between platelet receptors with fibrinogen and von Wille brand 
factor (vWF) (Lee et al. 1981). The optimal effect occurs 3 days after the first 
administration and lasts for at least several days, and its effect on restenosis is 
documented in three abstracts (Figure 3). 
In a multi-center trial in the United States (White et al. 1987), patients were 
randomly assigned to ticlopidine 750 mg/day, a combination of aspirin 650 
mg/day and dipyridamole 225 mg/day, or to placebo. Restenosis was defined as a 
diameter obstruction of ~70% at follow-up angiography 6 months later, by visual 
assessment. There was no difference in restenosis rate; in the 65 patients who 
received ticlopidine the restenosis rate between the 2 actively treated groups; in 
the 65 patients who received ticlopidine the restenosis rate was 29%, compared 
with 18% of 57 patients who received aspirin plus dipyridamole. The restenosis 
rate was 20% among the 54 patients taking placebo. There was no difference in 
acute complication rate. QCA in a small subset of patients (32%) yielded similar 
results. 
In Japan, data collected retrospectively showed a lower restenosis rate when 
patients received a combination of ticlopidine 200mg/day, nicorandil 30mg/day 
and aspirin 300mg/day (Kitazume et al. 1988). 
In the Ticlopidine Angioplasty Coronary Trial (TACT), there was no bene-
fit of therapy with ticlopidine 500 mg/day versus placebo in 266 patients rando-
mised for prevention of restenosis (loss of 50% of the gain achieved at PTCA) 
(Bertrand et al. 1990). However, acute closure was significantly reduced in the 
ticlopidine group compared with placebo. These patients did not receive conco-
mitant heparin or aspirin. The French experience is confirmed by the results of a 
Spanish trial (Iniguez et al. 1991), which assigned a total of 179 patients to 
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ticlopidine 250 mg or placebo after a single lesion angioplasty. There was no dif-
ference in the restenosis rates between the two groups (28% with ticlopidine ver-
sus 24% with placebo). Possibly the time interval from first administration to 
angioplasty was too short for ticlopidine to become effective. Overall there seems 
no role for ticlopidine in restenosis prevention. 
3.2.10 Serotonin Antagonists In the 1950s, the isolation was reported of a sub-
stance, extracted out of serum, that is responsible for a tonic reaction of vascular 
smooth muscle cells (Page 1958). Due to its properties it was called serotonin (5-
hydroxytryptamine; 5-HT). Interaction with intact endothelial cells causes them 
to produce endothelial-derived relaxation factor (EDRF) which leads to the 
relaxation of the surrounding muscular layer. In the setting of damaged endothe-
lium, however, serotonin gains direct access to the smooth muscle cells, causing 
them to contract. Serotonin seems to be an important mediator in cyclic flow 
reduction in stenotic and injured arteries. It is released from the dense granules in 
aggregating platelets. It is a weak agonist of platelet activation, but it enhances the 
activity of other platelet agonists like ADP, TxA2, catecholamines and thrombin 
via a positive feedback loop. In vitro experiments show the stimulation of mitoge-
nesis, migration and retraction of vascular smooth muscle cells following seroto-
nin exposure (Rooman et al. 1990). In low concentrations it substantially enhan-
ces the mitogenic response ofthese cells to PDGF (Nemecek et al. 1986), as well 
as the proliferation of cultured fibroblasts and matrix synthesis (De Clerck & 
Janssen 1990). 
Ketanserin is a potent 5-HT z-receptor antagonist, with weak alpha 1-recep-
tor blocking properties. It inhibits serotonin-induced platelet activation and vaso-
constriction, and has also been shown to inhibit DNA synthesis in vascular 
smooth muscle cells in vitro following serotonin stimulation. Klein et al. (1989) 
studied the effect of ketanserin on the incidence of early and late restenosis (Figure 
3). Ketanserin 0.1 mg/min or placebo was given intravenously for 24 hours after 
PTCA to 21 patients. After 24 hours, 3 patients in the placebo group had an 
occlusion compared with none in the ketanserin group. Follow-up angiography 4 
to 6 months later showed no difference in restenosis rates (29% versus 33%). 
The large multi-centre interventional trial, PARK (Post- Angioplasty 
Restenosis Ketanserin), has recruited and randomised more than 700 patients to 
Ketanserin 40 mg twice daily or placebo, both in combination with aspirin. 
Analysis of post-angioplasty angiograms revealed a loss in MLD of 0.27 mm in 
the ketanserin group versus 0.24 mm in the placebo group (Serruys et al. 1992). 
When restenosis is defined as a loss in MLD of;::: 0.72 mm, the restenosis rate was 
15 versus 14%. Thus, no significant effect of ketanserin on angiographic parame-
ters could be demonstrated (Figure 3). 
The same conclusions were drawn from another double-blind randomised 
trial in 97 patients (Heik et al. 1992). Ketanserin administration started 1 day 
before angioplasty (10 mg iv), increased to 40 mg bid for 2 weeks, and continued 
at a dosage of 20 mg bid until follow-up. All patients received aspirin 100 mg per 
day. Changes in arterial dimensions, measured by QCA, were not significantly 
different between the groups. 
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Table III 
The effect of drug therapy on restenosis per patients after successful coronary angioplasty 
with follow-up angiography and or clinical follow-up. 
Author Drug Dose Patients total F-up 
ERAlFaxon 1992 Enoxaparin placebo 40 mg q.d. s.c. 459 86% 
Thornton ct a!. 1984 ASA Coumadin 325 mg/day 2-2.5 norm l'Tr 248 72% 
Urban et al. 1988 Coumadin+Vcrapamil > 2.5 nor l'Tr 110 77% 
Vcrapamil Not Reported 
Hirshfeld et al. 1987 Heparin Different 209 NR 
duration 
Ellis et al. 1989 Heparin (18-24h) < 2.5 norm l"IT 416 61%, 
Dextrose 
Lehmann ct al. 1991 Heparin (daily) 10,000 I. U .lday 30 77% 
Walford et al. 1991 Heparin 1.000 I.U.lhour 211 88%, 
Placebo 
Dc Vries ct aJ. 1991 LMWH 5.000 I.U.lday 49 94% 
Schmidt et al. 1990 LMWH Fragmin 80 U/kg 22 100% 
ASA 100-300 g ASNday 
Dyckmans ct a!. 1988 ASA 1500 mg/day 203 40% 
ASA 320 mg/day 
Mufson ct al. 1988 ASA 1500 mg/day 453 37% 
ASA 80mg/day 
Schanzcnhachcr 1988 ASA 1000 mg/day 79 100% 
ct al. ASA 100 mg/day 
Kadel et al. 1990 ASA 1400 mg/day 188 92% 
ASA 350 mg/day 
Find eta!. 1988 ASA 100 mg/day 40 73% 
Placebo 
Tayloret al. 1991 ASA 100 mg/day 216 98')(, 
Placebo 
303 lesions 
Schwartz ct al. 1988 ASA + Dipyridamol 990-225mg/day 249 100% 
Placebo 
Chesebro ct al. 1989 ASA + Dipyridamol 975-225 mg/day 207 85% 
Plal.:cho (QCA) 
White etal. 1987 ASA+Dipyridamol 650-225mg/day 236 75% 
'j'idopidinc 750 mg/day 
Placebo 
ASA+Dipyridamo! 76 32% 
'ridopidinc 
Placebo 
Yabe et al. 1989 TXA2 synth inhibitor 600 mg/day 33 100% 
Placebo 
Scrruys ct a!. 1991 "'xA2 receptor blocker 40 mg/day 650 89,)(. 
Placebo 
Feldman et al. 1992 GR32191 20mg 1089 86% 
GR32191 40mg 
Placebo 
Find ctaJ. 1989 Sulotroban 4x800mg 107 53% 
Placebo 
Time Definition restcnosis Restenosis (%) drug \'s placebo Sign Risk ratio 95%CI 
6 months loss> 50% gain 52%, 51% p::::ns 1.0 0,76 to 1.07 
6-9 mths loss> 50'X, gain stress test - : + 27%, 36% p=ns 0,7 0.5 to 1.1 
5 months > 50%DSFup 29'}\\ 37% p=ns 0,8 0.4 to 1.4 
4-12 mths > 50% DS Fup I .onger heparin less 
(visual) restenosis 
3-9mths > 50% DS Fup 41% 37% p=ns 1.1 0,8 to 1.5 
(visual) 
NR NR 82% 33% p<0,05 2,5 0,8 to 7,8 
19 months Clinical 22% 24% p=ns 0,9 0,6 to 1.6 
4-6mths > 50% reduction in lumen diameter 39"(" NR 
3 months reduction of 27% 54% p=ns 0,5 0,2 to 1.5 
residual stenosis area> 30%, 
reduction of stenosis diameter> 50% 
6 months > 50% DS Fup 21% 31% p=ns 0,7 0.4 to 1.5 
3-8mths > 50%DS Fup 51% 47% p=ns 1.1 0,8 to 1.5 
(visual) 
6 months Clinical 21% 17% p=ns 1.2 0,5 to 2,9 
(re-I'TCA, CABG) 
4-6mths NR 31% 21% p=ns 1.5 0,9 to 2,5 
6 months > 50% DS Fup 33% 14% p=ns 2,3 0,5 to 10,1 
(visual) 
6 months > 50%, reduction 35% 43% p=ns 0,8 0,6 to 1.1 
in lumen diameter and> 50%, 
reduction of the gain 
25% 38% p=0,03 0,7 0.5 to 0,95 
4-7 mths > 50%DSFup 38% 39% p=ns 1.0 0,7 to 1.3 
(QCA) 
5 months MLD (l'ost-I'TCA) 0,14mm 0,18mml' p=ns 
- (Fup) 
6 months > 70%DS Fup 18% 29% p=ns 0,9 0.4 to 1.9 
(visual) 20% p=ns 1.4 0,8 to 2,8 
> 70% J)S ['tiP 33% P=l1S },3 0.5 /0 3.7 
(QCA) 39% p=ns 1.6 0,7 to 3,3 
25% 
>3 mths loss> 50%, gain 22% 53% p=ns 0.4 0,2 to 1.1 
6 months MLD (post-I'TCA) 0.31 ±0,53 TxA2 p=m; 
-MLD (Fup) 0,30 ±0,54 I' 
6 months ,,0,62 mm 39% 35% p=ns 1.2 0,9 to 1.6 
change in MLD 
6 months loss of;::: 50%1 65% 61% p=ns 1.1 0,7 to 1.6 
of the initial gain 
Table III continued 
Author Drug Dose Patients total F-up 
~'\-Hcart ct aL 1992 Sulotroban 3200 mg/day 755 82% 
ASA 325 mg/day 
Placebo 
Timmcrmans ct al. 1991 Ridogrcl 300 mg iv bolus 32 100% 
300 mg p,o, b,d, 
plus Heparin 10,000 l.V, bolus 
LOOO l.V,/hour/24 hours 
Knudtson ct 31. 1990 Prostacyclin+ ASA + D 5 ng/kg/min 270 93% 
ASA + Dipyridamol (D) 325 + 225 mg/day 
Gershlkk et aL 1990 l'rostacydin 4 hg/kg/min 132 80% 
Placebo 
Raizncr ct al. 1988 Ciprostcnc 120 ng/kg/min 311 80% 
Placebo max. 48 hours 
Darius ct al. 1991 Ciprostcnc 120 mg/kg/min, 32 67% 
Placebo for 48 hours 
Kitazumc ct al. 1988 ASA (Placebo) 300 mg/day 280 100% 
ASA+'I'iclopidineCrie) + 200 mg/day 
ASA +'I'ic+ Nkorandil + 30 mg/day 
Bertrand ct 31. 1990 '!'iclopidinc 500 mg/day 266 93% 
Placebo 
Klein 1989 Kctanscrin 0,1 mg/min (24 hr) 43 100% 
PARK 1992 Kctanscrin + ASA 80 mg/250-500 mg 704 84 % 
ASA 250-500 mg 
Brozovich ct al. 1991 ACE-inhibitor different dosages 322 rctrosp. 
non ACE-inhibitor 
Scrruys c( a!. 1992 Cilazapril 40 mg/day 700 89% 
Placebo 
O'Keefe et aL 1992 Colchicine L2 mg/day 197 74% 
Placebo 
Grincs ct al. 1991 Cokhicinc 1 mg/day 253 79% 
Placebo for 1 month 
Okamoto ct al. 1992 Trapidil 600 mg/day 97 74% 
ASA + D 300 + 150 mg/day 
A1arcsta ct al. 1992 Trapidil 300 mg/day 251 46% 
ASA 300 mg/day 
Hose ct al. 1987 Steroid 48 mg/ day 66 88% 
Placebo 
Stone ct aJ. 1989 Mcth. prednisolone 125mg mp/day 102 53% 
prednisolone 240mg p/week 
Pepine ct al. 1990 Steroid LOgmp 722 71% 
Placebo 
Hirayama et al. 1992 Ebsclcn 200 mg p,o bid 79 100% 
Placebo 
Corcos ct aJ. 1985 Diltiazcm+ASA+D 270 mg/day 92 100% 
ASA+D 650-225 mg/day 
O'Kecfc era!. 1991 Diltiazem + ASA + D 240-360 mg/day 201 60% 
ASA+D 325-225 mg/day 
\V'hitworth ct al. 1986 Nifcdipine+ASA 40 mg/day 241 82% 
ASA 
Time 
6 months 
6 months 
6mth 
5-7mth 
6 months 
6 months 
6 months 
6 months 
4-6 mths 
6 months 
6 months 
6 months 
NR 
6 months 
6 months 
NR 
3 months 
6 months 
4-8 mths 
3 monrhs 
5-lOmths 
12mths 
6 months 
Definition rcstenosis 
MLD (post-PTCA) 
-MLD (Fup) 
Clinical 
>50%DS Fup 
loss> 50% gain 
loss> 50%, gain 
> 50%DS Fup 
(visual) 
Clinical 
(MI,rc-P'I'CA,CAllG,Dcath) 
change in %, -D.S. 
(pre Fup) 
> 50%DSFup 
loss> 50'1., gain 
NR CQCA) 
MI.D (F-up-prc) 
MI.D ;0:0.72 mm 
Clinicall>50% Fup 
MI.D (post-PTCA) 
-MLD (Fup) 
return :;?'70'Y" DS 
and loss of:;? 50 ly., gain 
Clinical and 
thallium exercise test 
loss> 50% gain 
loss of gain 
> 50%DS Fup 
> 50% DS Fup 
> 50%DS Fup 
(caliper) 
loss:;? 50%, gain 
> 70% DS Fup 
(visual) 
:;? 70% AS + loss 
of:;? 50% gain 
loss> 50').{, of gain 
> 50%DS Fup 
Rcstcnosis('x,) drug \'s placebo 
Sulo: -0.45 mm 
ASA: -0.37 mm 
Plac: -0.48 mm 
10% 
27% 
31% 
41% 
17% 
-28%DS 
27% 
16% 
50% 
33% 
0.27 mm 
15% 
3% 
-0.27 ±0.51 mm 
-0.29 ±0.49 mm 
41% 
48% 
19% 
43% 
33% 
59% 
43% 
19% 
15% 
36% 
29% 
p=ns 
32%, 
34% 
53% 
34% 
-18%DS 
38% 
41% 
29% 
0.24 mm 
14% 
30% 
45% 
41% 
42% 
48% 
33% 
56% 
43% 
38% 
22% 
32% 
33% 
Sign Risk ratin 95%CI 
non-randomiscd 
p=ns 0.9 0.6 to 1.3 
p =ns 0.9 0.6to 1.5 
p=ns 0.8 0.6 to 1.0 
p<O.OI 0.5 0.3 to 0.8 
p<0.05 
p=ns 0.7 0.2 to 2.0 
p=0.002 0.4 0.3 to 0.7 
p =ns 1.3 1.0to 1.8 
p=ns 1.1 0.4 to 2.8 
p=ns 
p=ns 1.1 0.8 to 1.6 
p<0.05 10 0.01 to 0.99 
p=ns 1.0 0.7 to 1.4 
p=ns 0.9 0.6 to 1.4 
p=ns 1.1 0.6 to 1.9 
p<0.05 0.5 0.2 to 1.0 
p=ns 0.8 0.5 to 1.4 
p=ns 1.0 0.6 to 1.7 
p=ns 1.1 0.7 to 1.7 
p=ns 1.0 0.8 to 1.2 
p<0.05 0.5 0.25 to 0.97 
p=ns 0.7 0.3 to 1.7 
p=ns 1.1 0.7 to 1.9 
p=ns 0.9 0.5 to 1.4 
Table III continued 
Author 
Hoberg (.'1 al. 
Siad ot al. 
Rcis cta!. 
J\\ilncr ct aJ. 
Dchmcfct 31. 
Grigg ct al. 
':ranzen l't aJ. 
Cheng l't 31. 
Bairati l't al. 
Sahni l't al. 
1990 
1987 
1989 
1989 
1988 
1989 
1990 
1990 
1992 
1989 
Drug 
Vorapamil+ASA+D 
ASA+D 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Oli\'coil 
max EPA 
ASA 
max EPA 
Oli\'coil 
I.OV3statin 
Placebo 
Dose 
480 mg/day 
660 + 330 mg/day 
2.4 g/day 
6.0 g/day 
4.5 g/day 
3.2 g/day 
3.0 g/day 
3.15 g 
10 caps./day 
300mg 
started 2 weeks prior 
toPTCA 
15 g 
20-40 mg/day 
Patients total F-up 
196 88% 
162 85% 
186 30% 
194 23% 
100% 
82 100% 
108 94% 
151 85% 
50 86% 
205 58% 
157 50% 
AS::::: Area stenosis; ASA= Acctylsalkylk Add; D:::: Dipyridamole; Ds= Diameter stenosis; F-up= Follow up ('Y<, ofsuct.:cssful PTCA); mp:::: 
methylprednisolone; ms= monthsj nor P'I~I'::::: normal prothrombin time; NR= Not Reported; ns::::; not significant; p= p-valuc; pl= patient; 
Sign:::: Significance; TXA2::: Thromboxanc A2 synthetase inhibitor; tic::::: tklopidinc 
Time Definition restcnosis Restcnosis(%,) drug \'S placebo Sign Risk ratio 95%CI 
5 months loss of;?: 50% gain 
in unstable pat. 56% 62% p=ns 0.9 0.6 to 1.3 
in stable pat. 38% 63% p<0.05 0.6 0.4 to 1.0 
6 months Clinical 16% 33% p<0.05 0.5 0.2 to 1.0 
Stress test - f\~ + 67% 58% p=ns 1.2 0.7 to 1.8 
6 months > 70%DSFup 34% 23% p=ns 1.5 0.9 to 2,5 
6 months > 50%DSFup 18% 27% p=ns 
Clinical 
Stress test-f\~ + 19% 35% p<O.OI 0.6 0.4 to 1.0 
6 months > 50% DS Fup 19% 46% p<0.007 0.4 0.2 to 0.8 
(visual) 
3-5 mths loss> 50'}I" of gain 34% 33% p=ns 1.0 0.6 to 1.8 
(caliper) 
6 months NR 37% 33% p=ns 1.1 0.7 to 1.8 
6 months > 50% DS at Fup 20% 26% p=ns 0.8 0.3 to 2.3 
6 months MLD follow-up 35.6% 53.3% p=0.05 0.7 0.4 to 1.0 
- MI.D post-I'TCA 
zO.50mm 
2-10 mths > 50%DS Fup 14% 47% p<O.OOI 0.3 0.2 to 0.6 
Risk ratio with 95O/" confidence intervals (CI). An risk ratio of < 1 means that a lower restenosis rate is seen among the patients treated with the 
new drug compared with those who receivcd placebo. A statistical significant (p < 0.05) lower restenosis rate is seen in those studies where the 
95% confidence intervals do not cross risk ratio of 1. Risk ratio of more than 1 indicates a higher rcstcnosis rate among the paticnts tr-cated with 
the new drug. 
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3.2.11 GlycoproteinIIb/lIIa receptor blockers The clinical importance of the 
glycoprotein IIb/IlIa (GP IIblIIIa) receptor is indicated by the effect of its absen-
ce in patients with Glanzmann thrombastenia who suffer from mucocutaneous 
bleeding (George et al. 1984). The GP IIb/IIla complex is one of the most abun-
dant platelet cell surface protein (Phillips et al. 1988), which, when activated, 
binds to the adhesive protein vWF, fibronectin, vitronectin and fibrinogen, pos-
sibly by sharing a common binding site or peptide recognition sequence, and can 
be considered to be a final common pathway by which all antagonists act as initia-
tors of platelet aggregation. The dimeric structure of fibrinogen makes binding 
to, and thus aggregation of, two separate platelets possible. GP IlblIIla receptor 
antagonists may be effective in research in restenosis prevention, because of their 
ability to decrease acute platelet mass adherent at the site of angioplasty. 
The antithrombotic properties of monoclonal antibodies against the 
GPIIblIIla receptor in dogs and baboons showed a remarkable inhibition of pla-
telet deposition onto thrombogenic surfaces (Coller et al. 1986; Hanson et al. 
1988) . 
Chimeric 7E3 is a fragment of a genetically reconstructed murine immu-
noglobulin G (IgG) antibody, inwhich portions of the murine-derived antibody 
have been replaced by corresponding regions from human IgG. Subsequently, 
the protease papain cleaves the Fab fragment, resulting in a pure substance with a 
high affinity for GPIIblIIla. Receptors blocked by c7E3 are unable to bind the 
natural ligands fibrinogen and vWF, thereby preventing platelet aggregation. 
Platelet adhesion, however, and as subsequent release of mitogens from alpha-
granules, is unaffected. 
The activity of c7E3 was demonstrated by Kaplan et al. (1991 a) who obser-
ved platelet deposition in an ex vivo whole artery system, following balloon 
angioplasty. Platelet deposition at the site of injury was reduced 70% by c7E3, 
when compared with heparin. One month after rabbit femoral artery was dilated 
with prior infusion of a GP IIblIIIa antagonist, lumen diameter in the treated 
group was significantly wider than in the controls (Azrim et al. 1991). 
C7E3 appears to be safe during PTCA, with inhibition of platelet function 
in a dose-dependent fashion, and may be useful in prevention of abrupt closure 
and possibly of restenosis (Coller 1990; Ellis et al. 1990). 
Numerous cysteine-rich peptides, containing the tripeptide Arg-Gly-Asp 
(RGD), have been isolated from the venom of various vipers, and have shown 
potent inhibitory effects on platelet aggregation and fibrinogen binding (Gould 
et al 1990). This RGD sequence is found in many extracellular matrix and plate-
let adhesion proteins, such as the GPIIb/IIla receptor, acting as a common bin-
ding sequence. Barbourin, a peptide from the southeastern pygmy rattlesnake, 
shows a very high specificity for only the GPIIb\IIIa receptor. This venom deri-
ved protein contains a Lys-Gly-Asp sequence (KGD) as the recognition site 
(Scarborough et al. 1991). A report from Hanson et al. (1991) reported the eva-
luation of two cyclic synthetic peptides (SB-l, and SB-6). Using these barbour-
in-based structures, platelet deposition was significantly reduced on Dacron 
implants in baboons. 
Shebuski and coworkers (1990) used synthetic Echistatin in a dog model. 
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Intravenous infusion with Echistatin 10 and 20 Jlg/kg/min was a potent aggrega-
tion inhibitor, prolonging bleeding time 3-fold. In vivo experiments, evaluating 
the effects of RGD- and KGD- containing peptides on thrombus formation and 
subsequent neointimal formation after balloon induced vessel wall injury, are still 
awaited. 
3.3 Anti-proliferative drugs 
After the disruptive action of balloon dilatation, smooth muscle cells respond by 
proliferation. Cell characteristics shift from the contractile to the synthetic phe-
notype, which results in an extra cellular matrix deposition. Since one of the key 
features of restenosis is the uncontrolled proliferation of vascular smooth muscle 
cells, antiproliferative agents have been considered as an attractive concept. 
3.3.1 Angiotensin converting enzyme inhibitors Animal studies. Several 
organs contain local angiotensin converting enzyme (ACE) systems (Dzau 
1988). It appears that both the production of angiotensin II (A II) and its interac-
tion with specific A II receptors (e.g. on medial smooth muscle cells) may take 
place in these tissues independent of the plasma renin angiotensin system (Dzau 
1988). In the hypertensive rat model, the formation of a neointima (SMC prolife-
ration) in aging rats is accelerated, and it has been demonstrated that treatment of 
chronic hypertensive rats with ACE inhibitors reduces the medial hypertrophy of 
muscular arteries (Owens 1987), and it has been postulated that the local renin-
angiotensin system plays an important role in the remodelling process after arte-
rial injury (Powell et al. 1989a). Furthermore, there is evidence to support the 
role of A-II as a co-mitogen responsible for intimal hyperplasia after PTCA 
(De amen et al. 1991). Several research groups have investigated the effect of A-
Il and ACE-inhibition on the proliferation of vascular smooth muscle cells. 
Genes encoding platelet derived growth factor (PDGF-A), transforming growth 
factor-f3 (TGF-f3), and thrombospondin could be induced by A-II to express m-
RNA activity, and thus result in cell proliferation (Scott-Burden et al. 1990; 
Naftilan et al. 1989; Powell et al. 1989b, 1991), but could not be inhibited by an 
ACE inhibitor or metabolites. 
Thus the antiproliferative effect of ACE-inhibition is mediated through A-
Il, and consequently may prevent the proliferative response. In rats, neointima 
formation was reduced by 80%, 14 days after balloon dilatation of the left carotid 
artery when an ACE inhibitor was given either 6 days before, 1 hour before or 2 
days after angioplasty and continued until 14 days after the procedure (Powell et 
al. 1989b). This effect seems to be dose dependent and is synergistic with the 
effect of heparin. There was no effect with administration of a single dose or 
when it was discontinued 2 days after balloon dilatation. Further study has shown 
that captopril 100 mg/kg/day also reduced intimal hyperplasia to almost the same 
extent. Two other non-ACE inhibitor vasodilators, verapamil and hydrazaline, 
demonstrated a lesser effect (Muller et al. 1989). These results indicate that 
hemodynamic effects on vascular walls may influence the formation of intimal 
hyperplasia after balloon catheterization, and that ACE-inhibitors may reduce 
intimal hyperplasia through additional mechanisms related to inhibition of the 
angiotensin system. 
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However, Lam et al. (1990) found no effect on atherosclerotic changes after 
balloon angioplasty of the carotid artery in 3-month-old pigs, despite adequate 
plasma ACE activity inhibition. Similarly, Bilazarian et al. (1991) demonstrated 
in a hypercholesterolemic rabbit atherosclerotic model of balloon angioplasty 
that cilazapril started 1 week prior to angioplasty of the iliac artery until final 
angiography gave less reduction in diameter compared with the placebo group. 
Miyauchi et al. (1992) showed that this effect on restenosis was limited to vessels 
with intimal damage but without interruption of the internal elastic membrane. 
Cilazapril 10 mg daily, starting 7 days before balloon inflation and continued for 
21 days could not reduce intimal hyperplasia when both the intima and the media 
were damaged. 
Bilazarian (1992) studied angiotensin II antagonism in rabbits. To determi-
ne whether the effects were due to a reduction of A II or to another effect of ACE-
inhibitors, this group gave losartan potassium 50 mg/day (a direct inhibitor of A 
II) or placebo starting 1 week before balloon angioplasty, continuing until 4 
weeks later. Minimum lumen diameter was not reduced significantly, which sug-
gests that reduction of angiotensin levels is not the primary mechanism leading to 
neointima formation inhibition. 
Santoian et al. (1991) treated normolipidaemic swines with enalapril prior 
to balloon angioplasty until they were sacrificed at 14 or 28 days. They could not 
show significant effects on reduction of neointimal hyperplasia. Huber et al. 
(1991) administered two different ACE-inhibitors in 20 animals, 6 days prior 
and 28 days after injury in porcine coronary arteries. Mean neointimal thickness 
was not significantly different versus controls. 
Human studies Several studies have assessed the effect of ACE-inhibition on 
renarrowing of the coronary vessel after treatment with balloon angioplasty in 
humans. 
Recently Freed et al. (1993) reported the results of a nonrandomized pilot 
study using multiple drugs, namely enalapril 2.5 mg bid, lovastatin 20-40 mg 
bid., and colchicine 0.6 mg bid. This drug cocktail was administered from 1 week 
prior to intervention to folluw-up angiography. Despite the multiple targets of 
drug action, restenosis occurred in 33% of 50 patients. 
Brozovich et al. (1991) retrospectively analyzed records of 322 patients 
with a successful angioplasty and separated them into 2 groups according to pre-
sence (N=36) or absence (286) of a drug regimen that included an ACE inhibi-
tor. Restenosis (return of symptoms of angina with a significant stenosis on the 
angiogram) occurred in 30% of the patients treated without ACE-inhibitors ver-
sus 3% in the group who received this class of drug. Thus, it appears that inhibi-
tion of ACE may significantly reduce the incidence of restenosis after successful 
PTCA. 
Currently, a large multicentre randomised trial in Europe (MERCATOR = 
Multi-center European Research Trial with Cilazapril after Angioplasty to pre-
vent Transluminal coronary Obstruction and Restenosis) has just been comple-
ted to determine the effect of cilazapril on the incidence of restenosis (MERCA-
TOR study group 1992). More than 700 patients were randomised to cilazapril 
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or placebo starting 4 to 6 hours after PTCA, in addition to standard therapy of 
aspirin 200 mg. After 6 months (or earlier if indicated by symptoms), a follow-up 
angiogram was performed. The loss in minimal luminal diameter at follow up was 
0.29 ± 0.49 mm in the control group and 0.27 ± 0.51 mm in cilazapril treated 
patients. Using a dichotomous, frequently used definition of restenosis (loss of> 
50% of the gain of PTCA or > 30% increase in diameter stenosis), the restenosis 
rate was 39% in the control group and 37% in cilazapril recipients. Treatment did 
not reduce the incidence of clinical events. A similarly designed trial (MARCA-
TOR), investigating cilazapril 1, 5, or 10 mg/day versus placebo has recruited 
more than 1400 patients in the United States and Canada. The results ofthis trial 
do not indicate a role for cilazapril in restenosis prevention (Faxon et a!. 1992a). 
Final end point data have yet to be published, as well as the results of an ongoing 
study in Belgium that was discontinued after randomisation of 508 patients to 
fosinopril 40 mg/day or placebo because of a disappointing interim analysis 
(Desmet et a!. 1992). Thus, there seems no role for ACE inhibition in restenosis 
prevention. 
3.3.2 Colchicine Colchicine is an alkaloid derived from the plant Colchicium 
autumnale, which causes arrest in the metaphase of cell division by binding to 
tubulin and interfering with microtubule-related functions, including synthesis 
and secretion of polymorphonuclear cell and monocyte chemotactic factors and 
collagen; increase in collagenase activity (Muller et a!. 1991); inhibition of the 
proliferation and migration of smooth muscle cells; and inhibition of the release 
of chemotactants by leucocytes (Currier et a!. 1989). Recently Bauriedel et a!. 
(1991) showed a loss in regional pseudopodial activity in smooth muscle cells 
cultured from human plaque tissue after adding colchicine. 
To study the effect of colchicine on restenosis in vivo, atherosclerotic rab-
bits with > 50% diameter stenosis underwent iliac trans luminal angioplasty 
(Currier et a!. 1989). Colchicine was started 2 days before angioplasty (0.02 or 
0.2 mg/kg per day) until follow-up angiography at 4 weeks. High dose colchicine 
significantly decreased the diameter of stenosis at follow up, although no effect 
was seen with the lower dose. It has to be mentioned that 0,2 mg/kg per day in 
humans would almost certainly will give severe adverse effects. 
O'Keefe et a!. (1992) randomised 197 patients (2: 1) to colchicine 1.2 
mg/day versus placebo within 24 hours of PTCA, until 6 months follow-up 
angiography. Because of side effects (diarrhoea and dyspepsia), there was a 6.9% 
withdrawal rate of colchicine-treated patients. The restenosis lesion rate (return 
to > 70% stenosis and loss of 50% of initial gain) was 22% in both groups. 
In a double-blind placebo controlled study, 253 patients were randomised 
to colchicine 1 mg daily or placebo, initiated prior to balloon angioplasty and 
continued for 1 month (Grines et a!. 1991). Clinical evaluation and exercise thal-
lium tests in 79% of the studied population demonstrated no impact or clinical 
evidence of early or late restenosis. Thus colchicine seems to be ineffectiv:e for 
the prevention of restenosis after PTCA (fig 3). 
Wilensky et a!. (1992) evaluated the antiproliferative concept with locally 
delivered colchicine. A solution of 0.1 or 10 IlM/L was delivered using a porous 
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balloon drug delivery catheter in animals. Contalateral arteries served as controls 
in the treated animals. The arterial dimensions, determined by angiography and 
histological examination, revealed no significant differences. Thus colchicine 
seems to be ineffective for the prevention of restenosis after PTCA. 
3.3.3 Platelet-Derived Growth Factor Antagonists Animal studies Prolifera-
tion of vascular smooth muscle cells during the development of atherosclerosis 
and after coronary angioplasty might be initiated by the release of growth factors. 
Smooth muscle cells from diseased human arteries are known to possess mitoge-
nic activity and these cells express the gene for the PDGF-A chain selectively 
(Ferns et al. 1991). Besides an excessive proliferative response, the formation of 
connective tissue of great importance in luminal narrowing. In this way, it could 
play an important role in the development of restenosis (Libby et al. 1988; Ross 
1989; Majesky et al. 1990). 
The squalene epoxidase inhibitor terbinafine, usually used as an antifungal 
agent, has shown inhibitory PDGF an FGF activity in in vitro experiments. 
However, pretreatment with terbinafine 200 mg/kg/day for two days prior to bal-
loon angioplasty followed by 100 mg/kg/day for 28 days in 16 hypercholesterol-
aemic rabbits resulted in an only slight decrease in luminal narrowing compared 
with 15 controls on quantitatively analysed angiograms (Haber et al. 1991). 
Reduction in luminal diameter was 0.62 and 0.71 mm, respectively. 
Trapidil (= triazolopyrimidine) has been shown to inhibit cellular prolifera-
tion induced by PDGF in cell culture, and intimal thickening in damaged carotid 
arteries. In a model of atherosclerosis, rabbits were assigned to placebo (n=8) or 
trapidil 60 mglkg/day (n=9). The medication was started 2 days before balloon 
dilatation of the external iliac artery and continued for 4 weeks. Follow-up angio-
graphy showed a greater luminal reduction in the control group than in the trapi-
dil group compared with baseline values (p < 0.001), and there was significantly 
less histologic al evidence of intimal hyperplasia associated with trapidil admini-
stration (Liu et al. 1990). 
Human studies Okamato et al. (1992) randomised 97 patients to trapidil 600 
mg/day, beginning 1 week before PTCA and continuing for 6 months, or to 
aspirin 300 mg/day and dipyridamole 150 mg/day. Restenosis (loss of ;::: 50% of 
initial gain) occurred in 7 of 36 trapidil recipients and in 15 of 36 control patients 
(42%) who had follow-up coronary angiography. Thus, trapidil has been shown 
to be effective in preventing restenosis after PTCA in this small group of patients 
(Fig. 3). 
Nishikawa et al. (1992) randomised 160 patients to either trapidil 200 mg 
tid, or to dipyridamole 50 mg tid, both in combination with aspirin, starting 2 
days prior to intracoronary intervention and continued for a 4 month period. 
Quantitatively assessed restenosis (> 50% loss of the initial gain) was present in 
13 of 65 in the trapidil treated group (20%), and in 27 of the 72 controls (38%). 
Coronary dimensions evolved from 22 vs 21 % stenosis directly after balloon 
angioplasty, to a final stenosis severity of 39 % in the trapidil group and 49% in 
the dipyridamole group. 
Drugs 1993;46(1): 18-5 2 (Part I) alld (2): 249-262 (Part Il) 
Maresta and coworkers (1992) intend to enrol 360 patients III a double-
blind randomised study comparing trapidil 100 mg tid with aspirin 100 mg tid. 
Preliminary results based on 260 patients, of whom 159 are restudied showed a 
slightly better outcome in the trapidil-treated group (loss of the gain of 33% vs 
41 % . Final analysis of this studie is awaited, but these studies indicate a possible 
role for trapidil in restenosis prevention. 
Experimental work with monoclonal antibodies against PDGF is currently 
going on and described in the chapter 'future directions' (section 4). 
3.3.4 Angiopeptin It has been known for some time that hypophysectomy inhi-
bits neointimal plaque formation in response to endothelial injury (Tiel et al. 
1978; Fingerle et al. 1992). The last group recently presented evidence that 
smooth muscle cells do not alter after hypophysectomy, but that proliferative 
capacities require pituitary hormones in order to respond after injury. This sug-
gest that an endocrine factor may be involved in neointima formation. 
Somatomedin (insulin-like growth factor; IGF-l) has been shown to be 
involved in the repair of the intima in injured arteries. Further, it is (like PDGF) a 
potent mitogen for porcine aortic smooth muscle cells, and when added together 
to quiescent cultures their effects are synergistic (Hansson et al. 1987; Clemmons 
et al. 1985). Recently the effect of a newly synthesised class of pituitary growth 
hormone inhibiting agents on vascular smooth muscle cell hyperplasia after 
endothelial cell injury in-vivo has been investigated. These compounds are pepti-
de analogues of somatostatin, and have high affinity for somatostatin receptors 
on pituitary cells. They inhibit the release of pituitary growth hormone and soma-
tomedin. One of these agents, angiopeptin, was shown to inhibit vascular smooth 
muscle cell proliferation in response to a variety of vascular injuries. This seems 
to be a result of a local effect directly on autocrine or paracrine mechanisms in 
cell replication (Foegh et al. 1989). This new group of agents is currently under-
going investigation as inhibitors of several variants of 'accelerated atherosclero-
sis' (postangioplasty, cardiac transplantation and coronary bypass surgery). 
The somatostatin analogue octreotide reduced smooth muscle cell prolife-
ration, stimulated by PDGF and somatomedin, in terms of thymidine uptake by 
58% at a concentration of 100nM/L (Wargovich and Grant 1992). No significant 
effects on chemotaxis were seen in these cells. 
Animal studies Hong et al. (1991) administered saline or angiopeptin in 3 doses 
(1, 10, or 100 Ilg/ml) during angioplasty in rabbit abdominal aortas. Electron 
microscopy after 3 weeks showed in all the angiopeptin allocated groups that the 
intima was lined by endothelial cells, while the control group showed mainly 
modified SMC and intimal hyperplasia. Using isotope-labelled angiopeptin, 
there was evidence that inhibition of SMC-proliferation occurs at the nuclear 
level. 
A significant decrease of smooth muscle cell proliferation has also recently 
been reported a porcine modelin (Santoian et al. 1992). After angioplasty with 
oversized balloons and 14 days' subcutaneous administration of angiopeptine, 
the treated group showed a significant improvement in intimal and luminal area 
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(p=0.008) compared with untreated controls. After two more weeks without 
angiopeptin treatment, this beneficial effect was no longer seen. Santoian et al. 
(1993) demonstrated a greater inhibition of hyperplasia with systemic versus 
local angiopeptin administration. 
Conte et al. (1990) showed that angiopeptin 20 ~g/kg/day given one day 
before injury of the iliac artery and aorta and then continued for 2 or 6 signifi-
cantly reduced intimal thickness in rabbit iliac arteries, when examined after 3 
weeks. 
Howell et al. (1991) showed a significant effect of angiopeptin 1 0 ~g/kg 
given subcutaneously twice daily on intimal hyperplasia after 23 days, when the 
initial dose was given prior or during angioplasty. Angiopeptin treatment was 
ineffective when started 8 or more hours following angioplasty. 
Both of these studies indicate an early mechanism of growth inhibition by 
angiopeptin. 
Human studies An important restenosis prevention study in the US involving 
1240 patients tested angiopeptine in four treatment groups. The results of a 
European trial, recruiting a total number of 450 patients to receive either routine 
angioplasty with aspirin and heparin therapy, or with an infusion of angiopeptin 
6mg daily, starting 24 hours prior to PTCA and continued for 72 hours, will be 
published soon. These studies should answer the promising results achieved with 
angiopeptin in animals are applicable to the prevention of restenosis in humans. 
3.3.5 Cytostatic agents In the proliferative concept, the use of cytostatics seems 
very useful. The principle concern with these agents is the potential for serious 
adverse effects, because of the capability of these drugs to damaging other rapid-
ly dividing cells, e.g. those in the gastrointestinal tract, bone marrow and repro-
ductive system. 
Interest in the antimitotic approach has been stimulated by a study of 
Voisard et al. (1991) who collected human VSMC from primary stenosing 
lesions and from restenotic lesions, and observed a significantly increased growth 
rate in the latter group. Etoposide added to the cultures was able to inhibit VSMC 
proliferation by more than 50% . This agent has not yet been tested in vivo. 
Recently the effects of locally administered doxorubicin on restenosis were 
reported by Currier et al. (1992) in hypercholesterolemic rabbits. Remarkably, 
local doxorubicin infusion showed significant inhibition of luminal renarrowing 
(reduction in lumen diameter from 1.56 to 1.00 mm) compared with balloon 
angioplasty combined with saline infusion (1.51 to 0.55 mm), but not when com-
pared with balloon angioplasty alone (1.40 to 0.89) These changes suggest that 
the damage to vascular tissue caused by local drug delivery is greater than the 
antiproliferative effects of doxorubicin. 
Barath et al. (1989) hypothesised that cytostatic agents may prevent reste-
nosis by selective toxicity against active and proliferating smooth muscle cells 
without damaging normal smooth muscle cells. In their study, rabbits were divi-
ded into 4 groups: the first group was a control group, the second group had only 
a balloon dilatation of the aorta, the third group received the cytostatic agents 
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vincristine 0.075 mg/kg and dactinomycin 0.015 mg/kg, and the fourth group 
underwent balloon dilatation and received cytostatic agents. Three days later, 
electron microscopic findings showed that these cytostatic agents prevented 
smooth muscle cell proliferation without damaging the normal smooth muscle 
cells. 
McKenney et al. (1991) examined the effects of administering cyclosporine 
15 mg/kg, starting 3 days prior to angioplasty for 4 weeks, in 10 hypercholesterol-
emic rabbits. Comparison of angiographic and histological data with 10 controls 
showed no beneficial effect; on the contrary, an increase in media thickness 
occurred in the treated group, because of increased accumulation of foam cells. 
Similarly local delivery of methotrexate via an infusion balloon catheter into 
carotid arteries following balloon angioplasty in 10 Yucatan minipigs resulted in 
no difference in intimal proliferation compared with placebo (Muller et al. 1990). 
Murphy et al. (1990) used methotrexate 1.25 mg/day for 5 days each week or 20 
mg intramuscular, or azathioprine 25 mg/day in stenotic porcine coronary arte-
ries. They found no difference in stenosis size (measured by histology) in the dif-
ferent groups. 
In another in vivo study, Cox et al. (1991) placed polymer-coated balloon-
expandable stents into the circumflex artery of 40 pigs. Four groups were stu-
died: the first received an uncoated tantalum stent, the second a heparin-coated 
stent, the third a methotrexate-coated stent, and the fourth group received a stent 
coated with both heparin and methotrexate. Analysis, 28 days after implantation 
revealed no significant differences in percentage restenosis or intimal area 
between the four groups. 
The results reported so far suggest that there seems to be no role for cytosta-
tic agents in the prevention of restenosis in human coronary vessels. 
3.3.6 Photodynamic Therapy Deckelbaum et al. (1992) evaluated the effect of 
methoxsalen (8-methoxypsoralen) 1 ~g/ml in combination with different doses of 
visible light (420 nm) on the proliferation of cultured bovine smooth muscle 
cells. Low dose light caused a high percentage of proliferation inhibition, whereas 
high doses were cytotoxic. 
March et al. (1992) tested ultraviolet radiation exposure in combination 
with the photoactive agent methoxsalen. They determined strong synergism in 
inhibiting DNA synthesis in cultured bovine aortic smooth muscle cells. 
Progression through the cell cycle could be blocked at any phase by inverse varia-
tions of delivered dose and energy. 
A Japanese group (As ahara et al. 1993) used the combination of mercury-
xenon flash lamp light and a haematoporphyrin derivative 24 hours before irra-
diation in rabbit aortas. Photodynamic therapy applied at different intervals after 
angioplasty demonstrated the most effective intima suppression at 1 week. 
The new concept of photodynamic therapy seems promising, but needs 
more in vitro testing and in vivo validation. 
3.3.7 New antiproliferative drugs Using a Wolinsky porous infusion catheter, 
Wilensky et al. (1991a) injected a solution of a thiol protease inhibitor (TPI) into 
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atherosclerotic rabbit femoral arteries immediately following angioplasty to eva-
luate the effect on restenosis. They found a smaller reduction in minimal luminal 
diameter after 2 weeks in the TPI-treated group than in the control group. They 
hypothesised that the process of vascular remodelling after angioplasty is signifi-
cantly modified by TPI. 
Betz et al. (1990) used a calcium-calmodulin antagonist and found it to be 
effective in inhibiting smooth muscle cell proliferation after application of athe-
rogenic stimuli in a dose-dependent manner. These newer drugs could thus be 
used for inhibiting stenosis of intimal proliferation. 
Lafont et al. (1992) reported the antiproliferative action of the well known 
anti oxidant a-tocopherol (vitamin E). Rabbits, pre-treated with a-tocopherol 
and a cholesterol-rich diet, underwent balloon angioplasty 28 days after induc-
tion of a stenotic lesion by air dessication. Angiographic follow up after 21 days 
showed a significantly greater minimum diameter in the treated group (1.70 vs 
1.07 mm, p < 0.01). Histological evaluation of the narrowed segments showed 
significantly less intima and media area than in the control group (0.69 vs 1.16 
mm2,) and thus confirmed the angiographic results of this approach. 
3.4 Anti-inflammatory agents 
Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) have pro-
ven immunosuppressive potency. Since restenosis can be explained as the result 
of a general wound healing process in injured vascular tissue (Forrester et al. 
1991), inhibition of the inflammatory phase is an interesting goal. It is evident 
that accumulation of immuno-active cells and release of soluble mediators that 
stimulate migration, growth and activation of VSMC and fibroblasts, leads to a 
complex immunological and inflammatory response. 
3.4.1 Corticosteroids Corticosteroids affect the quantity and the quality of cir-
culating and accumulating lymphocytes and monocytes, while also inhibiting 
P AF-formation (MacDonald et al. 1987). Responsiveness of monocytes to lymp-
hokines and the lymphocyte proliferation are suppressed, probably due to decre-
ased release of PDGF and macrophage-DGF (Berk et al. 1991). Furthermore 
SMC chemotaxis and proliferation, as well as collagen synthesis by fibroblasts is 
inhibited by this class of drugs. The reduction in proliferation is the consequence 
of decreased RNA and protein synthesis inhibition (Gordon et al. 1987, Berk et 
al. 1991). 
The results of local dexamethasone delivery in the carotid artery of rats, 
using silicone drug-eluting polymers as carriers, have been described (Villa et al. 
1993). In 8 control animals, placebo polymer implants did not induce neointima 
formation. However, in treated and de-endothelialised segments, the neointimal 
area was significantly affected at 3 weeks and, due to systemic steroid activity, 
this effect was also seen in segments that did not contain the polymers in the 
adventitia. 
To test these drug clinically, Rose et al. (1987) randomised 66 patients to 
placebo or methylprednisolone from 48 hours before to 5 days after PTCA. 
Angiographic restenosis (> 50% stenosis at 3 months' follow-up) revealed no dif-
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ference between the two groups, 33% iJ?- each. The same results were achieved 
when corticosteroids were given to 102 patients with restenosis after PTCA 
(Stone et a!. 1989). In addition to aspirin, dipyridamole and a calcium antago-
nist, patients received methylprednisolone 125 mg intramuscular 1 day before 
repeat-PTCA and prednisone 240 mg for 1 week. Only the 54 patients under-
going follow-up angiography were analysed. Restenosis (> 50% diameter narro-
wing) was found in 59% of the patients in the group treated with steroids compa-
red with 56% ofthe patients receiving standard treatment. 
Similarly, in a multi centre trial in the United States (Pepine et a!. 1990),850 
patients were randomly assigned to methylprednisolone or placebo 2 to 24 hours 
before PTCA. In 71 % of the patients, follow-up angiography was performed. 
The incidence of restenosis (> 50% diameter stenosis) was 43% both groups. 
These trials demonstrate that administration of corticosteroids has no influ-
ence on the incidence of rest enos is (Figure 3). 
3.4.2 Nonsteroidal Anti-Inflammatory Drugs Ibuprofen is known to decrease 
platelet-thrombus deposition in arterial grafts. In a study of normal porcine com-
mon carotid arteries pretreated with heparin, balloon angioplasty was performed 
and followed by a bolus (12.5 mglkg) and infusion (75-100 J-Lg/kg/min) of ibupro-
fen or placebo. Quantitative 111 In labeled autologous platelet deposition at the 
site of angioplasty was significantly reduced by ibuprofen (Lam et a!. 1987). 
Whether this will affect the risk of late restenosis is unknown. 
Ebselen is a newly synthesised selenium containing compound with strong 
anti-inflammatory characteristics. Recently a Japanese group reported a rando-
mised study that included a 3-month follow-up angiography (Hirayama et a!. 
1992). Twenty-nine patients received Ebselen 200 mg p.o. b.i.d., and the control 
group comprised 50 patients given placebo. Lesion restenosis rate (loss of ~ 50% 
of the initial gain) was 48.2% in the placebo recipients and 28.6% in the Ebselen-
treated group (p < 0.05) (Figure 3). These results suggest strong preventive 
effects on restenosis. Further details of this studie, as well as a larger scale trial 
with Ebselen are eagerly awaited. 
3.5 Calcium antagonists 
Coronary spasm is frequently seen during and shortly after PTCA and may have 
a role in the pathogenesis of restenosis (David et a!. 1982). Platelet deposition at 
damaged endothelium induces coronary spasm and the formation and subse-
quent organisation of thrombus (Steele et a!. 1985, Wilentz et a!. 1987). Calcium 
antagonists may thus reduce the incidence of restenosis by inhibiting vasospasm. 
In an animal model (Faxon et a!. 1984) and in 3 randomised trials in humans 
(Corcos et a!. 1985; O'Keefe et a!. 1991; Whitworth et a!. 1986), calcium antago-
nists have not been shown to influence the incidence of restenosis. However, ver-
apamil was effective in patients with stable angina pectoris (Hoberg et a!. 1990). 
Moreover, nifidepine and nicardipine are effective in trials investigating athero-
sclerosis progression and regression, so there may still be a role for calcium anta-
gonists in preventing restenosis or the development of new atherosclerotic lesions 
(Lichtlen et a!. 1990; Waters et a!. 1990) (Figure 3). 
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3.5.1 Diltiazem In a study from the Montreal Heart Institute (Corcos et al. 
1985), 92 patients received diltiazem 270 mg/day for 3 months and underwent a 
recatherisation 5 to 10 months after balloon angioplasty, or earlier if symptoms 
returned. All patients also received daily aspirin 650 mg and dipyridamole 225 
mg for 6 months. Patients treated with diltiazem had a restenosis rate of 15% ver-
sus 22% in the patients not receiving the drug (restenosis defined as stenosis of 
~70% at follow-up angiography). The average decrease in diameter during fol-
low-up was 4% in the diltiazem group and 7% in the control group. It was conclu-
ded that diltiazem had no effect on restenosis and that coronary spasm is not a 
major mechanism of restenosis. 
In a further trial, a total of 201 patients were randomised to receive high 
dose diltiazem (started 1 day before PTCA, mean dosage 329 mg/day) or to 
placebo (O'Keefe et al. 1991). Repeat angiography at 1 year was obtained in 60% 
of the patients. Restenosis was assessed by quantitative angiographic techniques 
and was defined as return to ~ 70% or luminal area stenosis and loss ~ 50% of the 
initial gain with angioplasty. No difference in procedural complications (6 of 102 
diltiazem vs. 8 of the 99 placebo recipients) or restenosis rate (36% versus 30%) 
were observed. 
An abstract from Unverdorben et al. (1992) reported the beneficial effects 
of Diltiazem 180 mg, compared with placebo in 170 patients. Recatheterisation 
at 3 to 4 months showed a significant effect on average luminal narrowing (38.6 
vs 50.3%, p< 0.01), while the restenosis rate ( ~ 50%-criterium) also appeared to 
be significantly lower (18/84 vs 33/86 patients p < 0.03). These effects were more 
pronounced in subgroups such as diabetic patients, those with hypercholesterol-
emia or classified in CCS class II, and in calcified plaques. 
3.5.2 Nifedipine In a 6 month follow up trial 241 patients were randomly assig-
ned to receive either nifedipine 40 mg/day or placebo (Whitworth et al. 1986). All 
patients also received aspirin 325 mg/day. Restenosis was defined as a loss of 
more than 50% of the gain achieved at the time of the PTCA. In patients who 
were compliant with medication and underwent follow-up angiography (84 
patients in both groups) there was no difference in restenosis rates: 29% in the 
nifedipine group and 33% in the placebo group. 
3.5.3 Verapamil Recently Hoberg et al. (1990) conducted a restenosis preven-
tion trial in which 196 patients were randomised to verapamil 480 mg/day or 
placebo in combination with aspirin 660 mg/day and dipyridamole 150 mg/day. 
Follow up angiography at 6 months was performed to detect recurrence of the 
lesion (~ 50% loss of the initial gain). In a subgroup of 88 patients with unstable 
angina there was no beneficial effect of verapamil treatment (restenosis rate 56% 
versus 62% with placebo). However, in a subgroup with stable angina, there was a 
significant reduction in restenosis (38% vs 63%), demonstrating a relative risk of 
0.6 ( p = 0.038). This indicates that a high dose of verapamil prevents restenosis 
after successful PTCA in patients with stable angina. No difference was found in 
the group with unstable angina before PTCA. 
Data pooling of these four clinical trials using calcium antagonists reveals no 
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effect of this type of drug on recurrence of stenotic lesions (Figure 3). 
3.6 Lipid Lowering Drugs 
3.6.1 Fish Oils Epidemiological trials have shown that a diet rich in omega-3 
polyunsaturated fatty acids (present in high concentrations in most salt water 
fish) may account for the low incidence of coronary disease seen in Eskimos. 
Animal research has shown that these polyunsaturated fatty acids inhibit athero-
sclerosis in general. This can be partly explained through a reduction in triglyce-
rides and VLDL cholesterol. Reduced VLDL levels is the consequence of sup-
pression of hepatic synthesis and increased clearance by the liver or peripheral 
tissues. Another effect is on eicosanoid metabolism and function by inhibition of 
platelet production of TXA2 while production of endothelial PGI 2 is only slight-
ly reduced, and is partially compensated by the synthesis of PGI3 (Leaf 1990). 
These effects enhance vasodilatory and antiaggregatory effects. 
Omega-3 fatty acids also inhibit the production of leukotriene B 4 by a 
mechanism of competition with arachidonic acid that results in the production of 
the less potent leukotriene B5 (Lee et al. 1985). Other cardiovascular and hemo-
dynamic effects of fish oil include changes in membrane qualities, resulting in 
platelet aggregation inhibition (Croset & Lagarde 1986), and reduction in blood 
viscosity (Terano et al. 1983). Furthermore, vasodilatation is stimulated by 
increased endothelial-dependant relaxation and reduced sensitivity to vasospas-
tic stimuli. Finally, reduction in blood pressure and increased fibrinolytic activity 
(Barcelli et al. 1985) have to be mentioned in the ever growing list of fish oil 
qualities. 
Slack et al. (1987) showed that adding 2.4 g fish oil (rich in eicosapentae-
noic acid (EPA» each day to the usual post-PTCA regimen of calcium channel 
blocker, nitrates, aspirin and dipyridamole could reduce the incidence of clinical 
restenosis in patients with single vessel disease (16 vs 33% in the placebo group). 
In 49 patients with multi-vessel disease, no influence could be shown. 
However, Reis et al. (1989) demonstrated in a double-blind trial that sup-
plementing the normal diet with 6.0g of fish oil daily, starting just before PTCA 
until 6 months later, had no influence on restenosis rate in 186 patients in whom 
PTCA was successful. Angiographic restenosis (70% diameter stenosis at a site 
previously dilated to <50%) was present in 34% of the group taking fish oil and 
23% of the control group. However, patients without symptoms and who perfor-
med a negative exercise test were classified as not having restenosis, so only 68 
patients (37%) underwent repeat angiography; almost all patients had a recurren-
ce of chest pain, which contributed to a selection bias at follow-up angiography. 
Milner et al. (1989) found that the addition of 4.5 g/day fish oil to the nor-
mal diet of 194 patients had a positive influence on clinical restenosis, with 19% 
(16 of the 84 patients) in the fish oil group versus 35% (35 of the 99 patients) in 
the placebo group having a recurrence of chest pain. However, in the first week, 
11 of the 95 patients stopped taking the medication because of side effects. 
In another study, 82 patients were randomly assigned, in a non-blinded 
manner, to aspirin plus dipyridamole with or without EPA 3200 mg/day, the 
equivalent of 18 capsules (Dehmer et al. 1988). Treatment was started 7 days 
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before PTCA and was discontinued 6 months later. In all 82 patients, a second 
angiogram (on average 3 to 4 months after PTCA) was performed. Restenosis (~ 
50% narrowing of the dilatation site at follow-up angiography) was seen in 46% in 
the placebo group and 19% of those receiving EPA. This trial suggests, that 
omega-3 fatty acids may effectively reduce restenosis in high risk patients, provi-
ded that they comply with the dosage regimen and that treatment is started 7 days 
before PTCA. 
In contrast, no difference in angiographically defined restenosis rates was 
observed in another 108 patients randomly assigned to 10 capsules of fish oil 
(34% rate) or placebo (33%) (Grigg et all. 1989). Medication was started the day 
before angioplasty and continued until 4 months after angioplasty. All patients 
also received aspirin and verapamil. 
Comparisons between fish oils and other treatments have been performed. 
Franzen et al. (1990) randomised 200 patients to assess the effect of 3,15 g 
omega-3-fatty acids versus olive oil. Follow-up angiography after 4 months 
showed 37% restenosis in the fish-oil group (25/67) and 33% restenosis in the 
olive oil group (21/62). Bairati et al. (1992) randomly assigned 205 patients to a 
daily dose of 'Maxepa' 15 g (each capsule containing EPA 0.18 g and docosa-
hexaenoic acid 0.12g) or olive-oil from 3 weeks before PTCA until an angiogram 
6 months later, while also performing 201Thallium-scintigraphy at 3 months. 
This procedure showed a significant benefit (p=0.02) in the group given fish oil. 
At 6-month follow-up angiography, restenosis occured less often in the fish-oil 
group (22 vs 40% p=0.03). This group therefore documented the protective 
effect of fish-oil on the recurrence of coronary stenosis six months after PTCA. 
Fifty other patients were randomised to 10 Maxepa-capsules or aspirin 300 
mg daily for 2 weeks prior and 6 months after elective PTCA (Cheng et al. 1990). 
Angiography at 6 months revealed a restenosis rate of 20% in those taking fish-oil 
(4/20), and 26% in the aspirin group (6/23). 
Very recently, Kaul et al. (1992) presented the results from a randomised 
trialin which 107 patients received aspirin and calcium antagonists alone or along 
with EPA and docosahexaenoic acid, starting 1 to 7 days before intervention. 
Restenosis occurred in 38% of the patients receiving fish oils, and in 29% of the 
controls. The length of pretreatment period did not influence the restenosis per-
centage. 
It is thus clear that a consensus regarding the use of fish-oils to prevent re-
stenosis can not be reached (Figure 3). These conclusions are in part related to 
differences in the design of the individual studies. Although all studies were ran-
domised, only 4 were conducted double-blind. Different dosages and formula-
tions were used and patient compliance and follow up rates varied in the studies. 
There were also differences in the timing of initiation of therapy and variable 
methods (coronary angiography, stress test, symptoms) used for the detection of 
restenosis. 
Nevertheless, when meta-analysis is performed on the pooled data, there is a 
more convincing and powerfull relative risk as shown in figure 3. The upper value 
of the 95% confidence interval is 1.01, thus approaching the level of significance. 
Two large scale trials, the EMPAR- and the FORT-trials, are currently 
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recruiting patients and we can probably draw final conclusions after the results of 
these studies have been published (Figure 3). 
3.6.2 Cholesterol Lowering Drugs Hypercholesterolaemia is a well known risk 
factor for ischaemic heart disease. Lipid modification is an important goal in 
secondary prevention in halting the progression of atherosclerosis in general, and 
possibly after angioplasty. The total cholesterollHDL-cholesterol ratio post-
PTCA seems to be related to the risk for restenosis (Reis et a!. 1990). 
Recently it was shown that lovastatin reduces intimal hyperplasia after bal-
loon angioplasty in rabbits with hypercholesterolaemia (Gellman et a!. 1991), 
which is confirmed by observations in normolipidaemic rats (Ferns et a!. 1991). 
Plaque size of the dilated carotid artery decreased significantly in lovastatin trea-
ted animals, reducing the formation of neointimal plaques. Constantinescu et a!. 
(1992) demonstrated that the effect might be the result of direct inhibition of 
smooth muscle cell proliferation. Lovastatin added to cultured SMC's and EC's 
that were stimulated with either PDGF or EGF, showed a dose dependent inhibi-
tion in cell proliferation (p < 0.01). 
However, two trials with postangioplasty patients in which the effect of lipid 
lowering on the incidence of restenosis after PTCA were tested, yielded conflic-
ting results. In the first trial (Sahni et al. 1989), 157 patients were randomly 
assigned to lovastatin or to placebo following successful PTCA, for an unstated 
period of time. Only 50% of the patients underwent follow-up angiography at an 
average of 4 months after PTCA (50 patients in the lovastatin group and 29 
patients in the control group). Restenosis (narrowing of ~50% at follow-up 
angiography) was seen in 14% of the sites in the lovastatin group and 47% in the 
placebo group, reaching the level of significance in this select group. 
In a second nonrandomised trial (Hollman et a!. 1989), an aggressive treat-
ment was used in 55 consecutive patients to lower serum cholesterol, including 
dietary modification, colestipol and lovastatin, starting on the day of PTCA. 
After 2 weeks, cholesterol levels were reduced by 50%. A restenosis rate of 34% in 
44 of 55 patients was obtained. There was no difference in cholesterol levels 
between patients with and without restenosis. 
4. Future directions 
Molecular biology has provided us with detailed information about an important 
family of 'peptide cell regulator factors' (PRF) (Ross 1989; Majesky et a!. 1990; 
Michell 1989; Schneider & Parker 1990; Waterfield 1989; Green 1989). 
Although it seems to be a long way from the bedside of the patient, this new fami-
1y could lead to drugs that prevent restenosis after PTCA. In recent years it has 
become clear that cell proliferation and differentiation are controlled by many 
peptides and other agents through their interactions with cell surface receptors 
that send signals to the cell interior. 
4.1 Antibodies to Growth Factors and Inositol Diphosphate PDGF has been 
shown to stimulate SMC-migration in an in vivo system. Intravenous infusion of 
PDGF for one week resulted in a 15- fold increase in intimal lesion area following 
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injury with a filament loop catheter. In addition, analysis of auto radiograms after 
suppletion of (3H)-thymidine demonstrated a 4-fold increase in dividing cells 
and a 20-fold increase in non-dividing cells, suggesting the increase in cell num-
ber is due mainly to migration a awien et al. 1991). 
Ferns et al. (1991) used goat polyclonal antibodies to PDGF to examine the 
formation of intimal lesions in de-endothelialised dilated rat carotid arteries, and 
administered anti-PDGF before and 9 days after the procedure. This resulted in 
a 40.9% reduction in the area of the neointima (P< 0.01). A (3H)-Thymidine test 
showed no significant difference in labeling indices, and so suggests that the 
decrease in initial area is primarily due to reduction of chemotactic migration. 
The lack of effect on mitogenesis is probably the effect of endogenously produ-
ced PDGF-AA, a homodimer peptide chain that in in vitro studies needs larger 
amounts of anti-PDGF than PDGF-AB or -BB to block mitogenic activity 
(Raines et al. 1989). 
Transforming growth factor-f3 (TGF-f3) can either stimulate or retard cell 
growth, depending on concentration, cell age and density. Majesky et al (1991) 
showed in a rat carotid artery model increased TGF-f3 synthesis after balloon 
injury, which stimulated SMC proliferation. Of particular interest is the report by 
Nikol et al. (1992) who observed the in vitro expression of TGF-f3 in primary 
atherosclerotic and restenotic lesions. Messenger-RNA in restenotic material, 
obtained by directional coronary atherectomy, was detected at a significant hig-
her level than in atherosclerotic cell cultures. This may indicate a role for TGF-f3 
in an exaggerated repair response following vessel wall injury. 
Shah et al. (1992) injected antibodies to TGF-f3 in disrupted dermal tissue 
in rats and investigated the wound healing process. Scar tissue of the treated ani-
mals had a lower rate of angiogenesis and infiltration of macrophages, which can 
release their TGF-f3 stores. Furthermore, the collagen and fibronectin fibers of 
this tissue were found to have a smaller volume and normal orientation, and 
leaving scar tissue strength unaltered by TGF-f3 down-regulation. Bonan et al. 
(1992b) described the in situ delivery of anti-TGF-f3 antibodies in the coronary 
arteries of 5 minipigs. The extent of vessel wall injury, however, as well as was the 
restenosis-injury index (ratio of neointimal area to the total wall area over extent 
of injury) was the same in treated and untreated animals. This study suggests an 
ineffective role for 13-TGF antagonism. 
Epstein et al. (1991) linked the nonspecific but effective Pseudomonas exo-
toxin A, lacking its cell recognition domain (PE40), to TGF- a. This growth fac-
tor is recognized by the EGF receptor, present in abundance on rapidly prolifera-
ting SMC's. Due to this new recognition site, PE40 is able to attach to cells 
expressing this EGF receptor, be internalised, and inhibit protein synthesis. The 
PE40-TGF- a complex has an extreme affinity to cells expressing the EGF 
receptor. In the same way, Cascells et al. (1990) used a saporin-FGF conjugate to 
inhibit DNA synthesis and intimal thickening in injured vessels. 
Basic FGF is another mitogen, synthesised in both endothelial and SMC's, 
and is thought to be stored in the subendothelial matrix (Vlodavsky et al. 1987). 
The replicative capacities were evidently shown in endothelium after denudation 
with a filament loop in carotid arteries of rats. In damaged vessels, labelled thym-
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idine index increased from 1l.5% in controls to 54.8% in treated animals. 
Arteries with an intact endothelium did not respond to this mitogen. 
Lindner and Reidy (1991) investigated the effect of a rabbit antibody to b-FGF 
on proliferation in cultured cells, after exposure to bFGF, PDGF-BB, EGF and 
calf-serum. The anti b-FGF antibody appeared to be highly specific in vitro. 
Administration in rats prior to and following balloon inflation reduced the SMC 
response significantly. One single injection of anti b-FGF prior to balloon angio-
plasty caused a similar reduction in (3H-) thymidine incorporation as when the 
angioplasty was followed by 5 additional injections, every 8 hours. 
All the above results suggest a significant role of growth factors in the 
response of SMC's to vessel wall injury. 
Among the important signals that have been implicated in these processes 
are the phosphorylation of tyrosine residues on proteins (Figure 4) and changes 
in the intracellular concentrations of the messenger molecules c-AMP, diacyl-
glycerol, Inositol-1,4,5-triphosphate (IP3) and Ca++, which directly or indi-
rectly exert most of their regulation on the phosphorylation and dephosphoryla-
tion of serine and threonine residues of particular proteins (Michell 1989). 
Recent studies have demonstrated that mitogens such as PDGF and thrombin 
rapidly induce the hydrolysis of phospatidylinositol biphosphate (PIP2) by 
phospholipase C (Michell 1989; Takenawa & Fukami 1989). 
PIP2 hydrolysis produces two compounds. The first of these is inositol tri-
phosphate, a water-soluble molecule whose formation triggers the mobilisation 
of Ca ++ in the cytoplasm. Within cells there is a membrane compartment, pro-
bably a part of or closely related to the endoplasmic reticulum, into which Ca ++ 
is continuously pumped by an ATP-driven pump, so maintaining the cytoplas-
mic concentration at approximately 0.1 umollL. When receptors trigger the for-
mation of IP3, it binds to IP3 receptors on the membrane enclosing this reservoir, 
thus opening channels through which Ca ++ is released to raise the cytoplasmic 
Ca ++ concentration to somewhere in the range of 0.2-0.1 umollL within 
seconds. It has long been known that regulation of cytosolic Ca ++ levels is central 
to control of cell growth, and that this regulation may go awry in malignantly 
transformed cells. The second product of PIP2 hydrolysis is 1,2 diacylglycerol; 
this compound activates one or more of the protein kinase C (Figure 4). 
These signalling pathways have been considered to play important roles 
in cellular responses. Unfortunately, they are not the sole signal transduction 
system. At least four structural classes of growth factor receptors have been 
identified, all of which phosphorylate on tyrosine residues. It is not clear to 
what extent these different tyrosine kinases share the same protein substrate. 
In some cases the ligand-binding and tyrosine kinase domains of a receptor 
protein are separate portions of a single polypeptide chain that spares the 
plasma membrane, whereas in others these sites are on separate subunits of a 
multisubunit membrane-spanning receptor protein. In this system there is 
clear evidence that receptors transmit their information to phospholipase C 
via a coupling protein G (guanine-nucleotide-dependent) (Figure 4). 
A Japanese group (Takenawa & Fukami 1989) has developed a monoclonal 
antibody against the PIP2. Microintracellular injection of the antibody into the 
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transformed cells causes reversible and dose-dependent decrease in DNA syn-
thesis and in the rate of cell proliferation, and reverts the cell morphology to that 
of untransformed cells, the normal phenotype. As predicted from the proposed 
scheme for growth factor transduction, microinjection and overproduction of 
phospholipase C or protein kinase C also can substitute for exogenous mitogens, 
whereas antibody to 1.4 inositol diphosphate or protein kinase C prevents proli-
feration (Figure 4). Thus, development and local release of new agents which 
inhibit inositol-phospholipid metabolism may be useful for treatment of human 
restenosis. 
4.2 Gene Transfer First steps are being taken to explore the field of genetics. 
Methods for the incorporation of foreign DNA into the endothelial and VSMC 
have been developed recently and could be useful in protecting vessels from vas-
cular diseases, including atherosclerosis and restenosis. The most elegant way to 
deal with this sophisticated technique is to augment genetic sequences, leaving 
the defective host genes unaltered. 
Transfection can be achieved by physical means such as microinjection 
(Anderson et al. 1980), or electroporation (Neumann et al. 1982), or by a chemi-
cal approach, using Iiposomes as carriers (FeIgner et al. 1987), or as shown by 
Leclerc et al. (1992), by bombardment of vascular muscle cells, using DNA-
coated micro projectiles as carrier for transfer. A commonly used medium is the 
replication-defective retroviral vector, although amphotropic adeno- and 
DNA-viruses can be used also. The advantage of defective retroviruses is that 
these produce efficient infection followed by integration, and hence stable gene 
expression. In 1989, Nabel and colleagues succeeded in in vitro implantation of 
genetically modified endothelial cells expressing f3-galactosidase using a double 
balloon system to introduce the cells. Histochemical staining of this enzyme 
was observed in the intimal layer several weeks later and thus proved gene-
expression. 
Introduction of new genetic material into the wall of coronary arteries can 
give rise to the detection of enzyme activity. Transfection of luciferase DNA 
could be effected by bombardment of vascular muscle cells in vitro, using DNA-
coated microprojectiles (1 ~m diameter) and Biolistic PDS-1000 as delivery sys-
tem (Leclerc 1992). Transfection of luciferase -an enzyme not expressed in 
mammalian cells- has been described in rabbits (Leclerc et al. 1991) and dogs 
(Chapman et al. 1991), and was achieved by exposing DNA either in a dual bal-
loon catheter system or a porous perfusion balloon-system. Increased enzyme-
activity can be detected following a percutaneous approach, which was also pro-
ved by Lynch et al. (1991), who simply introduced transduced cells into a 
denudated artery and detected enzyme levels over 4 months of observation follo-
wing transplantation. These recent developments suggest that human VSMC can 
be drastically affected by gene therapy. 
4.3 Sense-Antisense Approach In this competitive approach, oligonucleotides 
are used to block messenger-RNA action. This antisense technology has been 
used to inhibit c-myc protein production in hematopoietic cells (Holt et al. 
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1988), resulting in an inhibition of proliferation. Simons and Rosenberg (1992) 
demonstrated that smooth muscle cell proliferation, results in an elevation of c-
myb m-RNA levels, and the generation of the oncogene c-myb. This oncogene is 
critically important in the change of the fenotype and in cell growth regulation. 
Interfering in the process of intimal hyperplasia at the post-nuclear level might 
give us the possibility to block one specific cell response. 
Simons et al. (1992) used the rat carotid arteries to investigate the role of c-
myb and oncogene suppression by its complementary antisense oligonucleotide 
in neointimal formation in vivo. The sense oligonucleotide or the corresponding 
antisense molecule was applied locally to the injured vessel wall in a plurionic gel, 
and resulted in minimal intimal smooth muscle cell accumulation, in contrast to 
the controls. The same group also studied the effect of a mismatching antisense 
(two basepairs not complementary), compared to sense and to antisense oligonu-
cleotide, on the ratio of intimal to medial cross sectional area. Respectively ratios 
were 1.05, 1.02 and 0.16, which indicates the high specificity and potency of the 
antisense oligonucleotide. 
Alteration of proto oncogene expression is a very attractive concept, and the 
developments in this field might result in a complete interruption of the hyper-
plastic response of intimal tissue, at the level of the ultimate common pathway. 
5. Conclusions 
Despite 13 years of clinical experience and research in the field of restenosis after 
PTCA, there have been no major breakthroughs in pharmacologic interventions. 
Assessment of the value of drug trials that have been performed in the past is 
extremely difficult because of differences in selection of patients, methods of 
analysis and definition of restenosis. Recently our group has reviewed the influ-
ence of these three factors on the outcome and conclusion of restenosis studies 
(Beatt et al. 1990). Although there is no scientific proof that the tested drugs are 
effective, many clinicians continue to prescribe them to 'prevent restenosis'. 
However, some positive results in selected patients have been reported with 
the use of fish oil, trapidil, verapamil and with lovastatin in post-angioplasty 
patients. Furthermore, we seem to have found an animal model that more closely 
mimics the restenotic lesion found in humans (Schwartz et al. 1991 b). In the near 
future the results will be known of ongoing multicentre trials investigating ACE-
inhibition, serotonin antagonists, hirudin, LMWH, angiopeptin and other pro-
mising drugs such as inhibitors of thrombin production, growth factor blockers, 
prostacyclin analogues and monoclonal antibodies against platelet membrane 
receptors (GP IIb/IIIa) and von Wille brand factor. The outcome of these trials 
may bring us closer to the solution of the restenosis problem. 
Investigators are also looking for local drug delivery systems that allow ade-
quate local drug concentrations without adverse systemic side effects. Wolinsky 
and Thung (1990) demonstrated the feasibility of delivering potentially thera-
peutic agents, ranging from small molecular weight dyes to proteoglycans like 
heparin into the vascular wall. For this purpose they used a perforated catheter, 
and an injection/inflation pressure up to 5 bar, and demonstrated that pharmaco-
logical agents can be selectively delivered to the arterial media and intima. 
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Several other experimental studies have been recently carried out using the 
microporous balloon technique (Van Lierde et al. 1991; Kaplan et al. 1991 a; 
Hong et al. 1991). In the latter study, reduced platelet deposition at the site of 
angioplasty was observed with angiopeptin, without a systemic anticoagulant 
effect. 
Despite these promising experiments, there remains a significantly higher 
incidence (55%) of rupture of the lamina elastica intern a after the use of a micro-
porous balloon compared with conventional balloons (29%) (De Scheerder et al. 
(1992). Hong et al. (1992) inflated a balloon with multiple channels to 6 atmo-
spheres in rabbit iliac arteries. Using this drug delivery balloon they were able to 
deliver insulin and peroxidase without detectable media dissection or disruption, 
although damage of the lamina elastica interna was not reported. The group of 
Lambert (1992) recognised the problem of wall injury, caused by the jet and 
stream effects. For this purpose they designed a balloon with minimal pore size 
and maximal pore density. Balloon inflations during 30 seconds to 5 atmospheres 
in several artery models were performed. Analysis by light microscopy and scan-
ning electron microscopy, revealed endothelial denudation, without clear suben-
dothelial trauma. Proper deposition of the dye was tested by videodensitometric 
measurements, as well as by microscopic cross sectional analysis. 
De Scheerder et al. (1992) furthermore reported the rapid loss of the drug 
from the vessel wall, possibly due to the lack of specific receptors. Only during 
the first 20 minutes after the start of drug delivery were the measured tissue con-
centrations greater than plasma concentrations. 
A perfusion balloon with 32 pores on the surface which allowed pressure-
mediated drug delivery has been evaluated using a dye inplace of a drug (Ruiz et 
al. 1992). No mechanical damage to the vessel wall was seen at the site of balloon 
inflation, while the test dye penetrated to the media and in one animal to the 
adventitia. 
Wilensky et al. (1991 b) employed micro-particles as carriers for drugs. This 
microcarrier drug delivery system could prohibit rapid elimination by the in-
creased network of vasa vasorum in atherosclerotic lesions that causes early out-
ward diffusion. For this study they injected polystyrene particles, 5 flm in diame-
ter, which appeared to be deposited in the intimal and medial layers and the 
adventitia, and which could still be detected after an interval of 14 days. Recently, 
this delivery system containing dexamethasone was successfully applied in rat 
carotid arteries (Villa et al. 1993) (see section 3.4.1). 
Red blood cells have also been investigated as micro carrier (Yellayi et al. 
1991). Heparin was bound effectively to red blood cells in vitro during heating. 
This concept to deliver drugs to the arterial wall has to be explored further. 
Cox et al. (1991) used balloon expandable stents, coated with heparin 
and/or methotrexate in coronary arteries of animals. Although they could not 
show significant differences in SMC proliferation, they demonstrated local relea-
se of the drug over a 3-week period. The concept of bio-absorbable stents is 
receiving attention in in vitro studies. Bier et al. (1991) studied a stent, construc-
ted of purified type I collagen, which expands by hydration assisted by balloon 
inflation. Lumen diameter was moderately reduced without any substantial 
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blood flow reduction. Ebecke et a1. (1991) used the bio-degradable polymer 
poly-I-Iactide. This material was incorporated by incubation with pentosal and 
oligonucleotides. Release of the pharmacological agents was dependent of the 
molecular weight of the poly-I-lac tide used. 
These developments, combining temporary vessel dilatation and slow local 
release of pharmacological agents, seem to possess promising potential in the 
research against restenosis. 
At this moment, enormous efforts are being put into the search for.a treat-
ment modality that will solve the problem of restenosis. Experimental and clinical 
research continues to attempt to find a drug that prevents restenosis in the long 
term. The more we discover regarding the underlying mechanisms, the more 
opportunities there are for further research. Whether this endeavour is only sear-
ching for 'the Holy Grail', or whether there is a feasible drug treatment that works 
on the process of restenosis, without serious adverse effects, remains uncertain. 
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Chapter 2 - Thrombus and restenosis after PTCA 
Background Experimental studies suggest that mural thrombus may be invol-
ved in post angioplasty restenosis. The aim of our study was to examine the role 
of angiographically identifiable thrombus in the clinical situation. 
Methods and Results The study population comprised 2950 patients (3583 
lesions). The presence of angiographically identifiable thrombus either before 
or after the procedure was defined as the presence of a generalized haziness or 
filling defect within the arterial lumen. Restenosis was assessed using both a 
categorical (>50% diameter stenosis at follow-up) and a continuous approach 
(absolute and relative losses). The study population included 160 lesions with, 
and 3423 lesions without angiographically identifiable thrombus. The catego-
rical restenosis rate was significantly higher in lesions containing angiographi-
cally identifiable thrombus, 43.1 % versus 34.4%, p<O.Ol; relative risk 1.449; 
CI 1.051-1.997. The absolute and relative losses were also higher in lesions 
containing angiographically identifiable thrombus (absolute loss 0.43±O. 66 
versus 0.32±O.52; relative loss 0.16±O.26 versus 0.13±O.21, bothp<0.05). 
The higher restenosis in these lesions was due primarily to an increased inciden-
ce of occlusions at follow-up angiography in this group: 13.8% versus 5.7%, 
p<O.OOl. When lesions that went on to occlude by the time offollow-up 
angiography were excluded from the analysis, the restenosis rate between the 
two groups was similar by both the categorical (34.1 % vs 30.4%, p=ns, relative 
risk 1.183; CI 0.824 to 1.696) and continuous (absolute loss, 0.23±O.46 
vs 0.24±O.42, p=ns, relative loss 0.09±o.17 vs 0.09±0.16 p=ns) approaches. 
Conclusions Our results indicate that the presence of angiographically 
identifiable thrombus at the time of the angioplasty procedure is associated 
with higher restenosis. The mechanism by which this occurs is through vessel 
occlusion at follow up angiography. Measures aimed at improving outcome 
in this group of patients should be focused in this direction. 
(Circulation 1996;93:889-897) 
Since the introduction of coronary angioplasty by Gruntzig et al [1] and the sub-
sequent refinements in equipment, the indications for the technique have been 
expanded to include patients with unstable angina [2-4] and acute myocardial 
infarction [5]. In these situations, however, angioplasty carries increased risks, 
thought to relate, in part, to the presence of thrombus. A number of studies have 
demonstrated that the presence of angiographically identifiable thrombus either 
before or after dilatation of a coronary stenosis carries an increased risk of acute 
occlusion [6,7]. The influence of thrombus on long-term restenosis, however, is 
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less clear. Experimental work suggests that local platelet deposition with the sub-
sequent release of a number of chemotactic and mitogenic factors, such as plate-
let-derived growth factor and thrombin, [8] may mediate the fibroproliferative 
response. Recurrent platelet aggregation at the site of injury with associated vaso-
constriction and the consequent increased frequency and severity of cyclic coro-
nary blood flow variations may also play an important role in the subsequent 
development of neointimal proliferation [9]. Although one study suggested that 
thrombus formation and incorporation into the vessel wall may playa pivotal role 
in restenosis [10], this has not been confirmed by other investigators [11]. Few 
clinical studies have actually assessed the role of angiographically identifiable 
thrombus on subsequent restenosis. The aim of this study was to examine the role 
of angiographically identifiable thrombus on long-term restenosis in a large series 
of patients undergoing successful balloon angioplasty and routine follow-up 
QCA assessment. 
Methods 
Patients The study population was taken from the 3582 patients with significant primary 
stenoses in native coronary arteries who were prospectively enrolled into four major res-
tenosis trials [12-15]. These demonstrated that active therapy had no effect on restenosis 
or clinical outcome in the first 6 months after balloon angioplasty, so for the purposes of 
this study the data for the active and placebo groups were pooled. Patients, men or 
women, were eligible for study entry if they were symptomatic or asymptomatic, had sta-
ble or unstable angina pectoris, and showed angiographically significant narrowing in one 
or more major coronary arteries. Patients with recent « 1 week) or evolving myocardial 
infarction and those with significant left main coronary artery disease were excluded from 
the study. 
Angioplasty procedure and follow-up angiography Coronary angioplasty was perfor-
med with a steerable, moveable guide-wire system by the femoral route. Standard balloon 
catheters were used. The choice of balloon type and brand as well as inflation duration 
and inflation pressure were left to the discretion of the operator. Patients were followed 
up for 6 months, at which time a follow-up study was performed. If symptoms recurred 
within 6 months, coronary angiography was carried out earlier. If no definite restenosis 
was present and the follow-up time was <4 months, the patient was asked to undergo furt-
her coronary arteriography at 6 months. 
Quantitative angiography Three coronary angiograms, in total, were obtained for each 
patient: before and after PTCA and at angiographic follow-up. To standardize the 
method of data acquisition and to ensure exact reproducibility of the angiographic stu-
dies, measures were taken as previously described and all angiograms were processed in a 
central angiographic core laboratory [12-15]. The angiograms \vere recorded in such a 
manner that they were suitable for QCA by the computer-assisted Coronary Angiogra-
phy Analysis System (CAAS), which was described and validated earlier [16]. Because 
the computer algorithm is unable to measure total occlusions, a value of Omm was substi-
tuted for the MLD and a value of 100% for the percent diameter stenosis before PTCA. 
In these cases, the post angioplasty reference diameter was substituted for vessel size. 
Definitions Angiographically identifiable thrombus was defined as the presence of a fil-
ling defect within the coronary lumen, surrounded by contrast material, seen in multiple 
projections and in the absence of calcium within the filling defect [17,18]. Alternatively, 
the persistence of contrast material within the lumen or visible embolization of intralumi-
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nal material downstream was also taken to represent intracoronary thrombus. 
Total occlusion was present if no anterograde filling beyond the lesion was visible 
or if faint, late anterograde opacification of the distal segment was present in the absence 
of a discernible luminal continuity [19]. Occlusion at follow-up angiography was similar-
ly defined. 
Vessel size refers to the reference diameter of the relevant coronary segment and is 
represented by the interpolated reference diameter before PTCA. MLD is the point of 
maximal luminal narrowing in the analyzed segment. 
Restenosis: Many criteria have been proposed for the assessment of restenosis [20-
21]. For the purposes of this study, we used, firs, the categorical approach with the tradi-
tional cut-off point of >50% diameter stenosis at follow-up and second, a continuous 
approach using absolute and relative losses [21]. 
Absolute gain and absolute loss represent the improvement in MLD achieved at 
intervention and the absolute change during follow-up, respectively, measured in milli-
metres. Absolute gain is the MLD after PTCA minus MLD before PTCA. Absolute loss 
is the MLD after PTCA minus MLD at follow-up. 
Relative gain and relative loss depict the improvement in MLD achieved at inter-
vention and the change during follow-up, respectively, normalized for vessel size. 
Relative gain is [MLD after PTCA minus MLD before PTCA] divided by vessel size. 
Relative loss is [MLD after PTCA minus MLD at follow-up] divided by vessel size. 
Absolute net gain is the MLD at follow-up minus MLD before PTCA. 
Net gain index is the net gain normalized for the vessel size. Net gain index is [MLD 
at follow-up minus MLD before PTCA] divided by vessel size. 
Statistical analysis Data were analyzed with the SAS statistical software package. A chi 
square test was used to assess differences in categorical variables. A Student's t-test was 
used to assess differences in continuous variables. To test the assumption that the varian-
ces were equal, the folded-form F statistic was used. Whenever this assumption was viola-
ted, the Cochran and Cox approximation of the t test was used. Differences in variables 
with an ordinal scale (severity of clinical outcome) were assessed with the Wilcoxon rank-
sum test. The difference in event-free survival time between the two groups was evalu-
ated by the Kaplan-Meier method with the log rank and Wilcoxon tests. To study the 
relationship between a binary outcome parameter (occlusion at follow-up, the occurrence 
of a clinical event) and multiple categorical and continuous determinants, multiple logis-
tic regression analysis was used. To study the relationship between continuous outcome 
parameters and multiple categorical and continuous determinants, multiple linear regres-
sion analysis was used. Lesion characteristics were investigated with a lesion-based analy-
sis and patient characteristics with a per patient analysis in which a single lesion was rand-
omly selected in patients with multivessel angioplasty. Values of p<.05 were considered 
significant. 
Results 
Baseline patient characteristics, procedural results, and clinical follow-up 
The study population comprised the 2950 patients (3583 lesions, 1.21 lesions 
per patient) who successfully completed the study and had follow-up QCA. The 
overall QCA restudy rate was 86% of all patients undergoing successful PTCA 
with a residual QCA stenosis of <50%. Of 3583 lesions in 2950 patients, 160 
lesions in 158 patients complied with the angiographic definition of thrombus 
present either before or after PTCA. 
The two groups were comparable in terms of age and sex, but patients 
with angiographically identifiable thrombus at PTCA were more likely to have 
Table I 
Demographic data of patients with and without thrombus preangioplasty or post angioplasty 
included in analysis. 
Clinical variable Thrombus present Thrombus absent 
Patients, n 158 2792 
Lesion, n 160 3423 
Men, 'X, 83 82 
Age,y 57 ±9.3 55.3 ±9.3 
Ever smoked, % 74 75 
Current smoker, % 22 18 
Hypertension, % 36 31 
Diabetes, % 8 11 
Hyperlipidemia, % 35 32 
History of previous PTCA, % 4* 
History of previous MI, % 61 42# 
History of previous CABG,% 3.5 4.5 
Pain at rest, % 28 34 
No. of vessels diseased, % 
lVD 61 59 
2VD 33 32 
3VD 6 9 
MI indicates myocardial infarction; CABG, coronary artery bypass graft surgery; and VD, 
vessels diseased. * p<0.05, # p<O.OO 1 
Figure 1 
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sustained a previous myocardial infarction and less likely to have had a previous 
PTCA (Table I). There were, however, substantial differences in lesion and pro-
cedural characteristics between the two groups (Table II). Thrombotic lesions 
were more likely to be located in the RCA than in the LAD and had a much higher 
proportion of total occlusions and multiple irregularities. They were also more 
likely to require a larger balloon and a greater number and duration of inflations. 
After the procedure, this group of lesions was also more likely to have a dissection 
(Table II). 
Forty-four (28%) of the patients with angiographically identifiable throm-
bus present and 625 (22.4%) of the patients without thrombus had a clinical end 
point during follow-up (p=0.116). The individual components of death, myo-
cardial infarction, coronary artery bypass graft surgery and repeat PTCA were 
0%, 8.3%, 2.6% and 17.2% respectively, for lesions containing angiographically 
identifiable thrombus and 0.2%, 2.6%, 2.5% and 17.0% for lesions without 
thrombus (p=0.053). The mean time to clinical end point was significantly less in 
the angiographically identifiable thrombus group (63±63 vs 92±56 days, p<0.05, 
Figure 1a), and when we compared the pattern of occurrence of clinical end 
points by way of the log rank test, the probability value was 0.051, whereas the 
Wilcoxon test, which places more emphasis on early survival times, rendered a 
value of p=0.026, indicating the diverging survival curves in the beginning. 
When lesions that went on to occlude at the time of follow-up angiography were 
excluded from the analysis, there was no significant difference in the mean time 
to clinical end point (Figure 1b), and the log rank test gave a value of p=0.209 
whereas the Wilcoxon test rendered a value of p=0.159, suggesting that the 
excess early events were related to the occlusions at follow-up angiography. 
To exclude the possibility of a selection bias influencing our results, we also 
examined the incidence of thrombus-laden lesions and clinical end points in the 
14% of the population in whom full QCA measurements were not available and 
who were therefore excluded from the study population. The incidence of throm-
bus in these patients (6.7%) was comparable to that in our study population 
(5.4%, p=ns). Of these patients with thrombus, 22.6% and of patients without 
thrombus, 22.6% had a clinical end point during follow-up (p= 1.000). The indi-
vidual worst clinical end point components of death, myocardial infarction, coro-
nary artery bypass graft surgery, and repeat PTCA were 3.2%. 9.7%, 3.2% and 
6.5%, respectively, for lesions with and 3.5%, 3.2%, 5.8% and 10.2% for lesions 
without thrombus (p=0.403). 
QCA analysis Satisfactory QCA was performed in a mean of 2.12 matched 
angiographic projections per lesion had performed (Table III). The reference 
diameter did not change from before to after the procedure but was significantly 
larger in lesions containing angiographically identifiable thrombus, and this dif-
ference remained at follow-up (Table III). Although the MLD before angioplasty 
was significantly smaller in lesions containing angiographically identifiable 
thrombus, the MLD after angioplasty was similar. The residual percent stenosis 
after PTCA was higher in the angiographically identifiable thrombus group, as 
were the absolute and relative gains (Table III, Figure 2). At follow-up, although 
the MLD was similar in both groups, the percent stenosis was significantly higher 
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Table II 
Baseline angiographic and procedural data of lesions. 
Lesion type Thrombus 
Number oflesions 160 
Lesion location, 'XI 
LAD 33.8 
LCX 20.6 
RCA 45.6 
Type of lesion 'x. 
Multiple irregularities 13.0 
Total occlusion 20.0 
Tandemlesion 1.3 
Branch point in lesion 28.0 
Lesion calcification 16.9 
PTCA procedure 
Nominal size of largest balloon, mm 3.00 ±0.43 
Balloon-to-artery ratio 1.12±0.18 
Total number of inflations 4.2 ±2.9 
Total duration of inflation, s 380 ±325 
Maximum inflation pressure, atm 8.35 ±2.53 
Post PTCA result 
Dissection at the dilated site, 'x. 54.4 
Table III 
No thrombus 
3423 
43.2 
25.0 
31.8 
7.6 
6.8 
4.2 
32.8 
12.1 
2.85 ±0.43 
1.13±0.19 
3.53 ±2.3 
308 ±266 
8.48 ±2.50 
33.1 
Significance level 
0.0040 
0.0400 
0.0000 
0.1120 
0.4460 
0.0990 
0.0001 
0.4345 
0.0013 
0.0016 
0.5423 
0.0000 
Quantitative analysis of 160 lesions with and 3423 lesions without thrombus before or after angioplasty 
included in analysis. DS indicates diameter stenosis. 
Thrombus present 
No. 
Reference diameter, mm 
Before angioplasty 
After angioplasty 
At follow-up 
MLD,mm 
Before angioplasty 
After angioplasty 
At follow-up 
Differences in MLD 
Absolurte gain, mm 
Relative gain 
Absolute loss, mm 
Relative loss 
Absolute net gain, mm 
Net gain index 
Loss index 
Percentage stenosis 
Before angioplasty 
After angioplasty 
At follow-up 
DS at follow-up > 50% 
Thrombus 
160 
2.77 ±0.54 
2.80 ±0.53 
2.87 ±0.64 
0.88 ±0.52 
1.80 ±0.35 
1.37 ±0.71 
0.82 ±0.53 
0.34 ±0.19 
0.43 ±0.66 
0.16 ±0.26 
0.49 ±0.72 
0.18 ±0.27 
1.57 ± 13.59 
67.78 ± 18.27 
35.15 ±7.45 
51.71 ±23.70 
43.13 
No thrombus 
3423 
2.60 ±0.54 
2.65 ±0.51 
2.67 ±0.56 
1.01 ±0.39 
1.75 ±0.36 
1.44 ±0.58 
0.75 ±0.41 
0.29 ±0.16 
0.32 ±0.52 
0.13 ±0.21 
0.43 ±0.57 
0.17±0.23 
0.46 ±2.44 
60.63 ± 14.30 
33.38 ±8.37 
45.71 ±19.00 
34.36 
Significance level 
0.0006 
0.0007 
0.0000 
0.0001 
0.0868 
0.1552 
0.0000 
0.0002 
0.0070 
0.0339 
0.1970 
0.5050 
0.0002 
0.0000 
0.0039 
0.0001 
0.0280 
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in lesions containing thrombus (Figure 2, Table III), as were the categorical res-
tenosis rate (43.1% vs 34.4% p<O.Ol; relative risk, 1.449; CI, 1.051-1.997) and 
the absolute and relative losses (Table III, Figure 3). 
The higher restenosis rate in the angiographically identifiable thrombus 
group was predominantly due to an increased number of occlusions at follow-up 
angiography (13.8% vs 5.7%, p<O.OOl; Relative risk, 2.639; 95% CI, 1.645 to 
4.233). When lesions that went on to occlude at follow-up angiography were 
excluded from the analysis, there remained a tendency for a higher categorical 
restenosis rate in the thrombus group (34.1 % vs 30.4%; relative risk, 1.183; CI, 
0.824 to 1.696), but this was no longer statistically significant (p=0.411). The 
absolute and relative losses were now also similar (0.23±O.46 vs 0.24±0.42 and 
0.09±O.17 vs 0.09±O.16, respectively, both p=ns). 
Multiple linear regression analysis We have previously demonstrated that ves-
sel size, MLD before PTCA, absolute gain, and LAD location make a significant 
contribution to late angiographic outcome [22]. Adding thrombus to this model 
significantly improved its predictive value. Least-squares means for absolute loss 
were 0.404 for lesions with thrombus and 0.318 for lesions without thrombus. 
The probability value of adding the variable thrombus to the model was 0.037. 
Adding thrombus to the model when lesions that went on to occlude at follow-up 
angiography were excluded did not improve its predictive value. Least-squares 
means for absolute loss were 0.222 for lesions with thrombus and 0.243 for 
lesions without thrombus. The probability value of adding the variable thrombus 
to the model was 0.549. 
To ascertain whether the trend towards a worse clinical outcome in patients 
with thrombus was related to differences in the underlying baseline characteris-
tics, we corrected for these variables to see whether thrombus had an indepen-
dent predictive value. We performed logistic regression with the above-mentio-
ned baseline characteristics as covariates resulting in a value for the variable 
thrombus of p=0.038, implying that thrombus has a positive relationship with the 
probability of a clinical end point. Performing the analysis when lesions that went 
on to occlude at follow-up angiography were excluded gave a value of p=0.183, 
suggesting that the positive relation with the probability of a clinical end point 
was related to occlusion at follow-up angiography. 
Uni and multi-variate analyses of occlusions at follow-up angiography The 
finding that the higher restenosis in lesions containing angiographically identifia-
ble thrombus was predominantly due to an increased number of occlusions at fol-
low-up angiography prompted us to examine the time to clinical and angiograph-
ic follow-up and a number of variables predictive of late occlusion in this group 
(Table IV). The time to clinical and angiographic follow-up was significantly 
shorter in lesions that occluded at the time of angiographic follow-up. These 
lesions had a higher incidence of total occlusion, a tighter stenosis before PTCA, 
a longer duration of inflation with the use of a smaller balloon in a smaller vessel 
with a tighter residual MLD, and a greater likelihood of a dissection after PTCA. 
Logistic regression analysis confirmed the presence of a total occlusion before 
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Table IV 
Univariate analysis of patient-, lesion-, and procedure-related characteristics relevant to occlusion 
at follow-up angiography in 160 lesions containing thrombus. 
Lesion type Occlusion at No occlusion at Significance level 
follow-up (n=22) follow-up (n=138) 
Anginal class, 'X) .365 
None 4.6 11.6 
CCS class I 9.1 13.8 
CCS class II 40.9 26.8 
CCS class III 31.8 22.5 
CCS class VI 13.6 25.4 
Duration of angina, wk 106 ±219 63 ± 132 0.326 
Medication at screening, 'X) 
Antivoagulants 0 0.7 1.000 
Thrombocyte aggregation inhibitor 68.2 65.2 0.976 
Aspirin 80.0 74.2 0.872 
Dipyridamole 20.0 7.8 0.317 
Laboratory investigations 
Hemoglobin 8.70 ± 1.00 8.81 ±0.86 0.593 
Hematocrit 0.42 ±0.04 0.42 ±0.04 0.863 
Platelet count 274 ±55 267 ±80 0.691 
Lesion location, 'X) 0.085 
LAD 13.7 37.0 
LCX 22.7 20.3 
RCA 63.7 42.8 
Lesion characteris tics, 'X) 
Concentric 26.3 36.6 0.542 
Multiple irregularities 10.5 13.4 1.000 
Branch point in stenosis 16.7 16.4 1.000 
Coronary artery bend 15.6 24.1 0.615 
Calcified lesion 31.8 14.5 0.088 
Total occlusion 45.5 15.6 0.003 * 
Degree of collateral supply 0.138 
No collaterals 66.7 81.3 
Slight (mininal perfusion) 0 7.3 
Medium (partial perfusion) 26.7 7.3 
Major (complete perfusion) 0 1.0 
not assessed 6.7 3.1 
PTCA procedure 
Nominal size of largest balloon, mm 2.81 ±0.40 3.03 ±0.43 0.0264 
Balloon-to-artery ratio 1.10 ±0.19 1.12 ±0.18 0.7172 
Total number of inflations 4.5±3.2 4.2 ±2.9 0.6687 
Total duration of inflation, s 530 ±484 356 ±289 0.0248 * 
Maximum inflation pressure, atm 9.10 ±2.93 8.24 ±2.45 0.2159 
Post PTCA result 
Dissection at the dilated site, 'X) 77.3 50.7 0.036 
Quantitative angiographic measurements 
Reference diameter, mm 
Before angioplasty 2.62 ± 0.53 2.79 ±0.54 0.3101 
After angioplasty 2.54 ±0.39 2.84 ±0.54 0.0036 * 
MLD,mm 
Before angioplasty 0.55 ±0.56 0.93 ±0.49 0.0052 
After angioplasty 1.66 ±0.30 1.82 ±0.35 0.0277 
Table IV vervolg 
Lesion type 
Differences in MLD, mm 
Absolute gain 
Relative gain 
Percentage stenosis 
Before angioplasty 
After angioplasty 
Lesion length post-PTCA, mm 
Days to follow-up 
Occlusion at 
follow-up (n=22) 
1.11±0.60 
0.44 ±0.23 
79.00 ±20.40 
34.35 ±8.38 
6.14±1.99 
127 ±79 
No occlusion at Significance level 
follow-up (n=138) 
0.89 ±0.51 0.1161 
0.33±0.18 0.0360 
65.99 ± 17.33 0.0088 
35.28 ±7.35 0.6276 
6.26 ±2.35 0.8032 
160 ±460 0.007 
CCS indicates Canadian Cardiovascular Society angina classification. LAD, left anterior descending; 
LCX, left circumflex; RCA, right coronary artery. Values are mean ± SD. 
* Retained in multivariate model. 
Table V 
Result of multiple logistic regression analysis to evaluate the respective contributions of clinical, angio-
graphic, and procedural variables to occlusion at follow-up angiography in lesions containing thrombus. 
Variable Regression coefficient Standard error of P 
regression coefficient 
Presence of total occlusion pre-PTCA 0.379 0.163 0.021 
Total inflation time, s 0.002 0.0006 0.002 
Reference diameter post-PTCA, mm -1.634 0.630 0.009 
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PTCA and total inflation time (seconds) to be positively related and the reference 
diameter after PTCA (millimetres) to be negatively related to occlusion at fol-
low-up angiography (Table V). 
Discussion 
Our study has specifically addressed the role of angiographically identifiable 
thrombus in long term restenosis in a large patient population with a control 
group, a high angiographic follow-up rate, and QCA at a pre-determined time 
interval. We have demonstrated, using both a categorical and a continuous 
approach, that restenosis is significantly increased by the presence of angio-
graphically identifiable thrombus during coronary angioplasty. Furthermore, we 
have also shown that the mechanism for this is an increased rate of occlusion at 
follow-up angiography and that this is positively related to the presence of a total 
occlusion before PTCA and the total duration of balloon inflation and negatively 
related to the residual stenosis after intervention. If lesions that subsequently 
occlude at follow-up angiography are excluded from the analysis, then restenosis 
is similar in both groups. These findings support and expand on our current 
understanding regarding the role of thrombus in long-term luminal renarrowing 
and occlusion after successful PTCA. 
Our findings support a. role for thrombus in restenosis after successful 
PTCA in terms of both clinical and angiographic outcomes. They suggest that 
the contribution thrombus makes to restenosis relates to vessel occlusion by the 
time of follow-up angiography. The timing of this occlusion is unclear. If it 
occurred early, it is likely to have been the end result of an acute thrombotic pro-
cess, whereas if it occurred late, it would be the final end result of the process of 
restenosis itself. We do not know when the occlusion at follow-up angiography 
occurred in our patients, so our results must be speculative. We suspect, how-
ever, that it occurred early. In support of this is the higher incidence of previous 
myocardial infarction in the thrombus group (successful dilatation of the infarct-
related vessel is associated with a higher rate of early silent occlusion [23]) and 
the Wilcoxon test indicating early divergence in the survival curves when occlu-
sions at follow-up angiography are included. Additional evidence comes from the 
much earlier occurrence of clinical and angiographic end points in the thrombus-
laden lesions that had occluded by the time of follow-up angiography and the fact 
that the excess in clinical end points is driven by a much higher incidence of acute 
myocardial infarction. Our hypothesis that the occlusions occurred early is also 
supported by evidence in the literature suggesting that 2% to 8% of elective 
PTCA lesions [24] occlude during the first 24 hours, silently in many cases. 
Thus, although our data support a role for thrombus in vessel occlusion by the 
time of follow-up angiography and hence restenosis, they do not provide any 
strong evidence to support a role for angiographically identifiable thrombus in 
late myointimal hyperplasia. Further prospective studies are thus required to eva-
luate this important matter further. 
Univariate regression analysis was suggestive of a number of procedural and 
angiographic variables related to occlusion at follow-up angiography. These 
included the presence of a total occlusion and a tighter stenosis before PTCA, a 
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longer duration of inflation with the use of a smaller balloon diameter in a smaller 
vessel with a tighter residual MLD, and a greater likelihood of a dissection after 
PTCA at the dilated site. Thus, the more difficult dilatation of a more complex 
lesion in a smaller vessel with a less satisfactory result would be more likely to 
occlude by the time of follow-up angiography. Multivariate regression analysis 
confirmed the presence of total occlusion before PTCA and a longer total infla-
tion time to be positively related to the risk of subsequent occlusion and the refe-
rence diameter after PTCA to be negatively related. The relationship between 
total occlusion and subsequent risk of occlusion may be secondary to the highly 
thrombogenic surface generated by the successful dilatation of a total occlusion, 
without a pre existing endothelial lining [25]. Successful dilatation of a total 
occlusion may also expose flowing blood to activated thrombin bound to fibrin in 
the internal layers of a previously formed thrombus. The prothrombotic proces-
ses stimulated by the activated thrombin would be even more severe that those 
associated with the deeply injured artery and would further accelerate thrombosis 
after PTCA in these lesions [26,27] thus contributing to both enhanced local 
thrombus formation after successful dilatation of these lesions and an increased 
likelihood of thrombotic occlusion. The total inflation time may represent the 
more complex dilatation of a total occlusion, multiple irregularities, or a more 
complicated angioplasty. This is further supported by the higher incidence of 
dissections requiring prolonged inflation in lesions that occlude by the time of 
follow-up angiography. The negative relation between increasing vessel size and 
subsequent occlusion is probably representative of the local flow dynamics [28]. 
Our study has a number of limitations. First, it was a retrospective analysis 
of prospectively gathered data and is hence subject to the limitations inherent in 
any retrospective analysis. For example, there are significant differences in the 
baseline clinical, angiographic and procedural characteristics between the two 
groups that could have been responsible for, or associated with, the outcome of 
the procedure, including the presence of thrombus. Patients with angiographic 
evidence of thrombus before or after angioplasty had a significantly greater histo-
ry of previous myocardial infarction and a significantly lower proportion of pre-
vious coronary angioplasty, both of which may have had an impact on the clinical 
and angiographic outcomes. There is evidence for a silent early occlusion after 
successful acute dilatation of infarct-related vessels [5,23] and that after stent 
implantation in coronary vessels supplying an infarcted segment, the low flow 
makes the vessel more prone to thrombotic occlusion [29]. Similar mechanisms 
may be operating in our study, but we do not know whether the vessel dilated was 
the infarct-related vessel, and we do not know the length of time since myocardial 
infarction, except that it was longer than 1 week. Similar arguments also apply to 
the history of previous PTCA. Again, we do not know whether the present proce-
dure was performed at the same site, and it is not possible to draw conclusions 
about what effect it may have had on subsequent clinical and angiographic outcomes. 
There were also significant differences in lesion location and lesion charac-
teristics. There was a higher proportion of lesions containing thrombus in the 
RCA and less in the LAD. This may have had an impact on angiographic outco-
me in two ways. First, the RCA is significantly larger than the LAD, and this may 
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explain why the reference diameter in lesions containing thrombus was signifi-
cantly larger. Second, there are significant differences between the two vessels in 
terms of local flow dynamics, vessel geometry and external compressive forces 
[30] that may have a substantial influence on the subsequent risk of occlusion 
[31]. Although lesion location was not a major risk factor in our multivariate ana-
lysis of occlusions at follow-up angiography, it is nonetheless interesting to note 
that the trend was for lesions which occluded to be in the RCA (p=0.085). Thus 
similar mechanisms may be operating in our study. 
The type of lesion was also significantly different, with a greater proportion 
of total occlusions in the thrombus group. Successful dilatation of these may have 
enhanced local thrombus formation and may have contributed to the increased 
incidence of occlusion at follow-up angiography [23,32]. It may also partly 
explain the smaller MLD before PTCA and greater absolute and relative gains in 
this group of lesions. Differences in lesion location and characteristics could also 
have been responsible for the significant differences in the PTCA procedure. For 
example, the prevalence of RCA lesions could explain the larger nominal size of 
the largest balloon, whereas the greater number of inflations and total duration of 
inflation may reflect the more complex dilatation of a total occlusion, multiple 
irregularities, or a more complicated angioplasty. 
Although we tried to compensate for these differences in baseline character-
istics by using multivariate analysis and demonstrated that thrombus has a pre-
dictive value on restenosis and clinical outcome independent of the underlying 
clinical and angiographic characteristics, nonetheless, we cannot exclude the 
possibility of covert factors not available in the study influencing outcome. For 
example, we do not know what proportion of the angiographically identifiable 
thrombus group had a successfully treated occlusive dissection, a recognized risk 
factor for restenosis [33], and total occlusion as a late outcome [34]. 
Second, although the angiographic definition of thrombus we used is the 
standard definition found in the literature, [17,18] the individual sensitivity and 
specificity of the three criteria have, to the best of our knowledge, never been 
addressed. In addition, contrast angiography, although the gold standard for ran-
domized studies, has a poor sensitivity for intra coronary thrombus [18]. When 
we used the above angiographic definition and coronary angioscopy as the gold 
standard, we found the specificity of contrast angiography to be good (100%) but 
the sensitivity to be poor (19.4%). This is in keeping with other evidence in the 
literature. Coronary angioscopy, for example, suggests a very high incidence of 
macroscopic mural thrombus, not identifiable by contrast angiography, after bal-
loon angioplasty [35,36] whereas directional atherectomy suggests that throm-
bus may contribute to arterial narrowing in 8% to 25% of restenosis cases [37]. 
Thus, although our results apply to angiographically identifiable thrombus, they may 
not apply to patients with mural thrombus not visualized by contrast angiography. 
Finally, the study relies on data pooled from four separate restenosis trials 
[12-15]. We believe that the pooling of data was justified, however, since the 
number of patients with angiographically identifiable thrombus present in each 
individual study was limited. Furthermore, the entry criteria for the studies were 
broadly similar, the data pooled were those common to all studies, and the angio-
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graphic criteria were standardized, with one central angiographic core laboratory 
performing the QCA analysis in all studies. In addition, the resulting large study 
population provides a unique opportunity to obtain accurate QCA data at a pre-
determined time interval in a field in which few such data exist to date. 
Clinical implications Our data support previous work suggesting that local 
thrombus formation may result in acute occlusion [7,38,39) and expand it to 
include late subacute occlusion and hence restenosis. This may have important 
clinical implications with regard to recent studies using monoclonal antibodies 
and synthetic peptides directed against the platelet glycoprotein IIblIIla receptor 
[40-42). Although preliminary data suggest that they reduce the need for corona-
ry revascularisation procedures in high-risk angioplasty patients (42), most of the 
reduction occurred in the first 30 days after intervention, and the effects were not 
verified at the angiographic level. Our data would suggest that perhaps some of 
their improved clinical outcome may relate to eliminating subacute occlusion in a 
subset of the population without necessarily affecting the restenosis process. 
Conclusions 
Our results indicate that the presence of angiographically identifiable thrombus 
at the time of the angioplasty procedure is associated with a higher rate of angio-
graphic restenosis. The mechanism by which this occurs is through increased 
vessel occlusion at follow-up angiography. Measures aimed at improving out-
come in this group of lesions should be focused in this direction. 
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Chapter 3 - Experiences of a quantitative corollary allgiographic core laboratory 
Introduction Since its introduction more than 14 years ago [1], percutaneous 
trans luminal coronary angioplasty [PTCA] has been attended by a 17% to 40% inci-
dence of rest enos is, typically developing within 6 months of the procedure [2-5]. 
Each year the number of patients undergoing PTCA has increased and now approa-
ches the number treated with coronary artery bypass grafting [CABG]. In the last 10 
years, experimental models have given us more insight into the restenosis phenome-
non and pharmacological agents have been developed aiming to prevent or reduce 
restenosis. Many of these agents have been investigated in clinical restenosis preven-
tion trials [4-7] and although these agents were able to reduce restenosis in the ani-
mal model, most of the clinical trials failed to demonstrate a convincing reduction in 
the incidence of restenosis in man. In these clinical trials, the primary endpoint has 
been either angiograph-ic [change in minimal luminal diameter at follow-up; > 50% 
diameter stenosis at follow-up; loss> 50% of the initial gain] and / or clinical [death; 
nonfatal myocardial infarction; coronary revascularization; recurrence of angina 
requiring medical therapy; exercise test; quality of life ]. The use of an angiographic 
parameter as a primary endpoint provides the necessary objectively whereby the 
patient population required for statistical analysis numbers between 500 and 700, 
whereas more than 2000 patients are necessary if a clinical endpoint is used [6]. 
Despite the widespread and long-standing use of coronary angiography in cli-
nical practice, as well as the outstanding improvement in image acquisition, the 
interpretation of the angiogram has changed very little and is still reviewed visually. 
However, visual assessment is a subjective evaluation with a large inter- and intra 
observer variability and can therefore not be used in important scientific studies for 
example restenosis prevention trials [8-9]. QCA has the advantage of being more 
accurate and reproducible in the assessment oflesion severity, than visual or hand-
held calliper assessments. At the Thoraxcenter, the computer-assisted Cardiovas-
cular Angiography Analysis System [CAAS] using an automated edge detection 
technique was developed and validated [8,10]. Over the last 3 years, we have been 
the angiographic 'core laboratory' (using the CAAS-system) in 4 restenosis preven-
tion trials with recruitment of patients in Europe, US and Canada. In order to obtain 
reliable and reproducible quantitative measurements over time from coronary 
[ cine] -angiograms, variations in data acquisition and analyses must be minimized. 
(P.W. Serruys, D.P. Foley and P.J. de Feyter (eds.). Quantitative Coronary 
Angiography in Clinical Practice. Kluwer Academic Publishers 1993, the Nether-
lands, 121-135.) 
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Potential problems with angiographic data acquisition and analysis 
[Table I] 
1. Pincushion distortion Pincushion distortion of the image intensifier introdu-
ces a selective magnification of an object near the edges of the image as compared 
with its size in the center [Figure I A]. An inaccuracy in the measurement of the 
minimal lumen diameter of the stenosis over time could be introduced if, for 
example, the stenosis after the angioplasty procedure is filmed in the center and 
at follow-up near the edges of the image intensifier. To overcome this potential 
problem, a cm grid has to be filmed in each mode of the image intensifier in all the 
catheterization rooms to be used before the clinic can start to recruit and rando-
mize patients for a restenosis prevention trial. With this cm grid film, the CAAS 
system calculates a correction factor for each intersection position of the grid 
wires so that the pincushion distortion can be corrected for [Figure 2 B]. 
Fortunately, the newer generations of image intensifiers introduce significantly 
less distortion than the older ones from the early and mid 80's; the degree of dis-
tortion is even less when the lower magnification modes are used with multi-
mode image intensifiers. At present time there are in our database pincushion 
correction factors of 734 different modes of magnification [113 clinics with 285 
angiorooms] from all over Europe, United States and Canada. 
2. Differences in angles and height levels of the x-ray gantry As it is absolute 
mandatory to repeat exactly the same (baseline) views of the coronary segments 
in studies to evaluate changes in lumen diameter over time, we have developed at 
the Thoraxcenter an on-line registration system of the x-ray system parameters 
such as parameters describing the geometry of the x-ray gantry for a particular 
cine-film run [rotation of U-arm and object, as well as distances from isocenter to 
focus, table height], and also selected x-ray exposure factors [kV, mAl. When 
repeat angiography is scheduled, the geometry of the x-ray system is set on the 
basis of the available data, so that approximately the same angiographic condi-
tions are obtained. In a clinical study with repositioning of the x-ray system, it 
was found that the angular variability, defined by the standard deviation of the 
absolute differences of angular settings, was < 4.2 degrees and that the variability 
in the various positions of image intensifier and x-ray source was < 3.0 cm [8,11]. 
As on-line registration of the x-ray system settings is not available in all hospitals, 
we have developed a technician's worksheet that has to be completed during the 
PTCA procedure with detailed information of the procedure [view, catheter 
type, catheter size, balloon type, balloon size, balloon pressure, kV, mA, medica-
tion given] [Figure 2]. In this way minimization of differences in x-ray settings at 
follow-up angiography is ensured. Furthermore, each center intending to partici-
pate in one of the trials is required to provide 2 sample cine-angiograms from 
each of its catheterization rooms for verification of their ability to comply to our 
standards. 
3. Differences in vasomotor tone of the coronary arteries As the vasomotor 
tone may differ widely during consecutive coronary angiographic studies, it 
should be controlled at all times. An optimal vasodilatative drug for controlling 
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Potential problems with angiographic data acquisition and analysis. 
Pincushion distortion of image intensifier 
2 
3 
4 
5 
Differences in angles and height levels of x-ray system settings 
Differences in vasomotor tone 
Variation in quality of mixing of contrast agent with blood 
Catheter used as scaling device (angiographic quality, influence of contrast in 
catheter tip on the calibration factor, size of catheter) 
6 
7 
Deviations in size of catheter as listed by the manufacturer from its actual size 
Variation in data analysis 
Table II 
Influence of nitroglycerin on the mean diameter of non diseased segments in 
202 patients in single projection. 
Mean Diameter Without Nitro 
(mm) Post-PTCA N = 34 
Pre-PTCA 3.12 ±0.63 
Post-PTCA 3.01 ±0.64 
Follow-up 3.18 ±0.55 
Delta (Post - Pre) -0.11 ±0.27 
Delta (Fup - Pre) +0.06 ±0.22 
Figure 1 
Exalllple of pillCllshioll distortioll 
illtroduced by the image il/tel/slfier 
(A, see arrow) al/d of the calculated 
correctioll factor with the lise of the 
filmed ClIl-grid (8). 
With Nitro 
Post-PTCA N = 168 
2.74 ±0.63 
2.75 ±0.59 
2.82 ±0.63 
+0.02 ±0.21 
+0.07 ±0.22 
t-test 
p < 0.001 
P = ns 
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the vasomotor tone of the epicardial vessel should produce a quick and maximal 
response without influencing the hemodynamic state of the patient. Only nitrates 
and calcium antagonists satisfy these requirements. On isolated human coronary 
arteries calcium antagonists are more vasoactive but they act more slowly; in the 
in-vivo situation, however, the nitrates are more vasoactive than the calcium 
antagonists [12-15]. 
We have measured in 202 patients the mean diameter of a normal segment 
of a non-dilated vessel in a single view pre-PTCA, post-PTCA and at follow-up 
angiography 6 months later. In cases where a stenosis of the left anterior descen-
ding artery [LAD] had been dilated, a non-diseased segment in the left circum-
flex artery [LC] was analyzed and vice versa; where dilatation of a stenosis in the 
right coronary artery [RCA] was performed, a non-diseased segment proximal to 
the stenosis was used for analysis. All patients were given intracoronary [either 
0.1 to 0.3 mg of nitroglycerin or 1 to 3 mg isosorbide dinitrate [ISDN] before 
PTCA and before follow-up and all but 34 received similar dosage before the 
angiogram immediately after PTCA. Table II summarizes the results of the ana-
lyses; a decrease in mean diameter of -0.11 ± 0.27 [mm] was observed in the seg-
ments of patients studied without intracoronary nitrates post-PTCA, whereas a 
small increase was seen of +0.02 ± 0.21 [mm] in the group with intracoronary 
nitrates prior to post-PTCA angiography [p < 0.001]. No difference in the mean 
diameter between pre-PTCA and follow-up angiography was measured. 
In summary, the vasomotor tone should be controlled in quantitative 
coronary angiographic studies. This is only achieved by means of a vasodilator 
drug that produces fast and complete vasodilation without any peripheral effects. 
Therefore, we strongly advocate the use of 0.1 to 0.3 mg nitroglycerin or 1 to 3 
mg ofISDN pre-PTCA, after the last balloon inflation before repeating the views 
used pre-PTCA and at follow-up angiography. 
4. Influence of contrast agent on vasomotor tone of epicardial coronary 
agents Jost et colleagues have clearly demonstrated that the vasodilative changes 
in vessel dimensions due to contrast medium administration are significantly 
smaller with the use of a non ionic rather than ionic contrast medium [16]. 
Therefore, in quantitative coronary angiographic studies, non ionic contrast 
media with iso-osmolality should be applied. 
It has been suggested to administer the contrast medium by an ECG trigge-
red injection system. This is however not [yet] feasible during routine coronary 
angioplasty even in a setting of a clinical trial. 
5. Catheter used as scaling device for measurements of absolute diameters 
Angiographic versus microcaliper measured size of catheter The image quality of the 
(x-ray radiated) catheter is dependent on the catheter material, concentration of 
the contrast agent in the catheter and kilovoltages of the x-ray source. Reiber et 
al. in 1985 showed that there was a difference of +9.8% in angiographically meas-
ured size as compared with the true size for catheters made from nylon. Smaller 
differences were measured for catheters made from woven dacron [+0.2%], poly-
vinylchloride [-3.2%] and polyurethane [-3.5%] [17]. It was concluded that nylon 
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Table III 
Comparison of the true sizes of 7F, 8F, 9.5F, I OF and IIF catheter segments with angiographically 
measured dimensions (measurements were averaged over the two different fillings (water and contrast 
medium), each at two different kilovoltages (60 and 90 kV). 
True size Angiographically measured size Average diff 
(mm) (mm) (%) 
7F Catheters 
Schneider 2.26 2.23±O.03 -1.16 
Scimed 2.21 2.36±O.07 6.77 
USCI 2.31 2.29±O.18 -1.03 
8F Catheters 
Medtronic 2.58 2.6I±O.05 1.58 
Schneider 2.63 2.67±O.01 1.60 
Scimed 2.58 2.66±O.06 3.01 
USCI 2.59 2.69±O.03 3.76 
9F Catheters 
Schneider 2.95 2.94±O.03 -0.06 
9.5 F Catheter 
DVI 3.17 3.2I±O.18 1.18 
10 F Catheter 
Medtronic 3.25 3.30±O.04 1.42 
Schneider 3.29 3.39±O.07 3.15 
11 F Catheter 
DVI 3.66 3.52±O.11 -3.93 
Mean value ±standard deviation 
Figure 3 
Relationship between the calibration 
factor (1IIIn/pixel) calculated using an 
contrast empty (flushed) catheter versus 
a contrast filled catheter. A considerable 
/lulI/ber of lIleaSllrelllellts with the 
contrast filled catheter ate above the line 
of identity. 
0.251----------;:;;====::;:=:;-/~7] 
0.2 
0.15 
FULL 0.1 
0.05 
0.05 0.1 
EMPTY 
}' = 0.007 + 1.045 X 
R.::::: 0.86,' P< 0,001 
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catheters could not be used for quantitative studies. Recently our group has char-
acterized the angiographic properties of newer generation catheters (Table III). 
Also for these catheters small differences were found between the true size and 
the angiographically measured size (average difference: -1.16% to 6.77%). 
Therefore, it was concluded that these catheters may be used for quantitative stu-
dies when the CAAS edge detection algorithm is applied. 
Influence of variation in contrast filling of the catheter on calibration It was also 
demonstrated that catheters made from woven dacron, polyvinylchloride and 
polyurethane when flushed with saline had, identical image contrast qualities 
whereas differences in image contrast at various fillings [air, contrast with 3 diffe-
rent concentrations [Urografin-76, Schering AG, Berlin, Germany; 100%, SO%, 
2S%] of the catheters acquired at different kilovoltages was seen [17]. 
In addition, we measured the calibration factor in 9S catheters from IS dif-
ferent clinics to compare contrast with filled saline catheter. Figure 3 summarizes 
our results. In a considerable number of cases, a difference in calibration factor 
was present with an average calibration facwr of 0.143 ±0.020 [mm/pel] for the 
flushed [contrast empty] catheter versus 0.lS6 ± 0.030 [mm/pel] for the catheters 
filled with contrast [p < 0.001]. This means that with the use of a contrast filled 
catheter instead of a flushed catheter, the minimal luminal diameter will have an 
apparent increase in diameter value of ± O.OS mm pre-PTCA, ± O. IS mm post-
PTCA and ±0.20 mm for the reference diameter. 
For this reason we strongly advise the clinics to flush the catheters before 
each cine-run to have an 'identical flushed catheter' for calibration throughout 
the study period. 
Size of the catheter Until recently only 7F and 8F catheters have been used for fol-
low-up angiography and from earlier studies it is known which of the catheters 
are preferred for quantitative analysis [17,18]. However, SF and 6F catheters are 
available and increasingly being used for follow-up angiography. Koning et al. 
have carried out a study to determine whether these catheters can be used for cali-
bration purposes (Internal Report), (Table IV). They found that the differences 
between the true and angiographically measured diameters of the SF and 6F 
catheters in all cases were lower for 6F than for the SF catheters. Secondly, the 
Argon catheters showed the largest overall average difference, followed by the 
Edwards catheters and the SF USCI catheter. The Cordis catheters, the 6F right 
Judkins Medicorp, the 6F Schneider and 6F USCI have the lowest average diffe-
rences between the true and measured diameters. However, none of the catheters 
satisfy earlier established criteria [17], being that the average difference of the 
angiographically assessed and true diameter is lower than 3.S% and that the stan-
dard deviation of the measured diameters be smaller than O.OS mm, under the fol-
lowing conditions: filled with 100% contrast concentration, filled with water, 
acquired at 60 kV and 90 kV. On the basis of these results, it was concluded that 
SF or 6F catheters should not be used for QCA studies using the CAAS-system at 
the present time. 
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Table IV 
Comparison of the true sizes of the SF and 6F catheter segments with angiographically measured dimen-
sions (measurements were averaged over the three different fillings (water, contrast medium concentra-
tions of 185 and 370 mg IIcc), each at two different kilovoltages (60 and 90 kV). 
True size (mm) Angiographically Average diff (%) 
SF Catheters 
Argon 
Cordis 
Edwards 
Mallinckrodt 
Schneider 
USCI 
6F Catheters 
Argon 
Cordis 
Edwards 
Medicorp (left) 
Medicorp(right 
Mallinckrodt 
Schneider 
USCI 
1.66 
1.73 
1.66 
1.73 
1.69 
1.61 
1.98 
2.01 
1.96 
1.97 
1.99 
1.97 
1.94 
1.99 
measured size (mm) 
1.85 ±0.09 
1.79 ±0.15 
1.80 ±0.08 
1.72 ±0.14* 
1.79 ±0.07 
1.75 ±0.14 
2.14±0.07 
2.03±0.11 
2.10 ±0.07 
2.07 ±0.04 
2.02 ±0.10 
1.91 ±0.15* 
2.00 ±0.09 
2.06 ±0.08 
11.3 
3.2 
8.5 
-0.8 
6.1 
8.5 
8.1 
1.1 
7.1 
5.1 
1.6 
-2.9 
3.0 
3.4 
Mean value ± standard deviation, * measurements of the Softouch tip will be more favourable 
Table V 
Intra- and inter-observer variability of 96 catheter diameter measurements with an electronic 
microcaliper. 
Intra-observer variability 
N Overall mean Mean of diff P-value 
9F 
8F 
7F 
6F 
30 
114 
132 
12 
2.75 
2.56 
2.25 
1.94 
Inter-observer variability 
N 1 vs 2 Mean diff 
9F 20 0.00 
8F 76 0.00 
7F 88 0.00 
6F 8 -0.02 
0.008 
0.009 
0.001 
-0.002 
S.d. diff 
0.04 
0.03 
0.01 
0.03 
S.d. = stalldarddeviatioll; dlff = dl//erellc 
NS 
NS 
NS 
NS 
1 vs 3Mean diff 
0.00 
0.00 
-0.01 
-0.01 
S.d.ofdiff 
0.026 
0.028 
0.008 
0.006 
S.d. diff 
0.02 
0.02 
0.02 
0.00 
2 vs 3 Mean diff 
0.00 
0.00 
0.00 
0.01 
S.d diff 
0.04 
0.03 
0.02 
0.03 
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6. Deviations in the size of the catheter as listed by the manufacturer In our 
experience, the size of the catheter as specified by the manufacturer often devia-
tes from its actual size, especially disposable catheters. If the manufacturer can-
not guarantee narrow ranges for the true size of the catheter, all catheters should 
be measured by a micrometer. Therefore, all catheters used during the angioplas-
ty procedure and at follow-up are collected, labelled and sent to the angiographic 
core laboratory for actual measurement. 
As the actual measurement can be hampered by individual variation, we 
have evaluated the inter- and intraobserver variability of catheter measurements 
at the Core Laboratory. A total of 96 catheters with different sizes [6F to 9F] were 
measured by 3 different analysts independent of each other. One month later, all 
three analysts measured the same catheters for a second time, unaware of the 
results from the first time (Table V). The intraobserver variability was excellent 
with a mean difference of less than 0.01 mm and a standard deviation of the diffe-
rence of less than 0.03 mm for all catheter sizes. Similarly the interobserver varia-
bility between the 3 analysts showed a mean difference of less than 0.03 mm and a 
standard deviation depending on the size between 0.00 and 0.04 mm. We conclu-
de that the catheter can be measured with an excellent accuracy and precision. 
7. Variation in data analysis Minimal luminal diameter From the contours of 
the analyzed segment,following pincushion correction and calibration, a diame-
ter function can be determined by computing the distances between the left and 
right edges. From these data a number of parameters can be obtained. Direct 
measurements include 1) minimal luminal diameter, 2) lesion length 3) obstruc-
tion and reference area. Interpolated measurements include the reference diame-
ter while percent diameter stenosis and percent area stenosis are derived meas-
urements. 
Particularly, the minimal luminal diameter is of great importance as it pre-
sents to the inverse fourth power in the formulas describing the pressure loss over 
a coronary obstruction. Moreover to determine the effect of interventions on the 
severity of coronary obstructions, one should compute the changes in minimal 
luminal diameter and not those in percent diameter stenosis, as the reference 
position in general will also be affected by intervention. 
A major limitation of edge detection (aside from the technical quality of the 
cine-film) is the analysis of the post-angioplasty result. In particular, dissections 
are a frequent occurrence following PTCA and the resulting haziness, irregular 
borders or extravasation of contrast medium makes edge detection difficult. 
There is no ideal solution to this problem. If a dissection is present on the post-
angioplasty angiogram, the computer 'decides' whether the extra luminal defect is 
included or excluded in the analysis, thereby avoiding subjective bias. 
To determine the accuracy and precision of the post-angioplasty luminal 
assessment by edge detection, a consecutive series of 117 end-diastolic post-
PTCA cine-frames were analyzed by two independent analysts. The agreement 
by the standard deviation of the between-analysis difference was 0.21 mm. 
Therefore, quantitative coronary angiography shows that a small discrepancy 
exists in the post-PTCA luminal assessment between two analyses. This observa-
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tion suggests that the edge detection is an acceptable method for objectively 
assessing the result of coronary balloon angioplasty. 
Reference diameter Although the absolute minimal luminal diameter is one of 
the preferred parameters for describing changes in the severity of an obstruction 
as a result of an intervention, percent diameter stenosis is a convenient parameter 
to work with in individual cases. The conventional method of determining the 
percent diameter stenosis of a coronary obstruction requires the user to indicate a 
reference position. It is clear that this computed percent diameter stenosis of an 
obstruction depends heavily on the selected reference position.In arteries with a 
focal obstructive lesion and a clearly normal proximal arterial segment the choice 
of the reference diameter is straightforward and simple. However in cases where 
the proximal part of the arterial segment shows combination of stenotic and ecta-
tic areas, the choice may be difficult. To minimize these variations, we have 
implemented many years ago an interpolated technique, which is not user defi-
ned to determine the reference diameter at the actual stenosis site without opera-
tor interference. This basic idea behind this technique is the computer estimation 
of the original diameter values over the obstructive region (assuming that there 
was no coronary disease present) based on the diameter function. Following this 
approach the reference diameter is taken as the value of the polynomial at the 
position of the minimal luminal diameter. The interpolated percent diameter ste-
nosis is then computed by comparing the minimal diameter value at the site of the 
obstruction with the corresponding value of the reference diameter function. 
Length of analyzed segment Anatomic landmarks such as bifurcations are used 
for the manual definition of start and end points of arterial segments so as to min-
imize the problem of non identical analyses. For that purpose, drawings are made 
by the investigator of all different views suitable for quantitative analysis, pre-
PTCA, post-PTCA and at follow-up. In addition, a hard-copy is made of every 
drawing, to enable analysis of the exact same segments at follow-up angiography. 
Manual corrections For those parts along the detected arterial segment, where 
the observer does not agree with the automatically detected boundaries, manual 
correction by means of a writing table are possible. If the manual corrections are 
performed after the first iteration of the edge detection procedure, the system is 
allowed to find an optimal path within these limits during second iteration. It has 
been our experience that in almost all cases the contour will then follow the desi-
red path at these locations. An advantage of this approach is that the final contour 
will still be based on the available edge detection information within the limita-
tions set by the observer. This type of correction may be set as 'soft' correction. 
In those situations where the soft correction still does not result in the desired 
contour after the second iteration, the user may apply a final 'hard' correction. 
The computer registers for both the left- and right- hand contours the length of 
the arterial segments that were manually corrected, expressed as percentages of 
the total length of the analyzed contour sides. 
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Frame Selection Usually, an end-diastolic cine-frame is selected for the quanti-
tative analysis of a coronary obstruction to avoid blurring effect of motion, If the 
obstruction is not optimally visible in that particular frame [e.g. by overlap by 
another vessel] a neighbouring frame in the sequence is selected. However, since 
a marker is not always present on the cine-film, the visually selected cine-frame 
may not be truly end-diastolic. Beside that, individual analysts may choose diffe-
rent frames even when the same selection criteria are followed. In addition, it is 
possible that the frames are selected from different cardiac cycles, in relation to 
the moment of contrast injection. Reiber et al have critically assessed this pro-
blem in 38 films whether selection of the frame [3 frames preceding, 3 frames 
immediately following the frame and the same frame as chosen by the senior car-
diologist as the reference end-diastolic frame, but one cardiac cycle earlier or 
later] resulted in significant differences in the measurements. They found no sig-
nificant difference in the mean and the standard deviation of the differences for 
the obstruction diameter, interpolated reference diameter, percent diameter ste-
nosis, extent of the obstruction and area of atherosclerotic plaque obtained in 
various frames with respect to the 'select reference frame'. Therefore, it is con-
cluded that the selection of a true end-diastolic cineframe for quantitative analy-
sis is not very critical and that in case of overlap it is possible to select a neigh-
bouring frame [19]. 
Quality control in the MERCATOR trial 
In the MERCATOR-trial - a restenosis prevention trial with a new angiotensin 
converting enzyme inhibitor cilazapril - in which 26 clinics have participated, 
quantitative coronary angiography was used to determine the primary endpoint 
as defined by the rate and extent of restenosis. Before the clinics could start to 
recruit patients for the study, they had to supply 2 sample cinefilms for analysis to 
demonstrate that they could comply with the required standards. Of all participa-
ting clinics 1 or more em-grid films of all modes of all image intensifiers were 
received at the core laboratory to allow correction for pincushion distortion of the 
image intensifiers. All clinics received a set of radiopaque plates to be able to 
make it clear on the film whether nitroglycerin or isosorbide dinitrate was given 
before the contrast injection, which field size of the image intensifier was used, 
the balloon pressure and balloon size used etc. In a period of 5 months Gune 1989 
-November 1989), a total of 735 patients were recruited with a minimum of 8 
patients and a maximum of 56 patients per clinic. Five of the 735 patients were 
not included in the final analysis of the trial because their cinefilm could not be 
quantitative analyzed; in 1 patient the film developing machine broke down so 
that no post-PTCA film was available for analysis; in 2 patients analysis was not 
possible due to a large coronary artery dissection; in 1 patient no matching views 
were available and in 1 patient poor filling of the vessel had occurred [due to the 
use of a catheter with side holes] making comparison with the baseline film unre-
liable. 
In 2 patients pre-PTCA, 34 patients post-PTCA and in 4 patients at follow-
up angiography intracoronary nitroglycerin or isosorbide dinitrate had not been 
administered as assessed by the absence of the plate on the film and nothing had 
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The average number of matched projec-
tiolls (pl'e-PTCA, post-PTCA and at 
follow-up) that zvere used for qualltita-
tive analysis ill the kIERCATOR trial 
per segment are givell ill the circles, 
The numbers betweell the brackets are 
the totalllllmber of stelloses for that 
particular segment. 
Chapter 3 - Expcl1'cnces of a quantitative coronmy allgiographic core laboratory 
been recorded in the column 'medication given during the procedure', In 26 
patients, a 5 or 6 French catheter was used at the time of follow-up angiography, 
In 8% of the views pre-PTCA, 12% of the post-PTCA views and 12% of the fol-
low-up views, the images had to be analyzed with a contrast-filled catheter becau-
se no flushed catheter was available, Figure 4 shows the average number of 
matched views available for QCA analysis per segment dilated, 
Qualitative assessment 
In addition to quantitative measurements, an angiographic core laboratory can 
assess qualitative or morphologic factors, such as type of lesion (according to the 
AHA classification), description of the eccentricity of the lesion and type of dis-
section after the procedure, using modified NHLBI criteria, to establish the roles 
of these descriptors in the restenosis process, Recently, we have studied the inter-
observer variability for the description of the lesion and the type of dissection 
[20,21], Using the Ambrose classification there was an agreement of 80% 
between the two assessors of the core laboratory and for dissection there was an 
agreement of 87%, At the present time, no additional data is available but will 
become available in the near future, 
Conclusion 
The use of quantitative coronary angiography is an objective and reliable method 
to evaluate changes in arterial dimensions over time, An angiographic core labo-
ratory plays a crucial role in minimizing the problems of data acquisition and data 
analysis as well as the overall quality of the trial. Beside that an angiographic core 
laboratory may help demonstrating the reproducibility of qualitative factors and 
their role in the occurrence of acute and late complications of PTCA, 
Furthermore, in our experience it has been possible to standardize angio-
graphic data acquisition from 82 different clinics in Europe, United States and 
Canada, 
II2 
QCA ill Clillical Practice, Kluzver Academic Publishers 1993; 121-135 
References 
I. Griintzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery 
stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;30 1:61-8. 
2. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary 
angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 
consecutive patients at 1,2,3, and 4 months. Circulation 1988;77:361-71. 
3. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous 
transluminal coronary angioplasty: serial angiographic follow-up of 299 patients. 
J Am Coli CardioI1988;12:616-23. 
4. Serruys PW, Rensing BJ, Luijten HE, Hermans WRM, Beatt KJ. Restenosis following 
coronary angioplasty. In Meier B, editor. Interventional cardiology. Bern: Hogrefe and 
Huber publishers, 1990:79-115. 
5. CaliffRM, Ohman EM, Frid DJ, et al. Restenosis: the clinical issue. In Topol E, editor. 
Textbook of interventional cardiology. New York, Saunders, 1990:363-94. 
6. Popma IT, Califf RM, Topol EJ. Clinical Trials of restenosis following coronary 
angioplasty. Circulation. In press. 
7. Hermans WR, Rensing BJ, Strauss BH, Serruys PW. Prevention of restenosis after 
percutaneous transluminal coronary angioplasty: the search for a 'magic bullet'. 
Am Heart J 1991 ;122: 171-87. 
8. Reiber JH, Serruys PW. Quantitative coronary angiography. In: Marcus ML, 
Schelbert HR, Skorton DJ, Wolf GL, editors. Cardiac imaging: a companion to 
Braunwald's Heart Disease. Philadelphia: Saunders, 1991 :211-80. 
9. Beauman GJ, Vogel RA. Accuracy of individual and panel visual interpretation of coro-
nary arteriograms: implications for clincal decisions. J Am Coli Cardiol 1990; 16: 108-13. 
10. Reiber JH, Serruys PW, Kooyman CJ et al. Assessment of short-, medium-, and long-
term variations in arterial dimensions from computer-asisted quantitation of coronary 
cineangiograms. Circulation 1985;71 :280-8. 
II. Zijlstra F, den Boer A, Reiber JH, van Es GA, LubsenJ, Serruys PW. Assessment of 
immediate and long-term functional result of percutaneous transluminal coronary 
angioplasty. Circulation 1988;78: 15-24. 
12. Feldman RL, Marx JD, Pepine CJ, Conti CR. Analysis of coronary responses to various 
doses of intra coronary nitroglycerin. Circulation 1982;66:321-7. 
13. Lablanche JM, Delforge MR, Tilmant PY, Thieuleux FA, Bertrand ME. Effects 
hemodynamiques et coronaries du dinitrate d'isosorbide: comparision entre les voies 
d'injection intra corona ire et intraveineuse. Arch Mal Coeur 1982;75:303-15. 
14. Rafflenbeul W, Lichtlen PR. Release of residual vascular tone in coronary artery stenoses 
with nifedipine and glyceryl trinitrate. In Kaltenbach M, Neufeld HN, editors. New 
therapy of ischemic heart disease and hypertension: proceedings of the 5th international 
adalat symposium. Amsterdam. Excerpta Medica, 1983:300-8. 
15. Jost S, Rafflenbeul W, Reil GH, et al. Reproducible uniform coronary vasomotor tone 
with nitrocompounds: prerequisite of quantitative coronary angiographic trials. 
Cathet Cardiovasc Diagn 1990;20: 168-73. 
16. Jost S, Rafflenbeul W, Gerhardt U, et al. Influence of ionic and non-ionic radiographic 
contrast media on the vasomotor tone of epicardial coronary arteries. 
Eur Heart J 1989; I O:suppl F:60-5. 
17. Reiber JH, Kooijman CJ, den Boer A, Serruys PW. Assessment of dimensions and image 
quality of coronary contrast catheters from cineangiograms. 
Cathet Cardiovasc Diagn 1985: 11 :521-31. 
18. Leung WH, Demopulos PA, Alderman EL, Sanders W, Stadius ML. Evaluation of cathe-
ters and metallic catheter markers as calibration standard for measurement of coronary 
dimension. Cathet Cardiovasc Diagn 1990;21: 148-53. 
19. Reiber JH, van Eldik-Helleman P, Kooijman CJ, TijssenJG, Serruys PW. 
How critical is frame selection in quantitative coronary angiographic studies? 
Eur HeartJ 1989;IO:suppl F:54-9. 
II3 
Chapler 3 - Expen'ellces of a qllallliialive corOlla I)' allgiagraphic core laharalal)' 
20, Dorros G, Cowley M], Simpson], et al. Percutaneous transluminal coronary angioplasty: 
report of complications from the National Heart, Lung, and Blood Institute PTCA 
Registry, Circulation 1983;67:723-30, 
21, Ambrose ]A, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis 
of unstable angina pectoris,] Am Coll Cardiol 1985;609-16, 
II4 

Chapter 4 - Quantitative analysis of corollary guiding catheters 
Abstract Quantitative Coronary Angiography (QCA) is a validated and widely 
accepted method to investigate changes in arterial dimension over time. 
Calibration of measurements is enabled by the use ofthe coronary catheter as a 
scaling device. The dimensions and laminar composition of coronary catheters, 
however, have changed significantly over recent years and the suitability of the 
current generation of coronary catheters for calibration purposes has not been 
validated. We therefore recorded 57 coronary guiding catheters on cinefilm, 
and compared their automated quantitative measurements (Cardiovascular 
Angiography Analysis System; CAAS), with their true values (precision micro-
meter). We found an overall underestimation of quantitatively derived dimen-
sions, ranging from -8.9% to +4% for water-filled catheters and from -15.5% to 
-3.9% for contrast-filled catheters. In conclusion, while the current generation 
of coronary guiding catheters shows a wide variety in radiologic quality, it can 
be clearly detected by the CAAS system, and is suitable for calibration of QCA 
measurements (with the exception of the DVI atherectomy catheter), provided 
that calibration is done on contrast-empty catheters. (Catheterization and 
Cardiovascular Diagnosis 1994;33:55-60) 
Quantitative coronary angiography (QCA) is increasingly being used for both 
on-line analysis to guide interventional procedures as well as for off-line analysis 
in the study of restenosis and progression/regression. Despite the widespread and 
long-standing use of coronary angiography, as well as recent improvement in 
radiographic acquisition, the interpretation of angiograms in clinical practice has 
changed little over the years and is still assessed visually. Visual assessment, 
however, is subjective with a large inter- and intraobserver variability and should 
therefore not be incorporated in scientific research of restenosis prevention and 
progression-regression [1-3]. Computer-assisted or automated QCA is not only 
objective but also has the advantage of being more accurate and reproducible 
than visual or hand-held calliper measurements. 
At the Thoraxcenter, the computer-assisted Cardiovascular Angiography 
Analysis System (CAAS) using an automated edge detection technique was 
developed and has recently been updated [4]. The CAAS has been used in the 
angiographic 'core laboratory' in several multicenter pharmacological and device 
studies [5-7]. In order to obtain reliable and reproducible quantitative measure-
ments of coronary cine-angiograms, variations in data acquisition associated 
with the use of different coronary guiding catheters must be minimized. The 
actual size of individual catheters often differs significantly from the nominal size 
stated by the manufacturer. In order to obtain the true external diameter of the 
catheter, all catheters are measured by a digital micrometer, with a high degree of 
accuracy and precision (0.001 mm) [8]. This provides an accurate basis for cali-
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bration of the measurements of the catheter image obtained by QCA. 
Combining micrometer measurements and radiological size results in a cali-
bration factor (mm per pixel) which allows objective and absolute measurements 
of coronary artery dimensions. Consequently, QCA measurements based on 
catheter calibration have been previously shown to be highly reproducible [9]. 
The automated QCA measurement of a guiding catheter and the subse-
quent calibration factor are significantly influenced by the material of the cathe-
ter, the presence of radiographic contrast in the catheter lumen, and the settings 
of the X-ray equipment. QCA validation studies of previously available catheters 
have been reported [10-14] but the recent development of catheters of new mate-
rials in tri-laminar composition with altered radiopacity made reinvestigation of 
the radiographic quality of coronary guiding catheters necessary. 
Methods 
Catheters Mid-portions of a total of 57 coronary guiding catheters (Table I) were film-
ed. We selected frequently used and commonly available catheters from Scimed 
(Triguide series), Medtronic (Sherpa), Bard (Illumen), Cordis (6Fr Diaventional and 8 
Fr Brite tip), Schneider (Soft touch) and DVI (atherectomy catheters). 
Image acquisition and processing A monoplane Philips Poly Diagnost C2 machine 
equipped with an MCR X-ray tube and powered by an Optimus CP generator (Philips 
Medical Systems, Best, The Netherlands) was used for all radiographic imaging. The 5" 
(12.5cm) field mode of the image intensifier (focal spot 0.5 mm) was selected. Catheters 
were taped on a block of polymethylmethacrylate (P MMA or perspex) 25*250*250 mm, 
and filmed in the isocenter of the X-ray system. The distances from X-ray source to 
catheter and from X-ray source to the image intensifier were 75 and 100 em respectively. 
Each catheter was filmed at two kilo-volt levels. The X-ray system automatically 
adjusts the kilovoltage level to 60 and 90 kV upon the interposition of 125 or 250 mm 
PMMA polyethylene blocks, respectively. The incorporation of the PMMA polyethylene 
blocks results in more appropriate kilovolt levels and a scatter medium which more close-
ly imitates the X-ray scatter in the human thorax during cineangiography. 
Catheters were filmed at two filling conditions; filled with water and filled with 
100%, radiographic contrast (Iopamidol;370 mg iodine/ml, Bracco, Italy). A centimeter 
grid was filmed in exactly the same plane for scaling purposes. 
All catheters were imaged and acquired on 35-mm cinefilm (CFE Type 2711, 
Kodak, Paris, France) at a frame rate of 12.5 images/sec, using an Arritechno 90 cine 
camera (Arnold & Richter, Munich, Germany) with an 85 mm lens. The cinefilms were 
processed by a Refinal developer (Agfa-Gavaert, Leverkusen, Germany) for 4 minutes at 
28"C. The film gradient was measured in all cases to ensure that the optical densities of 
interest were on the linear portion of the sensitometric curve. 
QCA Edge detection For each individual catheter 8 cineframes were quantitatively ana-
lysed (water/60kV, water/90kV, Iopamiro/60 kV, Iopamiro/90kV, with two cineframes in 
each setting). All cineframes were analyzed using the new generation Cardiovascular 
Angiography Analysis System (CAAS II) (Pie Medical Maastricht, the Netherlands) [4). 
The principles of computer assisted quantitation of coronary cine-angiograms using this 
system have been previously described in detail [15). Briefly, the selected cineframes 
were digitized by a high resolution digital camera. The calibration factor for this study 
was determined by a manual definition of three pairs of points on horizontal lines of a 
centimeter grid in the center of the image. The calibration factor is thus expressed in mm 
per pixel. Catheter contours are then determined automatically with the edge detection 
algorithm over a length of approximately 15 mm. This edge detection is based on the 
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weighted sum of the first and second derivative functions applied to the digitized bright-
ness profile information along scan lines perpendicular to the local centerline directions 
of the catheter. All contour positions were corrected for the pincushion distortion indu-
ced by the image intensifier. 
Calibration The true size of the catheter, was measured by an experienced analyst as the 
mean of two orthogonal measurements of each individual catheter by an electronic preci-
sion-micrometer (Mitutoyo OP-IHS Tokyo,Japan; accuracy 0.001 mm) [8]. 
Data Analysis The mean ± standard deviation of the QCA measurements of cinefilm-
recorded catheters was calculated for each individual catheter from four cineframes 
comprising either contrast-filled catheters or water-filled catheters. This was averaged 
per French size and per manufacturer. The mean of two digital micrometer measure-
ments was taken as the true size. Radiographically measured size was compared to the 
true size and expressed as percent deviation, a positive percentage deviation meaning a 
larger QCA measurement compared to the true catheter size, and a negative percentage 
deviation meaning a smaller QCA measurement compared to the true catheter size. 
Results 
The data are averaged over the 60 and 90 kilo volt level and presented per manu-
facturer and french size, but subdivided in measurements of contrast-filled and 
contrast-empty catheters. Micrometer-derived diameters differed significantly 
from the manufacturer's nominal size. The micrometer measurements of the 
external diameter were on average 0.025mm smaller than the nominal diameter 
listed by the manufacturer (p<O.OOOI). 
Quantitative analysis of each catheter, either filled or empty of contrast, 
results in a lower value, compared to assessments by digital micrometer 
(P<O.OOO 1) (Fig. 1). This deviation is less in water-filled catheters (ranging 
between -8.9% and +4%), and more distinct in contrast-filled catheters (ranging 
between -15.5% and -3.9%). Overall the deviation results in an average weighted 
underestimation of -2.9% for catheters filled with water, and -7.1 % for contrast-
filled catheters, compared to micrometer measurements. Applying the edge 
detection procedure on water-filled catheters results consistently in a larger dia-
meter (0.11mm ± 0.07), when compared to analysis of contrast-filled catheters 
(P<O.OOOI) (Figs. 1 and 2) and thus generates less underestimation of the cathe-
ter diameter on cinefilm. 
Discussion 
Assessment of the true catheter size One of the vital components of the cali-
bration process is an accurate micrometer measurement of the coronary guiding 
catheter [12, 15, 16]. This is a mandatory step in the calibration since actual sizes 
of the catheter often differ from the nominal catheter sizes specified by the manu-
facturer. In our study it appears that catheters are 0.025mm smaller in diameter 
in comparison to the dimensions listed by the manufacturer (P<O.OOO 1) (Table 
II). Very low standard deviations demonstrate the high reliability of the digital 
micrometer assessment. Previously, this method has been validated [14]. Inter-
observer variability between 3 analysts measuring a total of 96 catheters ranging 
from 6 to 9 French, showed a mean difference of less than 0.03mm and a stan-
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Table I 
Summary of the Manufacturer, Composition of Material, Number and Sizes of the Catheters Studied. 
Material N Size (Fr) Manufacturer 
Teflon/PolyurethanefUltrax 7 9.S/ll DVI 
Polyurethane/Steel braid/Teflon 6 SilO Medtronic 
Teflon/Steel braid/Polyurethane 13 7-10 Schneider 
Teflon/Steel braid/Trilon 9 7/S Scimed 
Teflon/Kevlar braid/Pebax 12 7/S Bard 
Trilon/Steel braid/Nylon 10 6/S Cordis 
Table II 
Catheter Dimensions and Average Deviation 
Catheter Dimensions (mm) and Average Deviation (%) 
cine-film 
Material water-filled contrast-filled 
micrometer 
Size N mm mm % nun % 
TEFLON/PU/UL TRAX 
9.5fr 3 3.17±O.01 3.01±O.06 -S.2 2.77±O.OS -12.6 
Ilfr 4 3.66±O.02 3.32±O.16 -S.9 3.0S±0.05 -15.5 
PU/STEELITEFLON 
Sfr 2 2.5S±O.02 2.45±O.00 -4.S 2.39±0.01 -7.1 
10fr 4 3.2S±O.02 3.12±O.01 -4.0 3.01±O.02 -7.5 
TEFLON/STEELIPU 
7fr 3 2.26±O.02 2.10±O.01 -6.9 2.10±O.03 -7.2 
8fr 4 2.63±O.01 2.S0±O.02 -S.O 2.4S±O.02 -6.7 
9fr 5 2.9S±O.02 2.75±O.03 -6.5 2.72±O.03 -7.5 
10fr 3.29 3.18±0.03 -3.4 3.09±O.00 -6.1 
TEFLON/STEELITRILON 
7fr 4 2.21±O.02 2.30±O.05 4.0 2.12±O.06 -3.9 
8fr 5 2.5S±O.02 2.56±O.06 -1.0 2.41±O.07 -6.7 
TEFLON/KEVLAR/PEBAX 
7fr 6 2.25±O.03 2.30±O.02 2.4 2.16±O.04 -3.9 
8fr 6 2.S9±O.01 2.55±0.02 -1.9 2.49±O.02 -4.3 
TRILON/STEELINYLON 
6fr 5 1.95±O.00 1.91±O.01 -2.0 I.S1 ±O.02 -7.2 
8fr S 2.67±O.01 2.59±0.03 -2.9 2.48±0.02 -7.1 
TOTAL 57 guiding catheters 2.9%, -7.1 %, 
Micrometer (mm), catheter dimensions measured by a digital precision micrometer which is considered to 
be the true size; Water-filled, QCA dimensions of water-filled catheters; Contrast-filled, QCA dimensions 
of contrast-filled catheters. 
Materials: PU, poly urethane; Steel, stainless steel wire braid 
The percentage deviation is the difference from QCA derived dimensions in comparison to the true size 
(P<O.OOOI for both filling states). Consistently the analysis of contrast-filled catheter image results in a 
significant smaller diameter (P<O.OOOI vs water-filled). 
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dard deviation depending on the size between 0.00 and 0.04mm. The intraobser-
ver variability showed a mean difference of less than O.Olmm and a standard 
deviation of the difference of less than 0.03mm for all sizes. This indicates that it 
is possible to measure the true size of a catheter with a high degree of accuracy 
and precision [8]. 
Analysis of contrast-filled and contrast-empty catheters Additional reliabi-
lity of calibration can be achieved by the acquisition of the catheter image after 
flushing with saline or filling with blood in the same projection and field of view 
of the image intensifier, positioning the catheter in the centre of the radiographic 
image and operating a correction for pincushion distortion [8]. In this study, 
overall deviation of angiographically measured dimensions of contrast-empty 
catheters was approximately -2.9% (P<O.OOOl, range -8.9% to +4%) (Table II). 
When free of contrast, the edge detection algorithm reliably detects the external 
border of the guiding catheter. The weighted sum of the first and second derivati-
ve will result in a slightly smaller diameter than the true diameter. However, the 
presence of the misleading high density column of contrast medium inside the 
catheter lumen will cause a much higher underestimation of the catheter dimen-
sion since the edge detection will trace the contours of the contrast column, i.e., 
the internal diameter of the catheter, instead of the external diameter which is 
actually measured by the digital precision micrometer (Fig. 1). In our study, ana-
lysis of contrast-filled catheters resulted in an average underestimation of -7.8% 
(range -15.5% to -3.9%), and thus a subsequent overestimation of calibration 
factor and coronary dimensions of 8.5% ([[100/(100-7.8)]-1] *1 00). This clearly 
underlines the importance of calibration methodology, not only for longitudinal 
studies, but also for on-line clinical practice. 
In a previous study we have compared quantitatively analyzed cineframes 
using contrast-filled catheters and water-filled catheters (either filled with blood 
or flushed with saline) for calibration [14]. The measured calibration factor was 
0.156±o.030 mm per pixel with the contrast-filled catheter, and 0.143±o.020 
mm per pixel with the catheter filled with saline or blood (p<O.OOl) [8, 17]. The 
use of calibration obtained from contrast-filled catheters would have resulted in 
an average overestimation of 9.1 % (range -1 %/30%) of the measurements obtain-
ed from cineframes recording a contrast empty catheter. 
Catheter material and composition The use of catheters of low radiopacity 
should be avoided in QCA studies [12, 16]. Our study has highlighted the wide 
variation in radiopacity of coronary guiding catheters. Every guiding catheter 
must possess a minimal degree of radiopacity, in order to be visible on fluorosco-
pic or cinefilm images. For calibration purposes, a sharp contrast-gradient near 
the outer edge is vital for accurate contour detection. The outer layer of material 
must overcome the peak in the density profile caused by stainless steel braidings. 
Analysis of catheters with a highly radiopaque outer layer, or without presence of 
a 'distracting' stainless steel braiding in the middle layer (DVI and Bard), may 
result in less underestimation of the angiographic catheter size. Both may contri-
bute to the low deviation from the true size, and even positive values in the Bard 
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Figure 1 
QCA meaSilrements plotted against the 
true size, as measured by a precision 
micrometer. Diameters of contrast-filled 
catheters are underestimated m01'e than 
waterjilled catheters (p<O. 0001). 
Figure 2 
Schematic presentation of the percelllage 
deviation from the true size for contrast-
empty and contrast-filled coronary 
guiding catheters per manufacturer and 
per French size. 
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cathcters. The atherectomy cathcters, which also lack a steel braiding as well, 
introducc an extreme divergence in obtained values. These catheters, even filled 
with water give a deviation of -5.2 to -8.9% depending on their French size. The 
consistcntly poor reproducibility of the computer assisted measurements of each 
individual atherectomy catheter is expressed in a wide standard deviation, and is 
an indication for the relative radiolucency of the Ultrax outer layer. Average 
deviations from the true size of the remaining manufacturers was -4.2 and -5.9% 
for Medtronic and Schneider (polyurethane) catheters, and + 1.2, +0.3, and -
2.4% for Scimed (Trilon), Bard (Pebax), and Cordis (nylon) catheters, respecti-
vely, which is in concordance with the observations of Fortin et a!. (18). 
We measured the shafts of coronary guiding catheters, according to the pro-
tocol used by Reiber et al (12). The rationale of this approach is the following: 
catheter material at thc tip does not vary from the material used in the catheter 
shaft, with the exception of some diagnostic catheters (13). In general it is the 
addition of barium sulphate or other radiopaque substances to the nylon and 
nylon-like compounds in especially the outer layer of the coronary catheters and 
not the compound itself that defines radiopacity and radiographic qualifications. 
Conclusion 
Correct acquisition of the angiographic catheter dimension is critical for reliable 
calibration of QCA measurements, but when these conditions are respected, this 
technique can give accurate and reproducible results. The use of coronary gui-
ding catheters of poor radiographic quality, and catheters of different brands in a 
long-term angiographic follow-up study should be minimized. In a multicenter 
study, this issue is ideally standardized by providing each participating centre 
with similar guiding catheters, or diagnostic catheters of high quality which are 
used before and after angioplasty, as well as during the follow-up catheterization 
procedure. 
We conclude that coronary guiding catheters can only be analyzed reliably 
only when recorded in contrast-empty state. Although the rationale for calibra-
ting angiographic cine-images on a contrast empty catheter is evident, some 
angiographic core-labs persist in calibrating their cine-angiograms on a contrast 
filled catheter. The reason for this practice is apparently that these angiographic 
core-labs are using a QCA-system, which is unable to detect the edge of an empty 
catheter. This inability is related to the lack of resolution and potentially to the 
algorithm used in this system. 
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Abstract Although use of videotape for the recording of coronary angiograms 
continues to grow, the validity of quantitative coronary angiographic analysis of 
video images remains unknown. To estimate the reliability of angiographic ima-
ges recorded on videotape, experimental and clinical angiograms were recorded 
simultaneously on both 35 mm cine film and super-VHS videotape with normal 
images and with spatial filtering of the images (edge enhancement) on a digital 
cardiac imaging system. The experimental angiographic studies were performed 
with plexiglass blocks and stenosis phantom 0.5 to 3.0 mm in diameter. The 
clinical angiograms were recorded in twenty patients undergoing percutaneous 
transluminal coronary angiography (31 frames before and 20 frames after 
percutaneous transluminal coronary angiography). The cinefilm and corres-
ponding videotapes were analyzed off-line with the new version of the coronary 
angiography analysis system. For the experimental study, measurements of 
minimal luminal diameter obtained from cinefilm, normal video-tape, and edge 
enhanced videotape were compared with the true phantom diameter. In the 
clinical study, the agreement between measurements obtained from cinefilm 
and measurements from normal-image videotape and edge-enhanced videotape 
was examined. In the phantom series the accuracy and precision of quantitative 
coronary angiography measurement for cinefilm were -0.1 0 mm ±O.OS mm, for 
normal-image videotape -0.11 mm ±D.IS mm and for edge-enhanced videotape 
-0.10 mm ±0.11 mm. In the clinical series, the differences between measure-
ments from cinefilm and normal-image videotape were 0.14 mm ±0.20 mm and 
from cinefilm and edge-enhanced videotape were 0.04 mm and ±O.13 mm. 
In the experimental phantom study, the use of cine film resulted in the most 
precise measurements. In the clinical study, edge-enhanced videotape provided 
the highest agreement with measurements obtained from cinefilm. These 
indings suggest that cinefilm is more reliable than video as a recording medium 
for quantitative coronary analysis in scientific studies; however, for routine 
practice, videotape with edge enhanced images may provide an acceptable 
alternative. (American HeartJournal 1995; 129:471-5) 
Coronary angiography continues to be the gold standard for coronary artery ima-
ging in clinical practice. \X'ith the increasing demand for quantitative coronary 
angiography (QCA) and the development of digital acquisition systems, there 
has been a substantial growth in the deployment of videotape as a recording 
medium because of its easy handling, instant replay capability, and low cost [1-
126 
American Heart ]ou/"lla/ 1995;129:471-5 
4}. In some institutions videotape has replaced 35mm cinefilm as the original 
imaging medium. However, despite proposals for the replacement of cinefilm by 
videotape, the suitability of video recordings for QCA analysis has not been esta-
blished. To evaluate the potential application and reliability of videotape recor-
ding for QCA for clinical studies, recordings of experimental phantom stenoses 
[5-8] and clinical coronary artery stenoses before or after balloon angioplasty 
were assessed with the new version of a computer based coronary angiography 
analysis system (CAAS II) [5J. 
Methods 
Experimental image acquisition of ph an to III stenoses. 
For the in-vitro validation we used radiolucent plexigluss cylinders (SO mOl length) 20 
mm in ourer diameter) with precision-drilled concentric circular lumens (tolerance 0.01 
mm) of 0.5) 0.75,1.0) 1.5) 2.0, 2.5 and 3.0 mm in diameter. The length of each phanLOm 
stenosis channel was 20 nun and the adjacent 'normal' channel length of the proximal and 
distal segments was 30 mm. The plexiglass channel (including the artificial stenosis) was 
filled with contrast medium (iopamidol 370; 370 mg iodine/ml (Bracco, M.ilano, Iwly». 
Digital and cine film acquisition was performed with additional plexiglass blocks (12.5 em 
anteriorly and 5 cm posteriorly). These plcxiglass blocks provide a more appropriate kilo-
volt-le\'e1 and a scatter medium that more closely approximates the radiological scatter of 
the human thorax during angiography. Angiograms were performed with the 5-inch field 
of an image intensifier, with separate recordings and two different focal spots (0.5mm, 
which was used for most of the experimental and clinical series, and 0.8mm) and at an 
image acquisition rate of 25 frames/sec. The radiographic system settings were kept con-
stant (kilovolt, milliampere, x-ray pulse width) in each projection. All phantoms were 
imaged at the radiographic isocentcr of the X-ray gantry [9} and acquired simultaneously 
on 35-mm cinefilm (Kodak CFE Type 2711, Paris, France) and digitally (Philips Digital 
Cardiac Imaging (DCI) system; Philips, Best, The Netherlands). 
Coronary artcl'iographic procedure before and after percutancous translunlinal 
coronary angiography (PTCA) Coronary angiography was performed in multiple pro-
jections with SF polyurethane catheters (Cordis, Miami, Fla.) in 20 patients before and 
after PTCA at the Thoraxcenter, Rotterdam. To control vasomotion, intracoronary iso-
sorbide dinitrate (1-3 mg) [10] was administered before manual injection of contrast 
medium (iopamidol 370; 370 mg iodine/ml) at 37°c. The 5-inch field of the image inten-
sifier was selected and the radiographic settings were kept constant (kilovolt, milliampe-
re) x-ray pulse width) in each projection. All clinical images were simultaneously acqui-
red digitally by DCI and on 35-iUm cinefilm with frame rates of 25 images/sec. 
Image processing and spatial filtering (edge-enhanccment) in the DCI Both expcri-
mental and clinical angiographie images were stored on a 474 MB Winchester disk. The 
DCI system uses a matrix size of 512 x 512 pixels (average horizonwl pixel size 200 ~Im; 
density resolution 8 bits = 256 gray levels). The images were processed with the automa-
ted coronary analysis software package of the DCI system [8,11,12}. Edge-enhanced 
images were produced by spatial filtering on the DCI system. The algorithm of spatial fil-
tering operates by substituting new pixel values for the original pixel values on the coro-
nary angiogram [13J. A visible horizontal edge of the coronary artery is formed when a 
string of horizontally connecting pixels displays values which arc different from those 
immediately above or below. Similarly) a vertical edge of the coronary artery is formed 
when a string of \'ertically connecting pixels have \'alues different from those immediately 
to the right or to the len. Oblique edges are generated through combinations of horizontal 
and vertical componetlls. The default edge-enhancement mode of the DCI system was 
used. Spatial filtering amplifies the pixel differences between the opacified vessel and its 
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background, thereby providing a more distinct border to the coronary arlery. Images with 
and without edge-enhancement were then directly relayed to the video recorder 
(Panasonic 7330, Osaka, Japan) and recorded on S-VHS tape (Fuji-film double coating 
SE-60, Sizuoka,Japan). 
Stenosis characteristics Twenty-one experimental frames and the 51 pre-PTCA and 
post-PTCA clinical frames were selected for quantitative analysis, and their minimal 
luminal diameter was measured. Of the clinical angiograms, the 31 pre-PTCA frames 
consisted of 16 left anterior descending, 10 left circumflex, and 5 right coronary arlery 
lesions. Of the remaining 20 post-PTCA frames evaluated, 10 showed left anterior de-
scending, 8 left circumflex, and 2 right coronary artery lesions. All pre-PTCA lesions had 
> 50'1.. diameter stenosis. 
Correction of pincushion distortion Before the performance of the calibration and 
analyses of the stenoses, computerized correction for pincushion distortion was applied 
by the recording and subsequent off-line digitization of a centimeter grid placed in front 
of the image intensifier. 
Calibration of images For the experimental in vitro series, the measurements of the 
phantom stenoses were calibrated with a contrast-filled 3.0 mm-diameter circular chan-
nel in a plexiglass cylinder as a scaling device. This calibration frame was digitized and 
traced by the automated contour detection algorithm before the series of analyses of the in 
vitro phantoms was begun. In the clinical study, cinefilm and videotapes were calibrated 
by the usc of the recorded contrast-free catheter tip as a scaling device. The nontapering 
catheter tip was measured with a precision micrometer (JvUultoyo No.293-501, Tokyo, 
Japan; accuracy 0.00 1 mm). 
Quantitative analysis in CAAS II Cinefilms and corresponding frames of videotapes 
with and without spatial filtering (edge enhancement) were quantitatively analyzed off-
line by using the computer-based Cardiovascular Angiographic Analysis System (CAAS 
II; Pie Medical, Maastricht, The Netherlands) [5, 14-19J. In the experimental study l.l suf-
ficiently long segment of the plexiglass cylinders including the stenosis phantom was 
selected for analysis. In the clinical study frames without foreshortening or overlapping 
side branches were selected. Arterial dimensions of clinical frames were measured at spe-
cific distances from identifiable branch points in end-diastolic frames. The entire cinefra-
me of size 18 x 24 mm is digitized at a resolution of 1329 x 1772 pixels in the CAAS II sys-
tem. During image acquisition of videotape a time-base corrector was implemented to 
ensure high quality stand~still images [1]. The video signal from tapes with and without 
spatial filtering (edge-enhancement) were digitized at a resolution of 512 x 512 pixels by 
the CAAS II system. In the CAAS II system, the edge detection algorithm is based on the 
first and second derivative functions applied to the digitized brightness profile along 
scanlines perpendicular to a model using minimal cost criteria [20,21 J. The contour 
definition is carried out in two iterations. First, the user defines a number of center-line 
points within the arterial segment that are interconnected by a straight line and serve as 
the first model. Subsequemly, the program recomputes the centerline, determined auto-
matically as the midline of the contour positions that were detected in the first iterations. 
A computer-derived estimation of the original dimensions of the artery at the site of the 
obstruction was used to determine interpolated reference values ror arterial diameter and 
area. Manual correction of the automatically detected contours was neither necessary nor 
performed in either the experimental phantom nor the clinical studies (in routine practice 
at angiographic core laboratories, subjective manual correction of the detected COntours 
at the minimal luminal diameter is only occasionally performed in the casc of complex 
dissections with parallel luminal extravasation, which was not present in our clinical 
angiograms) 
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Linear regression analysis of QCA 
measurements obtained/rom cinefilm 
(GlNb;, normal-image videotape 
(VIDEO-N) and edge-enhanced video-
tape (VIDEO-E), agaillSt true pllall/om 
diameter. AfLD, minimal luminal 
diameter. 
Figure lA 
Shows cinefilm versus phantom. 
Figure lB 
Normal-image videotape versus 
phantom. 
Figure Ie 
Edge-enhanced videotape versus 
phantom. 
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II. 1.50 
Q 
~ 1.00 
;;: . ~ 0.50 / ,.0.992, y •. O.08+0.98x, SEE-O.1t 
9 0.00 0 0.50 1.00 1.50 2.00 2.50 3.00 3.50 
'" 
TAUE PHANTOM DIAMETER (mm) 
Table I 
Comparison of phantom diameter and minimal luminal diameter obtained from cineftlm, normal-image 
videotape, and edge-enhanced videotape in experimental in vitro phantom study. 
Recording medium Accuracy Precision Difference 
Cinefilm 
Normal-image 
videotape 
Edge-enhanced 
videotape 
E 1.00 S 
~ 
;; 0.50 
c 
. " 
~ 0.00 
• v 
~ -0 50 9 . 
~ 
-0.10 ±O.OS 1'<0.01 
-0.11 ±O.IS p<0.05 
-0.10 ±O.II p<O.OI 
PTCA cinefilm vs video-N 
.. 
. 
.'~o,o: .". 
' •• 0, • 
. . .'. ~ 
mean - 0.14, SD • +0.20 
+2SD 
mean 
-280 
~ -1.00 :O---;;O.~5~O-~t~.O~O;-~t~.~50;;---;;2.~O~O-~2~.5~Oc-~3~.OO 
Average MLD (Clnefllm & vIdeo-H) (mm) 
E 1.00 S 
~ 
"i' 0.50 
." 
'6 0.00 
~ 
~ -0 50 o . 
J 
~ 
PTCA clneflim vs video-E 
+28D 
... ' .: .. ~ . :.... 
,! . . .. .,.0 '0 mean 
-280 
mean· 0.04, SD • +0.13 
8 -1.00 ~O---OO~.5~O-~t~.O~O;--t~.~5~O-~2~.O~O-~2~.5~OC-~3C-.O·O 
Average MLO (clnofllm & vldeo·E) (mm) 
Correlation Lineal' regression SEM 
analysis 
0.997 y:::O.Ot +0.93x 0.05 
0.987 y:::O. t 3+0.85x 0.12 
0.992 y:::-0.06+0.98x 0.11 
Agreemelll betweenllleaSllreme1lts obtai-
ned from ciue/ilm and video recordings 
according to statistical approach propo-
sed by Bland aud Altmau (22). 
Figure2A 
Dtfference bellveell normal-image video-
tape and cinefilm meaSlfrements has been 
plotted against their mean. 
Figure 2 B 
Difference between edge-mhanced video-
tape alld cine/jIm measurements has beell 
plOIted agaillst thdr meal/. 
Abbreviations as ill Fig. 1. 
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Statistics In the experimental study, the individual measurements of minimal luminal 
diameter were compared with the true phantom diameter using the paired Student t-test 
and linear regression analysis. The mean of the signed differences between the true 
phantom diameters and the individual minimal luminal diameter values derived from 
measurements of cinefilm and of videotape were considered an index of accuracy and the 
SD of the differences an index of precision. In the clinical study, the mean ± SD of the 
signed differences between measurements of minimal luminal diameter derived from 
cinefilm and measurements of minimal luminal diameter derived from videotape were 
used as an index of agreement between measurements from the different recording 
media. This statistical approach to the comparison of two measurement systems has been 
previously recommended by Bland and Altman [22]. 
Results 
In vitro results The results of QCA measurements obtained from cinefilm, 
videotape with normal image, and videotape with spatial filtering (edge enhance-
ment) and their comparisons with the true phantom diameters are summarised in 
Table I and displayed graphically in Fig. 1. Of the three recording modes, cine-
film was found to provide the most precise measurement results. 
Clinical results The results of measurements from normal-image videotape are 
plotted against those from cinefilm in Fig. 2A [22]. The agreement between the 
two sets of measurements was poor (O.14mm ±o.20mm (p<.OI)). The results of 
measurements from edge-enhanced video are plotted against those from cinefilm 
in Fig. 2B [22]. Although the agreement between the two sets of measurements 
was better with edge-enhanced video than with normal-image videotape, the dif-
ference between the edge-enhanced videotape and cinefilm measurements still 
achieved statistical significance (O.04mm ±o.13mm (p<.05)). 
Discussion 
\Y./e have demonstrated that of the three image recording modes studied, cinefilm 
produces the most precise QCA measurements. The reasons for this finding may 
relate to the high resolution afforded by cinefilm frame analysis (1329 x 1772 
pixels) compared to the limited resolution provided by the analysis of a single 
video field (312 lines per field - each video frame consists of two interlaced 
fields). The noise introduced by the video recording process and by the videotape 
itself may contribute to the lower precision of the QCA measurements. This 
video-induced noise was not overcome by our compensatory steps of recording 
on super-VHS videotape to reduce the signal/noise ratio [3] and deploying a 
time-base corrector during image acquisition to overcome jitter [1]. As was 
expected, the introduction of a systematic noise such as that associated with 
video recording did not exert a significant effect on the accuracy of our QCA 
measurements. 
Our studies of both experimental and clinical images indicate that video 
recording with on-line spatial filtering results in more reliable QCA measure-
ments than videotape without enhancement. These findings support the view 
that on-line spatial filtering (edge enhancement) before the introduction of video 
noise provides a more distinct border to the coronary vessel (or phantom steno-
13 1 
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sis) which is more faithfully tracked by the off-line QCA edge-detection algo-
rithm than the vessel border of an unenhanced image. 
Study implications Financial considerations have now become an important 
factor in the administrative and technical decision-making process of most car-
diac catheterization laboratories. A single videotape can store the complete 
angiographic records of approximately 40 patients at a cost of less than $1 per 
patient; cinefilm increases the cost per patient to $40. Our findings suggest that 
the adoption of videotape with edge enhanced images may present an acceptable 
alternative to cinefilm for routine purposes and possibly for QCA purposes 
under certain circumstances. It should be recognized, however, that the addition 
of any noise or imprecision to the system of off-line QCA will increase the SD of 
the angiographic results of the study. In turn, this might increase the number of 
patients needed for detection of a statistically significant difference among two 
study populations under comparison [23]. Thus the inclusion of videotape in the 
design of a restenosis prevention or progression-regression trial may present a 
false economy by virtue of a concomitant increase in the number of patients 
required and subsequent greater total study costs. 
Study linlitation The edge-enhancement of images and subsequent QCA ana-
lysis in our study was performed by the Philips DCI system and CAAS II system. 
Further studies will be required to confirm whether our findings can be generali-
zed to other hardware or software systems. It is conceivable that if an on-line 
edge-enhancement algorithm was inaccurate, a systematic underestimation or 
overestimation of vessel diameters could be translated to subsequent off-line 
QCA measurements. 
Conclusion 
Despite the application of on-line edge enhancement, the selection of super-VHS 
video tape and the deployment of a time-base corrector in the processing of video 
images for off-line QCA, cinefilm continues to present a more reliable image 
recording medium of coronary angiograms for scientific studies. For routine 
practice, however) videotape with edge-enhanced images may provide an accep-
table alternative. 
American Heart Journal 1995j129:471-5 
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Chapter 6 - Qualilalive angiogram assessmelll: imer- and imra observer 'van'abililY 
Abstract The ABC classification of the American College of Cardiology and 
the American Heart Association is a commonly used categorization to estimate 
the risk and success of intra coronary intervention, as well as the probability 
ofrestenosis. To evaluate the reliability of qualitative angiogram readings, we 
randomly selected 200 films from single lesion angioplasty procedures. 
A repeated visual assessment (2: 2 months interval) by two independent obser-
vers resulted in kappa values of inter and intra-observer variability for the ABC 
lesion classification and for all separate items that compile it. Variability in 
assessment is expressed in percentage of total agreement, and in kappa value, 
which is a parameter of the agreement between two or more observations in 
excess of the chance agreement. Percentage of total agreement and kappa value 
was 67.80/0 and 0.33 respectively for the ABC classification, indicating a poor 
agreement. Probably this is due to the deficiency of strict definitions. Further 
investigation has to demonstrate whether improvement can be achieved using 
complete and detailed definitions without ambiguity, and consensus after panel 
assessment. (International Journal of Cardiac Imaging 1996; 12:21-30) 
In 1988 the task force of the American College of Cardiology and the American 
Heart Association (ACC/AHA) on assessment of diagnostic and therapeutic car-
diovascular procedures presented guidelines for percutaneous transluminal 
coronary angioplasty (PTCA) {I], which were recently updated for current expe-
rience and technology {2]. They proposed a lesion classification, based on morp-
hologic features that presumably influence the chance of successful outcome of 
coronary angioplasties and the risk of acute closure (table I). Lesions are catego-
rized into type A (success 2: 85%, low risk of abrupt closure), type B (success 60-
85% andlor moderate risk of abrupt closure), and type C (success :s;; 60% andlor 
high risk of abrupt closure), In 1990, Ellis and colleagues modified the type B 
lesions into type BI stenoses (only one adverse type B characteristic), and into 
type B2 stenoses (two or more adverse type B characteristics). This subdivision 
was based on multivariate analysis, indicating the cumulative weight of unfavou-
rable lesion characteristics {3]. The lesion scoring system is in widespread clinical 
use nowadays in order to attempt risk stratification for PTCA patients and selec-
tion of the interventional devices available. It is well known that visual estimates 
of lesion severity and several lesion features are less reliable as e.g. quantitatively 
evaluated characteristics (4]. To measure the inter and intra observer variability 
of the qualitative items that compose the ABC lesion classification, and the TI1'AI 
flow grade [5] (table II), two experienced corelab readers (VU and JH) perfor-
med a double independent and blinded reading of coronary angiograms. 
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Methods 
Patient Identification All cinefilms were made in the period between september \992 
and may 1993, in patients with proven coronary artery disease in muive arteries as shown 
by a diagnostic angiofilm. All patients were treated for unstable angina pectoris, accor-
ding to the Braunwald classification [6]. 
Assessment of Coronary Angiograms 
To assess the reliability of qualilati\'e angiogram readings, we randomly selected 200 
angiograms from the pool of cinefilms available in the cardiovascular research laboratory 
Cardialysis. All the cinefilms recorded an intracoronary inten'ention of a single lesion. 
Those films were assessed independently by 2 observers. To assess intra-observer varia-
bility, the same set of cinefilms was analyzed at least 8 weeks later by the two observers 
who were blinded for the results of the first analysis. Except for concentricity, we used the 
definitions for morphologic characteristics from the original ACC/AHA task force pro-
ject [1,2]. We used the more differentiating Ambrose classification [7J to assess concen-
tricity aspects and regularity of the lesion. Concentric and tandem lesions are smooth, like 
type I eccentric lesions. We defined multiple irregularities as concentric and irregular, 
and type II eccentric lesions as eccentric and irregular. We additionally scored TIMI 
flow. The assessors were blinded for clinical data, and therefore could not differentiate 
between TIMI flow grade 0 c.q. total occlusion existing less or longer than three months 
(ergo a type B or type C characteristic). We added tOlal occlusion to the four categories of 
the modified lesion classification. 
Statistical Analysis Calculations revealed that a group size of 200 coronary cinefilms 
would be marc than sufficient to achieve a reasonable to precise kappa-value (see 
appendix). 
The degree of agreement was measured as percentage of total agreement, and using the 
kappa statistics, which is a parameter of the agreement between two or more observations 
in excess of the chance agreement (8}. If there is perfect agreement, then kappa:::: + 1.00 
and in case of pure chance agreement, then kappa = 0.00. It is usual to consider kappa 
values greater than 0.75 to represent excellent agreement beyond chance, and values 
below 0.40 to represent poor agreement beyond chance and to values between 0.40 and 
0.75 to represent fair to good agreement beyond chance. Kappa value was calculated as 
(observcd -expectcd)1 (I-expected). 
Double data entry secured accuracy. BMDP was used as statistical software package. 
Results 
In the first assessment one film was not assessable, therefore a total of 199 films 
were analyzed. The inter-observer variability between observer 1 and 2 (table III) 
showed poor agreement for ABC lesion classification (k=0.33) and the modified 
(A, Bl, B2, C) classification (k~O.29), length of lesion (k~0.35), and branch 
point involvement in stenosis (k=0.39). Fair to good agreement was found for 
Ambrose classification (k~0.48), relationship to coronary artery bend (k~0.48), 
vessel calcification (k~O.53), TIMI flow grade (k~O.57), and thrombus 
(k~O.60). Perfect agreement was found for ostial lesion (k~l.OO) and tortuosity 
(k~l.OO). 
Percentage of total agreement was found lowest in Ambrose classification 
(49.7%), and lesion length (67.8%). The agreement on modified (A, Bl, B2, C) 
ABC classification was only 47.7%, and on the original tri-modal ABC score 
improved to 67.8%. Kappa however raised only from 0.29 to 0.33. Agreement for 
calcification and branch point involvement was rcached in 89.4 and 80.9% of the 
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Table I 
Lesion Specific Characteristics of Type A,B, and C Lesions [1,2] 
Type A lesions (minimally complex) 
discrete « 1 0 mm length) 
concentric 
readily accessible 
nonangulated segment, <45° 
smooth contour 
Type B lesions (moderately complex) 
tubular (10 to 20 mm length) 
eccentric 
moderate tortuosity of proximal segment 
bifurcation lesion requiring double guide wires 
moderatcly angulated segment, >45°,<90° 
Type C lesions (severely complex) 
diffusc (>20 mm length) 
total occlusion> 3 months old 
excessive tortuosity of proximal segment 
less than totally occlusive 
Iinle or no calcification 
not ostial in location 
no major branch involvement 
absence of thrombus 
moderate to heavy calcification 
lotal occlusions < 3 months old 
some thrombus present 
ostial in location 
irregular contour 
inability to protect major side branches 
extremely angulatcd segment, >90° 
degenerated vein grafts with friable lesions 
Ellis and colleagues modified the type B lesions into type ill stenoses (only one adverse type B characteris-
tic), and into type H2 stenoses (two or more adverse type B characteristics). This subdivision was based on 
multivariate analysis, indicating the cumulative weight of unfavourable lesion characteristics 13]. 
Table II 
Assessment of TIMl Flow Grade 
0: no flow, 
I: penetration with minimal perfusion (contrast material passes beyond the area of obstruction but 
'hangs up' and fails to opacify the entire coronary bed distal to the obstruction for duration of the 
cine run) 
II: delayed perfusion (opacification of the coronary bed distal to the obstruction, but rate of entry 
and/or clearance of the contrast medium is reduced) 
III: complete perfusion 
Table III 
Inter-observer Variability Between Observers 1 and 2 (N= 199) 
Length oflesion Observer 2 
Observer 1 l<IOmm lOM20 mm >20mm N.A. 
<IOmm 110 6 I 0 
10-20mm 43 14 3 0 
>20mm 3 5 0 2 
N.A. O. 0 II 
Total 156 26 4 13 
Kappa value = 0.35, 95 'If, confidence interval 0.25-0.35, agreement is 67.8%,. 
N.A. = Not applicable 
Total 
117 
60 
10 
12 
199 
Ambrose lesion type Observer 2 Eee. III liee.IIB Tandem Total 
Observer 1 Cone. Eee.IA Eee. IIA Mult. irreg. N.A. 
Concentric 48 I 2 0 3 0 56 
Eccentric type 2 3 I 7 0 0 0 14 
IA Eccentric type IE 44 14 34 3 3 0 100 
Eccentric type IJA 0 0 I 3 0 0 6 
Eccentric type JIB 2 I 0 0 0 0 0 4 
Multiple irregularities I 0 0 0 I 0 0 3 
Tandem lesion 0 0 0 0 I 2 0 4 
N.A. 0 0 0 0 0 0 II 12 
Total 100 20 38 4 II II 3 12 199 
Kappa value = 0.48, 95 'X, confidence interval 0.43-0.53, agreement is 49.7'1". 
Cone. = concentric, Ece. = eccentric, 1\1ult. irreg. = multiple irregularities, Tandem = tandem lesion, 
N.A. = Not applicable 
TIL\H flow grade Observer 2 
Observer 1 TIMIO TIMI I TIMl II TI,\I/ III Total 
TIMIO 8 3 0 0 II 
TIMI! 0 4 6 
TIM! II 0 3 II 9 23 
TIM! III 0 13 145 159 
Total 8 II 25 ISS 199 
Kappa value = 0.57, 95 % confidence interval 0.45-0.68, agreement is 84.4'J{, 
Ostial lesion Observer 2 
Observer 1 No Yes Total 
No 190 0 190 
Yes 9 0 9 
Total 199 0 199 
Kappa value = 1.00, agreement is 95.5'% 
Tortuosity Observer 2 
Observer 1 No Moderate Severe Total 
No 196 I 0 197 
Moderate I 0 0 
Severe 0 0 
Total 198 0 199 
Kappa value = 1.00, agreement is 98.5'% 
Branchpoint involved in the stenosis Observer 2 
Obsen'er 1 No Yes 
No 143 6 
Yes 32 18 
Total 175 24 
Kappa value:;:::; 0.39) 95 'X, confidence interval 0.26~0.52, 
agreement is 80.9'% 
Relationship to coronary artery bend Observer 2 
Observer 1 No Yes 
No 186 4 
Yes 4 4 
Bad quality 0 
Total 191 8 
Kappa value:;:::; 0.48) 95 'X, confidence interval 0.22-0.74, 
agreement is 95.5%, 
Observer 2 
Total 
149 
50 
199 
Total 
190 
8 
199 
Presence of thrombus 
Observer 1 No Yes Total 
No 
Yes 
190 
2 
3 193 
4 6 
Total 192 7 199 
Kappa value:;:::; 0.60) 95 ry" confidence interval 0.34-0.86, 
agreement is 97.5% 
Presence of calcium Observer 2 
Observer 1 No Yes 
No 164 12 
Yes 8 14 
Bad quality 0 
Total 173 26 
Kappa value:;:::; 0.53, 95 % confidence interval 0.38-0.68, 
agreement is 89.4%, 
Total 
176 
22 
199 
Lesion type Observer 2 
Observer 1 A III Il2 C '1'.0 Bad quality 
A 20 2 0 0 0 0 
Bl 28 39 6 2 0 0 
Il2 15 34 28 3 0 0 
C 1 3 4 0 0 2 
T.O. 0 I 0 8 2 
Total 64 79 39 5 8 4 
Kappa value based on A) B I, H2 and C classes = 0.29) 95 'X, confidence interval 0.21-0.37, 
agreement is 47.7%. 
Kappa value based on A, Band C classes = 0.33) 95 'J{, confidence interval 0.25-0.41, 
agreement is 67.8%. 
T.O :::: totally occlusive coronary artery 
Table IV 
Intra-observer Variability for Observer 1 and 2 (N=197) 
Each cell gives the number of observations for observer 1 (top) and observer 2 (bottom). 
Length oflcsion ObservCI' 2 
Observer 1 <!Omm 10-20 mm >20mm N.A. Total 
<IOmm 92 23 0 0 115 
144 9 0 154 
10-20mm 19 39 2 0 60 
9 13 3 26 
>20mm 0 4 6 0 10 
1 0 3 0 4 
N.A. 0 0 0 12 12 
2 9 13 
Total 111 6 8 12 197 
156 23 8 10 197 
Kappa value observer 1 = 0.57, 95 'J{, confidence interval 0.47-0.67, agreement is 75.6'%. 
Kappa value observer 2 = 0.61, 95 'J{, confidence interval 0.51-0.71, agreement is 85.8% . 
N.A. = Not applicable 
Total 
22 
75 
80 
10 
12 
199 
Ambrose lesion typc Obsen'er 2 Ecc.IB Ecc.IIB Tandem Total 
Observcr 1 Cone. Eee.IA Ecc.IIA i\lult. irreg. N.A. 
Concentric 37 3 16 0 0 0 0 0 56 
91 6 0 0 0 0 99 
Eccentric type 0 7 6 0 0 0 0 14 
2 11 4 2 0 0 0 0 19 
IA Eccentric type IE 8 7 84 0 0 0 0 0 99 
9 5 22 0 0 1 0 38 
Eccentric type IIA 0 6 0 0 0 0 0 0 6 
2 0 0 0 0 0 4 
Eccentric type lIB 0 3 0 0 0 0 0 0 3 
2 4 2 0 0 11 
Multiple irregularities 1 0 0 0 0 0 3 
0 1 0 0 0 10 0 0 11 
Tandem lesion 0 0 0 0 0 0 4 0 4 
0 0 0 0 0 0 3 0 3 
N.A. 0 0 0 0 0 0 0 0 12 
1 0 0 0 0 9 12 
Total 46 26 106 1 0 5 12 197 
107 23 34 6 2 11 4 10 197 
Kappa value observer 1 ::= 0.61, 95 % confidence inten'ai 0.53-0.69, agreement is 67.5% . 
Kappa value observer 2 = 0.66, 95 % confidence interval 0.59-0.73, agreement is 75.1%. 
Cone. :::: concentric, Ecc. = eccentric, Mult. irreg. = muhiple irregularities, Tandem = tandem lesion, 
N.A. :::: Not applicable 
TIi\H flow grade Observcr 2 
Observer TIMIO TIMII TIM! II TIMI III Total 
TIMIO 11 0 0 0 11 
7 1 0 0 8 
TIMII 4 0 6 
7 2 11 
TIMI II 0 0 9 13 22 
0 3 14 7 24 
TIMI III 0 0 3 155 158 
0 2 8 144 154 
Total 12 4 13 168 197 
8 13 23 153 197 
Kappa value observer 1:::: 0.70, 95 '% confidence interval 0.59-0.81, agreement is 90.9%. 
Kappa value observer 2 = 0.66, 95 '% confidence interval 0.56-0.76, agreement is 87.3% . 
Ostial lesion Observer 2 
Obsen'cr 1 No Yes 
No 188 
197 0 
Yes 7 
0 0 
Total 189 8 
197 0 
Kappa value observcr 1 :::: 0.87, 95 'X, confidence intcrval 
0.72-1.02, agreement is 99.0%. 
Kappa value obscr\'Cr 2 :::: 1.00, agreement is 100.0%, . 
Tortuosity Ohserver 2 
Obscrver 1 No ~loderate Severe 
No 194 0' 
193 3 0 
jv10derate 0 0 
0 0 
Sevcrc 0 0 
0 0 0 
Total 194 2 
194 3 0 
Kappa value obscrver 1 :::: 0.80, 95 % confidence interval 
0.47-1.13, agreement is 995%, . 
Kappa value observer 2 :::: 1.00, agreement is 98.0% . 
Branchepoint involved in Obscrver 2 
the stenosis Observcr 1 No Yes 
No 143 4 
163 10 
Yes 22 28 
7 17 
Total 165 32 
170 27 
Kappa value observer I :::: 0.61, 95 % confidence interval 
0.50-0.72, agreement is 86.8% . 
Kappa value observer 2 :::: 0.62, 95 'If, confidence interval 
0.47-0.77, agreement is 91.4'%. 
Total 
189 
197 
8 
0 
197 
197 
Total 
195 
196 
o 
197 
197 
Total 
147 
173 
50 
24 
197 
197 
Relationship to coronary artery bend 
Observer 1 Observer 2 
No Yes 
No 188 0 
189 0 
Yes 2 6 
3 5 
Bad quality I 0 
0 0 
Total 191 6 
192 5 
Kappa \'alue observer 1 = 0.85, 95 'X. confidence interval 
0.69-1.01, agreement is 98.5'% . 
Kappa value obsen'er 2 = 0.76,95 '1., confidence inten'al 
0.55-0.97, agreement is 98.5%. 
Presence of thrombus Ohsen'er 2 
Observer 1 No Yes 
No 190 
187 3 
Yes 2 4 
2 5 
Total 192 5 
189 8 
Kappa value observer 1 = 0.72, 95 % confidence interval 
0.46-0.98, agreement is 98.5'X •. 
Kappa \'alue obsen'er 2 = 0.65, 95 % confidence interval 
0.42-0.85, agreement is 97.5'){, . 
Presence of calcium Observer 2 
Ohserver 1 No Yes 
No 172 2 
162 9 
Yes 14 8 
13 13 
Bad quality 0 
0 0 
Total 187 10 
175 22 
Kappa value observer 1 = 0.46, 95 % confidence interval 
0,28-0.64 1 agreement is 91.4%" 
Kappa value observer 2 = 0.48, 95 'X, confidence interval 
0.59-0.73, agreement is 88.8'X,. 
Total 
188 
189 
8 
8 
I 
0 
197 
197 
Total 
191 
190 
6 
7 
197 
197 
Total 
174 
171 
22 
26 
I 
0 
197 
197 
Lesion type Observer 2 
Observer 1 A B1 Il2 C T.O 
A II 10 0 0 
47 16 0 0 0 
ill II 42 20 I 0 
13 54 8 2 0 
B2 19 58 0 
4 12 21 I I 
C 0 3 1 6 0 
0 0 4 0 
T.O. 0 0 0 0 12 
0 0 0 0 7 
Bad quality 0 0 0 0 0 
0 2 I 0 
Total 23 74 80 8 12 
65 84 30 8 8 
Kappa value based on A, B I, B2 and C classes observer 1 ::::: 0.49, 
95 % confidence interval 0040-0.57, agreement is 65.5% . 
Kappa value based on A, Bl, il2 and C classes observer 2:::: 0.55, 
95 'Yr, confidence interval 0.47-0.63, agreement is 67.5% . 
Kappa value based on A, Band C classes observer 1 :::: 0.61,9 
5 % confidence interval 0.54-0.68, agreement is 85.3% . 
Kappa value based on A, Band C classes observcr 2 :::: 0.59, 
95 %, confidencc interval 0.52-0.66, agreement is 77.7% . 
T.O:::: totally occlusive coronary artery 
Figure 1 
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cases. In all the other items the percentage of total agreement is over 90%. 
Both observers demonstrated excellent agreement in intra-observer variability 
for tortuosity, relationship to coronary artery bend and ostial localization. All 
other studied lesion characteristics showed fair to good agreement for intra-
observer variability (table IV). 
Discussion 
Kappa statistics are a well known method of evaluating agreement between 
observers. This method is most useful when observations are frequent and have a 
Gaussian distribution. However the limitation arises when observations arc rela-
tively rare Or even exceptional. One single outlying observation can then dramati-
cally affect the kappa values. Figure 1 illustrates the relationship between kappa 
value and the distribution of observations over the cells. It shows clearly that per-
cent agreement can remain constantly high (98%), while kappa value ranges from 
-0.010 to 0.96. The graph also depicts the possible abrupt change in kappa value 
when the majority of observations is concentrated in only one cell. Kappa value 
can change from -0.010 to 0.490 when one observation is differently positioned 
over the cells (figure 1). 
It is well known that visual estimates of lesion characteristics are less accurate in 
comparison to quantitatively derived parameters. Several variability and quality 
control studies have been conducted. Beauman and Vogel [9] compared visual 
estimations of lesion severity to quantitative analyses of percent diameter stenosis 
of coronary and phantom obstructions. Quantitatively assessed coronary arteries 
comprising a 50% diameter stenosis, and 50% phantom stenoses recordings were 
visually scored in ranges from 15 to 80 percent, and 30 to 95 percent respectively. 
Determination of the reference diameter showed that only 41 % of the estimations 
were within 10% of the limits of the quantitatively derived diameter. 
Another study [10] in 50 lesions reports the inter observer agreement of 73% for 
stenosis length (defined as the length of that portion of the stenosis that had a 
~30% reduction in luminal diameter using the adjacent normal vessel diameter as 
a 'yardstick' or unit) and 64% for lesion eccentricity (defined as asymmetrically 
positioning in one or more views), resulting in kappa values of respectively 0.38 
and 0.25. 
A report from our core lab {II] from 1990 reported the discordance in interobser-
ver measurements in 151 lesions of 21 % for lesion eccentricity (24% in our 
study), 29% for branch point involvement (18% in our study), 14% for location in 
a bend (3.5%), 2% for presence of thrombus (2.5%),10 % for presence ofcalcifi-
cation (10%), and 25% for the lesion type according to the ACC/AHA classifica-
tion (32%). 
A recently presented study in 403 coronary lesions [12] demonstrated an excel-
lent agreement for type C lesions (k:::::0.85). Good agreement was shown for 
TIMI flow (k=0.73), ABC classification (k=0.48), angulation and side branch 
(k::::: 0.48 and 0.40 respectively). Poor achievement was reached in eccentricity, 
tortuosity, lesion calcification, and in the distinction of discrete, diffuse and 
tubular lesion length. 
IJIlernati01lal JOllrnal of Cardiac Imaging 1996; 12:21-30 
Mild discrepancies between the two assessors can be explained by insufficient 
quality in image acquisition, when e.g. overlap or foreshortening hampers asses-
sment. Especially very proximal lesions in the left anterior descending artery are 
sometimes very difficult to explore visually, and are therefore subject of discor-
dant descriptions. 
Another source of incongruous assessment can be the experience of the angio-
graphist. In this study one of the two MD's is interventional cardiologist (VU), 
while the other is a permanent assessor in the core lab of Cardialysis OH). 
An issue of essential relevance which contributes to the poor agreement within 
and between investigators is a clear description of the definitions of items to be 
assessed. The original and updated combined AHNACC [1,2] paper mentions 
the individual items on which the ABC classification is based, without detailed 
delineation of these clements. Many dissimilar definitions are in use throughout 
the literature. Although basically comparable, they differ in details, and cause 
discrepancies in cinefilm readings. Length of lesion e.g. can be interpreted e.g. as 
the length of plaque, related to the pre-defined size of the catheter on the image. 
An adjusted definition is the length where the stenosis ~70% of the lumen diame-
ter, or ~50% , or ~30% . This can then be expressed in absolute diameters or in 
terms of normal lumen diameter ratio (10). Lesion length can also be defined as 
the calliper measurement of the distance from the proximal to the distal shoulder 
of the lesion in the projection that best elongated the stenosis. Cut-off points were 
chosen as <10 and >20 mm [3]. \Y/e propose to usc the definitions as listed in 
table V. They leave a minimum of space for different explanation and interpreta-
tion. 
Panel assessment gives a substantial improvement in inter and intra obser-
ver agreement [9]. It is clear that the weighted sum of several simultaneous obser-
vations eliminates the most extreme disagreements, where the isolated assessor 
can develop his own interpretation and thus deviate from the original definitions. 
Serial observations as in pre-readings, with knowledge of the results of the 
first observer's judgement may result in higher kappa-values for qualitatively 
assessed lesion characteristics. The mechanism of improved agreement in case of 
pre-reading however differs from improved agreement following panel asses-
sment. In serial readings, the first judgement is merely dominant and respected 
by the second reviewer, who tends to compliance, implicating an improved out-
come. 
Conclusions 
The data demonstrate a substantial discordance of agreement between two 
observers and also a partial lack of reproducibility of the results. These findings 
may be attributed to, among others: quality of data acquisition on film; experien-
ce of angiography assessors; and mainly Jack of strict definitions. Further investi-
gation, preferably by panel assessment might be performed, only after agreement 
upon complete and detailed definitions for each angiographic variable. Besides, if 
we want to estimate procedural success rates and the risk for procedural compli-
cations we have to debate operator experience and clinical variables. 
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Table V 
List of Proposed Definitions to be Used for Qualitath'e Assessment of Coronary Angiograms. 
Symmetry; Lesions arc judged for their symmetry depending on their appearance in any of mUltiple pro-
jections. Eccentric lesions are asymmetrically positioned in one or more views. 
Categories: Concentric, Eccentric. 
Roughness; The stenosis was judged to be rough if its luminal edge was irregular, or had a sawtooth com-
ponent [3]. 
Categories: Discrete/smooth, Irregular contour. 
Length oflesion; Estimation of the length of that portion of the stenosis that has a ;::0.50% reduction in 
luminal diameter. A contrast empty catheter tip is used for 'visual calibration'. 
Categories: < 10 mm, 1 0 ~ 20 mm, > 20 mm, NA. 
TI~U flow grade; [5] 
0: no flow, 
I: penetration with minimal perfusion (contrast material passes beyond the area of obstruction but 'hangs 
up' and fails to opacify the entire coronary bed distal to the obstruction for duration of the cine run) 
II: delayed perfusion (opacification of the coronary bed distal to the obstruction, but rate of entry and/or 
clearance of the contrast medium is reduced) 
III: complete perfusion 
Occlusion; Total obstruction without anterograde flow TIMI o. The distal vessel mayor may not be filled 
by through retrograde or anterograde collateral (bridging) flow [13]. 
Categories: No total occlusion, Total occlusion. 
Branch pointj A branch point is considered present if any part of the lesion> 30 'X, narrowed is adjacent to 
a branch vessel that has a diameter of 25% or more of the diameter of the vessel being scored [3]. 
Categories: Branch point involved, Branch point not involved 
Bifurcation stenosis; The stenosis was recorded as a bifurcation stenosis if a branch vessel of medium or 
large size originated within the stenosis and iof the side branch was completely surrounded by significant 
stenostic portions of the lesion to be dilated [3]. 
Ostial lesion; When it invol,'ed the origin of the proximal LAD, LCX Or RCA. When 'ostial' and 'bifurca-
tion' occurred together they were counted as only one ACC/AHA class B characteristic {3}. 
Categories: Ostial, Not ostial located. 
Bend point; A bend point is considered present if in any angiographic projection orthogonal to the lesion, 
any part of the lesion is located in a portion of the vessel that has a;::o. 45 degrees angulation at end diastole. 
CASS Registry [10] and ACC/AHA classification [1,2] 
Categories: Not located in a bend point, lvmd bending, bend point> 45, <90 degrees, Severe bending, 
bend point> 90 degrees. 
Calcifications; Calcifications are present if fixed radiopaque densities having the appearence of calcifica-
tion are noted in any projection in the area of the stenosis to be dilated. 
Categories: None, Little, Heavy calcification. 
Intra coronary thrombus; Intra coronary thrombus is defined as; presence of intraluminal non calcified 
central filling defect or lucency surrounded by contrast material seen in multiple projections, or persisten-
ce of contrast material within the lumen, or a visible embolization of intraluminal material downstream 
[14J. 
Categories: Absent, Present. 
Tortuosity; Stenoses distal to two bends are in general scored as moderately tortuous, and those distal to 
three or more bends were considered to be associated with excessive tortuosity. 
Categories: No tortuosity, Moderately tortuosity, Excessive tortuosity. 
Tandem lesions were defined as adjacent separate lesions, more than three lumen diameters apart. This 
lesion does not include multiple separated lesions in different portions of the same vessel. 
Categories: Tandem lesion, No tandem lesion. 
buernational JOllmal oj Cardiac Imaging 1996; 12:21-30 
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Table VI 
Appendix 
The decision to review 200 angiofilms was based on the degree of agreement between the 
angiographic corelab Cardialysis and the investigators in the Helvetica study with regard 
to lesion type according to the ACC/AHA classification. This agreement was accomplis-
hed by a non-blinded review of cine-angiofilms by two assessors in the angiographic core-
lab. Kappa values for this study population were consequently calculated for each lesion 
type separately (A, B 1, il2 and C) and across all categories. The overall kappa value was 
0.64 (90% CI 0.61 to 0.68). 
To calculate the kappa value within the core lab, we used the inter rater data generated 
from the corclab and investigator with a standard deviation of 0.60 (standard error 0.02 
in 905 lesions). The expected kappa was set at 0.70, since it is assumed that the generated 
kappa value of the core lab will be greater than that calculated between core lab and the 
investigator (0.64). The lower accepted kappas were assumed to be 0.69, 0.68, 0.67, 
0.66, and 0.65. The number of lesions to be reviewed, assuming a one-sided significance 
level of 0.05, power of 0.90 or 0.80, is listed in table VI. Based on these calculations we 
decided to review 200 angiofilms. 
Number of Patients or Lesions Needed to be Reviewed 
(Alpha:::: 0.05, Standard Deviation:::: 0.60). 
lower kappa limit number of patients needed 
0.69 
0.68 
0.67 
0.66 
0.65 
power:::: 90% 
1700 
425 
189 
107 
68 
power:::: 80% 
1230 
308 
137 
77 
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Chapter 7 - Argatroball: a dose verification swdy 
Abstract Background Thrombin is a key enzyme in thrombogenesis. 
In animals, specific anti-thrombotic therapy at the time of percutaneous trans-
luminal coronary angioplasty reduced the incidence of subacute occlusion and 
inhibited the restenosis response. Argatroban is a highly selective synthetic 
thrombin antagonist that binds in a competitive manner. This is a report of a 
dose verification study, assessing safety and feasibility of intravenous argatro-
ban administration in patients undergoing percutaneous trans luminal coronary 
angioplasty. 
Methods Before angioplasty an intravenous bolus of30~g/kg was admini-
stered, followed by a continuous infusion of3.5 ~g/kg/min for 72 hours. Bolus 
injection was repeated and infusion rate was increased in order to achieve an 
activated coagulation time (ACT) of over 300 seconds. Following interim-ana-
lysis, the bolus and initial infusion rate for the subsequent treatment groups 
was determined. Study endpoints were the occurrence of adverse events, coagu-
lation tests, and qualitative angiogram reading. Patients were monitored by 
continuous 12-lead electrocardiographic recording over 24 hours, and under-
went control angiography 18-24 hours following angioplasty. 
Results Four treatment groups, comprised 2,8,9, and 11 patients, respective-
ly, were studied. The first two patients were excluded from analysis, since the 
initial dose was ineffective to attain an ACT authorizing coronary angioplasty. 
The group with the highest dosage received a 250 ,..g/kg intravenous bolus of 
argatroban, foHowed by a 4 hour infusion of 15 ~g/kg/min. At 4 hours the 
infusion rate was lowered to 3.8 J.l.g/kg/min and continued for 68 hours without 
adjustment for catheter removal. The adverse event profile included myocardial 
infarction, aorto-coronary bypass graft, bail-out procedures and repeat coro-
nary angioplasty. Thrombin-time (TT), activated partial thromboplastin time 
(aPTT) and pro-thrombin time (PT) were significantly related to argatroban 
plasma concentration, as demonstrated by regression analyses (R-square 0.64, 
0.71, and 0.84 respectively). Prothrombin fragment 1 and 2 and thrombin-
antithrombin III complex did not fit into a mathematical model, but showed 
slightly increased levels after reduction or cessation of the infusion rate. 
Conclusions This dose verification study, including 30 patients at four dose 
levels, indicated that argatroban infusion in coronary angioplasty patients 
can be administered safely, and results in an adequate and predictable level of 
anticoagulation. Gournal of Thrombosis and Thrombolysis 1996;3:367-375) 
.1ournal oj Thrombosis and 11lrombolysis 1996;3:367-375 
Angioplasty of coronary narrowings greatly enlarges the arterial lumen. Never-
theless, the short term therapeutic benefit of percutaneous transluminal coronary 
angiopiasty (PTCA) can be limited by formation of mural thrombus and subse-
quent abrupt closure of the coronary artery. In addition, organization of mural 
thrombus and proliferation of smooth muscle cells lead to vessel restenosis, also 
adversely influencing medium- and long-term result. The central role of throm-
bin in these events is a result of its cffects on the clotting cascadc, leading to fibrin 
and thrombus formation; on platelct aggregation, causing the liberation of 
growth factors; and finally its direct mitogenic effect on smooth musclc cells [I]. 
A low thrombin level is sufficient to activate phospholipid membrane bound fac-
tor V, which is part of the pro-thrombinasc complex, and can therefore strongly 
acceleratc thrombin formation [2J. Interferencc with this positive feedback loop 
by potent and specific thrombin inhibition is a very effective antithrombotic stra-
tegy [3, 4J. 
Argatroban, ((2R,4R)-4-methyl-l- [N 2_( (3-methyl-1 ,2,3,4-tetrahydro-8-
quinolonyl) sulphonyl)-arginyl]-2-piperidine carboxylic acid) is an arginine 
derivate that binds competitively to thrombin [5]. Compared with heparin, it has 
sevcral potential advantages. Argatroban is synthetic and therefore has no natural 
inhibitors. It does not need antithrombin III as a co-factor, and it is non-antige-
nic. Heparin is a mixture of heterogenous sizcd depolymerized molecules, and 
therefore its bioactivity may vary depending on the particular lot. In contrast, the 
anticoagulant effect of argatroban is conccntration dependent [61 and comprises 
both free and clot bound thrombin. 
Specific antithrombin therapy using argatroban has been shown to be su-
perior to heparin treatment in numerous experimental animal models of arterial 
thrombogenesis [7-19J. At doses causing comparable prolongation of activated 
partial thromboplastin time (aPTT), argatroban has been demonstrated to be 
significantly more effective than heparin for the prevention of platelet rich 
thrombotic occlusion in an animal model (20]. Several human trials with argatro-
ban have been completed using dosage regimens up to 25 )J.g/hr Lv. for 2 hours 
[21J or 20 [Igihr Lv. for 2 hours after a 10 Jlg bolus [22J. These studies have 
demonstrated a moderate dose-dependent 4.5-fold increase in thrombin time, 
and a 1.6-fold prolongation of aPTT with no effect of concomitant aspirin admi-
nistration. The doses administered in human studies were low compared to those 
used in animal models, and at these low doses, the elimination half time is 24 
minutes [23J. Based on these findings it was felt safe to investigate this drug in 
patients with a hypercoagulable condition such as patients with unstable angina 
or undergoing PTCA. 
Recently argatroban was infused over 4 hours in patients experiencing 
unstable angina pectoris [24J. Infusion of the drug (0.5 to 5.0 Jlglkg/min) resulted 
in a dose dependent increase in the aPTT and effectively prevented recurrences 
of ischemic episodes. Notably, 9 out of 43 patients experienced an episode of 
unstable angina shortly after drug administration was terminated. The authors 
attributed this to a rebound phenomenon. 
There has been limited experience with the use of argatroban in PTCA 
patients (Fitzgerald, data not published). In his study, 12 patients were randomi-
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zed to receive either a bolus of 30 ~lg/kg argatroban, followed by an intravenous 
infusion of 2 ~Ig/kg/min over 2 hours, or a bolus injection of 10000 IU of heparin 
and a subsequent 4 hour infusion of 1000 IU/hour. 
In order to further define the optimal dose of argatroban for patients under-
going coronary angioplasty, the pre-Argaplasty trial was initiated. This dose veri-
fication study was undertaken to assess safety and feasibility of administration of 
argatroban in patients undergoing balloon angioplasty and to broaden our under-
standing of the response to the coagulation syst~m to this agent. 
Methods 
Stud), design This stud), was nn open, non-randomized dose verification study, carried 
out in three hospitals in the Netherlands. The study was conducted according to G .C.P. 
regulations. Patients were allocated to study medication after giving written informed 
consent. This study assessed the safety and feasibility of the use of three different doses of 
argatroban (group A, Band C respectively) in patients undergoing PTCA. Acetyl salicy-
late (250 mg intravenous) was administered just prior to angioplasty, and 160 mg acetyl 
salicylate was administered orally for the next 3 days. 
Patient selection Patients with stable or unstable angina pectoris due to one or more 
angiographically significant lesions in the native coronary system amenable to balloon 
angioplasty were considered eligible for this study. The main exclusion criteria were 
acute myocardial infarction or thrombolytic therapy within two weeks prior to PTCA; 
current treatment with oral anticoagulant drugs; and history of peptic ulcer disease, 
upper gastro-intestinal bleeding or stroke. 
Coronary angiograms and angioplasty Coronary angiogwms were obtained immedia-
tely before and after balloon nngioplasty, and repeated 18-24 hours afterwards. To stan-
dardize the method of data acquisition and to ensure the exact reproducibility of the 
angiograms performed after the intervention and at follow-up, measures werc taken as 
described earlier [25, 26}. Choice of angioplasty device, balloon pressure, and duration of 
inflation were left to the discretion of the operator. All angiograms were read at 
Cardialysis B.V., Rotterdam, the Netherlands. 
Argatroban dose regimen and dose adjustment argatroban was provided by Synthe-
labo Recherche (L.E.R.S.), Bagneux Cedex, Franee. It's clearance and half-life are 5.0 
±D.5 mllkg/min and 24.4±3.5 minutes, respectively, in healthy volunteers. As argalIoban 
is a photo-sensitive drug, it was dispensed in opaque ampoules containing 0.5 mg/Ill\. 
The maximum total daily authorized dose was 10 mglkg bodyweight. 
The first eight patients (group A) were to receive a bolus of 30 pg/kg argatroban, 
followed by a 3.5 pg/kg/min infusion during the next 72 hours. When the ACT exceeded 
300 seconds, angioplasty was authorized approximately 45 minutes after administration 
of the bolus and the start of the argatroban infusion. For an ACT less than 300 seconds, 
an extra 30 ~lg/kg bolus was administered, and the rate of infusion was increased by 0.5 
~lg/kg/min increments until the ACT exceeded 300 seconds. Following PTCA, the infu-
sion rate was adjusted to maintain the aPTT between 100 and 120 seconds (2.5 to 3 times 
normal value) according to the adjustment algorithm shown in table 1. Following interim-
analysis, the bolus and initial infusion rate for the adjacent treatment groups (group Band 
C) were determined. 
The femoral sheath was removed after reduction of the infusion rate to a predeter-
mined level of 2.0 ~lg/kg/min, in order to obtain an aPTT of less than 80 seconds (less 
than twice normal value). One hour after sheath removal, infusion rates were restored to 
their pre\'ious setting. The patients were kept on strict bed rest for the next 24 hours. 
154 
Table I 
Argatroban adjustments after the angioplasty procedure according to aPTT values. 
aPTT (seconds) 
times x normal value (NV) 
<80 sec 
<2 times NV 
80-100 sec 
2 to 2.5 times NV 
101-120 sec 
2.5 to 3.0 times NV 
121-140 sec 
3.0-3.5 times NV 
141-160sec 
3.5 to 4.0 times NV 
>160 sec 
>4 timesNV 
Table II 
Discontinuation 
(duration in minutes) 
15min 
30min 
Demographic data on the studied population per dosage group. 
Group B (N=8) Group C (N=9) 
Male gender 6 (75%) 5 (56%) 
Caucasian 7 (88'%) 9 (100%) 
Age (range) 53 (37-70) 57 (33-74) 
Weight (range) 76 (62-105) 65 (60-85) 
PreviousMI 2 (25%) 2 (22%) 
Previous PTCA 1(13%) 5 (56%) 
Previous CABG 0(0.0%) I (11'1.,) 
Hypertension 3 (38%) 5 (56%) 
NIDDM 0(0.0%) 2 (22%) 
Hypercholeslcrolaemia 3 (38%) 4 (44%) 
Current smoker 2 (25%) 1 (11%) 
Stable angina 4 (50%) 6 (67%) 
Unstable angina [40] 4 (50%) 3 (33%) 
class I 0 
class II 4 2 
class III 0 0 
Two vessel disease 1 (12%) 2 (22%) 
Dose change in Jlg/kg/hour 
+ 1 ~Ig/kg/min increase 
+0.5 ~Ig/kg/min increase 
No change 
-0.5 ~lglkg/min decrease. 
-1 ~lglkg/min decrease 
-2 ~lg/kg/min decrease 
Group D eN=ll) 
6 (55%) 
11 (100%) 
59 (49-77) 
72 (56-92) 
5 (45%) 
5 (45%) 
I (9%) 
4 (36%) 
I (9'){') 
2 (18%) 
2 (18%) 
6 (55%) 
5 (45%) 
3 
I 
2 (18%) 
Categorical variables are presented in absolute values and percent N ('%). MI = myocardial infarction; 
PTCA = percutaneous transluminal coronary angiography; CAllG = coronary artery bypass graft 
surgery; NIDDM. = non-insulin dependent diabetes mellitus; unstable angina class I-III = according to 
the Braunwald classification [40]. 
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Study endpointsj evaluation of efiicacy and safety Study endpoints were the occur-
rence of major adverse cardiac events and bleeding complications, electrocardiographic 
changes as detected by continuous 12-lead recording, coagulation test results and quali-
tative angiogram interpretation. Efficacy was evaluated on the basis of occurrence of 
death, non-fatal myocardial infarction, revascularization procedures, and bleeding com-
plications. All deaths were considered cardiac unless documented to the contrary. 
Myocardial infarction was diagnosed on the basis of new Q-waves (Minnesota Code 
[27]) or an increase of creatinine kinase more than twice the upper limit of normal with a 
concomitant increase in myocardial bound fraction. Bailout stenting was considered 
equivalent to coronary artery bypass grafting (CAB G) if patency of the target vessel 
could not be maintained otherwise. If a stem was implanted electively after the initial 
PTCA (i.e. not comprising a bail out procedure), this was considered to be equivalent to 
repeat angioplasty. Repeat angioplasty was defined as re-insertion of a guiding catheter 
followed by angioplasty at the previously dilated site. The occurrence of typical anginal 
symptoms or electrocardiographic evidence of myocardial ischemia at rest or during 
exercise in case of atypical anginal symptoms and an angiographic diameter stenosis of > 
50 percent by visual inspection was required to justify repeat angioplasty or bypass 
surgery. 
Safety was evaluated on the basis of bleeding, which was classified as major if it was 
overt and led to a haemoglobin fall of at least 5 g/dl or 15% haematocrit; required transfu-
sion of five or more units of whole blood or packed cells; or occurred intracranial, retro-
peritoneal, or into a major joint [28]. Minor bleeding was defined as oven, gross haema-
turia, or haematemesis, or if it led to a fall in haemoglobin of at least 3 grams per decilitre, 
or at least 10% haematocrit. Haemaluria was classified as macroscopic when clinically 
evident, and as microscopic in the presence of more than 4 erythrocytes per high-
power field. 
Secondary endpoints Coronary angiograms were analyzed for TIMI flow assessment 
[291, as documented at re-catheterization 24 hours following balloon angioplasty. 
Continuous 12-Iead electrocardiography over 24 hours was analyzed for ischemic episo-
des of recurrent ischemia, defined as at least 0.1 mV ST -segment elevation for at least onc 
minute. Finally, blood samples were taken at various points in time to assess the dose 
response relationship of various coagulation parameters. Determination of ACT was 
done extemporaneously in the catheterization laboratory on whole blood samples. 
Bleeding time was performed at screening, 12 hours and 72 hours after commencement 
of the study medication. Blood samples for activated partial thromboplastin time 
(aPTT), pro-thrombin time (PT), thrombin-time (TT, thrombin concentration 4 to 20 
IU/ml), thrombin-antithrombin-complex (TAT) and pro-thrombin fragment one and 
two (Fl. 2) were drawn in the arm contra to that receiving medication. Those samples 
were centrally assessed in a haemostasis core-lab. 
Statistical analysis Mainly descriptive statistics were carried out. Continuous variables 
were expressed as medians with their range, while categoric variables were expressed as 
absolute numbers and percentages. Two patients (group A) were not included in the sta-
tistical analysis since the initial dose regimen, as specified in the protocol, was ineffective 
in terms of ACT. Regression analyses of the different coagulation parameters on argatro-
ban plasma Icvels were performed. Linear models were fitted and expanded with a loga-
rithmic, square or cubic term. 
Results 
Patient population and dose regimen The first two patients (group A) enroled 
in the trial received a bolus of 30 j.lg/kg argatroban foHowed by an infusion of a 
rate of 3.5 Jlglkg/min in order to obtain an ACT before balloon angioplasty of 300 
seconds. However, despite repeated bolus injections and multiple increases in the 
Table III 
Qualitative angiographic data on the studied population per dosage group. 
Treatment group Group B Groupe GroupD 
(Number oflesions) (N~9) (N~IO) (N~ 13) 
Restcnotic lesion 1 (11%) 4 (40%) 4(31%) 
Total occlusion 2 (22%,) 1 (10%) t (8%) 
Type of lesion (AHA/ACe) 
Type A 1 (11%) 1 (10%) 1 (8%) 
TypeDI 3 (33%) 0 4 (30%) 
Type D2 5 (56%) 9 (90%) 7 (54%,) 
Typee 0 0 1 (8%) 
TIMI flow posI-PTCA 
TIMIO 0 1 (10%) 1 (8%) 
TIMII 0 0 0 
TIMI II 0 1 (10%) 0 
TIMI III 9 (100%) 8 (80%) 12 (92%) 
Dissections 
Absent 7 (78%) 5 (50%) 7 (53%) 
Type A 1 (II 'X,) 1 (10%) 1 (8%) 
TypeD 0 330%) 4(31%) 
TypeC 1 (11%) 1 (10%) 0 
TypeD 0 0 1 (8%) 
Thrombus post-PTCA 0 1 (10%) 0 
TIM.! flow at 24 hes 
TIMID 0 0 1 (8%) 
TIMII 0 1 (12%) 0 
TIM! II 0 0 0 
TIMI III 9 (100%) 7 (88%) 10 (84%) 
Not applicable 0 0 1 (8%) 
Categorical variables arc presented in absolute values and percent N (%). 
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infusion rate to 5.0 ~lg/kg/min, the ACT level did not exceed 200 seconds. 
lYledication in these patients was replaced by routine (i.e. heparin) treatment. 
Following detailed review of the first two patients, the next dosage group 
(group B) was assigned to receive a bolus of 60 ~g/kg, followed by a 4 hour infu-
sion of 8 ~lg/kg/min. At 4 hours the infusion rate was lowered to 4 ~g/kg/min and 
was continued for 68 hours, so that the maximum daily dose would not be ex-
ceeded. In the absence of bleeding, no dosage adjustments were made. After the 
re-catheterization, the infusion rate was transiently reduced for catheter removal 
to 2.0 ~glkg/min to achieve all. aPTT level of less than twice the normal value. 
One hour after sheath removal, the infusion rate was restored. Eight patients were 
treated according to this schedule. JYlajor bleeding was not observed, ACT incre-
ased only moderately, and based on the results of F 1.2 and TAT, a higher admi-
nistration level was investigated. 
In parallel with a phase I study carried out in 9 healthy volunteers [unpu-
blished data], the third dosage group (group C) received a bolus of 250 ~g/kg, 
followed by a 4 hour infusion of 10 llg/kg/min. At 4 hours the infusion rate was 
lowered to 3.8 ~(g/kg/min and continued for 68 hours. This dosage group compri-
sed nine subjects. For sheath removal the same procedure was followed as in the 
foregoing patients. Evaluation of clinical data indicated satisfying safety levels, as 
bleeding was not observed. Furthermore, haemostatic parameters revealed that 
at 45 minutes thrombin generation was not totally controlled, and that reduction 
of infusion rate to 2 /lg/kg/min for the sheath removal was accompanied by in-cre-
ased thrombin conversion and activity. Interim analysis demonstrated that the 
aPTT level, at an infusion rate of 3.8 ~(g/kg/min, was around twice the normal 
value. Based on these data, the patients in the fourth dosage group (group D) 
received a bolus of 250 ftg/kg, followed by a 4 hour infusion of 15 ~g/kg/min. At 4 
hours the infusion rate was lowered to 3.8 Ilg/kg/min and was continued for 68 
hours without adjustment for catheter removal. This dosage regimen group was 
comprised of 11 patients who received a total daily dose of 8.4 mg/kg. 
Demographic, clinical and angiographic data of the studied patients are 
summarized in tables II and III respectively. None of the patients had a history 
of bleeding or stroke. The small number of patients docs not allow for compa-
rison of the groups; however, the strict inclusion criteria ensure that they arc 
very similar. 
Study endpoints Crable IV) In group B, one patient experienced insignificant 
bleeding at the puncture site 7 hours after sheath removal during a 4 Jlg/kg/min 
infusion, and therefore the study medication was discontinued. One case of phle-
bitis at the site of the indwelling infusion needle was reported, which occurred 58 
hours after the commencement of the study medication. 
In treatment group C, two patients had a failed PTCA (one of which was a 
total occlusion before the attempt) and after discontinuation of argatroban infu-
sion were referred for elective bypass surgery. Another patient showed recurrent 
stenosis (>50%) with thrombus at the 24 hours control angiogram. Repeat 
PTCA (under argatroban therapy) was successful. In this group no bleeding 
complications were observed. 
Table IV 
Occurrence of clinical c\'cnts per dosage group. 
Death 
MI 
CABG 
Bail-out 
Repeat PTCA 
Any event 
12-lcad EeG ST monitoring 
Patients with ST -episodes 
Number of ST -episodcs# 
Duration of episodes 
(median in min:scc) 
Bleeding complications 
Epistaxis 
False aneurysm 
llJeeding at puncture site 
Group B (N:::::8) 
0(0%) 
8 (100%) 
1 (13%,) 
Group C (N=9) 
2 (22%) 
1* (11%) 
3 (33'%) 
9 (100%) 
1 (I 1%) 
0.9 
2:33 
Group B: bolus 0[60 Ilg/kg, followed by a 4 hour infusion 0[8 pg/kg/min. 
Group D (N=1l) 
1 (9%) 
1 (9%) 
3*(18'%) 
2 (18%) 
11(100%) 
3 (27%,) 
2.9 
32:07 
1 (9%) 
1 (9'%) 
1 (9%) 
At 4 hours the infusion rate was lowered to 4 Ilg/kg/min and was continued for 68 hours. 
Group C: a bolus 0[250 ~tg/kg, followed by a 4 hour infusion of 10 Ilg/kg/min. 
At 4 hours the infusion rate was lowered to 3.8 Ilglkg/min and continued [or 68 hours. 
Group 0: a bolus of250 ~Ig/kg> followed by a 4 hour infusion of 15 ~Ig/kg/min. 
At 4 hours the infusion rate was lowered to 3.8l-1g/kg/min and continued for 68 hours. 
* The repeat PTCA in group C and one repeat PTCA in group D was triggered by 
the recatheterization 
24 hours after the start of the infusion. 
# Normalized to 24 hours recording time during treatment 
MI = myocardial infarction; CABG = coronary artery bypass graft surgery; 
PTCA = percutaneous transluminal coronary angiography. 
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In treatment group D, one patient experienced a myocardial infarction due 
to a subacute re-occlusion. Repeat PTCA was attempted but not successful. 
Another patient showed recurrent stenosis (>50%) on the 24 hours control 
angiogram. Repeat PTCA was not satisfactory and a stent was implanted and 
argatroban was replaced with routine anticoagulants. During treatment with 
heparin and Acenocoumarol, this patient had prolonged epistaxis, necessitating 
blood transfusion. A second repeat PTCA was performed in this patient for 
occlusion at the stented segment. In addition, a false aneurysm was reported in 
one patient, and prolonged insignificant bleeding at the puncture site in another. 
There were no reported death or cases of haematuria in any of the four dose 
groups. Results of TIM.I flow assessment and 12-lead electrocardiographic 
monitoring are reported in tables III and IV respectively. The low number of 
patients enroled does not justify solid conclusions on angiographic and clinical 
results. Individual coagulation parameters may yield specific information on the 
unstable syndrome or complexity of the lesion, but this relationship remains spe-
culative. 
Dose-response relationship of argatroban plasma level and coagulation 
parameters The relationships between argatroban plasrna level and coagulation 
parameters (ACT, aPTT, TT and PT) are presented in figure 1. A clear dose-
response relationship is documented for each parameter. Table V presents the 
results of linear regression analysis. Inclusion of a squared variable in the model 
(c.g: y = a + bx + e2) for TT improved the R-square value from 0.639 to 0.653. 
Additional inclusion of a cubed variable (e.g: y = a + bx + e 2 + dx3) in the aPTT-
model only marginally improved the R-square value from 0.715 to 0.725. 
Although these improvements in the models for TT and aPTT arc statistically 
significant, we suggest restriction to the linear and square model respectively for 
pragmatic reasons. Logarithmic strategy in the aPTT -model resulted in an R-
square value of 0.64 (P < 0.001), which is inferior to the square model. No clear 
relationship could be detected between the argatroban plasma level and F 1.2 and 
T AT concentrations (Figure 2); however, a substantial number of measurements 
exceeded the normal range (1.29 nmol/L for F 1.2 and 3.2 ~lg/L for TAT). 
Discussion 
Argatroban was developed in Japan (Mitsubishi Chemical) where authorization 
for its use in the treatment of peripheral arterial disease was obtained in 1991 
(MD-805, available as Novastan). The rationale of this study was based on the 
finding that specific antithrombin therapies can inhibit mural thrombosis after 
deep arterial injury and prevent the growth of pre-existing thrombus on deeply 
injured arteries exposed to both high and low shear stresses [8]. Experimentally, 
injured arteries remain highly thrombogenic for several hours to days following 
balloon injury [30-33]. Therefore it was judged prudent to commence argatroban 
administration before the angioplasty procedure and continue during the next 72 
hours. The restriction of argatroban to intravenous administration limits its use 
to hospital setting. 
The initial dosage was based on previous studies in cardiac patients. Gold 
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Table V 
Relationship between coagulation parameters and argatroban plasma level. 
Parameter Formula P-value R-square 
BT NS 0.00 
ACT 190 + 36.8 * APL 0.000 0.54 
aPTT 33.2 + 23.9 * APL- 2.25 * APL2 0.000 0.71 
TT 5.53 + 23.7 * APL 0.000 0.64 
PT 11.4+4.88*APL 0.000 0.84 
APL = Argatroban plasma leyel; BT = bleeding time; ACT = activated coagulation time; 
aPTT = activated partial thromboplastin time; TT = thrombin time; PT = pro-thrombin time. 
Table VIA 
Thrombin-antithrombin III complex (normal range 0.60-3.20 pg/L) by dosage group (median and range 
shown in brackets). 
Time N GroupE N GroupC N Gl'oupD 
- 1/2 hr 8 4.1 (2.2-18.5) 9 2.6 (2.0-10.5) II 3.9 (2.0-11.0) 
1 hr 8 4.0 (2.0-6.0) 9 2.7 (2.0-31.5) II 3.3 (2.0-17.0) 
2 hrs 7 5.0 (2.4-12.0) 8 2.3 (2.0-4.2) II 4.8 (2.4-161.0) 
24 hrs 8 5.7 (4.5-20.0) 7 5.0 (4.0-6.8) 9 8.0 (4.3-52.5) 
72 hrs 7 3.2 (2.4-13.0) 7 2.6 (2.0-4.2) 8 3.8 (2.9-11.0) 
73 hrs 7 4.8 (2.3-28.0) 7 3.0 (2.0-6.3) 8 5.5 (2.2-36.0) 
74 hrs 7 4.3 (3.2-125.0) 7 3.6 (2.0-13.0) 8 5.0 (2.0-10.6) 
Table VIB 
Prothrombin fragment I and 2 (normal range 0.57-1.29 nmoUL) by dosage group (median and range 
shown in brackets). 
Time N GroupB N Group C N GroupD 
- 112 hr 8 0.93 (0.43-2.10) 9 1.10 (0.45-1.50) II 1.30 (0.55-3.40) 
I hr 8 0.76 (0.50-1.30) 9 1.10 (0.80-3.20) II 1.80 (0.90-3.40) 
2 hrs 7 1.30 (0.60-2.20) 8 1.35 (0.90-2.20) II 2.00 (0.60-7.00) 
24 hrs 8 1.80 (0.95-3.80) 7 1.90 (1.45-2.60) 9 2.90 (0.85-4.00) 
72 hrs 7 0.70 (0.47-1.05) 7 1.05 (0.90-1.30) 8 1.35 (0.85-2.10) 
73 hrs 7 0.95 (0.65-2.20) 7 0.95 (0.70-1.30) 8 1.45 (0.75-5.00) 
74 hrs 7 1.00 (0.70-11.25) 7 0.90 (0.62-1.80) 8 1.13 (0.34-2.50) 
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and his colleagues infused argatroban (0.5 to 5.0 ~g/kg/min) over 4 hours in 
patients with unstable angina pectoris [24]. This dose regimen was effective 
against the recurrence of ischemic episodes. Fitzgerald (not published) treated 
angioplasty patients with an initial bolus of 30 Jlg/kg argatroban, followed by an 
intravenous infusion of 2 Jlg/kg/min over 2 hours. Based on toxicity studies in ani-
mals, tbe total daily dose should not exceed 10 mg/kg bodyweight. 
A significant correlation was observed between the argatroban plasma level 
and the dose response curves for several coagulation parameters. The predictabi-
lity of the aPTT and the PT in particular, is very good and can be described 
mathematically with statistical significance. However, the predictability of bleed-
ing time is low. Measurements of ACT with the Hemochron system yields values 
approximately 30% higher than the results assessed with HemoTec ACT asses-
sment [34], which may have influenced the R-square value. The dose response 
curves of argatroban and coagulation tests demonstrate the feasibility of accurate 
dosing of this compound in contrast to heparin, with which non-specific plasma 
protein binding, variable bio-availability, non-linear dose dependent clearance 
and important individual differences among patients frequently result in under-
dosing or overdosing. 
Levels of F 1.2 and TAT reflect the degree of pro-thrombin conversion and 
thrombin activity, respectively. Sampling was performed from separate peri-
pheral vein punctures to avoid bias caused by the indwelling catheter [35, 36]. 
These measurements indicate the systemic status of the coagulation system. 
Sampling from the great cardiac vein may have been more accurate, representing 
a less diluted effect on the local stimulus to the coagulation system. Absolute inhi-
bition of thrombin generation by thrombin blockade remains an Utopian con-
cept, since argatroban requires an insignificant pro-thrombin conversion before 
it can display its antithrombin activity. Zoldhclyi et al. [37] recently reported the 
failure to block thrombin generation in patients, despite a 10,OaO-fold molar 
excess of free hirudin over the thrombin-hirudin complex. Furthermore, these 
coagulation products are extremely sensitive, to such an extent that only perfect 
atraumatic vein punctures can provide blood with unaffected, non-elevated 
levels. 
Conceivably, a superior marker for thrombin blockade would be the fibrino-
peptide A concentration [38}. This peptide is a product of thrombin induced 
fibrinogen conversion and is therefore a direct mirror of the performance of non-
blocked thrombin. 
Rebound is described after cessation of i.v. argatroban infusion in patients 
with unstable angina pectoris [24, 39]. In this study we did not uncover any clini-
cal evidence for a rebound phenomenon in this cohort of patients. However, 24 
hours after start of the infusion (just prior to sheath removal when the infusion 
was transiently interrupted), a substantial elevation of TAT and F 1.2 levels was 
observed (table VI, figure 3). A lesser increase in TAT and F 1.2 levels was detec-
ted one and two hours after the termination of the argatroban infusion (73 and 74 
hours after the start of the infusion, respectively). This disparate response to ces-
sation of argatroban administration may reflect the process of vessel wall passiva-
tion. It has to be emphasized that repetitive vena punctures within a short period 
Journal of Thrombosis and Thrombolysis 1996;3:367-375 
of time may result in subsequent less optimal sampling quality, and therefore 
demonstrate artificially elevated levels of TAT and F I .2' 
Conclusions 
This dose-finding study demonstrates that argatroban infusion in patients under-
going PTCA may be safely administered, and produces an adequate and predic-
table level of anticoagulation. This trial provides useful and consistent informa-
tion on the response of the coagulation system when exposed to argatroban. 
Indirect parameters indicate ongoing thrombin conversion (pro-thrombin frag-
ment 1 and 2), and activity (thrombin-antithrombin complex). An apparent safe 
and adequate dosage regimen was identified and this dose is now undergoing 
further evaluation in a double blind, double dummy, 2: 1 randomized and heparin 
controlled study. The effect of argatroban effect on the restenosis process follo-
wing coronary angiopiasty must be determined in a larger investigation. 
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Abstract One of the main areas of interest in interventional cardiology is the 
understanding, and ultimate prevention of rest enos is after an initially successful 
percutaneous transluminal coronary angioplasty. Restenosis is the recurrence 
ofluminal narrowing following angioplasty, and still frustrates the late results 
in the treatment of angina pectoris. Experimental, pathological and clinical stu-
dies suggest that restenosis may occur via activation of the coagulation cascade, 
platelet activation and thrombus formation. Thrombin itself is identified as the 
most potent platelet activator, and has a pivotal role in the coagulation system. 
Futhermore, thrombin directly mediates smooth muscle cell proliferation by 
stimulating thrombin receptors at the smooth muscle cell surface. Thrombus 
indirectly induces excessive intimal smooth muscle cell proliferation by means 
of released mitogens (growth factors), which may contribute to late restenosis. 
Therefore direct and irreversible thrombin blockade by hirudin is deemed to be 
effective in the prevention of rest enos is following angioplasty. 
The HELVETICA trial is a multicentre randomized double blind 
heparin controlled study, designed to compare the effects of two dose regimens 
ofrecqmbinant hirudin (CGP 39 393fT"REVASC) with those of heparin on 
event-free survival, safety and tolerability and luminal renarrowing using quan-
titative coronary angiography no later than 26 weeks after the coronary angio-
plasty procedure. (European Heart Journal1995(supplement L); 16:56-62) 
In spite of the immediate therapeutic success of coronary angioplasty, restenosis, 
the recurrence of luminal narrowing foHowing percutaneous transluminal coro-
nary angioplasty (PTCA) still hampers longterm outcome in the treatment of 
obstructive coronary artery disease [IJ. Experimental, pathological and clinical 
studies suggest that several responses to luminal enlargement, such as vessel wall 
injury, occur, and there is evidence that thrombin and thrombus trigger of the 
restenosis process. 
Exposure of the coHagen of the media as well as the material of the squeezed 
atheromatous plaque activate the coagulation system and various coagulation 
factors (V, VIII, XIlI) ensure rapid thrombin generation via an autocatalytic 
reaction and a positive feedback loop [2]. Thrombin converts soluble fibrinogen 
into fibrin and induces fibrin cross-linking by activation of factor XIII. 
Thrombin itself is also a very potent platelet activator. Platelet deposition 
and platelet degranulation at the site of endothelial denudation early after angio-
plasty (minutes to days) can induce coronary spasm and the formation of mural 
thrombus, which may promote restenosis [3-8}. Due to thrombin activation, pla-
telets release various pro-coagulant factors and mitogens (growth factors), which 
add respectively, to the formation of thrombus and encourage intimal smooth 
muscle cell proliferation, contributing to late (7 to 150 days) restenosis [3,9-17]. 
European Heart Journal 1995(supplcmcm 1.),0/6:56-62 
Thrombin receptor stimulation at the smooth muscle cell surface may directly 
mediate smooth muscle cell proliferation. 
The incidence of restenosis ranges from 17% to 40%, depending on the 
angiographic, clinical or physiological definition and study design. l\1any phar-
macological interventions have been used in prospective randomized trials to 
prevent restenosis [18,19], but despite a sufficient number of patients and there-
fore statistical power, complete angiographic follow-up, and quantitative angio-
graphic analysis, to date no compound has been able to reduce or control luminal 
renarrowing after initially successful PTCA. To assess their respective abilities in 
the prevention of restenosis after coronary angioplasty in patients with unstable 
angina, hirudin, with its direct and highly selective action was compared with 
heparin in a multicentre, double blind, randomized trial. 
Potential role of recombinant-hirudin (CGP 39 393fT"'REV ASC) in pre-
vention of rest enos is Hirudin, a potent, selective and direct thrombin inhibitor, 
composed of only 65 amino acids, was originally extracted from the salivary 
gland of the medicinal leech. The recombinant hirudin CGP 39 393/"'REVASC 
is expressed in yeast and differs from the natural hirudin only by the absence of a 
sulphate group in the Tyr-63 position. The favourable element of hirudin in 
comparison to other serine protease inhibitors is its ability to irreversibly block 
thrombin at multiple sites [20] without the need for circulating cofactors such as 
antithrombin III, thereby preventing direct activation of clotting factors V, VII 
and VIII. Furthermore hirudin is able to inhibit clot-bound thrombin, and can 
thus restrict further thrombus formation which may occur during thrombolysis 
[21 J. 
This recombinant molecule has demonstrated its powerful anti-thrombotic 
qualities in venous shunt and arterial thrombosis models [22,23J, and reduced 
platelet deposition to only a single layer foHowing balloon injury to carotids of 
pigs [24J. Sarembock et aJ. [25J showed significantly less rcstenosis 28 days after 
dilatation assessed by quantitative angiography and histopathology in hyperchol-
esterolaemic rabbits following administration of TMREVASC as compared to 
heparin. 'The group of Buchwald [26J demonstrated a significantly lower platelet 
count and fibrin deposition on implanted stents in minipigs with the use of hiru-
din compared to heparin. 
Recombinant-hirudin (CGP 39 393fT"REV ASC) in patients undergoing 
coronary angioplasty The effect of recombinant hirudin (CGP 39 
393(TMREVASC) in angioplasty patients was recently evaluated in a multicentre 
double blind pilot study [27}. One hundred and thirteen patients were randomi-
zed in a 2: 1 fashion, to receive either 20 mg recombinant hirudin as an intrave-
nous bolus prior to angioplasty followed by a 24 h infusion of 0.16 mg/kg/hr 
(N=74), or to 10,000 IU of heparin bolus Lv. followed by a 12lU/kg/hr infusion 
for 24 h (N::::39). In the heparin treated group, four patients experienced a peri-
procedural myocardial infarction and/or emergency coronary artery bypass graft 
(CABG), compared to only one emergency CARG, and one elective CABG 3 
weeks after PTCA in group allocated to recombinant hirudin. Haemorrhage at 
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Table I 
Inclusion and exclusion criteria in the HELVETICA study. 
Inclusion criteria 
Cooperati\'e male or female patients, aged 30-75 years, who had developed the following conditions within 
the past 3 months: new onset of angina pectoris or worsening of the angina pattern (i.e. worsening of 
angina pattern by two classes according to the classification of the Canadian Cardiovascular Society 
class [32] or need for additional antianginal medication) and/or angina at rest may be considered for 
inclusion in the trial [modified from 28). 
Patients should be designated to undergo a percutaneous transluminal coronary angioplasty (balloon, 
directional or rotational atherectomy Or excimer laser) of one or more coronary vessels as a result of 
diagnostic angiography, during which stenosis of greater than 50%, suitable for dilation, was obser-
ved. Patients must give written informed consent. 
Exclusion criteria 
General exclusion criteria 
Women of childbearing potential or nursing mothers. Women are considered to be of childbearing poten-
tial unless they are post-hysterectomy, one or more years post-menopausal or one or more years 
post-tubal ligation. 
Previous participation in the present trial. 
Major non-cardiac surgical intervention planned within the next 6 weeks. 
Life expectancy of less than one year. 
Factors making follow-up difficult or unlikely (e,g, not fixed address, psychological instability, drug or 
alcohol addiction etc,). 
Body weight> 100 kg, 
Criteria related to the angioplaslY 
Unprotected left main disease, 
Planned multistage procedure. 
Planned implantation of a stent, 
Planned angioplasty solely of a coronary bypass graft. 
Factors contraindicating angioplasty or coronary angiography (e,g. graft or severe atherosclerosis of the 
lower limbs, severe iodine allergy). 
Cardiovascular and haematologic criteria 
Myocardial infarction with a rise in creatine kinase (CPK) 3 times (or CK-MB 2 times) above the upper 
normal limit within the past 2 weeks. 
Evolving myocardial infarction. 
Cardiopulmonary resuscitation manoeuvres within the past month. 
Cerebra-vascular accident within the past 6 months, 
Known pericarditis. 
Known bacterial endocarditis, 
Known left heart thrombus. 
Cuff systolic blood pressure < 90 mmHg. 
Cuff diastolic blood pressure (measured at the disappearance of sounds) above 100 mmHg and/or systolic 
blood preSSure abo\'e 180 mmHg. 
History of gastrointestinal, pulmonary or intraocular bleeding. 
Known diabetic retinopathy. 
Signs or symptoms of acute internal or external haemorrhage, 
Known congenital or acquired haemostatic disorders and/or liver disease. 
History of heparin-induced thrombocytopenia, 
Known significant anaemia (haemoglobin < 110,0 giL [=6.2 mmoUL)), 
Known thrombocytopenia « 100,000 platelets/mm3). 
Other exclusioll criteria 
Major surgery, biopsy or puncture of a non-compressible vessel within the past month. 
Se\'ere trauma within the past 3 months. 
Lumbar puncture (within the past 7 days). 
Known intolerance to acetyl salicylic acid. 
Acute or chronic renal impairment (defined as an increase of serum creatinine above 1.5 mglt OOmL 
(130 ~lmol) or a fall in creatinine clearance below 90 mUmin) .. 
Known severe hepatic disease. 
Documented peptic ulcer or gastritis within the last 6 months. 
Known cavitary lung disease. 
Known inflammarory bowel disease. 
Participation in another study with an investigational drug within the past month. 
Previous alld concomitant treatments 
The use of corticosteroids, oral anticoagulants, non-steroidal anti-inflammatory drugs (with the exception 
of acetyl salicylic acid), dipyridamol, sulphinpyrazone, ticlopidine, melphalan, vincristine. I-aspa-
raginase is prohibited 48 hours prior to randomization. Oral anticoagulants and/or anti-platelet 
agents (with the exception of acetyl salicylic acid) may only be started or reinstituted 7 days after the 
angioplasty. 
The usc of any investigational drug (including hirudin, natural or recombinant) within 30 days prior to the 
start of the trial is prohibited. 
The use of fish-oil is prohibited during the course of the trial. 
Lipid-lowering drugs are allowed only when they are indicated on the basis of the patient's lipid levels 
according to the recommendations of the European Consensus Group. 
As a general rule, beta-blockers, calcium-antagonists and nitrates (both sublingual and oral, short- and 
long-acting) should be discontinued at hospital discharge to determine whether the patient has beco-
me asymptomatic after angioplasty. 
Calcium antagonists are allowed at randomization only when they are already being taken before randomi-
zation. Their discontinuation should, in all cases, be attempted at hospital discharge. A calcium-
antagonist may be given orally or intravenously in case of spasm during the angioplasty session. 
Beta-blockers may be continued as a secondary prevention in patients with a history of myocardial infarc-
tion prior to trial entry or as antihypertensive agents, provided that beta-blockade had been started 
before hand. In such cases, the dose should be kept constant. Other cardiac medications may be used 
on strict indication only. 
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the arterial puncture site was seen in four recombinant hirudin-treated patients, 
for which blood transfusion was needed, while in the heparin-allocated group one 
patient experienced visual impairment because of a cerebral infarction. Follow-
up angiography at 24 h revealed a complete perfusion in all hirudin treated 
patients, compared to 92% in the heparin treated group. Based on this very recent 
publication, it was concluded that recombinant hirudin can safely be administer-
ed to patients undergoing balloon angioplasty for stable angina pectoris. 
The HELVETICA trial; hirudin in an european restenosis prevention trial 
versus heparin treatment in PTCA patients. 
Aim of the trial. The HELVETICA study is a double-blind, randomized, and 
heparin-controlled multicentre trial, which is carried out in Belgium, f,'rance, 
Germany, Italy, Spain, Sweden and the Netherlands. The primary objective of 
the present trial was to compare the effects of two dose regimens of recombinant-
hirudin to that of unfractionated heparin on the event-free survival in patients 
planned to undergo PTCA. Cardiac death, non-fatal myocardial infarction, 
CABG or bail out procedure (e.g. stent), repeat angioplasty or elective stent 
implantation were counted as clinical events. 
The secondary objectives were to compare the safety and tolerability of two 
CGP 39 393fT"REVASC dose regimens to those of heparin and to compare the 
effects on the quantitative cineangiographic measurement of the minimal luminal 
diameter (MLD) assessed at 6 months after PTCA. 
Design and treatment Eligible patients, whether already on heparin (Le. unsta-
ble angina) or not, who had developed recent onset or worsening angina or angi-
na at rest within the past 3 months [28] (Table I) and who were to undergo PTCA 
were randomly allocated just prior to angioplasty, to one of the two recombinant 
hirudin regimens, or to the control (heparin) group. The treatment groups are 
listed below.; 
Ulljractionated sodium heparin treatme1lt group Subjects were given a bolus of 
10,000 IU heparin i.v., followed by a continuous Lv. infusion of 15 IU/kg/h. The 
infusion period was followed by a placebo administered subcutaneously twice 
daily for 3 consecutive days. 
Treatmem groups Subjects were given a bolus of 40 mg recOlnbinant hirudin Lv., 
followed by a 0.2 mg/kg/h continuous Lv. infusion. In one group the infusion 
period was followed by administration of 40 mg subcutaneously twice daily for 3 
consecutive days, in the other by administration of placebo subcutaneously twice 
daily for 3 consecutive days. 
An optional blinded Lv. bolus could be given 1 h after the first i.v. bolus. 
This would comprise heparin in the heparin treatment group and placebo in both 
recombinant hirudin groups. The operator remained blinded for coagulation 
parameters, and therefore infusion rate could not be adjusted. 
The height of bolus and infusion rate in both the r-hirudin groups was based 
on the analysis of coagulation markers (thrombin-antithrombin complex (TAT) 
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and pro-thrombin fragment I and 2 (F 1.2)) in the pilot trial [27]. Concentrations 
of F 1.2 appeared to be somewhat higher in the hirudin group directly and 6 h 
after angioplasty (a median of 1.015 versus 0.795 nanomolc/litre (nmoI/L) and 
0.95 versus 0.8 nmol/L respectively). Although these differences did not reach 
statistical significance, this finding was nevertheless suggestive of enhanced 
thrombin generation during this period in hirudin treated patients compared to 
heparin treated patients. Therefore the bolus dose was doubled from 20 rug in the 
pilot trial to 40 rug in the present study, and the infusion rate of 0.16 mg/kg/h in 
the pilot phase was increased to 0.20 mg/kg/h in the present study. 
Heparin administration before randomization had to be discontinued at 
least 30 min before initiation of trial medication. Blinded trial medication was 
used to flush the various devices and materials during and after the PTCA 
procedure. 
Randomization is stratified for previous (i.e. last 24 h) heparin administra-
tion. \'\fithin-centre balance between treatments is obtained by randomizing in 
blocks. 
Acetyl salicylic acid (100 to 500 mg once daily) if not already being taken 
was started immediately and was continued for 14 days. Oral anticoagulants 
and/or other antiplatelet agents could be reinstituted or started 7 days after 
PTCA according to local routine. 
Sample size considerations The sample size considerations are based on the 
assumption that the event free period is exponentially distributed with a constant 
hazard rate and that each patient is followed-up for 30 weeks. Based on the 
results of previous trials (29] over a 6-months observation period, the event rate 
in the control group was expected to be 30%. This corresponds to a hazard rate ::::; 
0.06. To detect at least a 30% reduction in the event rate in the hirudin group 
(hazard rate = 0.037) at a level alpha of 2.5% (adjusted) with a power of 80% a 
sample size of 357 patients per treatment group was required (observation period 
6 months) [30]. A sample size calculated on the event rate at 26 weeks yielded 
368 patients per treatment group. 
Trial chronology All out- or in-patient candidates for PTCA were screened for 
potential participation in the study. Inclusion and reason for exclusion (Table I) 
were documented in order to compare the study population with the entire 
PTCA popUlation in the 30 participating centres. After written informed con-
sent, patients were randomized according to the allocation given by the central 
telephone allocation service. Heparin administered for unstable angina had to be 
discontinued at least 30 minutes before initiation of trial medication. Bolus injec-
tion and a weight-adjusted infusion of study medication were started simultane-
ously before angiography was begun. The Lv. infusion was continued for 24 h, 
without dose adjustments. Pre- and post- angioplasty coronary angiography are 
performed according to the requirements for quantitative analysis. The sheath 
was removed no less than 3 h after the end of the infusion period, just prior to the 
first subcutaneous injection of 40 mg hirudin or placebo twice daily for 3 conse-
cutive days. A follow-up visit was required 2 weeks after the PTCA. A visit 26 
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weeks following PTCA documented anginal status, 12-lead electro cardiogram, 
current medication and any adverse experience. A symptom-limited bicycle er-
gometry was performed before the control angiogram was Ill.ade. It was decided 
that final clinical follow-up for evaluation of clinical endpoints would occur 30 
weeks after PTCA to allow sufficient time for performance of justified (based on 
recurrence of anginul symptoms or demonstrated exercise-induced ischaemia) 
elective reintervention or CABG as determined by clinical and angiographic fol-
low-up. 
Laboratory findings on coagulation parameters At predetermined time 
points, hlood samples for assays of activated partial thromboplastin time 
(APTT), F1.2 and plasma hirudin concentrations were taken. Blood samples 
were retricvcd by separate venepunctures at screening, just prior to start of the 
infusion, 6 and 24 h after angioplasty and just prior to and 3 h aftcr the last subcu-
taneous injection. Assays for APTT and prothrombin fragment F 1.2 were analy-
zed centrally at the Department of Haemostasis and Thrombosis in the Academic 
lVledical Center, Amsterdam, The Netherlands. Assays for plasma hirudin con-
centrations were unalyzed by BPK Ciba (Basle, Switzcrland). 
Evaluation and safety criteria Primary objective is the event free survivul with-
in the observation pcriod of 30 weeks, according to the method of Kaplan-i\1eier 
and compared by the (stratified) generulized \'\li1coxon test [31]. Clinical events 
were curdiuc death, non-fatuI myocardial infarction, CABG or bail out procedu-
re, repeat angioplasty or elective stent implantation at previously dilated sites. 
The secondary objectives were four-fold: (1) Noting all clinical events 
occurring within the first 96 h after sturt of trial medication; (2) taking account of 
the severity of a patient status graded as cardiac death> non-fatal myocardial 
infarction> CABG (or bail out procedure) > repeat angioplasty or elective stent 
implantation > anginal status (Canadian Cardiovascular Society classification 
[32]) post-PTCA or none of the above at 30 week follow-up; (3) assessing the 
lVlLD of the dilated sites measured by quantitative coronary angiography (QCA) 
at 26-week follow-up. If for any rcuson angiography is carried out prior to 18 
wecks after PTCA, further angiography within the recommended time window is 
required, unless a primary clinical endpoint, as defined, is reached; (4) noting the 
change in IVlLD of dilated sites between the immediate post-PTCA and the 26-
week follow-up coronary angiogram. 
Safety is evaluated on the basis of bleeding, immuno-allergic and other com-
plications. 
The HELVETICA study; the appealing aspects 
The Braum.vald classificatiol1 Grading of unstable angina according to the 
Braunwald classification {28], although clinical, can be related to the underlying 
diseuse. Sherman et al [33] described the correlation between the presence of an 
angioscopic finding of non-occlusive thrombi and recent onset of anginal episo-
des at rest. \'\lith the progression of time, these thrombi undergo lysis and organi-
zation, and unti-thrombin therapy might be less effective in PTCA patients when 
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compared to stable class I angina pectoris. This trial provides detailed informa-
tion on angina severity, clinical circumstances in which unstable angina pectoris 
occurs, electrocardiographic changes during chest pain, and the intensity of 
treatment under which anginal episodes occur. 
Dynamic versus static restenosis criteria,· MLD atjollow-up as a qualllitative angio-
graphic end-poilll. Restenosis following vessel wall injury, as in successful angio-
plasty, has been shown to be a proliferative reaction influencing virtually all coro-
nary obstructions which have been exposed to therapeutic angioplasty 
[13,34-37]. Luminal renarrowing of the coronary arteries should be viewed as the 
tail end of an almost normally distributed phenomenon rather than a unique di-
sease entity, developing in some lesions but not in others {38,39}. Restenosis cri-
teria currently in use can be classified at those which describe the change in lesion 
severity during follow-up (dynamic criterion) and those which merely describe 
lesion severity at follow-up (static criterion). Examples of the first category are 
the loss in lumen diameter of more than 0.72 mm as proposed by Serruys et al. 
[29,40-42] and a change in percent diameter stenosis. Examples of the second 
category are the criterion of >50% diameter stenosis at follow-up and a minimal 
luminal diameter of more than 1.4 mm at follow-up [43J. 
To reflect current clinical practice, by protocol the use of new interventional 
tools as directional or rotational atherectomy and excimer laser, are allowed in the 
HELVETICA study. However, because there are different interventional tools 
currently in usc discrepancies arise which are not reconciled by using dynamic 
restenosis criteria. Due to the different nature of the interventions applied here 
(e.g. atherectomy, balloon and excimer laser angioplasty), the immediate pro-
cedural outcome is no longer comparable; atherectomy induces a larger gain in 
minimal luminal diameter than conventional balloon therapy which makes the 
immediate post-procedural features dissimilar so that the loss during follow-up is 
no longer a helpful comparison of the long-term benefit. The most valid parame-
ter for the comparison of two interventional devices is the minimal luminal dia-
meter at follow-up because this static parameter, in itself, represents the final 
luminal improvement at follow-up. l\1oreover, the minimal luminal diameter at 
follow-up may have some functional component; in accordance with Danchin et 
al [43J, we [44J found that a minimal luminal diameter of 1.45 mm correlates with 
recurrence of anginal episodes (sensitivity and specificity of72%). This informa-
tion suggests that the absolute value of the minimal luminal diameter at follow-up 
may prove to be an even more useful parameter than parameters obtained by cli-
nical examination or exercise testing. Therefore a static restenosis parameter 
which describes lesion severity at follow-up angiography should be used when 
different interventionaI techniques are included in a trial. 
The use oj QCA secondary to clinical endpoints Evidence to support the usc of QCA 
as a surrogate endpoint for clinical coronary events, arises from studies on 
progression and regression, where initially isolated angiographic evidence of 
progression has been subsequently followed during 'longer-term' follow-up by 
higher clinical event rates. This positive predictive value of angiographic end-
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points has been demonstrated for both visual assessment [45] and semi-automa-
ted QCA [46,47]. Is the coupling of QCA and subsequent clinical events due to a 
paraphenomenon, or does the measurement of a severe coronary stenosis by 
QCA directly predict an increased risk of occurrence of a coronary event in this 
target vessel at the point of the minimal luminal diameter? Little et al. [48] and 
other investigators have revealed that coronary occlusions which produce a myo-
cardial infarction frequently occur at sites which previously contained minor, 
'insignificant) luminal narrowings and that the lesions with the most severe steno-
sis are often found to be patent in such patients [48-52].lt has been proposed that 
angiographic evidence of progression or regression in one segment may be a mar-
ker of disease activity which may involve other coronary segments but may not be 
apparent on the coronary angiogram [49]. Whether this holds true because QCA 
demonstrated severely restenotic lesions (large luminal loss over 6 months) follo-
wing intervention has yet to be verified. It has been proposed that the endolumi-
nal cap of a restenosed lesion is more stable and less susceptible to fissuring than 
a primary atherosclerotic plaque of equivalent luminal diameter. Thus it might be 
expected that the detection of restenosis following intervention by QCA might be 
morc predictive of functional reversible ischaemia, recurrence of angina and sub-
sequent symptomatic need for revascularization, rather than predicting myocar-
dial infarction and death. 
Markers/or activatiol1 of coagulation Prothrombin fragment 1 and 2 is a direct pro-
duct from prothrombin conversion and is therefore a sensitive marker for activa-
tion of coagulation. It can be used to monitor the biological efficacy of experi-
mental anticoagulants. The F 1.2 levels before treatment provide a clear view of 
the relationship between severity of unstable angina and the coagulative state. 
Furthermore we may be able to draw conclusions from the correlate coagulation 
markers prior to and after angioplasty and the rate of acute complications and 
long term restenosis. In this we may find support for the rationale of thrombin 
inhibition and restenosis prevention. 
Conclusion 
The rationale for use of recombinant hirudin in the HELVETICA trial is based 
on experimental evidence that demonstrated the strong anti-thrombotic proper-
ties of this compound. The mechanism of action of hirudin as a thrombin inhibi-
tor implies that it will prevent both acute occlusion due to thrombin induced 
thrombus formation and neointimal proliferation following vessel wall injury. As 
a consequence, trial medication is started before the procedure, Le. before wall 
injury takes place. The prospective, randomized, double-hlind, heparin control-
led strategy, the usc of multiple intervention techniques, the sample size calcula-
tion and both clinical and angiographic evaluation criteria provide an opportuni-
ty to evaluate the influence and impact of coagulation activation and the effect of 
thrombin inhibition on early and late outcome after PTCA, weighted against the 
risk of increased bleeding. 
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Abstract Background The likelihood of rest enos is is a major limitation of 
coronary angioplasty. \Y./e studied whether hirudin, a highly selective inhibitor 
ofthrombin with irreversible effects, would prevent restenosis after angioplasty. 
\Y./e compared two dose regimens of recombinant hirudin with heparin. 
Methods We randomly assigned 1141 patients with unstable angina who were 
scheduled for angioplasty to receive one ofthe following treatments: (1) a bolus 
dose of 1 0,000 IU of heparin followed by an intravenous infusion of heparin for 
24 hours and subcutaneous placebo twice daily for three days (382 patients), (2) 
a bolus dose of 40 mg of hirudin followed by an intravenous infusion of hirudin 
for 24 hours and subcutaneous placebo twice daily for three days (381 patients) 
or (3) the same hirudin regimen except that 40 mg of hirudin was given subcuta-
neously instead of placebo twice daily for three days (378 patients). The primary 
end point was event free survival at seven months. Other endpoints were early 
cardiac events (within 96 hours), bleeding and other complications of the study 
treatment, and angiographic measurements of coronary diameter at six months 
offollow-up. 
Results At seven months, event free survival was 67.3 percent in the group 
receiving heparin, 63.5 percent in the group receiving intravenous hirudin, and 
68.0 percent in the group receiving both intravenous and subcutaneous hirudin 
(P-value 0.61). However, the administration of hirudin was associated with a 
significant reduction in early cardiac events, which occurred in 11.0,7.9, and 
5.6 percent of patients in the respective groups (combined relative risk with 
hirudin, 0.61; 95 percent confidence interval 0.41 to 0.90; P=0.023). The mean 
minimal luminal diameters in the respective groups on follow-up angiography at 
6 months was 1.54, 1.47, and 1.56 mm (P~O.08). 
Conclusions Although significantly fewer early cardiac events occurred with 
hirudin than with heparin, hirudin had no apparent benefit with longer-term 
follow-up. (New England Journal of Medicine 1995;333:757-763) 
Platelet aggregation, the generation of thrombin, and the release of growth fac-
tors at the site of angioplasty have all been implicated in the process of restenosis 
[1,2]. Consequently, anticoagulants, anti platelet agents and specific antithrom-
bin agents have bcen considered for the prevention of rest enos is [3]. Thrombin is 
the most potent platclet activator known, stimulating the production of platelet-
derived growth factor and the secretion of prostacyclin, platelet-activating factor, 
and plasminogen-activator inhibitor. Thrombin has apparent mitogenic effects 
on lymphocytes and vascular smooth-muscle cells [4, 5]. 
New England Journal of Medicine /995; 333(12):757-63 
Hirudin, a 65-amino-acid compound originally extracted from the salivary 
gland of the leech, is a specific inhibitor of thrombin. The advantage of hirudin 
over other serine protease inhibitors is its potency in irreversibly blocking throm-
bin at multiple sites without the need for circulating antithrombin III [6]. Because 
of the small size of the hirudin molecule, this substance can inhibit clot-bound 
thrombin and restrict the further formation of thrombus [7]. 
Hirudin has reduced the deposition of platelets after vascular injury in pigs 
[8]. and lowered the rate of restenosis in hypercholesterolemic rabbits [9], provi-
ding a rationale for its use in patients undergoing angioplasty. In this trial we eva-
luated whether the inhibition of thrombin with hirudin improved event-free sur-
vival in patients undergoing coronary angioplasty. 
Methods 
Study population Patients with unstable angina and one or more clinically important 
new or restenotic coronary narrowings suitable for treatment with percutaneous translu-
minal coronary angioplasty were eligible for the study. From September 1992 through 
May 1993, 1154 patients from various institutions (listed in the Appendix) were rando-
mized. All had unstable angina, as defined by the new onset of angina pectoris or the wor-
sening of angina (Le., their condition changed by two or more classes according to the 
classification of the Canadian Cardiovascular Society[1 0] or they needed additional anti-
anginal medication), angina at rest, or both in the preceeding 3 months[ll}. The criteria 
for exclusion from the study were stable angina, a planned multistage procedure or stent 
implantation, myocardial infarction occurring within the preceding two weeks, hyperten-
sion, diabetic retinopathy and body weight over 100 kg. 
The study was conducted in accordance with the principles of the Declaration of 
Helsinki and its subsequent amendments and with the laws and regulations of the coun-
tries in where the trial took place. Before randomization, each patient gave written in-
formed consent. 
Antithrombin regimens The patients were randomly assigned in a double blind fashion 
to recehte recombinant hirudin (ThlREVASC, Ciba-Geigy, Basel, Switzerland [12)) in one 
of two dose regimens or to receive unfractionated sodium heparin. The randomization 
was stratified according to whether heparin had been administered in the preceding 24 
hours. Heparin had to be discontinued at least 30 minutes before the start of treatment 
with the study medication. 
The patients received one of the following three treatments: heparin (an intrave-
nous bolus injection of 10,000 IU of heparin followed by a continuous intravenous infu-
sion of 15 IV of heparin per kilogram of body-weight per hour for 24 hours, with placebo 
gi\ten subcutaneously twice daily for three consecuthte days, intravenous hirudin (an 
intravenous bolus injection of 40 mg of hirudin followed by a continuous intravenous 
infusion of 0.2 mg of hirudin per hour for 24 hours, with placebo given subcutaneously 
twice daily for three consecutive days), or intravenous and subcutaneous hirudin (an 
intravenous bolus injection of 40 mg of hirudin followed by a continuous intra\tenous 
infusion of 0.2 mg of hirudin per hour for 24 hours, with 40 mg of hirudin gi\'en subcuta-
neously twice daily for three consecutive days. If the angioplasty lasted more than one 
hour, an additional bolus dose of 5,000 IV of heparin could be administered at the option 
of the physician to the patients in the heparin group, or an equivalent amount of placebo 
could be given to the patients in the hirudin groups. The operators remained blinded to 
the results of clotting studies, and no adjustment of the rate of infusion of the study medi-
cation was allowed. A concomitant dose of aspirin (100 to 500 mg once daily) was given 
on the day of angioplasty, and this treatment was continued for at least 14 days. 
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Criteria for Evaluation RfficacyThe primary endpoint was event-free survi\'a130 weeks 
after angioplasty -that is, the absence of death, non-fatal myocardial infarction, coronary-
artery bypass grafting or the use of a 'bailout' procedure (e.g., stenting), or second angio-
plasty at previously dilated sites. Myocardial infarction was diagnosed on the basis of new 
Q-waves [according to the Minnesota Code13) or an increase in the serum creatinine 
kinase le\'e1 to more than twice the upper limit of the normal range, with a concomitant 
increase in the MB fraction. If a slent was implanted electively after the initial angioplasty 
(i.e. not as a part of a bailout procedure), the implantation was considered equivalent to a 
second angioplasty. Second angioplasty or bypass surgery needed to be preceded by typi-
cal anginal symptoms or, if there were atypical anginal symptoms, by electrocardiograp-
hic evidence of myocardial ischemia at rest or during exercise and an angiographically 
determined stenosis greater than 50 percent by visual inspection. 
Secondary endpoints were as follows: any of a ranked series of clinical events that 
incuded death from cardiac causes, non-fatal myocardial infarction, coronary-artery 
bypass grafting (or the usc of a bailout procedure), second angioplasty, and anginal status 
[according to classification system of the Canadian Cardiovascular Society 1 0) at the 30-
week follow-up evaluation; the occurrence of any of these evcms within 96 hours after the 
start of the study medication; the minimal luminal diameter of the dilated sites as mea-
sured by quantitative coronary angiography at the 26-week follow-up evaluation; and any 
change in the minimal luminal diameter of dilated sites from immediately after angioplas-
ty to follow-up angiography at 26 weeks. 
Safety Safery was evaluated with regard to bleeding and other complications. Bleeding 
was classified as major if it was overt and led to a decrease in the hemoglobin level by at 
least 2 g per decilitrc; if il necessitated the transfusion of two or more units of whole blood 
or packed cells; or if it occllrred intracranially, retroperitoneally, or at the site of a major 
joint [14}. Minor bleeding was defined as oven bleeding that did not meet these criteria. 
Angiography and assessment of coagulation For each patient, coronary angiograms 
were obtained in a standardized fashion immediately before and immediately after angio-
plasty, and at the six-months follow-up evaluation. The angiograms were analyzed in a 
core laboratory with the Cardiovascular Angiography Analysis System [15, 16}. 
Blood samples for the measurement of coagulation were obtained at regular inter-
vals before and after angioplasty. Blood samples for the determination of activated par-
tial-thromboplastin times and levels of prothrombin fragment one and two (a measure of 
the generation of thrombin) were obtained separately by atraumatic venipuncture and 
were analyzed in a central laboratory. 
Statistical analysis Outcomes were compared in an intention-to-treat analysis, which 
included all randomized patients in whom coronary angioplasty was attempted. Patients 
in whom no angioplasty was attempted (i.e. those whose indication for angioplasty 
changed or disappeared) were excluded from the analysis. A successful procedure was 
defined as one in which the stenosis was reduced by more than half; in the case of a failed 
recanalization of a total occlusion, the second lesion treated was considered to be the first 
site ofangioplasty. 
The distribution of event-free survival at 30 weeks was calculated according to the 
method of Kaplan and Meier, and distributions were compared by the Kruskal-Wallis test 
[17), for patients with muhiple events, the first event was considered. Event rates and 
rates of bleeding and other complications were compared by the Chi-square test. 
A linear logistic-regression analysis for ordered categories was performed for the 
ranked clinical outcomes, with pretreatment with heparin used as a covariate. The most 
se\'ere e\'ent in each patient was considered in the analysis. 
The minimal luminal diameters at the dilated sites 26 weeks after the angioplasty 
follow-up (the minimal luminal diameter was taken as the mean were compared by analy-
sis of variance, with the mean value for all sites used in cases of angioplasty at multiple 
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Table I 
Baseline Characteristics of the Study Patients According to Group Assignment (N and 0/.,). 
Heparin Intravenous Hirudin Intravenous and Subcuta-
(N = 382) (N = 381) ncolls Hirudin (N:;::; 378) 
Male sex 299 78.3 300 78.7 297 78.6 
Age (yr) 58.2±8.7 58.7±9.1 58.8±8.9 
Weight (kg) 76.0±10.9 75.9±11.1 76.7±lO.7 
Smoker 104 27.2 90 23.6 84 22.2 
Diabetes 44 11.5 42 11.0 40 10.6 
Previous MI 148 38.7 152 39.9 154 40.7 
Previous CABG 10 2.6 8 2.1 20 5.6 
Previous angioplasty 69 18.1 69 18.1 64 16.9 
Braunwald class 
I 131 34.3 146 38.3 139 36.8 
II 163 42.7 160 42.0 166 43.9 
III 88 23.0 75 19.7 73 19.3 
Exertional angina 
CCS class 1 7 1.8 10 2.6 6 1.6 
CCS class 2 82 21.5 69 18.1 66 17.S 
CCS class 3 144 37.7 163 42.8 171 4S.2 
CCS class 4 102 26.7 96 2S.2 89 23.S 
IV heparin used liS 30.1 110 28.9 109 28.8 
at screening 
Lesions 
Total no. 482 483 462 
Mean no. per patient 1.26 1.27 1.22 
Location before 
angioplasty 
RCA 148 30.7 136 28.2 139 30.1 
LAD 230 47.7 238 49.2 201 54.S 
LCX 104 21.6 109 22.6 121 26.2 
LM 0 0 0.2 
Pills minus values are means ±SD. Except as noted. all other values are numbers of patients followed 
in parentheses by the percentage of the group. 
MI denotes myocardial infarction. CABG denotes coronary-artery bypass graft surgery. 
CCS Canadian Cardiovascular Society. IV intravenous, RCA right coronary artery, LAD left anterior 
descending coronary artery, LCX left circumflex coronary artery, and LM left main coronary artery. 
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sites. All reported P values are two-tailed. Whenever possible, estimates of the magnitude 
of the treatment effect are provided, with corresponding 95 percent confidence intervals. 
Relative risks are presented for the combined hirudin groups as compared with the hepar-
in group. 
Results 
Study population A total of 1154 patients were randomized. Of 5686 patients 
screened, 21 percent were ineligible because they had stable angina, 16 percent 
for reasons involving logistics, and 11 percent because they had had myocardial 
infarctions during the previous two weeks. The remaining screened patients (32 
percent) were excluded for a wide variety of reasons. Thirteen patients were not 
included in the intention to treat analysis because no angioplasty was attempted. 
Among the remaining 1141 patients in whom angioplasty was attempted, 382 
were randomly assigned to heparin, 381 to intravenous hirudin, and 378 to intra-
venous and subcutaneous hirudin. Angioplasty was successful in 91.7 percent, 
and the results of angiographic follow-up were available for 86.4 percent. 
Clinical follow-up was complete for all but one patient. 
The clinical and angiographic characteristics of the patients at base line are 
shown in table I. The characteristics of the three groups were similar. Almost one 
third of the patients received intravenous heparin before randomization because 
of the severity of their unstable angina. 
Efficacy Among the study patients, 125 patients assigned to heparin, 139 assign-
ed to intravenous hirudin, and 121 assigned to intravenous and subcutaneous 
hirudin reached a primary endpoint. The distribution of patients free of events is 
shown in figure 1. No significant differences were observed among the treatment 
groups (P=0.61 by the Kruskal-\Vallis test), even after stratification according to 
pretreatment with heparin. 
The incidence of clinical events and angina at 30 weeks is shown in table II, 
with no significant differences among the three groups (P=0.61). An analysis of 
subgroups according to whether patients were pretreated with heparin yielded 
similar results. 
The incidence of early events (those occurring in the first 96 hours after 
angioplasty) is also shown in table II. Forty-two patients assigned to heparin, 30 
patients assigned to intravenous hirudin, and 21 patients assigned to intrave-
nous and subcutaneous hirudin had such events (relative risk in the combined 
hirudin groups, 0.61; 95 percent confidence interval, 0.41 to 0.90; P=0.023). 
Among the patients pretreated with heparin, there were 20, 7, and 7 events, 
respectively (combined relative risk with hirudin, 0.37; 95 percent confidence 
interval, 0.19 to 0.70; P=0.007). Because these results suggested a particular 
benefit of hirudin in the most unstable patients (those with Braunwald class III 
angina), an additional analysis was performed of the 236 patients who had angi-
na at rest during the 48 hours before randomization. The event rate among these 
patients was 21.6 percent in the heparin group, as compared with 5.3 percent 
among patients receiving intravenous hirudin and 12} percent among patients 
receiving intravenous and subcutaneous hirudin (combined relative risk with 
hirudin 0.41; 95 percent confidence interval, 0.21 to 0.78; P~0.006). 
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Figure 1 
Kaplan-Aleier Distribution of Patiems 
without Evellls ;11 the lutentioll to Treat 
Analysis (N""'-114I). The groups were 
compared by rhe Kruskal-1Fallis test. 
Figure 2 
Cumulative Distribution of the 
Reduction ill 1Hil1imal Luminal 
Diameter from Immediately after 
AngioplastJ' to Follow-up at seven 
months. 
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The imbalance in the number of deaths (table II) calls for a description of 
their exact causes. In the heparin group, three myocardial infarctions and one 
non-hemorrhagic cerebrovascular accident resulted in death. In the group recei-
ving intravenous hirudin, there was one sudden death. In the group receiving 
intravenous and subcutaneous hirudin, five patients had fatal myocardial infarct-
ions. In this group there were also two cerebrovascular accidents (one of which 
haemorrhagic), one episode of cardiac tamponade, and one sudden death; one 
patient died of respiratory insufficiency, and one of wound infection and sepsis 
after bypass surgery. 
Linear logistic regression analysis for ordered categorical data revealed that 
pretreatment with heparin was significantly associated with worse clinical outco-
mes at 7 months (P=0.03). The type of study medication did not influence out-
come in this modeL 
Base-line angiographic measurements and gains in luminal diameter achie-
ved by angioplasty were similar in the three groups (table III). The changes in 
minimal luminal diameter from immediately after angioplasty to follow-up were 
also similar (figure 2). 
Safety The incidence of bleeding complications is shown in table IV. No diffe-
rences with respect to major or minor bleeding were observed among groups. 
There were three cerebro vascular accidents. One patient receiving intravenous 
subcutaneous hirudin was readmitted to the hospital with hemiplegia 14 hours 
after the final subcutaneous injection; despite surgical evacuation of the intra-
cerebral hematoma causing the condition, the patient died six days after the start 
of the study treaUnent. Two intra-cerebral thrombotic events were observed. 
One patient (receiving intravenous and subcutaneous hirudin), who presented 
with symptoms of neurologic deficit one day after discharge from the hospital 
and who had multiple brain infarctions on computed axial tomography, died five 
days after the start of the study treatment. Another patient (in the heparin group) 
presented with massive pulmonary embolism. Paradoxical embolization through 
a patent foramen ovale caused an extensive, expanding cerebral infarction and 
led to the patient's death eight days after the start of the study medication. 
Anticoagulant effects Levels of prothrombin fragment one and two are shown 
in figure 3, The median levels peaked in both hirudin groups at the end of the 
procedure (from 1.1 nmol per liter at the time of screening to 1.4 nmol per liter in 
the group receiving intravenous hirudin, and from 1.0 to 1.3 nmol per liter in the 
group receiving intravenous and subcutaneous hirudin, whereas in the heparin 
group the levels were slightly reduced (to 0.9 nmol per liter) as compared with 
those at the time of screening (1.0 nmol per liter). Levels of prothrombin frag-
ment one and two measured at 24, 96, 98 hours subsequently returned to the 
base-line values in all three groups. 
lvleasurements of activated partial-thromboplastin time (figure 3) were 
higher at the end of the procedure in the subjects receiving heparin than in those 
receiving hirudin, an effect that disappeared after 24 hours. The infusion of 
hirudin resulted in a more stable effect. Slightly prolonged activated partial-
Table II 
Clinical Events in the First 96 Hours and the First 30 \X'eeks in the Intention-to-Treat Analysis. * 
Event Heparin Intravenous Hirudin Intravenous and 
(N = 382) (N = 381) Subcutaneous 
Hirudin (N = 378) 
96 hr 30wk 96 hr 30wk 96 hr 30wk 
Death 2(0.5) 4(1.0) 0(-) 1 (0.3) O( -) 11 (2.9) 
Myocardial Infarction 16(4.2) 20(5.2) 13(3.4) 19(5.0) 9(2.4) 23(6.1) 
Coronary bypass surgery 9(2.4) 21 (5.5) 6(1.6) 21(5.5) 3(0.8) 25(6.6) 
Bail-out proccdure 18(4.7) 18(4.7) 12(3.1) 12(3.1) 8(2.1 ) 8(2.1) 
Second angioplasty 13(3.4) 91(23.8) 7(1.8) 109(28.6) 5(1.3) 93(24.6) 
Any event 42(11.0) 125(32.7) 30(7.9) 139(36.5) 21(5.6) 121(32.0) 
Any cxertional angina 55(14.4) 71(18.6) 71(18.8) 
No cvent or symptoms 202(52.9) 171(44.9) 186(49.2) 
* At 96 hours, the combined relativc risk in thc hirudin groups as compared with the heparin group 
was 0.61 (95 perccnt confidencc interval, 0.41 to 0.90; P=0.023). 
Table III 
Mean (±SD) Angiographic Measurcments in thc Intention-to-Treat Analysis of Patients 
for Whom Follow-up Data Were Available. 
Variable Heparin Intravenous Hirudin Intravenous and 
(N = 330) (N=341) Subcutaneous 
Hirudin eN = 315) 
Refercnce luminal diameter * 2.69 ±0.51 2.67 ±0.51 2.70 ±0.51 
Minimal luminal diamcter 
Before angioplasty 0.99 ±0.38 0.97 ±0.39 1.03 ±0.35 
After angioplasty 1.80 ±0.37 1.78 ±0.36 1.82 ±0.37 
At follow-up 1.54 ±0.59 1.47 ±0.56 1.56 ±0.50 
Gain 0.81 ±O.41 0.82 ±O.44 0.79 ±0.41 
I.oss 0.26 ±0.52 0.32 ±O.50 0.26 ±0.45 
* As estimated by computer techniqucs on the basis of the diameters of segmems proximal and distal to thc 
site of the stenosis 
Table IV 
Bleeding Complications 
Complications Heparin Intravenous Hirudin Intravenous and 
(N = 382) (N = 381) Subcutaneous 
Hirudin (N = 378) 
Il/Imber (percent) of paliellts 
Major bleeding 
Overt, with decrease in 24 6.2 18 4.7 28 7.4 
Hb by 2': 2 gldl 
O\'ert, requiring transfusion 0 3 0.8 0 
of 2': 2 units whole blood 
or packed cells 
Intracranial 0 0 0.3 
Retroperitoneal or in 0 0 0 
a major joint 
All 24 6.2 21 5.S 29 7.7 
Minor bleeding 43 11.3 50 13.1 57 15.0 
Figure 3 
Levels of Prothrombin Fragment 1 alld 2 
and Activated Partial- Thromboplastin 
Times ill the Three Swdy Groups at 
Various Times before and after 
Allgioplasty. 
A denotes the group receiving heparill~ 
n the group receiving intravenous 
hirudin~ and 
C the group receiving intravenous and 
subcutaneous hirudill. The solid area 
inside each box indicates the median 
value~ and tlte left and right margins of 
the box indicate the upper limits of the 
first alld tllird quartiles, respectively. 
In the upper panel, the dotted vertical 
line indicates the upper limit of the I/or-
mal level of prothrombin fragment I and 
2 (J.4 Ilmol per liter). Heparin tended to 
co1/trol the generation of thrombin better 
than hirudin both immediately after 
allgioplasty and six hours after the start 
of illfusion. 
111 the lower panel, the activated partial-
thromboplastin time was measured up to 
a maximum of 150 seconds. Over the 
first 24 hours this value was more than 
double the base-line value in the hirud-
in-treated groupsJ whereas ill the hepar-
in-treated group it returned almost to the 
base-line level. 
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thromboplastin time were observed at 96 hours after angioplasty in the group 
receiving intravenous and subcutaneous hirudin. 
Discussion 
Although hirudin was associated with impressive reductions in the rate of major 
cardiac events in the first 96 hours after angioplasty as compared with heparin, 
the primary goal of this trial, a reduction in the rate of cardiac events at seven 
months, was not accomplished. Event-free survival at seven months did not 
differ among the treatment groups. 
At least three other trials using specific anti platelet drugs have demonstra-
ted beneficial effects on the acute complications of coronary angioplasty without 
favorably influencing long-term clinical outcomes [18-20]. These findings differ 
from the results of the Evaluation of c7E3 for the Prevention of Ischemic 
Complications (EPIC) trial [21, 22], in which the glycoprotein lIb/lila receptor 
was presumed to have been blocked completely and which showed a reduction in 
early cardiac events that was maintained with longer-term foHow-up. 
The dosage and duration of treatment in the present trial were chosen as a 
compromise among safety issues, logistic considerations and the scientific evi-
dence available when the trial was designed. Primarily, the dosage was based on 
safety data obtained in healthy volunteers, stable patients undergoing angioplas-
ty, and patients undergoing orthopedic surgery [23-25]. However, the results of 
assays of prothrombin fragment one and two immediately after angioplasty sug-
gest that the generation of thrombin was not satisfactorily inhibited in either 
hirudin group whereas the dosage of heparin we used resulted in an appropriate 
decrease in levels of prothrombin fragment one and two at six hours. It can be in-
ferred from these data that the adjustment in the infusion rate -from 0.16 mg per 
kilogram per hour in the pilot study of patients "'.lith stable angina [25] to 0.20 mg 
per kilogram per hour in the current trial of patients with unstable angina and 
presumably higher levels of thrombin generation- was too cautious a change in 
dosage. Zoldhelyi et al. [26] recently reported failing to block the generation of 
thrombin in their patients despite the presence of a 10,OOO-fold molar excess of 
free hirudin over the amount bound in complexes with thrombin. Infusion rates 
of hirudin in experiments with animals were as much as five times higher than 
those currently used, a finding that may explain the lack of a long-term effect in 
the present study [8,9]. 
\X'hcn hirudin was administered subcutaneously in healthy volunteers at a 
dose of 0.5 mg per kilogram twice daily, the activated partial-thromboplastin 
time 12 hours after the first injection was subtherapeutic [23], and it might be in-
ferred that the inhibition of the conversion of pro-thrombin was also inadequate 
in the first three days of the trial. A putative explanation for the apparent paradox 
by which the early outcome is improved although there is less appropriate control 
of thrombin may be that the dosage used was not sufficient to produce an ade-
quate level of anticoagulation, but was sufficient to limit the thrombin-mediated 
aggregation and activation of platelets, causing effects similar to those observed 
over the short term in the EPI C trial [8,21,22]. 
The optimal duration of treatment is unknown, even in animal models. 
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Conflicting findings about the time course of thrombogenecity in the injured ves-
sel wall have been reported [27-30J. In this study we decided to maintain our 
patients at effective levels of antithrombin activity as long as possible. Since ethi-
cal considerations necessitated monitoring the patient's safety in the hospital 
during the subcutaneous injections of hirudin) a reasonable compromise between 
the duration of hirudin administration and logistic considerations of the trial was 
presumably achieved by administering the drug intravenously for 24 hours and 
subcutaneously for three consecutive days. 
A clear beneficial effect of hirudin on platelet aggregation and thrombus 
formation was indicated by the prevention of acute ischemic events early after 
angioplasty. The failure of hirudin in this trial to alter the longer-term outcomes 
indicates either that thrombin generation and thrombus formation in the period 
immediately after angioplasty may be less important in the process of restenosis 
than previously believed or that complete reversal of the thrombogenecity of the 
injured vessel wall was not achieved or requires moretime. \Vhether the large 
decrease in major events observed with hirudin early after the infusion can be 
translated to improved long term outcome with prolonged subcutaneous admini-
stration of hirudin deserves further study. 
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Appendix 
The following institutions and in\'estigators participated in the HELVETICA (Hirudin 
in a European Trial versus Heparin in the Prevention of Restenosis after PTCA) trial. 
The number of patients enrolled at each centre is given in parentheses, followed by an 
asterisk when all patients in the cardiac catheterization laboratory at a center were 
screened and the results entered in a logbook. 
Medizinische Klinik III, Heidelberg, Germany (66) * - C. Bode, G. Schuler, S. Abed, 
H. Baumann; UniversiUitsklinik RudolfVirchow, Berlin, Germany (66) * - W. Rutsch, 
C. Brunckhurst, N. Kokott; Medizinische Universitatsklinik, Kiel, Germany (66) *-
R. Simon, M. Lins, G. Herrmann; Onze Lieve Vrouwe Gasthuis, Amsterdam, the 
Netherlands (60) - G.j. Laarman, F. Kiemeneij, H. Swart; Medisch Centrum De Klok-
kenberg, Breda, the Netherlands (54) * - A. van den Bos, M. Quarles van Ufford, 
U. Chin-Kon-Sung, G. Uytdehaagj Academisch Ziekenhuis Groningen, Groningen, 
the Netherlands (54) - R. van Dijk, P. Den Heyer, L. Drok,j. Klein; lstituto Apparato 
Cardiovascoiare, Bologna, Italy (54) * - A. Marzocchi, G. Piovaccari, C. Marrozinni, 
E. Cere; Academisch Ziekenhuis Dijkzigt, Rotterdam, the Netherlands (54) *-
P. Serruys, P. de Feyter, V. Umans,j. Herrman; Ospedali Riuniti, Bergamo, Italy (53) *-
G. Guagliumi, O. Valsecchi, A. Casari, A. Pili', A. Tasca; lv1edizinische Universitats-
klinik, Freiburg, Germany (52) * - A. Zeiher, H. Wollschlager, V. Schachinger; Hospital 
General Gregorio Maranon, Madrid, Spain (48) * - j. Delcan Dominguez, E. Garcia, 
j. Joriano,j. Elizaga; Sahlgrenska Hospital, G5teborg, Sweden (48) * - H. Emanuelsson, 
P. Albertsson, P. Hardhammar, L. EkSlr5m; Hospital Clinico San Carlos, Madrid, Spain 
(48) * - C. Macaya, F. Alfonso, R. Hernandez, A. Iniguez; CHU Sart Tilman, Liege, 
Belgium (44) * - V. Legrand, M. Bellekens, Ph. Marcelle, P. Doneux; Ospedale di 
Circolo, Varese, Italy (36) * - G. Binaghi, S. Repeao, E. Verna, B. Castiglioni; Hospital 
Marques de Valdecilla, Santander, Spain (30) * - 1'. Colman,J. Zueco, A. Figueroa; 
U.C.L. Saint-Luc, Brussels, Belgium (30) * - C. Hanet, W. Wijns,J. Cosyns, X. Michel; 
Ospedale Maggiore, Trieste, Italy (30) * - S. Klugmann, E. Della Grazia, L. Barbieri; 
Hopital Universitaire de Mont-Godinne, Y,'oir, Belgium (30) * - E. Schroeder, 
P. Chenu, D. Grolaux; CHR Nancy, Vandoeuvre les Nancy, France (26) * - N. Danchin, 
Y . Juilliere, F. Cherrier, C. Kettanij Onze Lieve Vrouwziekenhuis, Aalst, Belgium (26) * 
- G. Heyndrickx, B. de Bruyne. M. Goethals, P. Goemare; Franz Vol hard Klinik, 
Berlin-Buch, Germany (24)* - D. Gulba, G. Claus, S. Hauck; Centre Cardiologique 
du Nord. Saint Dennis, France (24) * -M-C. Morice, T. Royer, B. Glatt, E. Rosenblatt; 
Ziekenhuis De Weezenlanden, Zwolle, the Netherlands (24) - F. Zijlstra, 
H. Suryapranata, H. Schoenmaker, G. Velsink; Hospital Clinic i Provincial, Barcelona, 
Spain (23) * - A. Betriu, A. Serra. G. Sanz, M. Heras; Catharina Ziekenhuis, Eindhoven, 
the Netherlands (18) * - J. Bonnier, N. Pijls, M. el Gamal, S. Rouffcl; Ospedale 
Nuguarda, Milano, Italy (18) * - Campolo; Policlinico San Manco, Pavia, Italy (18) *-
G. Specchia. S. de Servi, F. Marisco; Centre Chirurgical Marie Lannelongue, Les Plessis 
Robinson, France (15) * B. Lancelin, B. Chevalier, Ph. Guyon, F. Philippe; CHRU 
Rouen Hopital, Rouen, France (15) * - B. Letac, H. Eltchaninoff, R. Koning, A. Cribier. 
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Steering committee 
P.W. Serruys (chairman), A. lletriu (Hospital Clinic i Provincial, Barcelona, Spain), 
F. Camerini (Ospedale Maggiore, Trieste, Italy), N. Danchin (Hopi tal Brabois, 
Vandoeuvre les Nancy, France), H. Emanuelsson (Sahlgrenska Hospital, G5teborg, 
Sweden), W. Rutsch (UnhtersiHitsklinik RudolfVirchow, Berlin, Germany), 
A. van den Bos (Medisch Centrum De Klokkenberg, Breda, the Netherlands), 
Ph. Close, R. Kerry (Pharma Division, Ciba-Geigy Ltd., Basle, Switzerland), 
].W. Deckers, P. Peerboom (Cardialysis B.V., Rotterdam, the Netherlands), 
]. Rijnierse (Ciba-Geigy B.V., Arnhem, the Netherlands), V. Umans (Thoraxcentrum, 
Rotterdam, the Nether-lands). 
Sponsor 
Ciba-Geigy Ltd, Pharma division, Basle, Switzerland Ph. Close, R. Kerry, P. KobL 
Angiographic Core Laboratory 
Cnrdialysis B.V. Rotterdam L. Rodenburg, P.F. Peerboom, E. Nibbering,]. Pa01eijer, 
].P.R. Herrman and V.A.W.M. Umans,].W. Deckers. 
Data Coordinating and Analysis Centre 
Ciba-Geigy Ltd, Switzerland - Ph. Close, R. Kerry, P Kobi, D. Bach, E. Grundl; 
Department of clinical epidemiology and biostatistics, Cardia lysis - R. Melkert. 
Hemostasis Core Laboratory 
Department of Haemostasis and Thrombosis, Academic Medical Centre, 
Amsterdam - H. Buller. 
Safety committee 
K. Fox (chairman, Royal Infermary, Edinburgh, United Kingdom), H. BOller (Academic 
Medical Centre, Amsterdam, The Netherlands), D. Chamberlain (Royal Sussex County 
Hospital, Brighton, United Kingdom), Z. Pelikan (Medisch Centrum de Klokkenberg, 
Breda, the Netherlands), J. Tijssen (Academic Medical Centre, Amsterdam, the Nether-
lands). 
Critical events committee 
H. Schmutzler (chairman, Universitdtsklinlk RudolfVirchow, Berlin, Germany), 
G. Heyndrickx (Onze Lieve Vrouwziekenhuis, Aalst, Belgium), A. Zeiher 
(Medizinische Uni\'ersitiitsklinik, Freiburg, Germany), G. Specchia (Policlinico San 
Matteo, Pavia, Italy). 
Angiogl'aphy committee 
R. Simon (chairman, Medizinische Universitdtsklinik, KieI, Germany), 
V. Legrand (CHU Sart Tilman, Liege, Belgium), G.J. Laarman (Onze Lieve 
Vrouwe Gasthuis, Amsterdam, the Netherlands), H. Suryapranata (Ziekenhuis 
De Weezenlanden, Zwolle, the Netherlands). 
Study directors 
J.W. Deckers (Cardialysis B.V., Rotterdam, the Netherlands) and 
Ph. Close (Clba-Geigy Ltd, Basle, Switzerland). 
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Chapter /0 - 11ldependem predictors of adverse clillical outcome 
Abstract Objectives Restenosis and related clinical events following percu-
taneous transluminal coronary angioplasty (PTCA) hamper the early and long 
term result of this therapeutic technique. It is believed to be a multi factorial 
response to vessel wall injury, induced by the mechanical enlargement of the 
lumen, that might be modified by the administration of anti thrombotic drugs. 
To identify predictors of early and Jate occurring major adverse cardiac events 
following coronary angioplasty, we analyzed qualitative and quantitative clinical, 
biological and angiographic data obtained in 1141 patients in a multivariable fas-
hion. Knowledge of these predictors, could improve selection of patients at risk 
for clinical events and luminal renarrowing on an objective and scientific basis. 
Methods Clinical and angiographic follow-up were obtained in an internatio-
nal, multicenter, double blind, prospective and heparin controlled restenosis 
prevention study, investigating the safety and efficacy of desirudin in patients 
undergoing percutaneous transluminal coronary angioplasty for unstable angi-
na pectoris. In this trial 1141 patients were randomized and treated for 1426 
lesions. Patients had an angiographic follow-up at 6 months, and a clinical fol-
low-up during 7 months. Over 200 qualitative and quantitative variables were 
evaluated in a multi variable model, with major adverse cardiac events occurring 
within 4 days or 7 months as dependent variable. 
Results Clinical and angiographic follow-up data were obtained in 100% and 
86.40/0 respectively. Adverse independent risk factors ofma;or adverse cardiac 
events occurring within the first four days following angioplasty were the pre-
sence ofBraunwald class III, age ;:::60 years, dissection and thrombus post-
PTCA. Presence oflesion type A, use oflong acting nitrates at the time of 
randomization and randomization to hirudin treatment were independent 
protective factors. Predictability of this model is 0.80. Adverse independent 
predictors ofmaior adverse cardiac events occurring within 7 months following 
angioplasty were the presence ofBraunwald class II and III, age ;:::60 years and a 
high level of prothrombin fragment 1 and 2 post-PTCA. Lesion length <10 mm, 
history of myocardial infarction and minimal lumen diameter post-PTCAwere 
independent protective factors. Predictability of this model is 0.65. 
Conclusions Using the multivariable approach, predictability of the 
occurrence of major adverse cardiac events within 4 days following PTCA is 
substantial, dependent from hirudin treatment and is mainly dependent 
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from pre-procedural variables. Predictability of the occurrence of major adverse 
cardiac events 7 months foHowing PTCA is modest. (Submitted to the Euro-
pean Heart Journal) 
Since Andreas Griintzig performed the first coronary balloon dilatation on 
September the 16th 1977 [IJ as an alternative to coronary artery bypass grafting 
(CABG), percutaneous transluminal coronary angioplasty (PTCA) has emerged 
as a widely accepted safe and effective treatment modality in selected patients 
with obstructive coronary artery disease. Despite expanded indication, including 
patients with unstable angina, multi vessel disease, or totally occluded coronary 
arteries, the initial successrate of this technique is high, and the complication rate 
low [2, 3J. However, acute vessel closure and late restenosis are inherent to 
PTCA and continue to compromise its efficacy. 
An abundance of clinical and angiographic studies have been carried out 
over the last two decades, in an attempt to identify predictors for angioplasty suc-
cess and the occurrence of major adverse cardiac events (NlACE) during and 
after PTCA. Although the exact pathophysiology and factors responsible for re-
stenosis are largely unknown, some clinical and angiographic variables have been 
identified as potential risk factors [4-22]. Due to differences in patient selection, 
method of analysis and definitions of endpoints, the study results arc sometimes 
conflicting [23, 24]. Knowledge of specific risk factors for cardiac events could 
be useful in selection of therapy tailored to the individual patient or, to the vcry 
extrcme might indicate PTCA as a contraindicated therapy because of multiple 
cumulative risk factors. Besides, selection of patients at risk for luminal renar-
rowing, enables constitution of a riskful target population for pharmacological 
and device studies aiming at the prevention of restenosis. 
This study was performed to analyze the relationship between clinical, bio-
logical, procedural and angiographic characteristics to the in-hospital (4 days) or 
late (7 months) development of cardiac death, non-fatal myocardial infarction) 
CABG, bail-out stenting or repeat-PTCA in 1141 angioplasty patients suffering 
exclusively unstable angina pectoris. 
Methods 
Patient identification The study cohort was constituted of 1141 patients in whom 
PTCA was attempted in the period between September 1992 and Iv1ay 1993. These 
patients were prospectively enroled in a European restenosis prevention study (HELVE-
TICA: Hirudin in an European restenosis prevention triaL Versus hEparin Trcatment In 
ptCA patients) comparing a two dose regimen of recombinant hirudin (CGP 39 
393fD'IREVASC) to heparin treatment (25). All patients were treated for unstable angina 
pectoris, due to either de novo or restenotic lesions in native vcssels, without having had a 
myocardial infarction in the two weeks prior to angioplasty therapy. Selection of angio-
plasty device (balloon, rotational or directional atherectomy, ex:cimer laser) was left to the 
discretion of the operator. Electh'e stent implantation or multistage angioplasty waS an 
exclusion criterium for the study. 
Patients in the HELVETICA study received one of the following treatments: 
unfractionated heparin (an Lv. bolus injection of 10,000 IU of heparin followed by a con-
tinuous Lv. infusion of 15 IU/kg/hr of heparin for 24 hours, with placebo given s.e. h.Ld. 
for three consecuti,'e days); intravenous hirudin (an i.v. bolus injection of 40 mg of 
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hirudin followed by a continuous intravenous infusion of 0.2 mg/kg/hr hirudin for 24 
hours, with placebo given s.c. b.i.d. for three consecutive days) or intravenous and subcu-
taneous hirudin (an i.v. bolus injection of 40 mg of hirudin followed by a continuous i.v. 
infusion of 0.2 rug/kg/hr of hirudin for 24 hours, with 40 mg of hirudin given s.c. b.i.d. for 
three consecutive days). A concomitant dose of aspirin (l00-500 mg once daily) was 
given on the day of angioplasty and continued for at least 14 days. 
Hirudin treatment was associated with significant reductions in the rate of MACE 
in the first 4 days after angioplasty as compared with heparin (relathte risk of desirudin 
versus heparin 0.61, 95%, CI 0041-0.90, p;::::; 0.023) [25]. At seven months however, a 
reduction in the rate of cardiac events by hirudin, was not accomplished. The distribution 
of Jv\ACE is outlined in table I and the distribution of clinical baseline characteristics are 
shown in table II. 
Angiography and coagulation assessment For each patient coronary angiograms were 
obtained for quantitative and qualitative evaluation, in a standardized fashion immediate-
ly before and after angioplasty, and at six-month follow-up. A successful angioplasty was 
defined as an angioplasty which reduces the diameter of the stenosis at the first lesion to 
less than 50'% on visual inspection immediately after the angioplasty. All 35 mm cinefilms 
were analyzed at a core laboratory (Cardialysis RV. Rotterdam, The Netherlands) using 
the Coronary Angiography Analysis System (CAAS) [26, 27]. The distribution of base-
line lesion characteristics is summarized in table III. 
Blood samples for the determination of coagulation parameters, including levels of 
activated partial thrombin times and prothrombin fragment 1 and 2, were obtained at 
regular intervals before and after angioplasty by atraumatic venipunctures and were ana-
lyzed in a central laboratory . 
Clinical endpoint Clinical endpoints were recorded during 7 months following angio-
pia sty and included death, non-fatal myocardial infarction, coronary artery bypass graft, 
bail out stenting and repeat angioplasty at previously dilated sites. Death was considered 
cardiac unless proof of the contrary. Myocardial infarction was diagnosed either on the 
basis of new Q-waves (Minnesota Code [28)) or on creatinine kinase increase of more 
than twice the normal upper limit with concomitant increase in myocardial bound frac-
tion. A bail out stent procedure was considered equivalent to coronary artery bypass graft 
if patency of the target vessel could not be maintained otherwise. Repeat angioplasty was 
defined as re-insertion of a guiding catheter followed by balloon angioplasty or stent 
implantation at the same site. Repeat angioplasty or bypass surgery needed to be prece-
ded by typical anginal symptoms or, in case of atypical anginal symptoms, c1ectrocardio-
graphic evidence of myocardial ischaemia at rest or during exercise and an angiographk 
diameter stenosis of > 50% by visual inspection. 
Statistical analysis Categorical variables arc presented as absolute numbers and as per-
centages of the entire patient population. Differences in these variables between sub-
groups of patients are evaluated by Chi2-tests. Continuous variables are expressed as 
mean ± 1 Standard Deviation (SD); differences are studied by unpaired Student's t-tests. 
Data were evaluated by per patient analysis. If multiple lesions were treated per patient, 
lesion-specific (angiographic) data were converted as follows: observations of conti-
nuous variables were averaged; all possible outcomes of categorical variables were defi-
ned as new variables with a yes/no outcome and counted subsequently. 
Univariable logistic regression analysis was performed to determine clinical, pro-
cedural as well as angiographic variables predictive for Major Adverse Cardiac Events 
(MACE; death, myocardial infarction, coronary bypass surgery and repeat PTCA) at 
short (4 days) and long (7 months) term follow-up. The relevance of several variables 
was evaluated by Chi2-analysis. Odds ratio's (OR) and their 95'J{, Confidence Intervals 
(CI) were reported. 
Multivariable logistic regression analysis was performed to evaluate the indepen-
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dcnce of univariablc significant predictors. A multivariate regression model was con-
structed by stepwisc procedurcs (forward addition and backward elimination). Recei\'er 
Operating Characteristic (ROC) analysis was performed to describe the predictive powcr 
of the model [29J. The area under the ROC-curve is reportcd. 
Statistical significance of all tests was stated at the 0.05 probability level. The SAS 
software package was uscd for statistical calculations {30]. 
Results 
Clinical foHow-up was complete for all but one patient. Angioplasty was success-
ful in 91.7%, and the results of angiographic follow-up were available for 86.4%. 
In total 121 early j'AACE were encountered in 93 patients (1.30 event per 
patient). In total 476 late MACE were encountered in 385 patients (1.24 event 
per patient). Table I demonstrates the distribution of types of events occurring 
within 4 days or 7 months. 
Baseline clinical and angiographic variables are listed in tables 11 and Ill, 
respectively. There was a similar distribution of characteristics over the three 
antithrombin regimens [25]. Patients were mainly male and non-smoker (78.5 
and 75.5% respectively). The mean (median) age was 58.6± (58.8±) years. The 
Braunwald unstable angina classification was class I in 36.5% of the patients, 
class II in 42.8%, and class III in 20.6%. At screening 29.3% of the patients recei-
ved heparin for their unstable syndrome (table 11). Seventy eight of the 1141 
patients had a total occlusion (three patients had two total occlusions, table III). 
The univariate relation of clinical and angiographic continuous and catego-
rical variables to l'AACE within 4 days and 7 months following PTCA is descri-
bed in table II-V and table VI-IX respectively. 
Multivariable analysis of clinical, procedural and angiographic related 
variables revealed that Braunwald III, age ~60 years, thrombus and dissection 
post-PTCA were independent risk factors for adverse in-hospital clinical outco-
me, and desirudin treatment, use of long acting nitrates at the time of randomiza-
tion and lesion type A were independent protective factors (table X). The area 
under the ROC-curve is 80%. 
Concerning 7-months follow-up, Braunwald class II and III, age ~60 years 
and higher levels of prothrombin fragment 1 and 2 appeared to be independent 
risk factors for adverse clinical outcome. A history of myocardial infarction, 
lesion length < 1 0 mm and a larger minimal lumen diameter post-PTCA were 
independent protective factors. The ROC area of this 7 months model is 65%. 
Outcomes of the multivariate analyses are summarized in table X and Xl. 
Discussion 
Clinicall'isk factors Prognosis and therapy of patients with unstable angina pre-
sent a wide heterogenecity. To enable critical evaluation of diagnostic and thera-
peutic strategies, and to facilitate clinical decision making and intercoHegial dis-
cussion [31], Braunwald defined clinically relevant and practically applicable 
subgroups of patients with unstable angina pectoris [32]. This classification 
including all subgroup categories (severity of disease, clinical circumstances, 
BCG changes and intensity of treatment) was prospectively investigated in 417 
consecutive (non-angioplasty) patients who were admitted for ischemic chest 
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Tablel 
Major Adverse Clinical Evcnts (N(%)) occurring within 4 days and 7 months. 
N=1141 MACE within 4 days 
N 
Death 2 
Myocardial Infarction 38 
CABG 18 
Bail-out 38 
Rc-PTCA 25 
Patient with any event 93 
MACE = Major Adversc Clinical Events, 
CAllG= Coronary artery bypass graft surgery, 
% 
0.2 
3.3 
1.6 
3.3 
2.2 
8.2 
Re-PTCA = repeat percutaneous transluminal coronary angioplasty, 
N = number of patients. 
.MACli within 7 months 
N 
16 
62 
67 
38 
293 
385 
% 
1.4 
5.4 
5.9 
3.3 
25.7 
33.7 
Table II 
Relationship of categorical patient characteristics to lvlajor Adverse Clinical Events 
occurring within 4 days following PTCA. 
Characteristic N %MACE Odds ratio P univariate 
Treatment group 
Hirudin 759 6.7 0.58 (0.38-0.89) 0.013 
Heparin 382 11.0 1.00 
Anginal class 
Braunwald I 416 5.8 1.00 
Braunwald II 489 7.6 1.34 (0.79-2.27) 0.284 
llraunwald III 236 13.6 2.56 (1.47-4.47) 0.001 
CCS class 1 23 8.7 1.43 (0.32-6.51) 0.641 
CCS class 2 217 5.5 1.00 
CCS class 3 478 6.5 1.04 (0.59-1.84) 0.883 
CCS class 4 287 13.2 2.30 (1.32-3.98) 0.003 
Current smoker 
No 862 9.1 1.00 
Yes 278 5.4 0.57 (0.32-1.01) 0.05 
Gender 
Male 896 8.2 1.00 
Female 245 8.2 1.00 (0.60-1.68) 0.99 
Age < 60 years 625 5.9 1.00 
Age 2 60 years 516 10.9 1.94 (1.26-2.98) 0.003 
Number of lesions 
One 899 8.6 1.00 
Two 198 6.1 0.69 (0.37-1.29) 0.245 
Three 44 9.1 1.07 (0.37-3.06) 0.903 
Medical history 
Previous CABG 
No 1103 8.1 1.00 
Yes 38 10.5 1.34 (0.47-3.86) 0.59 
Previous MI 
No 687 8.9 1.00 
Yes 454 7.1 0.78 (0.50-1.22) 0.27 
Previous PTCA 
No 940 8.3 1.00 
Yes 201 7.5 0.89 (0.50-1.58) 0.70 
Table II continued 
Relationship of categorical patient characteristics to Major ,\d\'erse Clinical Events 
occurring within 4 days following PTCA. 
Characteristic N O/O;\lACE Odds ratio P univariate 
NIDDM 
No 1055 8.0 1.00 
Yes S6 10.5 1.35 (0.65-2.79) 0.42 
IDDM 
No 1101 8.3 1.00 
Yes 40 5.0 0.58 (0.14-2.46) 0.46 
Hypercholesterolemia 
No 706 8.S 1.00 
Yes 435 7.1 0.80 (0.51-1.25) 0.32 
Hypertension 
No 661 8.0 1.00 
Yes 480 8.3 1.04 (0.68-1.60) 0.85 
History of stroke 
No 1129 8.2 1.00 
Yes 12 8.3 1.03 (0.13-S.03) 0.98 
History ofTIA 
No 1124 8.0 1.00 
Yes 17 17.7 2.46 (0. 70-S. 73) 0.15 
Medication at screening 
Heparin Lv. at screening 
No S07 7.3 1.00 
Yes 334 10.2 1.44 (0.92-2.24) 0.11 
Long acting nitrates 
No 512 10.2 1.00 
Yes 629 6.5 0.62 (0.40-0.95) 0.03 
Short acting nitrates 
No 676 6.8 1.00 
Yes 465 10.1 1.54 (1.01-2.36) 0.05 
Cholesterol lowering drugs 
No 982 8.7 1.00 
Yes 159 5.0 0.56 (0.27-1.18) 0.12 
Table III 
Relationship of categorical morphologic variables to Major Adverse Clinical Events 
occurring within 4 days following PTCA. 
Pre-procedural N N % MACE Odds ratio (95% CI) P univariate 
characteristics patients lesions 
Vessel dilated 
LAD 587 699 8.0 0.96 (0.63-1.47) 0.855 
l.CX 288 334 5.9 0.64 (0.37-1.11) 0.109 
RCA 363 423 9.1 1.20 (0.77-1.87) 0.428 
Concentric 432 485 4.4 1.00 
Eccentric 601 674 10.1 2.06 (J.25-3.39) 0.004 
Multiple irregularities, 239 267 9.9 1.93 (1.11-3.36) 0.020 
tandem lesion or total 
occlusion 
Patent vessel 1063 345 8.1 1.00 
Total occlusion 781 81 9.0 1.12 (0.50-2.51) 0.074 
Non-ostial 1071 1356 8.3 1.00 
Ostial location 70 70 5.7 0.67 (0.24-1.88) 0.444 
Branchpoint absent 846 1100 7.7 1.00 
Branchpoint in stenosis 295 326 9.5 1.26 (0.79-2.00) 0.335 
Non-angulated lesion 1036 1318 7.4 1.00 
Location in bend 105 108 15.2 2.24 (1.25-4.00) 0.007 
Thrombus absent 1077 1360 7.7 1.00 
Thrombus pre-PTCA 64 66 15.6 2.22 (1.09-4.51) 0.028 
Non-calcified lesion 962 1216 8.0 1.00 
Calcification 179 210 8.9 1.13 (0.64-1. 98) 0.678 
Lesion length (visual) 
< IDrum 802 956 6.9 1.00 
10-20 mm 291 312 10.0 1.44 (0.90-2.32) 0.131 
>20mm 69 73 13.0 1.90 (0.93-4.16) 0.079 
ABC lesion type 
type A 213 234 2.8 1.00 
type Bl 518 584 6.4 2.11 (0.80-5.57) 0.131 
type B2 430 483 11.4 4.03 (1.57-10.3) 0.004 
type C 114 123 11.4 4.07 (1.41-11.8) 0.010 
Type A 213 234 2.8 1.00 
Type BliB2/C 977 1190 8.9 3.13 (1.25-7.70) 0.015 
Table III continued 
Relationship of categorical morphologic variables to Major Adverse Clinical Events 
occurring within 4 days following PTCA. 
Post-procedural N N %~lACE Odds ratio (95% CI) 
characteristics patients lesions 
Dissection absent 639 857 2.9 1.00 
Dissection type A 172 181 8.7 1.390.75-2.55 
Dissection type B 221 236 7.2 1.100.61-1.98 
Dissection C,D,E or F 128 130 32.0 3.621.79-7.30 
Dissection absent 639 857 2.9 1.00 
Dissection present 502 547 14.1 5.54 (3.25-9.42) 
No tortuosity 1031 268 7.7 1.00 
lvloderate tortuosity 1101 158 11.6 1.57 (0.88-2.83) 
No thrombus post-p'rCA 1097 1379 7.2 1.00 
Thrombus post-PTCA 44 47 25.0 4.29 (2.09-8.81) 
Table IV 
Relationship of continuous clinical variables to Major Adverse Clinical Events 
occurring within 4 days following PTCA. 
Variable Eventfree Event P ulli-variate 
Age (years) 58.4±9.0 60.6±8.2 0.023 
Weight (kilogram) 76.4±11.0 73.8±10.0 0.030 
Platelets (*109 /L) 243±67 237±59 0.361 
Haemoglobin (gram/L) 141±13.7 139±12 0.061 
Haematocrit (%) 41.5±3.9 40.4±3.5 0.011 
Leucocytes (*109/L) 7.18±1.9 7.36±2.1 0.406 
F 1.2 (screening nmol!L) 1.54±2.5 l.39±O.86 0.248 
Ft.2 (post-PTCA nmollL) 2.24±3.84 2.30±3.40 0.912 
aPTT (post-PTCA sec) 136.6±56.8 148±58.1 0.116 
Table V 
Relationship of continuous angiographic variables to Jvlajor Adverse Clinical Events 
occurring within 4 days following PTCA. 
Variable Eventfree Event P uni-variate 
Reference dillm. pre 2.68±O.51 2.74±O.50 0.308 
Obstruction diam. pre O.98±O.39 0.98±O.39 0.963 
Obstruction diam. post 1.80±O.37 1.76±O.40 0.416 
Absolute gain 0.8I±O.42 0.85±O.47 0.501 
Relative gain 0.30±O.15 0.3I±O.16 0.591 
Lesion length pre-PTCA 6.84±2.24 7.57±2.58 0.005 
Area-plaque pre-PTCA 7.52±3.56 9. I 7±5.49 0.008 
P univariate 
0.290 
0.760 
0.000 
0.001 
0.129 
0.001 
OR (95% GI) 
1.03 (1.00-1.06) 
0.98 (0.96-1.00) 
1.00 (0.95-1.01) 
0.99 (0.97-1.00) 
0.93 (0.88-0.98) 
1.05 (0.94-1.17) 
0.97 (0.86-1.10) 
1.00 (0.94-1.07) 
1.00 (1.00-1.01) 
OR (95% GI) 
1.24 (0.82-1.88) 
0.99 (0.57-1.70) 
0.70 (0.29-1.67) 
1.27 (0.63-2.58) 
1.73 (0.24-12.7) 
1.14 (1.05-1.24) 
1.09 (1.04-1.15) 
Table VI 
Relationship of categorical patient characteristics to Major Adverse Clinical Events 
occurring within 7 months following PTCA. 
Characteristic N %~lACE Odds ratio P univariate 
Treatment group 
Hirudin 759 34.3 1.07 (0.83-1.39) 0.605 
Heparin 382 32.7 1.00 
Anginal class 
Braunwald I 416 26.2 1.00 
Braunwald II 489 37.8 1.71 (1.29-2.28) 0.000 
Braunwald III 236 38.5 1.77 (1.26-2.49) 0.001 
CCS class 1 23 43.5 1.77 (0.75-4.16) 0.191 
CCS class 2 217 29.5 1.00 
CCS class 3 478 29.3 0.95 (0.71-1.29) 0.750 
CCS class 4 287 44.6 1.85 (1.34-2.56) 0.000 
Current smoker 
No 862 35.7 1.00 
Yes 278 27.7 0.69 (0.51-0.93) 0.014 
Gender 
Male 896 33.7 1.00 
Female 245 33.9 1.01 (0.75-1.36) 0.960 
Age < 60 years 625 28.3 1.00 
Age;::>: 60 years 516 40.3 1.71 (1.34-2.19) 0.000 
Number of lesions 
One 899 32.4 1.00 
Two 198 36.9 1.22 (0.89-1.68) 0.224 
Three 44 47.8 1.91 (1.04-3.50) 0.037 
Medical history 
Previous CABG 
No I !O3 33.5 1.00 
Yes 38 42.1 1.45 (0.75-2.79) 0.270 
Previous MI 
No 37.1 8.9 1.00 
Yes 28.6 7.1 0.68 (0.53-0.88) 0.003 
Previous PTCA 
No 940 33.5 1.00 
Yes 201 34.8 1.06 (0.77-1.46) 0.720 
Table VI continued 
Relationship of categorical patient characteristics to Major Adverse Clinical Events 
occurring within 7 months following PTC1\. 
Characteristic N %MACE Odds ratio P univariate 
NIDDM 
No 1055 33.4 1.00 
Yes 86 38.4 1.24 (0.79-1.96) 0.346 
IDDM 
No 1101 34.1 1.00 
Yes 40 25.0 0.65 (0.31-1.33) 0.237 
H yperc h oIestcrol em i a 
No 706 36.4 1.00 
Yes 435 29.4 0.73 (0.56-0.94) 0.016 
Hypertension 
No 661 32.2 1.00 
Yes 480 35.8 1.18 (0.92-1.51) 0.203 
History of stroke 
No 1129 33.5 1.00 
Yes 12 58.3 2.78 (0.88-8.82) 0.082 
History ofTIA 
No 1124 33.7 1.00 
Yes 17 35.3 1.07 (0.39-2.92) 0.892 
~'ledication at screening 
Heparin i.v. at screening 
No 807 31.7 1.00 
Yes 334 38.6 1.35 (1.04-1.77) 0.025 
Long acting nitrates 
No 512 37.5 1.00 
Yes 629 30.7 0.74 (0.58-0.94) 0.016 
Short acting nitrates 
No 676 31.7 1.00 
Yes 465 36.8 1.26 (0.98-1.61) 0.073 
Cholesterol lowering drugs 
No 982 34.3 1.00 
Yes 159 30.2 0.83 (0.58-1.19) 0.307 
Table VII 
Relationship of categorical morphologic variables to Major Adverse Clinical Events 
occurring within 7 months following PTCA. 
Pre-procedural N N %~-IACE Odds ratio (95% CI) P univariate 
characteristics patients lesions 
Vessel dilated 
LAD 587 699 36.5 1.29 (1.00-1.64) 0.046 
LCX 288 334 31.6 0.88 (0.66-1.17) 0.373 
RCA 363 423 31.4 0.86 (0.66-1.12) 0.254 
Concentric 432 485 33.1 1.00 
Eccentric 601 674 35.7 1.24 (0.95-1.63) 0.111 
Multiple irregularities, 239 267 38.2 1.26 (0.91-1.74) 0.167 
tandem lesion or total 
occlusion 
Patent vessel 1063 345 34.0 1.00 
Total occlusion 781 81 30.8 0.86 (0.53-1.42) 0.562 
Non-ostial 1071 1356 33.0 1.00 
Ostial location 70 70 45.7 1.71 1.05-2.78) 0.031 
Branchpoint absent 846 1100 31.5 1.00 
Branchpoint in stenosis 295 326 40.3 1.47 (1.12-1.93) 0.006 
Non-angulatcd lesion 1036 1318 32.7 1.00 
Location in bend 105 108 44.7 1.67 (1.11-2.51) 0.013 
Thrombus absent 1077 1360 33.5 1.00 
Thrombus prc-PTCA 64 66 39.1 1.28 (0.76-2.14) 0.358 
Non-calcified lesion 962 1216 33.3 1.00 
Calcification 179 210 36.3 1.14 (0.82-1.59) 0.434 
Lesion length (visual) 
< lOmm 802 956 31.7 1.00 
10-20 mm 291 312 41.6 1.59 (1.20-2.11) 0.001 
>20mm 69 73 40.6 1.55 (0.94-2.57) 0.087 
ABC lesion type 
type A 213 234 28.6 1.00 
type ill 518 584 33.2 1.45 (0.96-2.18) 0.077 
type B2 430 483 40.0 2.00 (1.33-3.ot) 0.001 
type C 114 123 33.3 1.54 (0.91-2.61) 0.110 
Table VII continued 
Relationship of categorical morphologic variables to Major Adverse Clinical Events 
occurring within 7 months following PTCA. 
PostMproccdural N N %~lACE Odds ratio (95% CI) 
characteristics patients lesions 
Dissection abscnt 639 857 30.8 1.00 
Dissection type A 172 181 33.7 1.08 (0.76-1.55) 
Dissection type B 221 236 31.7 0.91 (0.65-1.26) 
Dissection C,D,E or F 128 130 50.0 1.41 (0.82-2.44) 
Dissection absent 639 857 30.8 1.00 
Dissection prcscnt 502 547 37.1 1.32 (1.03-1.69) 
No tortuosity 1031 268 32.4 1.00 
Modcrate tortuosity 1101 158 44.2 1.65 (1.l4-2.39) 
No thrombus post-PTCA 1097 1379 32.8 1.00 
Thrombus post-PTCA 44 47 54.5 2.46 (1.34-4.52) 
Table VIII 
Relationship of continuous clinical variablcs to Major Advcrse Clinical E\'cnts 
occurring within 7 months following PTCA. 
Variable Evcntfree Event P uni-variatc 
Age (years) 57.9±8.7 59.819.3 0.001 
Weight (kilogram) 76.8±11.0 75.1±10.7 0.016 
Platelets (*1091I.) 245±70 239±57 0.13 
Haemoglobin (gram/L) 142±14 141±13 0.32 
Haematocrit (%) 41.5±3.9 41.3±3.9 0.43 
Leucocytes (* 109/L) 7.2±2.0 7.2±1.8 0.93 
F 1.2 (scrccning nmol/L) I. 5±2. 5 1.5±2.2 0.87 
F 1.2 (post-PTCA nmollL) 2.1±3.5 2.6±4.4 0.053 
aPTI' (post-PTCA sec) 138±57 136±58 0.50 
P univariate 
0.660 
0.558 
0.216 
0.028 
0.008 
0.004 
OR (95% GI) 
1.02 (1.01-1.04) 
0.99 (0.97-0.99) 
1.00 (1.00-1.00) 
0.99 (0.99-1.00) 
0.99 (0.96-1.02) 
1.00 (0.94-1.06) 
1.00 (0.95-1.06) 
1.03 (1.00-1.07) 
1.00 (1.00-1.00) 
Table IX 
Relationship of continuous angiographic variables to Major Advcrse Clinical Evcnts 
occurring within 7 months following PTCA. 
Variable Eventfree Event P uni-variate 
Refercnce diam. pre 2.71±D.51 2.65±D.51 0.074 
Obstruction diam. pre 0.98±D.40 0.96±D.36 0.430 
Obstruction diam. post 1.84±D.35 1.72±D.38 0.000 
Obstruction diam. f-up 1.68±D.51 1.I8±D.50 * 
Absolute gain 0.83±D.43 0.76±D.45 0.013 
Absolute loss 0.16±D.43 0.54±D.52 * 
Relative gain 0.31±D.15 0.28±D.15 0.010 
Relative loss 0.06±0.16 0.20±D.19 * 
Lesion length pre-PTCA 6.84±2.25 6.98±2.34 0.350 
Area-plaque prc-PTCA 7.56±3.60 7.58±4.1O 0.247 
OR (95% el) 
0.80 (0.62-1.02) 
0.88 (0.64-1.12) 
0.42 (0.29-0.61) 
0.66 (0.48-0.92) 
0.30 (0.12-0.75) 
1.03 (0.97-1.08) 
1.02 (0.99-1.05) 
* Not all p-values are entered in to the table since their relation to the occurrence of clinical events 
is evidently inhcrent. 
Table X 
Independent predictors for the occurrcnce of Major Adverse Clinical Evcnts at 4 days. 
Variable P muiti-\'ariatc Odds ratio 95%CI 
Hirudin trcatment 0.036 0.61 0.38 - 0.97 
Long acting nitrates 0.018 0.57 0.36 -0.91 
Lesion type A 0.001 0.37 0.21 - 0.65 
Rrau!1wald class III 0.003 2.19 1.32 - 3.63 
Agc ~ 60 years 0.004 1.97 1.24-3.15 
Dissection 0.000 5.48 3.18-9.44 
Thrombus post-PTCA 0.001 3.73 1.71 -8.13 
Table XI 
Independcnt predictors for the occurrence of Major Adverse Clinical E\'cnts at 7 months. 
Variable P multi-variate Odds ratio 95%CI 
Braunwald class II 0.002 1.64 1.19-2.24 
Rraunwald class III 0.014 1.61 1.10-2.36 
Age ~ 60 years 0.001 1.61 1.22-2.11 
Fl.2 post-PTCA nOlollL 0.035 1.04 1.00-1.07 
History of MI 0.012 0.69 0.52-0.92 
Lesion length < 100lm 0.006 0.67 0.50-0.88 
MLD post-PTCA (mOl) 0.000 0.46 0.31-0.68 
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pain (33]. This study demonstrated the classification to be appropriate for risk 
stratification in clinical practice. 
The Braunwald classification may be especially relevant to the dynamic 
changes within the coronary arteries. The occurrence of anginal pain episodes 
over time may parallel repeated formation and recovery of an unstable plaque, 
resulting in a layered thrombus (34]. Furthermore, the clinical decrease in fre-
quency of symptoms over time corresponds to the decrease of angiographic pre-
sence of intracoronary thrombus over time (6]. 
Our data demonstrate a gradual increase in risk from Braunwald class I to 
class III for the occurrence of cardiac events. This observation matches the gra-
dual increased incidence of present smoking status (21.4% vs. 24.8% vs. 28.8% in 
respectively class I, II and III, P=0.033), female gender (19.2% vs. 21.1% vs. 
26.2%, P=0.044), previous PTCA (16.6% VS. 15.5% vs. 23.7%, P=0.049) and 
presence of a type C lesion (7.7% vs. 10.4% vs. 13.2%, P=0.022). \Xlhere corona-
ry angiography considerably underestimates the presence of intra coronary 
thrombus [35], Braunwald class was not related to the angiographic evidence of 
pre-procedural presence of intracoronary thrombus (6.0% vs. 5.7% vs. 4.7% in 
respectively class I, II and III, 1'=0.504). Braunwald class was surprisingly also 
not related to the pre-procedural levels of prothrombin fragment 1 and 2 (2.22, 
2.03, and 2.70 nmollL., P=0.093) [36]. 
Risk factors for adverse procedural outcome are related to the presence of a 
large myocardium at risk, while taking into account the extent of pre-existing 
non-viable myocardium. The protective effect of a previous myocardial infarc-
tion in our analysis may be due to the lesser amount of myocardium at risk in 
those patients, especially when the dilatation is in the vessel supplying the infarct 
related area. However, we could not reconstruct this hypothesis, because of res-
trictions in the available data and the retrospective nature of this investigation. 
In our study, increased age is an independent risk factor for the occurrence 
of MACE. The ;:::60 years cut off point was based on the median age of 58.8 years 
and includes 45.2% of the studied population. Despite the plausible relationship 
between higher age and the occurrence of MACE [7, 8, 9], we must not under-
estimate the fact that long term event free survival and life-expectancy after 
PTCA in patients under 35 years of age are seriously and detrimentally altered as 
well [10]. 
The subgroup of patients over 60 years of age significantly overrepresented 
females. Thirty percent of the patients over 60 years, and 14.4% in the younger 
population were females (P=O.OOl). Because of their higher age, female patients 
suffered significantly more frequent diabetes mellitus (15.5% of the females ver-
sus 9.8% of the male population, P=O.O 12) and hypertension (55.1 % of the fema-
les is hypertensive versus 38.5% of the males P=O.OOl). Despite this, the inciden-
ce of early and late events is exactly similar in man and women, suggesting that 
women's cardiovascular system is less extensive diseased [8, 37]. There is a trend 
towards a lower incidence of multiple lesion angioplasty in \vomen (19.4%) com-
pared to men (24.4%). 
A significantly lower age is observed in the smoking subgroup (54.4 ± 8.7 
versus 59.9 ± 8.6 years, p = 0.0001), who in addition have a lower incidence of 
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hypertension (32.7% vs. 45.1%, p=O.OOl) and diabetes mellitus (7.6% vs. 12.2%, 
p::::O.032), \X'hen multi variable correction for baseline characteristics is madc, 
smoking does not prevent the occurrence of clinical events and appears merely 
dependent from age. 
F 1.2 is a biological marker of prothrombin conversion, and the elevated 
levels post-PTCA might reflect the local coagulation activation by the disruptive 
action of successful angioplasty (36,38], In this study, samples for F 1.2 were 
taken from separate and peripheral venapunctures. Despite the fact that the 
measurement is from a diluted and systemic sample, an increased level of F 1.2 
post-PTCA remains a significantly independent predictor for the overall occur-
rence of IV1ACE 7 months after PTCA. This generates the question whether 
direct sampling from the great cardiac vein would underscore this relationship 
and possibly would disclose a threshold by which rcstenosis might occur. At least 
these data support the concept of thrombin inhibition and restenosis as scientific 
basis of the HELVETICA trial. 
Qualitative angiographic risk factors All lesion characteristics that induce an 
unequal distribution of the dilating forces or transferred energy, increase the risk 
of brutal vessel wall disruption. Radial forces in case of an eccentric lesion will be 
mainly directed in compression of the protruding tissue. In 1985, Ambrose {39] 
recognised the relationship between lesion morphology and both unstable angina 
and myocardial infarction. Also the negative role of coronary artery thrombus 
formation, most likely secondary to plaque rupture, inducing unstable angina 
pectoris is suggested by several investigators [4, 5, 6, 40J. Early angiographic 
assessment in patients who had rest pain within 24 hours demonstrated the pre-
sence of intracoronary thrombus in 50% of the patients [6]. This figure was only 
21 % in those with late elective angiography. 
In an NHLllI study (1500 PTCA patients), the complication rate was 26% 
in unstable patients, versus 17% in the stable group (p<O.OOl) [4lJ. It was 
recently demonstrated that culprit lesions in unstable syndromes show a focal 
vasoconstrictive response [42}. The presence of a vulnerable fissured plaque, and 
latent or active coagulant conditions is reflected by a significant contribution 
of,thrombus post-PTCA in the multivariate model for early outcome, and of 
F 1.2 in the long term multivariate modeL The two studies suggest a link between 
lesion morphology in unstable patients and the occurrence of clinical complica-
tions. The predominance of eccentric lesions in our study population reflects the 
acute process of ruptured plaque or partiaHy lysed thrombus which is present in 
unstable syndromes [39J. 
Although dissection increases the propensity for thrombus post-PTCA 
(p=0.049), it does not translate into increased levels of prothrombin fragment 1 
and 2. 
Location in a bend and branchpoint involvement increase the predispo-
sition for development of a dissection, as apparently do more severe lesions 
(minimal lumen diameter pre-PTCA 1.0l±o.38 mm in vessels without dissec-
tion, 0.94±O.39 mm in vessels with dissection, p=O.0006) and procedures in 
which a larger gain is achieved (O.84±O.45 mm in vessels with dissection vs. 0.79 
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±GAO mm in vessels without dissection P=0.05). Also visually estimated lesion 
length> 10 mm, as independent predictor of adverse long term clinical outcome, 
significantly contributed to the dissection of coronaries (p=O.OOl) and to thc for-
mation of post-procedural thrombus (p=O.043). 
Quantitative paraI11eters: J\linimalluI11en diameter post-angioplasty A lar-
ger minimal lumen diameter post angioplasty is an independent protective factor 
for late clinical outcome. This variable correlates significantly to minimal lumen 
diameter pre-angioplasty, absolute gain and vessel size. Previously our group 
reported the positive independent influences (p<O.OOOl) of vessel sizc, luminal 
gain and J\I\LD before PTCA on loss and M.LD at follow up [11]. This is con-
firmed in our study where J\'1LD post-PTCA is an independent predictor of late 
clinical outcome. 
Adlllinistl'ation of long acting nitrates and Hirudin treatment The admini-
stration of long acting nitrates at the time of randomization was a protective 
variable in the multivariate model for early clinical outcome. This relationship is 
not previously reported. This effect might conceivably be due to the protracted 
metabolization of nitrates to nitric oxide [43]. This results in both smooth muscle 
cell relaxation and inhibition of platelet aggregation and platelet activation 
through the stimulation of guanylate cyclase. Due to the retrospective nature of 
this trial however, we do not have any biological or haernostatic data supporting 
this assumption. At least there was no relationship between the use of long acting 
nitrates and loss in lv1LD. 
Hirudin administration was independently associatcd wiLh an impressive 
reduction of iV1ACE in the first 4 days after angioplasty. The primary goal of the 
HELVETICA trial however, the reduction of IvlACE at 7 months was not achiev-
ed. The event free survival at 7 months did not differ among the treatment 
groups. A putative explanation for the apparent paradox might he that the dosage 
used was insufficient to reach an adequate level of anticoagulation, hut sufficient 
to limit thrombin mediated platelet aggregation and activation, thereby exhibi-
ting effects similar to those observed acutely in the EPIC trial [31, 44, 45}. 
Relevance and predictability of the IlltIitivariate model Predictability of the 
4 day model is 80%. At the time of design of the trial, non-elective stent implanta-
tion was considered to be a bail-out procedure, equivalent to emergency CABG. 
To date however, bail-out stenting is routinely used in the standard armamen-
tarium of the interventionalists and no longer vic wed as a clinical event unless it 
causes untoward clinical effects. Therefore it might be argued that the importan-
ce of stenting in terms of clinical endpoints at the time of coronary angioplasty in 
this trial is overstated. On the other hand, up till now, no randomized trial has 
proven the merits of stenting or bail-out stenting in exclusively unstable patients. 
\Vhen bail-out stenting is not considered as a clinical endpoint in the analysis of 
the multivariate model, the predictability of the analysis remains high (79%). 
Remarkably hirudin treatment then loses significant contribution to the model. 
A pre-procedural risk assessment would eliminate peri-procedural and 
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post-PTCA variables from the model, therefore reducing it's prognostic value. 
Accordingly, when thrombus post-PTCA and dissection are excluded from the 
model, predictability lowers to 70%, and hirudin treatment remains as a favour-
able factor in the model. \"hen in this model bail-out stenting is not considered, 
predictability is less affected and only partially reduced to a level of 73%, while 
hirudin treatment loses it's significant contribution to the model. 
Long term predictability of the model is 66%. Contribution of bail-out sten-
ting to the long term predictability is low so that predictability is 65% if bail-out is 
not considered as a clinical endpoint. \"hen post-procedurall\tlLD and F 1.2 are 
not considered, and the model is limited to only pre-procedural characteristics, 
predictability of the model falls to 64%. 
Recently the activation status of circulating phagocytes just prior to PTCA 
was found to be predictive for late lumen loss [12]. The expression of the mem-
brane antigen CD66 by granulocytes was inversely associated with the relative 
loss at 6 months after p'rCA, while the production of IL-lf3 by stimulated rnono-
cytes was positively associated with the relative loss. Multivariable linear regres-
sion analysis showed that luminal renarrowing could be predicted reliably 
(R2~O.65; P<O.OOOI) based on these two biological risk factors. 
Another multivariable model identified predictors for luminal narrowing at 
6 months following PTCA by visually assessed lesion length, pre-procedural 
minimal lumen diameter, diabetes mellitus, duration of angina, relative gain in 
lumen diameter, and thrombus post-angioplasty [23J. To evaluate the effective-
ness to predict the amount of luminal narrowing at follow-up, the percentage of 
correct classified lesions was calculated for 5 intervals of predicted change in 
lumen diameter. Correct prediction of the model was poor. Only 10% of lesions 
in the middle 3 categories were correctly classified by the model. 
Conclusion 
In the HELVETICA trial, randomization to hirudin therapy was associated with 
impressive reductions in the rate of MACE in the first 4 days after angioplasty as 
compared with heparin. However, a reduction in the rate of cardiac events at 
seven months by hirudin, was not accomplished. In this ancillary study we 
demonstrate that the advanced multivariable model to predict in-hospital clinical 
outcome is fairly accurate (80%). The multi variable model for 7 months clinical 
outcome is somewhat less predictive (66%), The contribution of seven indepen-
dent variables however, creates a complex model. An ideal model contains only a 
very limited number of variables in order to simplify risk stratification. Finally, 
we should not forget that the NHLBI registry observed the significant relation-
ship between major complication rate and cardiologist's experience [41J. 
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Chapter II - The ClI/'relll role of tlmithrombi1l$ ill illlerVellliOllal cardiology 
Introduction Despite developments in technology and increased knowledge 
of mechanism of action and pathophysiology of intra coronary angioplasty pro-
cedures, the high initial success rates of percutaneous transluminal coronary 
angioplasties (PTCAs) remain hampered by early and late reocclusion [I]. The 
introduction of adjunctive devices in interventional cardiology has augmented 
indications for angioplasty in patients, which are expected to result in a higher 
complication rate. Several randomized pharmacologic multicenter trials have 
been designed to diminish the rate ofreocclusion, but until now no benefit is 
detected from the variety of drugs tested. 
It is evident that thrombin plays an unequivocal detrimental role in the vascular 
wall injury resulting from angioplasty procedures. Pharmacologic research 
currently concentrates on inhibition of prothrombin conversion and thrombus 
formation. Animal experimental work in this field is encouraging, and results of 
clinical trials will elucidate important questions about safety, efficacy and 
immunoallergic potential of modern antithrombins. (Current Review of 
Interventional Cardiology (edn3). Current t'Aedicine-1996;chapter 18) 
Thrombin 
Thrombin is the most potent known platelet activator and interacts with a variety 
of immunomodulatory cells and hematologic factors, Its action includes a stimu-
lation in the endothelial layer of platelet-derived growth factor production, pros-
tacyclin secretion, platelet-activating factor, and plasminogen activator-inhibi-
tor. In vivo, thrombin receptor expression was demonstrated by endothelial cells 
in intact vessel walls, macrophages, and vascular smooth muscle cells in athero-
sclerotic lesions and in endarterectomy specimens [2}. Selectin ,formation at the 
endothelial cell surface is stimulated by thrombin and plays a role in the incursion 
of monocytes and neutrophils to an injured vessel wall. In addition to this, throm-
bin has a direct chemotactic effect on monocytes [3], and has apparent mitogenic 
effects on lymphocytes [4] and vascular smooth muscle cells [5] (Figure 1). 
The transmembrane thrombin receptor exposes an amino terminal exten-
sion that bares two thrombin binding sites: the thrombin cleavage site and a 
hirudinlike domain [6]. The identification of the thrombin receptor has enabled 
sophisticated designs of molecules that fit exactly into those sites. 
In case of deep endothelial injury (as with a successful angiopJasty), blood is 
exposed to collagen and other substances of the sub intima, which are potent sti-
muli for platelet aggregation mediated by the release of adenosine diphosphate 
(ADP); serotonin; thromboxane A2 (TXA2)j and the adhesive molecules fibrin-
ogen, fibronectin, thrombospondin and von \'<'illebrand Factor. These substan-
ces, including thrombin, activate neighbouring platelets by way of different me-
tabolic pathways (TXAZ> ADP and a platelet-activating factor) and promote 
intramural thrombus formation, which could cause restenosis [7], In addition, 
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several growth factors, important ingredients of the platelet granulae are released 
during activation. Receptors for these factors are expressed in mesenchymal cells 
such as the smooth muscle ceHs and playa prominent role in late restenosis. 
Limitations of available antithrombotic drugs 
Currently, substantial research is focused on antithrombotic and antithrombin 
approach. Until now, no major breakthrough has been reported [8, 9J, although a 
clear progression in the understanding and interfering of the mechanism has occur-
red. The limitations of several antithrombin agents have been determined. 
\X'arfarins l action docs not block thrombin IS extrinsic pathway, but does hinder the 
action of several commonly used drugs. Another weakness of warfarin is the delay 
between administration and therapeutic effect, as is the case with ticlopidine. 
Aspirin has the ability to inhibit platelet TxA2 synthetase and subsequent 
platelet activation by irreversibly blocking the enzyme cyc1o-oxygenase that is 
responsible for the conversion of arachidonic acid to prostaglandin G 2 (PGG2). 
This intermediate prostaglandin can be transformed in the metabolic pathway to 
TxA2 and thromboxane B2. Aspirin results in a decreased production of this 
substance in platelets. It also results in cyclo-oxygenase blockade in the endothe-
lial cell [10], which is responsible for the conversion of arachidonic acid to pro-
staglandin 12 (PGI2). Thromboxane A2 is a powerful platelet aggregator and 
vasoconstrictor, but because the biologic actions of TxA2 and PGI 2 are oppo-
sing, acetylsalicylic acid is an antagonist of itself. In addition, it only partially 
inhibits platelet aggregation induced by ADP, serotonin, epinephrin, collagen, or 
thrombin. 
The effectiveness of heparin is limited in patients having insufficient anti-
thrombin III levels. Another major issue is the limited ability of the large heparin-
antithrombin III complex to gain access to clot-bound thrombin or factor Xa in 
the prothrombinase complex. Furthermore, heparin action is inhibited by fibrin II 
monomers, thrombospondin, and platelet factor 4, which is present in the plate-
let-rich thrombus. The dose-effect response is poor and relatively unpredictable. 
The action of low-molecular-weight heparin (LMWH) in factor X inhibi-
tion is hampered by the limited ability of the antithrombin III-LMWH complex to 
block phospholipid membrane- bound factor Xa; also LM\X'H shares the limita-
tions of heparin in gaining access to clot-bound thrombin and in functioning effec-
tively under conditions of insufficient antithrombin levels. As is true of heparin, 
LM\\{H is a widely varied mixture of sizes of depolymerized heparin molecules 
and therefore is subject to variety in effectiveness from lot to Jot. Both heparin and 
LM\X'H have effects on platelets that may manifest as thrombocytopenia. 
The potential advantages of specific antithrombins He in the fact that they 
overcome the limitations of conventional treatment. The ideal antithrombin drug 
is a small-sized molecule, able to penetrate the thrombotic material. It is synthetic 
and therefore has no natural inhibitors, does not need any co-factor, and does not 
express any antigenic properties. The dose-response relation is predictable. An 
important support to the success of such a drug is the development of local drug 
delivery systems, enabling the interventional cardiologist to block thrombins l 
action entirely at exactly the right spot, not affecting systemic hemostasis levels. 
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Animal experimental work and human studies 
Heparins Heparin is currently the most widely used anticoagulant drug in the 
management of acute thrombotic syndromes. It is a heterogeneous mixture of 
glycosaminoglycans with a molecular weight ranging from 2000 to 40,000 dal-
tons. The antithrombotic capacities are achieved by the reversible binding with 
the natural circulating anticoagulant antithrombin III. The binding is responsible 
for a lOOO-fold acceleration of antithrombin III-heparin binding to factor IIa. 
This complex also involves activated coagulation proteins (factors X, IX, XI 
and XII). 
Heparin and its low-molecular-weight derivatives have been shown to redu-
ce smooth muscle cell proliferation [11], inhibit smooth muscle ceU migration 
[IIJ, and decrease the number of cells transformed from a contractile to a synthe-
tic phenotype [12J. The anti proliferative actions of the heparins appear not to be 
related to anticoagulant properties because particular heparin subfractions retain 
their antiproliferative effects despite their lack of anticoagulant properties. 
Smooth muscle cell-bound heparin can be internalized, affecting the cell cycle 
with a consequent reduction in DNA and RNA synthesis by mechanisms unrela-
ted to oncogene expression {I3]. The effect on restenosis of various heparin 
doses and administration schedules has been investigated using regular heparin 
samples [14-17]. So far, no beneficial influence on the restenosis rate has been 
detected. Synthetic heparins and LM\\{H fractions, lacking the heterogeneous 
naturc, are now the subject ofrcsearch [18-22]. The clinically used LM\VH mix-
tures diverge in molecular weight from 1 to 10 kD. Whcre heparin operates as a 
template to link thrombin and antithrombin III, the heparins with a molecular 
weight ofless than 5400 daltons are too small to bind these proteins synchronous-
ly, but nonetheless are able to accomplish the binding of antithrombin to activa-
ted factor Xa. Inhibition of this central protease results in reduced thrombin 
generation. In animal experiments using LM\V'H, significant effects were detec-
ted on intimal hypertrophy or diameter reduction [23-25]. Heras and colleagues 
[26] analyzed the inhibition of thrombus formation using four doses (100, 200, 
400, and 500 U/kg) of LMWH (CY 216) in comparison with unfractionated 
heparin (100 U/kg) and placebo in deep carotid artery injury in pigs. 
Examination of the treated vessels after 1 hour, showed platelet deposition of 22, 
29, 9, 9, II, and 42 * 106/cm2. POI' fibrinogcn deposition, the numbers in the 
groups were 19, 19,21,14,12 (p< 0.05), and 35 molecules *10 12/cm2 Thus, 
the predominantly anti-factor X activity does not clearly inhibit the deposition of 
thrombotic material after deep arterial injury, when compared to unfractionatcd 
heparin. 
A group in Tubingen [27] reported the results of 400 anti Xa units/kg/day 
administration in 55 rabbits who underwent balloon angioplasty of an electrically 
induced lesion of the carotid artery. The LMWH (LU 47311, mean molecular 
weight 3.9 kD) was subcutaneously given from day 1 to day 7 after intervention. 
Observation period was 3, 7,14, and 28 days. At the end of the study period, inti-
mal wall thickness in the LMWH-treatcd rabbits increased from 13 (preangio-
plasty control group) to 20 cell layers in the treated animals (p<0.05 versus non-
angioplasty control group) and from 13 to 35 cell layers in controls (p<O.OI vs 
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nonangioplasty control group). The proliferative response of smooth muscle 
cells was evaluated by quantification of cells undergoing DNA synthesis. In con-
trols, this showed an increase in S-phase cells in the intima from 0.7% cells before 
dilatation to 10.2% and 7.7% 3 and 7 days after angioplasty. A mild increase in 
DNA synthesizing cells was observed in the treatment group (2.7% at 3 days, 
p<O.OI, and 1.9% at 7 days, p<O.OI). Normalization of proliferation 14 and 28 
days after dilatation occurred in both groups. 
Other factor Xa inhibitors Antistasin (r-ATS) is a 15- kD peptide isolated 
from the salivary glands of the Mexican leech [28]. It is a tight-binding and speci-
fic long-acting factor Xa inhibitor. It has been studied in a variety of thrombosis 
models and found superior to heparin in preventing platelet-rich thrombi in 
dacron-grafted arteriovenous femoral grafts [29] and as an adjunct to alteplase in 
a canine model of femoral arterial thrombosis [30]. It was found as effective as 
heparin in suppressing fibrinopeptide A (FPA) levels in a rhesus monkey disse-
minated intravascular coagulation model [31]. Because of the apparently strong 
immunogenecity of antistasin, however, further clinical development in its cur-
rent configuration is unlikely [32]. 
Tick anticoagulant peptide (TAP), is a short-acting inhibitor of factor Xa, 
originally isolated from the soft tick Ornithodoros moubata [33]. Both r-ATS and 
TAP were tested in New Zealand rabbits during balloon angioplasty, followed by 
2 hours of infusion [34). The reduction in luminal diameter as measured at 28-
day follow-up angiography was significantly less in the r-ATS and TAP groups 
compared to the control group, which received heparin (-0.17 ± 0.11 mm, - 0.26 
±0.22 mm, vs 0.66 ±0.58 mm, p" 0.02). 
Hirudin Hirudin is a specific and direct thrombin blocker. This anticoagulant 
drug is originally extracted from the salivary gland of the leech (Hirudo medici-
nalis). It is a 7-kD protein, composed of 65 amino acids. Thrombin has an active 
site pocket that can be blocked by the N-terminal three amino acids of hirudin, 
whereas hirudin's carboxyl tail forms several ionic and hydrophobic complexes 
with the fibrinogen anion-binding site, thus blocking thrombin-catalyzed fibrin-
ogen cleavage. The fortitude of hirudin in comparison to other serine protease 
inhibitors is in its potency to block thrombin instantaneously and irreversibly at 
multiple sites [35J without the need for circulating antithrombin III. Hirudin, 
because of its small volume, is able to inhibit thrombin tied to thrombus, and to 
restrict further thrombus formation also where the thrombin is clot bound or 
when thrombolysis takes place [36]. The recombinant configuration differs from 
the native hirudin by the absence of a sulphate group in the Tyr-63 position [37]. 
For this reason the recombinant variant is also called desulphatohirudin or dcsi-
rudin. The terminal half-life of desirudin in healthy, young volunteers is 50 to 65 
minutes [38]) with a halflife of its effect on the activated partial thromboplastin 
time (aPTT) of about 2 hours [39,40]. There is no specific antidote available for 
reversing the effects of hirudin. 
The effects of recombinant hirudin on the restenosing process following 
balloon-caused arterial injury are intensively studied in animal models. A signifi-
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cantly reduced platelet deposition to only one single layer was found using high-
dose hirudin (1.0 mg/kg bolus plus intravenous infusion for 1 hour) [41], and a 
significantly inhibited restenosis response as assessed by quantitative angiogra-
phy and quantitative histopathology [42J was found after hirudin administration. 
The group of Buchwald and colleagues [43J observed the significant effect of 
hirudin on platelet accumulation and fibrin deposition in stented minipigs. The 
effect of recombinant hirudin was evaluated in patients undergoing angioplasty 
for stable angina pectoris in a multicenter, double-blind pilot study [44J . A total 
of 113 patients were randomized in a 2: 1 fashion, receiving either 20 mg hirudin 
before angioplasty followed by a 24-hours infusion of 0.16 mg/kg/hr, or 10,000 
IU of heparin followed by a 12 IU/kg/hr infusion for 24 hours. At the end ofthis 
infusion period, angiography was performed to assess vessel patency and to 
obtain quantitative measurements. Coagulation parameters were frequently 
measured. In the heparin-treated group (39 patients), 4 patients experienced a 
peri procedural myocardial infarction or emergency coronary artery bypass graft 
(CABG), compared to only one emergency CABG and one elective CABG 3 
weeks after PTCA in the hirudin-allocated group (74 patients). Hemorrhage at 
the arterial puncture site was seen in four hirudin-treated patients, for which they 
needed blood transfusion, whereas in the heparin-allocated group one patient 
experienced visual impairment because of a cerebral infarction. Follow-up 
angiography at 24 hours revealed a complete perfusion in all the patients from the 
hirudin-treated group, compared to 92% in the heparin-treated group. Visual 
assessment furthermore showed one case of intra coronary thrombus in each 
group. Concentrations of prothrombin fragment one and two (F 1.2) appeared to 
be somewhat higher in the hirudin group directly and 6 hours after angioplasty (a 
median of 1.015 versus 0.795 nmollL and 0.95 versus 0.8 nmollL), indicating a 
slightly diminished thrombin inactivation. It was concluded that safety and tole-
rance for hirudin is similar to that for heparin [44, 45J, and it can be administered 
in patients undergoing balloon angioplasty for stable angina pectoris. This study 
surveyed only the short-term effects of thrombin antagonism, but it was followed 
by a multicenter, randomized, double-blind, heparin-controlled study, aimed at 
the prevention of rest enos is [46}. 
Recent reports on clinical trials in the setting of acute myocardial infarction 
(thrombolytics and concomitant aspirin) suggest a narrower safety window with 
recombinant hirudin than initially anticipated. Extremely high rates of intracra-
nial bleeding were encountered with streptokinase in GUSTO-II A (Global 
Utilization of Strategies to Open Occluded Coronary Arteries) (with heparin 
2.7% and with hirudin 3.2%) [47J, or with alteplase in TIMI 9A (Thrombolysis in 
Myocardial Infarction) (with heparin 1.9% and with hirudin 1.7%) [48J, and 
HIT-III (r-Hirudin for Improvement of Thrombolysis) (none with heparin and 
with hirudin 3.4%) [49J. A baseline creatinine of greater than 1.5 mg/dL, older 
age, lower bodyweight, and higher aPTT levels (100 versus 86 seconds in non-
stroke patients), were associated with bleeding in desirudin treated patients. 
Hirudin derived drugs The N-terminal three amino acids of hirudin block the 
thrombin active site pocket, while the C-tcrminal site form complexes with the 
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fibrinogen anion-binding site, thus blocking thrombin-catalyzed fibrinogen c1e-
avage. Structure of the latter peptide domain is mimicked in the synthetic peptide 
hirugen (Figure 2), the potency of which is about 50 times less in comparison 
with the activity of hirudin. The antithrombin activity of this dodecapeptide is 
solely due to the blockade of the fibrinogenolytic site and therefore especially 
valuable in preventing fibrin-dependent thrombosis [50]. 
X-ray crystallographic analysis enables assembling of highly specific com-
pounds especially designed to inhibit thrombin. Extremely detailed three-dimen-
sional reconstruction of the amino-binding and carboxyl-binding groups has 
enabled complex technology to link an inhibitor of the active site pocket (D-Phe-
Pro-Arg-Pro) to hirugen with optimal positions (at distances of 20 Angstrom) of 
both of the binding sequences opposite to their target molecules [51]. This drug 
called hirulog (see Figure 2) has been administrated safely to healthy human vo-
lunteers [52]. Hirulog induces a dose-dependent prolongation of all coagulation 
parameters, with a half-life of 40 minutes [53]. A dose escalating multicenter 
study [54] evaluated this drug in the setting of intracoronary interventions. In the 
latter, 291 patients received a bolus dose of 0.15, 0.25, 0.35, 0.45, or 0.55 mg/kg 
(group I to 5 encompassing 54, 53, 44, 74, and 54 patients), followed by a 4-hour 
infusion of 0.60, LOa, 1.40, 1.80, or 2.20 mglkg/hr. All patients were concomi-
tantly pretreated with 325 mg aspirin. A rapid onset and dose-dependent increa-
se in aPTT and activated clotting time (ACT) values at doses of 1.80, and 2.20 
mg/kg/hr ensued a sufficient anticoagulant state and reduced abrupt vessel c1os-
ure within the first 24 hours of the start of the procedure to less than 4% (5 out of 
128 patients) versus 11.3% (17 vessels c10sed in 151 treated patients) in the other 
three treatment groups. In this study, there was no control group treated with 
conventional anticoagulant drugs, but the results encouraged a double-blind, 
randomized clinical trial [55]. 
Synthetic thrombin inhibitors PPACK is the abbreviation of D-phenylanalyl-
L-prolyl-L-arginyl-chloromethyl ketone. This peptide sequence binds to the 
active site of thrombin. The effect of this substance, in combination and in com-
parison with 7E3, on platelet deposition was tested at the site of baHoon angio-
plasty in an ex vivo whole artery perfusion model [56]. Perfusion of the arterial 
segments with PPACK (10-5 M) reduced platelet deposition for 47% (N~4, 
p<O.04) with the use of this new antithrombin agent compared with the heparin 
model (2 U/mL). 
Argatroban ( (2R,4R)-4-methyl-I-[N 2_( (3-methyl-1 ,2,3,4-tetrahydro-8-
quinolonyl)sulfonyl)-arginyl]-2-piperidine carboxylic acid) is an arginine deri-
vative, that binds competitively to thrombin (Figure 2) [57). It is shO\\'n in animal 
experimental work that argatroban can prevent coronary thrombosis more effec-
tively than heparin in models of coronary thrombolysis and vessel wall injury [58, 
59). This highly specific thrombin inhibitor was infused during 4 hours in 
patients with unstable angina pectoris [60]. Infusion of the drug (0.5 to 5.0 
!lg/kg/min) increased the aPTT in a dose-related fashion and was effective 
against recurrence of ischemic episodes, but remarkably 9 of the 43 patients 
experienced an episode of unstable angina shortly after termination of the drug. 
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These patients in whom angina reoccurred received significantly higher doses of 
argatroban during infusion (p=0.007) and greater elongation of the aPTT 
(52±12 seconds in the non-angina group versus 66±15 in the nine patients with 
angina within 24 hours). The authors describe this phenomenon as a rebound 
effect. 
Fitzgerald (not published) treated 12 angioplasty patients, randomizing 
them either to a bolus of 30 j..lg/kg argatroban, followed by an intravenous infu-
sion of 2 ~g/kg/min during 2 hours, or to a bolus injection of 10,000 IU of heparin 
plus a 4-hour infusion of 1000 IU/hr. These results initiated the so called pre-
Argaplasty trial, a dose verification study, assessing safety and feasibility in 
patients undergoing balloon angioplasty for either stable or unstable angina 
[chapter 6 in this thesis]. A total of 30 patients were included at four dose levels, 
the highest being an intravenous bolus injection of 250 ~g/kg, followed by a 4-
hour infusion of 15 j..lg/kg/min. At 4 hours, the infusion rate was lowered to 3.8 
~g/kg/min and continued for 68 hours. At this level, aPTT was approximately 
two times normal value, and the sheath was removed without infusion adjust-
ment. Hemostatic, clinical, and angiographic data indicate that argatroban infu-
sion in coronary angioplasty patients can be administered safely and results in an 
adequate, predictable level of anticoagulation [chapter 6 in this thesis]. 
New antithrombins under development are aptamers (synthetic oligonucle-
otides that, similar to hirugen, bind only to the exosite of thrombin (61]). Among 
those low-weight thrombin inhibitors are SDZ-217766 [62] and RWJ-27755, 
which binds to only the catalytic site of thrombin [63,64]. The alkylating proper-
ties of the latter compound have, however, considerably tempered the enthu-
siasm for its clinical development [32]. DUP 714 is a boroarginine tripeptide 
{65]; its anticipated potential for oral administration has not yet resulted in 
human studies [32]. 
Other antithrombins still in development arc the thrombin receptor antagonist 
peptides [66] and the hirudisins - hirudin derivates combining lIb/IlIa receptor 
and thrombin inhibition. In the hirudisins, residues from 32 to 35 of hirudin have 
been replaced by the integrin motifRGDS and KGDS [67]. In addition to inhibi-
ting GP IIb/Illa receptor-dependent platelet interactions, the platelet-binding 
integrin motif is expected to target the antithrombin action of hirudin to platelets, 
possibly allowing lower and safer doses of hirudin in the treatment of thrombotic 
disease [68]. 
Experimental and clinical application oflocally delivered antithrombin 
into the vessel wall 
Many reasons for the discrepancy between results from animal models and 
human trials have been proposed. One explanation has been that doses used in 
the animal studies were in most instances at least an order of magnitude higher 
than the highest tolerable doses in humans. It has also been suggested that diffi-
culties in the sustained administration of certain compounds in. humans for ade-
quate periods of time to achieve measurable effects may have accounted for the 
failure of many of the pharmacologic therapies. Finally, the prevention of reste-
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nosis judged by histologic measurements in animal models may not translate to 
angiographic changes in humans [69]. In response to these limitations, the idea of 
local drug delivery techniques for the administration of pharmacologic com-
pounds at the site of coronary interventions has evolved [70]. Conceptually, local 
delivery techniques allow for high site-specific concentrations of therapeutic 
compounds without the complication .of systemic side effects. 
Administration of heparin using a porous balloon catheter was first accom-
plished by Wolinsky and Thung [70J. Using catheter-based percutaneous transhl-
minal administration, high concentrations of fluoresceinated heparin within the 
media could be detected up to 48 hours after infusion. It has been shown that 
locally delivered heparin can reduce the thrombogenicity of the vessel wall in the 
acutely injured pig carotid artery model [71]. Site specific administration of 
PPACK by way of a porous balloon catheter in an ex vivo model of arterial damage 
has been shown to reduce platelet deposition at the site of balloon injury {72J. In 
addition, Nunes and associates [73] have demonstrated decreased platelet deposi-
tion on dacron grafts after local treatment with PPACK. Dispensed from a hydro-
gel-coated angioplasty baBoon, PPACK showed considerable local effects without 
causing a prolongation of the coagulation parameters {73]. A similar reduction in 
platelet deposition was shown after the local administration of the thrombin inhi-
bitor r-hirudin in a porcine carotid artery model of vascular injury [74]. Using a 
double-balloon perfusion catheter, high local concentrations of r-hirudin were 
maintained for 60 minutes without the device causing additional vascular injury. 
Since the initial reports of the effectiveness of locally administered heparin 
[75J and LMWH [76, 77J to inhibition of smooth muscle cell proliferation, initial 
results of long-term studies using site-specific administration of many different 
drug classes are encouraging. The steady advances made towards the develop-
ment of clinically applicable atraumatic delivery modalities have allowed the 
transition from the animal laboratory to human applications. 
Preliminary data indicate the technique to be safe for use in human coronary 
arteries, at diverse anatomic sites {781. The feasibility of local drug delivery using 
the Dispatch delivery catheter, a non-dilatational infusion-perfusion catheter, 
has been evaluated in humans (79). Successful local delivery of heparin in 
humans was demonstrated for the first time using this device. A delivery efficacy 
of 1 % to 8% with a retention time up to 14 hours was shown [80). Preliminary 
long-term results of the initial patients treated with locally administered heparin 
at the time of angioplasty using this device are encouraging, showing a reduction 
in the need for re-intervention and in the degree of angiographica1iy defined re-
stenosis [79,81-831. Definitive long-term results are forthcoming. 
A group in Tubingen delivered 1500 anti-Xa units LM\VH Reviparin local-
ly using a porous balloon, besides 24 hours intravenous and 28 days subcutane-
ous administration of the compound [84]. No major complication occurred 
during the 28 days foHow-up period in the 15 treated patients. Data on restenosis 
will be available shortly. 
\\lith the increased use of percutaneously introduced stents for the treat-
ment of primary and recurrent coronary stenosis, the possibility of using coated 
or eluting stents as local drug delivery devices is currently being tested. There 
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have been two reports of reduction of subacute stent thrombosis in the rabbit 
carotid [85], and in stented pig coronary arteries [86] using heparin-coated 
stents. The pilot study of the Benestent II trial has shown that deployment of the 
Palmaz-Schatz heparin-coated stent was possible with a reduced anticoagulation 
regimen [87]. Furthermore, the long-term results seem encouraging with an 
expected restenosis rate lower that those reported in Benestent I (13% in the 
Ilenestent II pilot study compared with 20% in the Benestent J) [88, 89J. The 
dilemma that the inflammatory response of the coating can exceed the beneficial 
effect of the eluted material is an obstacle that must be overcome [90]. 
Phase III restenosis prevention studies 
The ERA (Enoxaparin Restenosis) trial [91J, conducted a study comparing 
enoxaparin (40 mg q.d. s.c.) to placebo, administered for 28 days, starting within 
2 hours of the sheath removal in the prevention of restenosis. A total of 459 
patients were enrolled and 86% completed the study protocol, including angio-
graphic follow-up. Treatment comparison resulted in an insignificant difference 
between the two groups (51% restenosis in the placebo group versus 52% in the 
treated group, OR 1.07, 1'=0.63). Analysis of demographic data and the use of 
other angiographic restenosis definitions could not reveal any difference in the 
two groups. 
The REDUCE (Restenosis prevention after PTCA, Early administration of 
LMWH (LU 47311), Double blind, Unfractionated heparin and placebo 
Controlled Evaluation) study is a double-blind, randomized multicenter trial 
comparing standard therapy (10,000 IU intravenous bolus unfractionated hepa-
rin before I'TCA, followed by 24,000 IU over 16 ±4 hours and placebo s.c. b.i.d. 
for a further 4 weeks, beginning at the evening after angioplasty) with a high-dose 
regimen of reviparin (7000 IU i.v. bolus before PTCA, followed by 10,500 IU 
over 16 ±4 hours, and 3500 IU s.c. b.Ld. for a further 4 weeks, beginning the eve-
ning after angioplasty) in patients undergoing angioplasty for a single de novo 
lesion. Concomitant aspirin was given. A total of 612 patients were recruited, of 
whom 306 patients received reviparin. The primary clinical endpoint was the 
event-free (freedom of death, non-fatal myocardial infarction, and revasculariza-
tion) survival within 30 weeks following angioplasty. The primary angiographic 
endpoint was defined in terms of absolute loss in minimal lumen diameter at the 
dilated site. Restenosis was defined as loss of more than 50% of the initial gain of 
PTCA, according to the NHLBI IV definition. Long term clinical outcome was 
similar in both treatment groups (33.3% in the reviparin-treated patients, 32.0% 
in the control group (RR 1.04,95% CI 0.83-1.31, 1'=0.71). The absolute loss in 
lumen diameter was 0.29 and 0.25 mm (analysis of covariance P:=0.59). The 
incidence of bleeding occurred with a similar frequcncy in the two treatment 
groups (2.3% in the reviparin group and 2.6% in the heparin control group 
RR:=0.88, 95% CI 0.32-2.41, 1'=0.8); however acute events within 24 hours 
occurrcd in 3.9% of the reviparin group and in 8.2% of the control group 
(RR=0.49, 95% CI = 0.26-0.92, 1'=0.027) (Karsch, unpublished results) [92J. 
The authors suggest that the lack of effect in this trial may be due to insufficient 
local drug concentrations which might be resolved by local drug delivery techni-
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ques, or that the lack in effect in primates [93] might reflect the presence of a 
heparin-insensitive pathway of smooth muscle cell activation. 
The HELVETICA (Hirudin in a European Trial versus Heparin in the pre-
vention of Restenosis after P'l~CA) trial is a multicenter, double-blind, randomi-
zed heparin-controlled study evaluating the clinical efficacy and safety of two 
hirudin dose regimens in 1154 angioplasty patients [46]. The primary endpoint 
was event-free survival 30 weeks after angioplasty. Patients received one of the 
following treatments: unfractionated heparin (an i.v. bolus injection of 10,000 IU 
of heparin followed by a continuous i. v. infusion of 15 IU/kg/hr of heparin for 24 
hours, with placebo given s.c. twice daily for three consecutive days), intravenous 
hirudin (an i.v. bolus injection of 40 mg of hirudin followed by a continuous 
intravenous infusion of 0.2 mg/kg/hr hirudin for 24 hours, with placebo given s.c. 
b.i.d. for three consecutive days) or intravenous and subcutaneous hirudin (an 
i.v. bolus injection of 40 mg of hirudin followed by a continuous Lv. infusion of 
0.2 mg/kg/hr of hirudin for 24 hours, with 40 mg of hirudin given s.c. b.i.d. for 
three consecutive days). A concomitant dose of aspirin (100-500 mg once daily) 
was given on the day ofangioplasty and continued for at least 14 days. To provo-
ke a more distinct outcome, this study included only patients suffering unstable 
angina because this group of patients is known to have higher restenosis rates [94, 
95,96J. 
The study population was not only limited to balloon angioplasty patients, 
but also techniques, as laser, directional, and rotational atherectomy were allow-
ed per protocol. Because at the time of design of this trial the anticoagulant drug 
strategies following stenting were very strict and subject to investigation, elective 
stent implantation was not allowed, and bail-out stenting resulted in discontinu-
ation of the study drug. The eventfree survival curve did not demonstrate diffe-
rences among the treatment groups (Kruskal-\Vallis test p=0.61). Early events 
(those in the first 96 hours after angioplasty) occurred in 7.9%, 5.6%, i.md 11.0% 
in the hirudin intravenous and subcutaneous, the hirudin intravenous and the 
heparin group (relative risk of hirudin versus heparin 0.37, 95% CI 0.19-0.70 
p=0.007). The incidence of clinical events and angina at 30 weeks was not signi-
ficantly different in the three groups (p=0.61). An angiographie follow-up in 
86.4% of the population was available and demonstrated an equal distribution of 
angiographic baseline and postangioplasty parameters as well as the loss in lumen 
diameter at follow-up. In patients receiving heparin pretreatment, early outcome 
was significantly superior in the hirudin-treated patients (combined relative risk 
with hirudin: 0.37, 95% CI 0.19 to 0.70, P=O.0016). Ilecause these results sugge-
sted a particular benefit of hirudin in the most unstable patients (Br.aunwald class 
III), an additional analysis was performed in 236 patients with angina at rest in 
the 48 hours before randomization. The event rate in this subgroup of patients 
was 21.6% in the heparin group versus 5.3 and 12.3% in the hirudin intravenous 
and Hirudin intravenous and subcutaneous groups (combined relative risk with 
hirudin 0.41, 95% CI 0.21 to 0.78, P=0.006). The eventfree 7-month survival in 
the heparin-pretreated or Braunwald class III subgroup of patients demonstrated 
no effect at the long term (Figure 3). 
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The results of prothrombin fragment one and two (F 1.2) assays immediate-
ly after angioplasty suggest that the thrombin generation in both hirudin groups 
was unsatisfactorily inhibited, whereas the dosage of heparin used in this trial 
resulted in an appropriate decrease of F1.2 at 6 hours after the intracoronary 
intervention. The authors suggest that the adjustment in infusion rate from 0.16 
mg/kg/hr in the pilot study [44J with stable patients to 0.20 mglkg/hr in the cur-
rent trial of unstable patients with presumably higher levels of thrombin genera-
tion was a too cautious change in dosage. Zoldhclyi and colleagues [97] reported 
the failure to block thrombin generation in patients, despite a 10,OOO-fold molar 
excess of free hirudin over thrombin-hirudin complex. Infusion rates of hirudin 
in animal experiments were up to five times higher than those currently used, and 
this might explain the lack of long-term effect in the present study [41,42J. 
Another putative explanation for the apparent paradox in improved early 
outcome despite less appropriate thrombin control might be that the dosage used 
was insufficient to reach an adequate level of anticoagulation but sufficient to 
limit thrombin-mediated platelet aggregation and activation, thereby exhibiting 
effects similar to those observed acutely in the EPIC (Evaluation of c7E3 for the 
Prevention ofIschemic Complications) trial [98,99]. 
In the hirulog angioplasty study [55J, 4312 patients suffering from unstable 
or postinfarction angina pectoris and scheduled for angioplasty were assigned to 
receive a body weight - adjusted dose regimen of either heparin or hirulog and 
concomitant aspirin (300 to 325 mg). The heparin-allocated patients (N=2039) 
received a bolus dose of 175 IV/kg followed by an 18- to 24- hour infusion at a 
rate of 15 IU/kg/hr. Hirulog-treated patients (2059 in total) were given a bolus 
dose of 1.0 mg/kg, followed by a 4-hour infusion at a rate of 2.5 rug/kg/hr and a 
14- to 20-hour infusion at a rate of 0.2 mg/kg. Primary endpoint was the in-hos-
pital occurrence of death; myocardial infarction; abrupt vessel closure; or need 
for CABG, intra-aortic balloon counterpulsation, or repeat coronary angioplas-
ty. Bivalirudin compared to heparin treatment was not able to lower the incidence 
ofin-hospital cardiac events in the cohort of 4098 treated patients (11.4% versus 
12.2% respectively, OR 0.9, 95% CI 0.8-1.1, p=0.44); however, results were 
positive in the subgroup of patients with post-infarction angina (9.1 % versus 
14.2%, OR=0.6, 95% CI 0.4-0.9, P=0.04). At 6 months follow-up, the cumulati-
ve incidence of cardiac events was similar in the two treatment groups (25.7% 
versus 26.6%, OR 1.0,95% CI 0.8-1.1, P::::O.54). There was no control angiogra-
phy included in this study. The level of clinical restenosis, as measured by the 
incidence of any complication after discharge, was also similar in the two treat-
ment groups (21.0% versus 21.3% OR 1.0,95% CI not reported, p=0.85). The 
incidence of bleeding in the bivalirudin-treated patients was significantly lower as 
compared to the heparin control subjects (3.8% versus 9.8%, OR 0.4, 95% CI 
0.3-0.5, P< 0.001). The latter was reflected by the lower levels of systemic anti-
coagulation in the bivalirudin-treated group, as assessed by the measurement of 
ACTs. The authors raise the probability that equivalent rates of ischemic compli-
cations, may be the result of equivalent degrees of localized thrombin inhibition 
achieved at lower levels of systemic anticoagulation as reflected by the markedly 
lower incidence of bleeding. This raised the question whether the preference for 
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the chosen dosage regimen was maybe too low. Supporting arguments for that 
were a significantly lower ACT just before the coronary intervention in the hiru-
log-treated patients, and thus conclusions of the hirulog study are based on non-
equivalent anticoagulant doses. However, because of the different properties of 
bivalirudin, in particular the activity against clot-hound thrombin, absence of 
natural inhibitors, and more predictable and less variable levels of anticoagula-
tion, it was not a goal to achieve identical ACTs with the two agents. l\t1oreover, a 
recent publication describes the absence of association between major bleeding 
and ACTs [100]. The experiences in both the hirulog and the hirudin trial em-
phasize the vital importance of critical investigation of dose finding studies for 
each subset of patients and clinical indication. Although the EPIC trial probably 
benefitted from an initially too potent combination of c7E3 and heparin, the dra-
matic reduction in clinical events appeared at the cost of bleeding. The reduction 
in clinical events justified further development and adjustment of the (heparin) 
dosage regimen to the narrow therapeutic window. 
At least four other trials using specific anti thrombotic drugs have demon-
strated beneficial effects on the acute complications of coronary angioplasty 
without favourably influencing long-term clinical outcomes [92, 101-103J. This 
is in contradistinction with the EPIC trial [98, 99J, which showed a reduction in 
early cardiac events that was maintained at long term follow-up. The study was 
not designed to detect angiographic restenosis; however the evident decrease in 
revascularization procedures and myocardial infarction may reflect the effect on 
the restenosis process. In the EPIC study, the event-free survival curve demon-
strates a significant initial difference in clinical outcome, which is even more dis-
tinct during 6 months' follow-up as shown by the manifest divergence of the sur-
vival curves. It has been speculated that interaction of the compound with 
vitronectin results in an antiproliferative effect, which might explain the latter 
finding. l'he significant surplus of major bleeding complications in the EPIC trial 
(14.0 vs 6.6%, p=O.OOI) emerged as a major drawback for the monoclonal anti-
body. To investigate the effect of c7E3 on angiographic restenosis, the EPILOG 
(Evaluation of PTCA to Improve Long-term Outcome by c7E3 Glycoprotein 
IIBIlIIA Receptor Blockade) trial was designed testing two c7E3 Fab (lnns versus 
placebo in a planned 4800 patients. To control bleeding complications, the 
heparin regimens in the treatment arms (standard and low-dose heparin) were 
adjusted for weight. This change resulted in a reduction of bleeding rates to that 
of the same order as that of placebo. Inclusion was stopped following recruitment 
of 2792 patients, when interim analysis on 1500 patients revealed that the 30-day 
incidence of combined death and MI was reduced from 8.1 % in the control arm 
to 2.6% and 3.6% in the low dose and standard heparin dose (104}. Compared 
with EPIC and because of the low bleeding rates, more patients received their 
complete c7E3 treatment, and differences in primary endpoint rates were there-
fore more distinct, despite the effect that in EPILOG patients with less complex 
lesions and patients suffering stable angina were randomized. \V'hether these 
results will translate into a significant reduction in angiographically assessed re-
stenosis awaits adjudication. 
237 
Chapter 11 - The Cltrrem role of amithroll/bins ill imervemional cardiology 
Conclusions 
The majority of clinical investigations with thrombin inhibitors has been in coro-
nary artery disease. Despite the evident limitations of heparin and aspirin) their 
role in interventional cardiology is currently not replaced by a specific thrombin 
inhibitor. Thrombin antagonists represent a promising class of anti thrombotic 
agents) that overcome the pharmacokinetic and pharmacodynamic restrictions of 
heparin and aspirin and appear safe for clinical application. The lack of specific 
antidotes with narrow therapeutic windows leaves a risk for overdosing) especial-
ly in the context of combined use with thrombolytics and impaired renal clearan-
ce' but the anticipated increase in bleeding complications in intracoronary inter-
vention studies is controlled. Notwithstanding all the theoretical advantages this 
class embodies, including the established significantly superior acute clinical out-
come in various restenosis prevention trials, phase III evaluation has not achieved 
a convincing improvement of the long term outcome. Numerous reasons have 
been proposed to explain this phenomenon, which is not yet clearly understood. 
Direct thrombin inhibitors at the currently administered dosage regimens do not 
block thrombin generation completely, as demonstrated by thrombin-antithrom-
bin complex and F 1.2 measurements, and enable some thrombin molecules to 
escape. Local drug delivery devices may be of critical importance in further 
attempts to restrict thrombin's action. All large-scale and FDA-approved reste-
nosis prevention trials examining antithrombins used only aspirin as concomitant 
drug, without investigating the potential of (weight-adjusted) concomitant 
heparin therapy as in the thrombolysis studies. Furthermore, there is much left to 
be learned from optimal dosing in specific conditions and indications, and final-
ly, the discrepancy between animal experimental work and human surveys may 
suggest a drug-independent or thrombin-independent pathway of smooth mus-
cle cell activation. 
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Overview of the thesis 
The two major shortcomings in interventional cardiology are abrupt vessel clo-
sure and late restenosis. A number of pharmacological trials have been conducted 
to address these phenomenons and reduce their clinically related presentation. 
The data presented and discussed in this thesis focus on the methodological 
aspects and results of clinical testing of direct thrombin inhibition aimed at the 
prevention of restenosis and related clinical events. 
Several experimental, pathological and clinical studies suggest that critical 
events in the development of acute clinical events and of restenostic tissue are 
activation of the coagulation cascade, platelet aggregation and thrombus forma-
tion, while several mediators, released from activated platelets, promote prolife-
ration and migration of various cell types. All of these steps give access for a 
diversity of pharmacological interventions. In chapter 1, the scientific basis of 
different entries are described and investigations in animals and human subjects 
carried out till the early nineties are described. 
Thrombin itself is identified as the most potent platelet activator, and has a 
pivotal role in the coagulation system, directly mediating smooth muscle cell pro-
liferation by way of stimulation of thrombin receptors at the smooth muscle cell 
surface. Thrombus indirectly induces an excessive intimal smooth muscle cell 
proliferation by means of released mitogens (growth factors), which may contri-
bute to late restenosis. Therefore direct and irreversible thrombin blockade is 
deemed to be effective in the prevention of restenosis following angioplasty and is 
the scientific basis of the studies performed and described in this thesis. 
\Y.!e investigated the role of angiographically identifiable mural thrombus 
before or after angioplasty in the evolution of angiographically defined restenosis 
(chapter 2). Using categorical and continuous criteria for restenosis, delineated 
the significant contribution of thrombus to detrimental long term (6 months) 
results. The higher degree of restenosis in the 160 lesion \I,lith thrombus was due 
primarily to an increased incidence of occlusion at follow-up angiography in this 
group. This evidence supports the rationale of restenosis prevention by an anti-
thrombotic approach. 
The section 'Methodology and Trial Design' focusses at aspects of qualita-
tive and quantitative angiogram reading and the design of phase II and III trials 
aimed at the prevention of restenosis. 
Evaluation of the effect of pharmacological agents at the coronary artery 
dimensions over time is facilitated by the use of quantitative coronary angiogra-
phy. At the Thoraxcenter, the computer assisted Cardiovascular Angiography 
Analysis System (CAAS), using an automated edge detection technique was 
developed and validated (chapter 3), This method of standardized data acquisi-
tion and data analysis enabJes multicenter investigations and has the advantage of 
being far more accurate and reproducible in the assessment of lesion severity, 
than visual or handheld caliper assessments. Besides that, an angiographic core 
laboratory may help demonstrating the reproducibility of qualitative factors and 
their role in the occu.rrence of acute and late complications of PT'CA. 
\Y.!e recorded coronary guiding catheters on cinefilm, and compared their 
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automated quantitative measurements with their true values (assessed by preci-
sion micrometer measurement). It is demonstrated that the current generation of 
guiding catheters shows a variety in radiological quality. Almost all guiding 
catheters are suitable for calibration of QCA measurements, provided that calib-
ration is done on contrast-empty catheters (chapter 4). 
In chapter 5 the validity of quantitative coronary angiographic analysis of 
video images is assessed and compared to 35mm cinefilm data, acquired from a 
phantom study and clinical angiograms. Simultaneous recording was performed 
on 35mm cinefilm and a super-VHS tape with normal images and images with 
spatial filtering (edge-enhancement). In the phantom series the accuracy and 
precision of quantitative coronary angiography measurement for cinefilm were 
-0.10 mm ±0.08 mm, for normal-image videotape -0.11 mm ±D.IS mm and for 
edge-enhanced videotape -0.10 mm ±O.11 mm. In the clinical series, the diffe-
rences between measurements from cinefilm and normal-image videotape were 
0.14 mm ±0.20 mm and from cinefilm and edge-enhanced videotape were 0.04 
mm and ±O.13 mm. In the experimental phantom study, the use of cinefilm resul-
ted in the most precise measurements. In the clinical study, edge-enhanced 
videotape provided the highest agreement with measurements obtained from 
cinefilm. These findings suggest that cinefilm is more reliable than video as a 
recording medium for quantitative coronary analysis in scientific studies; how-
ever, for routine practice, videotape with edge enhanced images may provide an 
acceptable alternative. 
\Y/e performed repeated visual assessment by two independent observers, to 
evaluate the reliability of qualitative angiogram readings (chapter 6). Inter-
observer variability is expressed as kappa value and the percentage of agreement, 
and is 0.33 and 67.8% respectively for the ABC lesion classification (AHNACC 
criteria). Kappa and percent agreement for 10 other variables range from 0.29 to 
1.00, and from 47.7 to 98.5% respectively. Intra-observer variability demonstra-
tes higher values. The importance of complete and detailed definitions is outli-
ned. 
In chapter 7, we report our findings of an open study, where we investigated 
the safety and feasibility of increasing doses of intravenous argatroban (a selecti-
ve synthetic thrombin antagonist that binds in a competitive way) in patients 
undergoing percutaneous transluminal coronary angioplasty. A total of 30 
patients was studied in escalating dose regimens. Analysis of the adverse event 
profile, safety and haemostasis parameters indicate that argatroban in coronary 
angioplasty patients can be administered safely, and results in an adequate and 
predictable level of anticoagulation. 
The HELVETICA trial is a multicentre, randomized, double blind and 
heparin controlled study, designed to compare the effects of two dose regimens 
of desirudin (recombinant desulphato hirudin(""REVASC) to those of heparin 
on event-free survival, safety and tolerability and luminal renarrowing by quanti-
tative coronary angiography at the latest 26 weeks after the coronary angioplasty 
procedure (chapter S). The outcome of this trial is decribed in the <Results' sec-
tion of this thesis. 
One thousand one hundred and fourty one patients with unstable angina 
who were scheduled for angioplasty were randomly assigned to receive one of the 
three treatments: a) a bolus dose of 10,000 IU of heparin followed by an intra"e-
nous infusion of IS IU/kg/hr for 24 hours and subcutaneous placebo twice daily 
for 3 days (N=382), b) a bolus dose of 40 mg of desirudin followed by an intrave-
nous infusion of 0.2 mg/kg/hr desirudin for 24 hours and subcutaneous placebo 
twice daily for 3 days (N=381) or c) the same desirudin regimen except that 40 
mg of dcsirudin was given subcutaneously instead of placebo twice daily for three 
days (N=378). The primary objective was to compare the effects of treatment on 
event-free survival up to 7 months. The secondary objectives were to compare 
the occurrence of in-hospital events (within 96 hours), safety and tolerability of 
desirudin, and the quantitative cineangiographic measurement of the obstruction 
diameter at follow-up angiography. 
Seven month, event-free survival was 67.3 percent in the group receiving hepar-
in, 63.5 percent in the group receiving desirudin intravenous and 68.0 percent in 
the group receiving both intravenous and subcutaneous desirudin (P=O.61) 
(chapter 9). However, administration of desirudin was associated with a signifi-
cant reduction in in-hospital events, which occurred in 11.0, 7.9, and 5.6 percent 
of patients in the respective groups (combined relative risk with desirudin: O.6C 
95 percent confidence interval 0.41 to 0.90, P-value 0.023). Minimal luminal 
diameter in the respective groups at 6 month follow-up angiography was 1.54 
mm, 1.47 mm and 1.56 mm (P=0.08). So, although significantly fewer in-hospi-
tal major adverse cardiac events were observed in the treated group, administra-
tion of desirudin as described relative to heparin was not associated with a signifi-
cant benefit on event-free survival or minimal luminal diameter at follow-up. 
To identify predictors of in-hospital (96 hours) or late (7 months) occurring 
major adverse cardiac events in the HELVETICA population, we analyzed clini-
cal, procedural and angiographic characteristics in a multi variable fashion (chap-
ter 10). Braunwald anginal class III, age ~ 60 years, presence of thrombus and 
dissection post-PTCA are independent risk factors for adverse in-hospital clini-
cal outcome, whereas desirudin treatment and lesion type A are independent pro-
tecth'e factors. Eighty % of the clinical outcome could be classified correctly 
using this model. Concerning 7-months outcome, Braunwald anginal class II and 
III, age;::: 60 years and elevated levels of prothrombin fragment 1 and 2 are inde-
pendent risk factors, while a history of myocardial infarction,lesion length <10 
mm and a larger minimal lumen diameter post-PTCA are independent protec-
tive factors. Using this model, 66% of the clinical outcome could be classified cor-
rectly. 
Ultimately, we can conclude that thrombin antagonists represent a very pro-
mising class of antithrombotic agents, that overcome particular restrictions of 
heparin and aspirin, and appear safe for clinical application (chapter 11). 
Notwithstanding alI the theoretical advantages this class embodies, including the 
established significantly superior acute clinical outcome in various restenosis 
prevention trials, phase III evaluation has not achieved a convincing improve-
mell.t of long term outcome. Further prospective and randomized research has to 
be addressed to dose-optimization and identification of subsets of patients who 
profit significantly from specific antithrombin therapy. 
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Samenvatting van de dissertatie 
Dc twee belangri;kste beperkingen in de hedendaagse interventie-cardiologie zi;n 
de acute vaat-afsluiting en de late restenose. Een aantal pharmacologische trials 
zi;n uitgevoerd om deze fenomenen te bestuderen en een vermindering van de 
klinische presentatie ervan te bewerkstelligen. Het zwaartepunt van de gcgevens 
zoals gepresenteerd en bediscussieerd in dit proefschrift ligt op de methodologi-
sche aspecten en resultaten van klinisch onderzoek met directe thrombine inhibi-
tie met als doe I de preventie van restenose en de daaraan gerelateerde klinische 
uiting. 
Verschillende experimentele, pathologische en klinische studies suggereren een 
drietal kritische momenten in de ontwikkeling van acute klinische complicaties en 
de vorming van restenose weefsel; activatie van de stollings cascade, aggregatie 
van bloedplaat;es en thrombose vorming, en het aanzetten tot proliferatie en 
migratie van verschillende eel typen door mediatoren die vri;komen uit geacti-
veerde bloedplaat;es. Elk van dcze stapp en geeft de mogeli;kheid voor een aantal 
pharmacologische interventies. In hoofdstuk 1 wordt de wetenschappelijke ach-
tergrond van deze mogeli;kheden bclicht en en worden dier-experimentele en 
humane studies zoals die uitgevoerd zijn tot in de negentiger jaren beschreven. 
Thrombine is geIdentificeerd als de meest krachtige plaat;es activator, en speelt 
een cruciale rol in het stollingssysteem. Het brengt proliferatie teweeg van gladde 
spiercellen door directe stimulatie van thrombine receptoren aan de oppervlakte 
van deze ceHen. De thrombose zelf induceert groei van gladde spiercellen door 
het vrijkomen van mitogenen (groei factoren), welke bijdragen aan de late reste-
nose. 
Directe en onomkeerbare blokkade van thrombine Iijkt daarom effectief in de 
preventie van restenose na een coronair angioplastiek en vormt de wetenschappe-
Hjke basis van de uitgevoerde studies zoals beschreven in dit proefschrift. 
\VIe onderzochten de rol van angiografisch gei'dentificeerde thrombose vo6r of na 
angioplastiek in de rol van angiografisch vastgelegde restenose (hoofdstuk 2). 
Het gebruik van categorische en continue criteria voor restenose maakte de signi-
ficante bi;drage van thrombose aan de ongunstige lange termi;n (6 maandcn) 
resultaten duideli;k. De sterkere mate van restenose in de 160 vernauwingen met 
thrombose was primair te wi;ten aan een toegenomen incidentie van occlusie ten 
tijde van follow-up angiografie. Deze gegevens ondersteunen het uitgangspunt 
van een antithrombotische benadering in de preventie van restenose. 
EvaJuatie van het effect van pharmacologische stoffen op coronaire dimensies in 
de tijd wordt mogeli;k gemaakt door kwantitatieve coronair angiografie (QCA). 
In het Thoraxcentrum werd het computer geassisteerde 'Cardiovascular 
Angiography Analysis System (CAAS) ontwikkeld en gevalideerd (hoofdstuk 3). 
Deze techniek waarbij op een gestandaardizeerde methode data acquisitie en 
analyse plaatvindt, maakt multicenter onderzoek mogelijk en heeft het voordeel 
veel accutater en reproduceerbaarder de mate van coronair vernauwing te kun-
nen meten dan visuele schatting of handmatig afpassen. Daarnaast kan een 
angiografisch corelab de reproduceerbaarheid van kwalitatieve elementen en hun 
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rol in het optreden van acute en late complicaties na angioplastiek blootleggen. 
Dc sec tie 'Methodology and Trial Design' concentreert zich op aspecten van 
kwalitatieve en kwantitatieve angiogram beoordeling, de vormgeving en resulta-
ten van fase II en fase III onderzoeken die restenose preventie als doel steUen. 
\'{Ie Icgdcn coronaire geleide catheters vast op cinefilm, en vergeleken hun geme-
ten dimensies (CAAS) met hun reele dimensies (bepaald met een micrometer). 
De huidige genera tie van geleidc catheters toont een grote varia tie in radiologi-
sche kwaliteit. Nagenoeg aile geleide catheters zi;n geschikt voor de calibratie van 
QCA-metingen, vooropgesteld dat deze calibratie plaatsvindt met een catheter 
tip die niet gevuld is met contrast-medium (hoofdstuk 4). 
\Ve verrichtten herhaalde visuele beoordeling door twee onafhankelijkc observa-
toren, om de betrouwbaarheid van kwalitatieve angiogram beoordeling te evalu-
crcn (hoofdstuk 5). De 'inter-observer' variabiliteit wordt uitgedrukt in de kappa 
waarde en als percentage overeenkomst in waarneming. Deze is 0.33 and 67.8% 
respectievelijk voor de ABC-indeling voor type vernauwing (AHA/ACC crite-
ria). Kappa en percentage overeenkomst voor 10 andere variabelen varieerde van 
0.29 tot 1.00, en van 47.7 tot 98.5% respectieveli;k. De 'intra-observer' variabili-
teit vertoont hogere uitkomsten. Hct belang van completc en gedetailleerde 
definities wordt hier aan de orde gcsteld. 
In hoofdstuk 6 worden de bevindingen beschreven van een open studie waarin de 
veiligheid en toepasbaarheid van oplopende doses van intraveneus toegediend 
Argatroban (een sclectieve synthetische thrombine antagonist, die een competi-
tieve binding aangaat) in patienten die een coronair angioplastiek ondergaan, 
worden geanalyseerd. Een totaal van 30 patienten werd bestudeerd in 4 oplopen-
de doseringsgroepen. Het proficl van ongunstige klinische uitkomst, veiligheid en 
haemostase parameters werden geanalyseerd en tonen aan dat Argatroban in 
patienten die een coronaire angioplastiek ondergaan veilig kan worden toege-
diend, en resulteert in een adequate en voorspelbare omvang van ontstolIing. 
De HELVETICA studie is een multicentre, gerandomizeerde, dubbel blind 
opgezette en heparine gecontroleerde studie, opgezet om de effecten van twee 
verschillende doseringsschema's van desirudine (recombinant desulphato hiru-
dine/L\\REV ASC) te vergelijken met die van heparine op de event-vrije overle-
ving, veiligheid, tolerantie en het optreden van restenose (gemeten met QCA) op 
26 weken na de coronaire angioplastiek (hoofdstuk 7). De uitkomsten van deze 
trial zijn beschreven in het onderdeel 'Results' van dit proefschrift. 
Elf honderd en cen en veertig patienten lijdend aan onstabiele angina pectoris en 
wachtend op een coronair angioplastiek werden at random toegewezen in een van 
de behandelingsgroepen: a) een bolus dosis van 10,000 IU heparine gevolgd door 
een intraveneuze infusie van 15 IU/kg/hr gedurende 24 uur en subcutaan placebo 
twee maal gedurende 3 dagen (N=382), b) een bolus dosis van 40 mg desirudine 
gevoJgd door een intraveneuze infusie van 0.2 mg/kg/hr desirudine gedurende 24 
uur en subeutaan placebo twee maal daags gedurende 3 dagen (N=381) of c) het 
zelfde desirudine regime behalve dat 40 mg desirudine subcutaan werd gegeven 
in de plaats van placebo twee maal daags gedurende drie dagen (N=378). Het 
prima ire doel was om het eefect te vergelijken van de behandeling op de 7 maan-
den event-vrije overleving. Het secondaire doel was evaluatie van complicaties 
ti;dens of direct na de angioplastiek binnen 96 uur), veiligheid en tolerantie van 
desirudine, en de kwantitative cineangiographische meting van de obstructie dia-
meter na 6 maanden. 
De 7 maanden event-vrije overleving was 67.3% in deheprine controle groep, 
63.5% in de groep die desirudine intraveneus ontvangt en 68.0% in de groep die 
desirudine zowel intraveneus als subcutaan ontvangt (P=0.61) (hoofdstuk 8). 
Echter, toediening van desirudine was geassocieerd met een significante reductic 
in vroege com plica ties (binnen 96 uur), welke verschenen in 11.0, 7.9 en 5.6% 
van de patienten in de respectievclijke groupen (gecombineerd relatief risico met 
desirudine: 0.61, 95% betrouwbaarheids interval 0.41 tot 0.90, P-waardc 0.023). 
Minimale luminale diameter in de respectieveli;ke groepen na 6 maanden angio-
grafie was 1.54 mm, 1.47 mm and 1.56 mm (P=0.08). Hocwcl dus significant 
minder vroege cardiale complicaties werden waargenomen in de met desirudine 
behandelde groep, was de toediening van desirudine zoals beschreven in vergelij-
king met heparine niet geassocieerd met een significant voordeel voor de compli-
catie-vri;e overleving of de minimale lumina Ie diameter na 6 maanden. 
Om onafuankelijke voorspellers van cardiale complicaties te identificeren, wer-
den klinische, procedurele en angiografische parameters van patienten in de 
HELVETICA studie op een multivariate wi;ze geanalyseerd (hoofdstuk 9). 
Angina pectoris klasse III volgens Braunwald, leefti;d 2: 60 jaar, aanwezigheid van 
thrombus en dissectie na de angipolastiek zijn onafuankelijke risico factoren voor 
ongunstige vroege klinische uitkomst, terwijl behandeling met desirudine en lesic 
type A (AHA/ACC classificatic) onafhankelijke beschermende factoren zijn. Met 
behulp van dit model kan in 80% van de patienten de vroege klinische uitkomst 
correct worden voorspeld. \Vat betreft de 7 maanden uitkomst zijn angina klasse 
II en III volgens de Braunwald classificatie, leeftijd 2: 60 jaar en verhoogde spie-
gels van prothrombine fragment 1 en 2 onafhankeli;ke risico factoren, terwijl een 
myocard infarct in de voorgeschiedenis, lesie lengte < 1 0 mm en een grotere mini-
male lumen diameter na de angioplastiek onafbankelijke beschermende factoren 
zijn. Met gebruik van dit model kan in 66% van de patienten de klinische uitkomst 
na 7 maanden correct worden geclassificeerd. 
Uiteindelijk kunnen we concluderen dat de thrombine antagonisten een veelbelo-
vende klasse van antithrombotische middelen vertegenwoordigd, die de specific-
ke tekortkomingen van heparine en aspirine overwint, en die veilig tocpasbaar 
zijn voor klinische toepassing (hoofdstuk 10). Echter, afgezien van de thcoreti-
sche voordelen die deze greep omvat, inclusief de vastgestelde significant superi-
eure acute klinische resultaten in diverse rcstenose preventie trials, hecft fase III 
evaluatie met deze pharmaca geen overtuigende verbetering van de lange termijn 
resultaten kunnen aantonen. Verder prospectief en gerandomizeerd onderzoek, 
gericht op optimalisering van de gebruikte dosis en identificatie van subgroepen 
van patienten die significant voordeel behalen van specifieke antithrombine the-
rapie. 
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